data_2n62_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n62 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -51.72 164.73 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 124.505 3.47 . . . . 0.0 113.339 -173.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 59.7 m -89.34 121.42 31.59 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.183 2.993 . . . . 0.0 110.546 169.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.83 -14.42 61.09 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.924 2.09 . . . . 0.0 112.138 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -65.54 -26.91 68.09 Favored 'General case' 0 N--CA 1.45 -0.459 1 C-N-CA 131.724 4.01 . . . . 0.0 108.729 167.25 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 31.9 m170 -134.42 -25.11 1.53 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.989 2.177 . . . . 0.0 112.047 -166.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 14.6 m -79.78 145.07 33.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 O-C-N 117.532 -3.23 . . . . 0.0 110.507 173.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . 0.53 6.8 p90 -167.25 -172.0 1.88 Allowed 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 114.912 -2.471 . . . . 0.0 117.042 -176.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . 0.254 . . -150.09 139.04 20.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 116.253 -2.179 . . . . 0.0 110.79 -148.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -147.4 144.11 28.44 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 119.061 -1.055 . . . . 0.0 113.54 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.531 0 CA-C-O 118.462 -1.188 . . . . 0.0 112.633 156.956 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 23.1 m . . . . . 0 N--CA 1.448 -0.544 0 CA-C-O 125.985 2.802 . . . . 0.0 117.95 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -163.15 121.72 2.04 Favored 'General case' 0 N--CA 1.449 -0.508 1 O-C-N 115.763 -4.335 . . . . 0.0 109.662 -177.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -142.35 144.09 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 O-C-N 128.657 3.723 . . . . 0.0 112.885 -157.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -135.3 157.81 45.96 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 122.008 2.185 . . . . 0.0 112.15 -150.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -76.91 -30.28 56.08 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 122.16 2.255 . . . . 0.0 111.541 175.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 22.0 p-10 -107.69 9.51 29.15 Favored 'General case' 0 N--CA 1.448 -0.571 0 CA-C-N 112.569 -2.105 . . . . 0.0 113.604 -172.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.85 153.49 28.79 Favored Pre-proline 0 N--CA 1.451 -0.409 0 CA-C-N 122.798 2.545 . . . . 0.0 113.199 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.9 172.66 8.08 Favored 'Trans proline' 0 N--CA 1.45 -1.069 2 C-N-CA 127.566 5.51 . . . . 0.0 107.248 159.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -127.66 160.16 32.5 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 127.49 2.993 . . . . 0.0 108.877 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -134.36 156.88 47.71 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 115.958 -1.972 . . . . 0.0 111.888 -172.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 35' ' ' PHE . . . . . 0.402 ' CE1' ' HE2' ' L' ' 104' ' ' MET . 9.1 p90 -160.08 172.84 16.76 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 126.767 2.027 . . . . 0.0 106.042 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 36' ' ' THR . . . . . . . . . . . . 0.253 8.2 m -135.03 142.62 46.43 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 124.172 1.939 . . . . 0.0 115.446 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . . 57.6 mt -108.67 114.93 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 O-C-N 118.404 -2.685 . . . . 0.0 111.211 -175.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -87.97 138.13 31.72 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 170.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -117.51 134.49 54.8 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 113.772 -1.558 . . . . 0.0 109.312 -166.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 79.7 t -150.17 141.61 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 C-N-CA 128.933 2.893 . . . . 0.0 110.974 -174.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.518 0 O-C-N 118.232 -2.792 . . . . 0.0 108.149 -174.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.453 0 N-CA-C 119.076 2.991 . . . . 0.0 119.076 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -60.51 135.44 57.75 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.269 -2.769 . . . . 0.0 116.145 176.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 40.6 p -89.03 7.12 36.47 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.038 2.236 . . . . 0.0 117.038 -172.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -169.3 -149.78 0.08 Allowed 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.674 2.79 . . . . 0.0 106.635 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -155.2 -153.51 6.55 Favored Glycine 0 C--N 1.335 0.496 0 N-CA-C 121.009 3.164 . . . . 0.0 121.009 -172.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.92 44.38 97.5 Favored Glycine 0 CA--C 1.522 0.486 0 O-C-N 120.412 -1.64 . . . . 0.0 111.167 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -87.09 163.76 38.93 Favored Pre-proline 0 N--CA 1.449 -0.489 0 CA-C-N 121.556 2.678 . . . . 0.0 105.212 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -90.97 78.83 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 CA-C-O 127.642 3.101 . . . . 0.0 117.69 177.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -84.68 163.11 19.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.03 2.932 . . . . 0.0 110.643 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -156.88 144.82 19.31 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.993 0.901 . . . . 0.0 111.968 166.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.07 136.3 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 128.63 2.772 . . . . 0.0 114.977 174.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -143.11 125.4 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 130.201 3.401 . . . . 0.0 112.359 -165.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 37.6 mm -121.7 103.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 1 O-C-N 116.149 -4.094 . . . . 0.0 110.493 -164.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -96.63 137.85 35.09 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.768 2.027 . . . . 0.0 111.635 -174.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.2 -159.98 16.26 Favored Glycine 0 C--N 1.336 0.559 0 O-C-N 118.677 -2.515 . . . . 0.0 115.262 169.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -69.76 150.61 68.43 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 N-CA-C 119.241 2.747 . . . . 0.0 119.241 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t70 70.09 -95.75 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 127.989 2.516 . . . . 0.0 111.312 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.05 29.23 3.24 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-O 117.334 -1.815 . . . . 0.0 114.488 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 36.4 mt -90.12 124.79 35.11 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 122.52 3.16 . . . . 0.0 117.88 -175.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 10.0 t -146.53 136.27 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 115.656 1.724 . . . . 0.0 115.656 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 17.5 t -135.77 132.64 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 124.068 0.947 . . . . 0.0 109.007 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.84 123.95 27.73 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-O 116.005 -1.95 . . . . 0.0 115.639 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -93.57 150.33 20.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.403 2.281 . . . . 0.0 114.131 -170.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . 0.551 42.1 tttm -76.15 94.8 3.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 124.193 0.997 . . . . 0.0 111.962 -179.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 14.2 t -64.95 143.97 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 O-C-N 118.211 -2.805 . . . . 0.0 104.425 154.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 27.8 m -141.8 133.99 27.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 124.404 2.05 . . . . 0.0 110.278 159.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -68.93 125.06 25.44 Favored 'General case' 0 N--CA 1.449 -0.505 1 O-C-N 116.249 -4.032 . . . . 0.0 113.559 172.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -69.91 -16.69 63.27 Favored 'General case' 0 N--CA 1.449 -0.506 1 C-N-CA 131.745 4.018 . . . . 0.0 118.348 174.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . 0.263 57.7 t30 67.07 45.34 1.75 Allowed 'General case' 0 N--CA 1.448 -0.54 0 O-C-N 118.851 -2.406 . . . . 0.0 112.248 -168.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -159.14 -2.86 0.08 Allowed 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 118.634 -2.541 . . . . 0.0 116.837 -177.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 101.39 -5.66 55.25 Favored Glycine 0 C--N 1.335 0.516 0 CA-C-O 115.494 -2.837 . . . . 0.0 112.025 -167.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 31.3 p -123.37 164.99 17.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 123.465 3.633 . . . . 0.0 115.577 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -132.86 137.74 46.79 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 126.568 2.418 . . . . 0.0 109.755 -175.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -91.52 150.83 20.59 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 108.597 -1.801 . . . . 0.0 108.597 168.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -141.36 146.73 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 O-C-N 127.4 2.47 . . . . 0.0 110.531 177.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.8 p -132.11 143.67 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 126.652 1.981 . . . . 0.0 106.346 -175.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 10.3 p90 -161.97 167.43 24.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 117.681 -3.137 . . . . 0.0 115.979 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -142.82 162.67 34.85 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 116.459 -1.734 . . . . 0.0 111.509 -170.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 84' ' ' ALA . . . . . 0.449 ' HB2' ' CD1' ' L' ' 90' ' ' TYR . . . -125.12 78.01 66.94 Favored Pre-proline 0 N--CA 1.449 -0.502 0 C-N-CA 125.671 1.589 . . . . 0.0 111.22 -178.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 85' ' ' PRO . . . . . 0.463 ' HD2' ' CE2' ' L' ' 90' ' ' TYR 0.417 73.5 Cg_exo -40.1 -23.37 0.12 Allowed 'Trans proline' 0 N--CA 1.449 -1.142 1 C-N-CA 128.38 6.053 . . . . 0.0 119.596 178.621 . . . . . . . . 4 3 . 1 . 001 nuclear orig core ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 85.6 t -123.32 132.52 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-O 117.368 -1.301 . . . . 0.0 108.867 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -60.59 85.29 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 131.024 3.73 . . . . 0.0 109.365 163.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 172.88 -171.72 44.59 Favored Glycine 0 CA--C 1.523 0.536 1 C-N-CA 132.56 4.886 . . . . 0.0 112.895 -160.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -71.5 140.26 49.88 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.059 1.744 . . . . 0.0 112.834 167.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 90' ' ' TYR . . . . . 0.463 ' CE2' ' HD2' ' L' ' 85' ' ' PRO . 14.1 m-85 -112.1 168.75 9.36 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 120.164 -1.585 . . . . 0.0 109.955 150.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -133.31 133.91 43.17 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.833 3.253 . . . . 0.0 112.39 -177.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.67 121.9 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 CA-C-O 125.448 2.547 . . . . 0.0 105.716 -169.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -135.75 118.72 16.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.937 2.495 . . . . 0.0 115.873 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.53 142.93 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 CA-C-N 113.16 -1.836 . . . . 0.0 112.718 -169.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -142.79 151.28 41.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 125.042 1.464 . . . . 0.0 108.712 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 4.0 tt -133.83 116.74 16.04 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 127.656 2.383 . . . . 0.0 106.412 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? 62.83 -49.7 0.19 Allowed 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 127.495 2.318 . . . . 0.0 116.864 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -170.43 16.64 0.06 OUTLIER Glycine 0 CA--C 1.523 0.535 0 C-N-CA 129.608 3.48 . . . . 0.0 114.495 162.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 21.6 m120 -128.05 149.23 70.42 Favored Pre-proline 0 N--CA 1.451 -0.397 0 C-N-CA 127.943 2.497 . . . . 0.0 111.538 -163.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -80.49 -176.24 3.09 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 121.138 1.225 . . . . 0.0 113.94 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 4.1 pt -139.17 -155.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 C-N-CA 129.809 3.244 . . . . 0.0 108.444 -177.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 9.0 pttm -136.17 172.75 12.55 Favored 'General case' 0 N--CA 1.45 -0.469 1 O-C-N 115.365 -4.584 . . . . 0.0 111.009 170.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 49.0 t30 80.28 -57.68 0.34 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 130.365 3.466 . . . . 0.0 106.799 -160.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 104' ' ' MET . . . . . 0.402 ' HE2' ' CE1' ' L' ' 35' ' ' PHE . 0.9 OUTLIER -83.06 154.35 67.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 126.403 2.314 . . . . 0.0 109.745 164.166 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -77.71 163.66 87.63 Favored 'Cis proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.666 -2.223 . . . . 0.0 113.359 -5.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 9.3 tp -162.98 147.68 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 113.24 -1.8 . . . . 0.0 113.941 -161.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.49 150.87 40.14 Favored 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 120.072 -1.643 . . . . 0.0 109.295 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 9.0 p -158.46 125.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 O-C-N 126.151 2.157 . . . . 0.0 111.019 -163.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -81.73 148.58 28.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 118.339 -0.838 . . . . 0.0 112.931 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 5.3 t -101.24 117.67 35.44 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 128.779 2.832 . . . . 0.0 108.125 -170.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 20.2 tt . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 116.205 -1.855 . . . . 0.0 114.631 178.044 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 9.1 m-30 . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 73.2 p -162.19 143.82 10.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 128.238 2.615 . . . . 0.0 111.282 177.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.259 11.6 m-85 -61.59 143.32 56.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 114.679 -2.582 . . . . 0.0 110.128 149.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 20.3 m -68.67 105.7 2.37 Favored 'General case' 0 N--CA 1.449 -0.515 0 O-C-N 126.155 2.16 . . . . 0.0 106.623 148.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.449 -0.507 0 C-N-CA 127.511 2.324 . . . . 0.0 110.12 -178.456 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 117.501 2.408 . . . . 0.0 117.501 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -50.29 -40.26 47.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 123.541 0.737 . . . . 0.0 110.195 164.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -101.04 6.42 43.41 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.778 -1.826 . . . . 0.0 114.206 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 57.3 mt -108.51 135.24 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 116.642 -3.786 . . . . 0.0 107.016 177.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 55.0 m -86.82 134.31 33.56 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.39 140.27 43.3 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 124.972 2.32 . . . . 0.0 112.975 165.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -158.86 119.26 3.22 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 119.722 -1.861 . . . . 0.0 108.309 -170.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -153.03 158.62 42.25 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.406 0.891 . . . . 0.0 113.406 -165.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 6.0 pt . . . . . 0 N--CA 1.451 -0.408 0 CA-C-O 114.745 -2.55 . . . . 0.0 110.009 163.24 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 1.3 t . . . . . 0 N--CA 1.448 -0.56 0 N-CA-C 117.523 2.416 . . . . 0.0 117.523 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -156.77 -132.12 1.45 Allowed Glycine 0 C--N 1.335 0.473 1 C-N-CA 132.711 4.958 . . . . 0.0 109.963 175.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 5.0 t -132.69 101.08 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 117.585 -3.303 . . . . 0.0 110.317 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -52.37 117.31 2.75 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-O 117.706 -1.14 . . . . 0.0 110.265 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 11.1 tp -84.52 -38.57 19.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 128.982 3.926 . . . . 0.0 107.864 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -155.36 149.65 25.94 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.414 3.085 . . . . 0.0 107.956 179.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . 86.99 156.09 28.79 Favored Glycine 0 CA--C 1.522 0.52 0 CA-C-O 124.912 2.395 . . . . 0.0 113.668 173.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -55.64 113.9 1.64 Allowed 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 110.33 -2.935 . . . . 0.0 117.682 -175.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -71.35 125.71 27.72 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.255 174.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 16.8 mm 44.73 120.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 130.583 3.553 . . . . 0.0 111.049 -160.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -98.19 139.6 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 113.218 -1.81 . . . . 0.0 110.951 -164.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 111.5 -149.7 18.0 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 114.344 -1.298 . . . . 0.0 113.509 -175.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 1.1 t -151.15 142.01 15.01 Favored Pre-proline 0 N--CA 1.449 -0.5 0 C-N-CA 131.591 3.956 . . . . 0.0 112.583 -171.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -89.82 150.33 4.98 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 120.436 0.758 . . . . 0.0 110.956 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -157.2 145.96 19.78 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 120.964 3.69 . . . . 0.0 120.964 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -92.78 150.06 20.89 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 120.483 -1.386 . . . . 0.0 112.058 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -83.19 135.48 34.77 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 120.433 -1.417 . . . . 0.0 111.14 -173.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 63.0 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 115.265 1.58 . . . . 0.0 115.265 155.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 49.8 mt -110.71 137.56 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 120.626 -1.296 . . . . 0.0 111.323 162.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 126.17 144.47 6.15 Favored Glycine 0 CA--C 1.523 0.555 0 C-N-CA 125.332 1.444 . . . . 0.0 115.228 -169.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -156.16 165.45 36.37 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 123.224 1.488 . . . . 0.0 108.925 176.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -92.98 150.59 20.44 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 117.441 -3.287 . . . . 0.0 107.842 175.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 16.1 mt -91.78 167.0 12.47 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 128.656 2.783 . . . . 0.0 106.739 2.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -139.55 -13.21 1.14 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.079 1.352 . . . . 0.0 114.459 162.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 5.6 t -100.45 138.89 36.91 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.601 1.96 . . . . 0.0 113.303 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 66.5 p -123.47 166.78 17.02 Favored Pre-proline 0 N--CA 1.448 -0.541 0 C-N-CA 129.494 3.118 . . . . 0.0 112.328 -173.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -50.12 149.48 11.91 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 124.576 3.517 . . . . 0.0 116.803 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.61 -19.67 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 O-C-N 125.559 1.787 . . . . 0.0 112.055 -176.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -159.75 159.47 32.83 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 127.185 2.194 . . . . 0.0 106.572 157.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 29.2 mm -82.18 119.72 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 126.84 2.056 . . . . 0.0 107.196 169.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 3.2 m -78.98 148.19 32.66 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 126.019 2.074 . . . . 0.0 115.21 -172.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -70.54 117.68 12.38 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 170.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -72.15 -20.42 61.61 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.464 2.394 . . . . 0.0 117.464 175.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -151.16 172.27 16.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.617 1.567 . . . . 0.0 109.907 -170.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -118.82 -41.18 0.61 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-O 125.055 2.475 . . . . 0.0 115.313 161.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 29.5 mm 85.74 -66.09 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.47 1 C-N-CA 132.124 4.17 . . . . 0.0 111.437 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -49.7 122.14 6.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 129.478 3.111 . . . . 0.0 108.263 -162.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.98 -167.42 1.39 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 114.624 -2.608 . . . . 0.0 116.115 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.471 0 O-C-N 126.348 2.28 . . . . 0.0 110.855 -173.793 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.387 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -62.91 137.61 63.63 Favored 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 122.606 2.204 . . . . 0.0 117.757 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 5.5 t -81.78 115.36 20.96 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 127.9 3.25 . . . . 0.0 111.349 155.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -50.05 -37.49 33.61 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 129.061 2.944 . . . . 0.0 112.919 166.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -63.77 -49.98 70.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 128.314 2.646 . . . . 0.0 111.6 176.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -113.53 -23.63 9.69 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.45 1.9 . . . . 0.0 113.452 -151.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 73.0 m -70.18 146.11 51.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 120.327 -1.483 . . . . 0.0 109.023 173.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 24.8 p90 -154.94 176.53 12.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.571 1.948 . . . . 0.0 111.492 -164.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -142.47 140.72 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 125.595 1.81 . . . . 0.0 110.748 172.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -147.26 134.92 21.05 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 125.884 2.754 . . . . 0.0 110.351 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.601 0 CA-C-O 125.306 2.615 . . . . 0.0 112.528 157.54 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t . . . . . 0 N--CA 1.447 -0.618 0 CA-C-O 121.737 0.779 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 35.1 tttt -149.23 98.89 2.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.624 1.202 . . . . 0.0 108.659 -154.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 37.9 t -141.52 131.92 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 114.278 -2.773 . . . . 0.0 111.344 -152.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -127.2 149.54 49.94 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 119.58 3.178 . . . . 0.0 119.58 -158.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -63.35 -14.18 47.16 Favored 'General case' 0 N--CA 1.448 -0.542 0 O-C-N 124.694 1.246 . . . . 0.0 113.114 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . 0.263 14.4 p-10 -113.02 3.33 16.12 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.741 2.126 . . . . 0.0 116.741 169.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.41 137.91 11.32 Favored Pre-proline 0 N--CA 1.45 -0.441 1 N-CA-C 122.177 4.14 . . . . 0.0 122.177 -167.537 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -77.78 160.49 30.97 Favored 'Trans proline' 0 N--CA 1.447 -1.22 1 C-N-CA 128.078 5.852 . . . . 0.0 111.178 -172.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -141.35 152.38 44.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 126.206 2.191 . . . . 0.0 113.795 -173.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 34' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' L' ' 80' ' ' VAL . 11.3 mt-10 -128.0 152.32 48.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 124.912 1.285 . . . . 0.0 111.583 -167.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . 0.305 4.1 p90 -160.44 153.86 22.12 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.692 2.397 . . . . 0.0 106.735 -173.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 1.2 m -121.53 129.04 52.65 Favored 'General case' 0 N--CA 1.448 -0.535 0 O-C-N 123.626 0.579 . . . . 0.0 110.269 -169.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.314 4.1 mt -73.93 104.79 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 166.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -91.92 115.28 27.93 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 124.284 1.993 . . . . 0.0 108.923 168.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.14 145.71 28.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 118.347 -2.721 . . . . 0.0 109.009 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t -140.02 129.05 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 110.292 -3.14 . . . . 0.0 110.552 -175.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 35.2 p30 . . . . . 0 N--CA 1.448 -0.54 0 CA-C-O 127.84 3.686 . . . . 0.0 117.856 -177.109 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 117.996 2.591 . . . . 0.0 117.996 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . 0.271 11.1 mmm180 -76.83 153.37 34.91 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.252 1.821 . . . . 0.0 110.603 -177.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 43.2 p -124.41 -1.53 8.09 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 128.513 2.725 . . . . 0.0 115.265 -165.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -161.52 167.29 25.72 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -168.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.63 175.56 40.53 Favored Glycine 0 C--N 1.335 0.498 1 N-CA-C 125.415 4.926 . . . . 0.0 125.415 175.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 66.4 49.08 59.07 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 125.745 1.641 . . . . 0.0 112.544 161.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -83.38 150.38 60.25 Favored Pre-proline 0 N--CA 1.449 -0.512 0 CA-C-O 115.014 -2.422 . . . . 0.0 116.948 151.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -91.7 59.74 0.96 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 106.833 -2.026 . . . . 0.0 106.833 -164.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -69.7 155.7 40.11 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 117.929 2.566 . . . . 0.0 117.929 156.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.98 146.78 31.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 116.516 -1.707 . . . . 0.0 109.78 178.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -125.64 140.26 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 119.979 1.263 . . . . 0.0 111.882 -173.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.96 29.55 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 114.272 -2.775 . . . . 0.0 111.956 -176.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 15.7 mt -135.75 134.04 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 1 C-N-CA 131.898 4.079 . . . . 0.0 110.13 -178.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -120.91 148.69 43.71 Favored 'General case' 0 N--CA 1.45 -0.444 1 C-N-CA 133.445 4.698 . . . . 0.0 110.901 -178.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -148.63 -162.61 10.34 Favored Glycine 0 CA--C 1.522 0.504 0 CA-C-O 124.714 2.285 . . . . 0.0 114.931 -171.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.42 149.37 86.63 Favored 'Trans proline' 0 N--CA 1.448 -1.153 1 C-N-CA 125.403 4.069 . . . . 0.0 110.892 -178.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.83 -125.61 0.95 Allowed 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.724 2.41 . . . . 0.0 109.461 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -89.83 -9.26 66.34 Favored Glycine 0 C--N 1.335 0.506 1 O-C-N 114.457 -5.152 . . . . 0.0 111.314 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 8.8 tp -62.32 124.58 21.28 Favored 'General case' 0 N--CA 1.447 -0.593 0 O-C-N 118.358 -2.848 . . . . 0.0 113.467 -155.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 15.4 m -108.51 156.49 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 150.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 89.0 t -122.64 136.22 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 125.609 1.818 . . . . 0.0 110.084 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -89.96 118.04 29.23 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -63.22 147.04 52.07 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 118.564 -2.585 . . . . 0.0 116.922 172.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -116.92 119.94 36.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 64.2 t -112.62 143.99 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 CA-C-O 123.55 1.643 . . . . 0.0 108.434 -173.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -139.77 117.53 11.63 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 114.47 -1.241 . . . . 0.0 112.253 170.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -81.27 121.88 26.73 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 129.052 2.941 . . . . 0.0 109.456 178.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -77.61 -5.38 50.08 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 115.704 -2.093 . . . . 0.0 115.274 175.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 71.22 24.3 3.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 125.628 3.831 . . . . 0.0 112.092 -175.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -149.16 -12.52 0.31 Allowed 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 117.103 -3.498 . . . . 0.0 111.028 -160.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 115.86 5.34 18.07 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 120.103 2.801 . . . . 0.0 120.103 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 18.8 p -136.15 157.34 47.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.342 3.057 . . . . 0.0 111.391 170.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -130.43 140.1 50.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 116.666 -1.635 . . . . 0.0 108.956 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -77.32 132.89 12.49 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 127.346 2.403 . . . . 0.0 114.86 160.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 80' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' L' ' 34' ' ' GLU . 2.6 t -126.14 128.52 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 127.733 2.666 . . . . 0.0 115.65 174.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -136.4 143.04 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 120.645 -1.284 . . . . 0.0 113.225 174.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -151.04 -178.94 6.9 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 114.79 -1.096 . . . . 0.0 111.607 175.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -137.27 107.22 6.29 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.56 1.944 . . . . 0.0 111.338 178.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 84' ' ' ALA . . . . . . . . . . . . 0.28 . . -68.63 110.43 5.87 Favored Pre-proline 0 N--CA 1.45 -0.453 0 C-N-CA 124.843 1.257 . . . . 0.0 109.54 164.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 85' ' ' PRO . . . . . . . . . . . . 0.264 50.0 Cg_endo -67.29 -10.02 27.22 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 126.546 4.831 . . . . 0.0 117.866 -167.987 . . . . . . . . 3 2 . 1 . 002 nuclear orig core ' L' L ' 86' ' ' VAL . . . . . 0.425 HG23 ' HH ' ' L' ' 90' ' ' TYR . 0.0 OUTLIER -153.61 154.16 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-N 119.827 1.194 . . . . 0.0 110.209 -175.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -43.97 130.15 5.88 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 150.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 145.37 -149.65 21.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 127.618 2.532 . . . . 0.0 111.643 -174.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -121.98 153.93 37.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 127.033 2.133 . . . . 0.0 113.391 -178.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 90' ' ' TYR . . . . . 0.425 ' HH ' HG23 ' L' ' 86' ' ' VAL . 52.6 m-85 -152.27 156.39 39.59 Favored 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.332 1.853 . . . . 0.0 108.398 -172.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . 0.325 2.9 t30 -133.55 114.32 13.43 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.007 1.323 . . . . 0.0 111.512 -165.021 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 20.5 t -108.55 139.17 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-N 112.972 -1.922 . . . . 0.0 110.246 -164.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -155.1 106.49 2.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.659 2.784 . . . . 0.0 117.162 -173.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -94.56 142.63 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 111.899 -2.41 . . . . 0.0 108.873 159.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 35.0 p -137.42 -144.36 0.19 Allowed 'General case' 0 N--CA 1.451 -0.384 0 O-C-N 128.946 3.903 . . . . 0.0 117.431 -173.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 6.0 tp -150.72 154.52 37.54 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 123.667 2.94 . . . . 0.0 115.016 168.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 33.3 ttm180 -64.36 94.88 0.12 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 124.202 1.953 . . . . 0.0 109.856 142.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . 121.41 -153.16 16.71 Favored Glycine 0 N--CA 1.448 -0.504 1 C-N-CA 131.032 4.158 . . . . 0.0 110.295 -171.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -71.47 113.87 23.21 Favored Pre-proline 0 N--CA 1.449 -0.487 0 CA-C-O 113.358 -3.21 . . . . 0.0 108.551 -170.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -74.63 160.29 41.4 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 O-C-N 127.079 3.147 . . . . 0.0 114.23 -165.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.7 pt -90.07 138.81 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 O-C-N 117.064 -3.522 . . . . 0.0 112.071 -159.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 23.0 mmtt -92.59 -178.73 4.97 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-O 117.352 -1.309 . . . . 0.0 109.396 -173.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 72.64 -44.44 0.59 Allowed 'General case' 0 N--CA 1.448 -0.537 0 CA-C-O 126.797 3.189 . . . . 0.0 110.894 -154.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 28.0 mmt -69.74 155.25 93.84 Favored Pre-proline 0 N--CA 1.448 -0.541 0 CA-C-O 112.347 -3.692 . . . . 0.0 107.741 153.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -75.13 159.92 97.19 Favored 'Cis proline' 0 N--CA 1.447 -1.213 0 O-C-N 125.453 2.291 . . . . 0.0 110.481 -18.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 12.5 tt -151.55 141.05 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.163 -1.38 . . . . 0.0 112.709 -174.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -95.62 136.14 36.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.659 3.183 . . . . 0.0 113.692 173.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.27 143.25 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 128.979 2.911 . . . . 0.0 103.284 -163.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -111.75 147.4 35.72 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 126.321 1.848 . . . . 0.0 113.807 177.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 41.0 t -127.43 138.96 53.11 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 125.747 1.905 . . . . 0.0 106.356 -172.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 1.3 pp . . . . . 0 N--CA 1.449 -0.48 0 C-N-CA 128.125 2.57 . . . . 0.0 110.413 -177.482 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . 0.32 26.3 p90 . . . . . 0 N--CA 1.45 -0.442 0 N-CA-C 119.554 3.168 . . . . 0.0 119.554 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 3.4 p -135.9 153.56 51.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 118.077 -2.89 . . . . 0.0 112.684 -166.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.338 56.9 t80 -66.22 154.51 39.64 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -174.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 12.9 t -60.42 149.24 34.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 130.256 3.422 . . . . 0.0 112.574 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 21.6 m . . . . . 0 N--CA 1.449 -0.52 0 CA-C-N 112.599 -2.091 . . . . 0.0 110.093 178.915 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.518 0 CA-C-O 123.067 1.413 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -68.08 131.09 44.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 O-C-N 118.093 -2.879 . . . . 0.0 110.426 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -63.52 121.98 15.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 118.28 2.696 . . . . 0.0 118.28 176.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 4.8 tt -138.65 160.14 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-O 124.004 1.859 . . . . 0.0 114.167 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 28.6 m -78.89 131.3 36.37 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 115.025 -2.417 . . . . 0.0 108.833 173.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 22.4 tp -61.8 142.62 57.2 Favored 'General case' 0 N--CA 1.451 -0.406 1 C-N-CA 132.264 4.226 . . . . 0.0 109.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -151.66 142.49 22.92 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 127.113 2.165 . . . . 0.0 110.336 178.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -75.54 69.75 2.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.43 3.492 . . . . 0.0 113.831 175.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 15.1 pt . . . . . 0 N--CA 1.448 -0.528 0 C-N-CA 130.52 3.528 . . . . 0.0 111.279 -171.927 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 38.1 m . . . . . 0 N--CA 1.449 -0.493 0 CA-C-O 124.175 1.94 . . . . 0.0 108.104 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -88.25 -175.04 47.68 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.911 -176.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 13.5 m -83.68 144.9 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 O-C-N 126.735 2.08 . . . . 0.0 111.732 155.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 53.5 tttp -69.05 130.26 42.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.703 2.401 . . . . 0.0 114.987 168.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 37.6 mt -100.42 -41.2 7.11 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 117.684 2.475 . . . . 0.0 117.684 -176.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -78.64 171.8 14.61 Favored 'General case' 0 N--CA 1.449 -0.509 1 C-N-CA 133.488 4.715 . . . . 0.0 113.457 -173.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -85.94 -154.79 24.59 Favored Glycine 0 C--N 1.336 0.534 0 C-N-CA 126.455 1.978 . . . . 0.0 109.592 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 18.2 ttmt -79.22 0.13 29.77 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 116.743 -1.599 . . . . 0.0 110.937 -174.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -62.35 148.04 46.47 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 122.478 2.399 . . . . 0.0 109.286 171.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 4.7 mt -131.28 129.43 62.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 1 C-N-CA 133.797 4.839 . . . . 0.0 106.997 178.02 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -100.16 141.67 32.67 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 127.356 2.91 . . . . 0.0 111.554 156.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 102.54 9.21 41.58 Favored Glycine 0 CA--C 1.523 0.588 0 CA-C-N 122.202 2.274 . . . . 0.0 117.964 166.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 46.2 m -65.39 134.23 95.6 Favored Pre-proline 0 N--CA 1.448 -0.557 1 CA-C-O 111.53 -4.081 . . . . 0.0 111.985 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -36.28 122.61 0.3 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 1 C-N-CA 128.439 6.092 . . . . 0.0 113.412 167.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -98.21 162.4 13.22 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.369 1.467 . . . . 0.0 109.668 172.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -64.72 148.41 51.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -164.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 91.6 mm-40 -117.56 143.27 46.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 O-C-N 119.545 -1.972 . . . . 0.0 109.242 163.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.1 139.91 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 119.031 -2.293 . . . . 0.0 111.331 -168.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 57.8 tp -146.42 117.5 7.79 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 110.474 -3.057 . . . . 0.0 108.872 168.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 81.12 173.93 48.28 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 127.195 2.331 . . . . 0.0 114.627 175.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 27.2 t30 -110.97 134.6 52.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -146.28 150.11 35.15 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 115.411 -2.233 . . . . 0.0 112.178 -170.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 55.6 mt -67.45 161.51 25.18 Favored 'General case' 0 N--CA 1.449 -0.483 1 C-N-CA 134.181 4.993 . . . . 0.0 109.836 0.279 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 55.7 t80 -62.51 137.82 58.34 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 126.13 2.871 . . . . 0.0 107.529 -177.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.98 119.56 33.7 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 117.356 -3.34 . . . . 0.0 112.201 -171.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 4.3 m -79.17 130.18 70.17 Favored Pre-proline 0 N--CA 1.451 -0.415 0 O-C-N 117.571 -3.206 . . . . 0.0 109.646 -162.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -64.3 125.17 14.59 Favored 'Trans proline' 0 N--CA 1.448 -1.185 1 C-N-CA 125.327 4.018 . . . . 0.0 109.267 173.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 6.9 p -163.07 159.36 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 130.171 3.388 . . . . 0.0 111.353 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 9.1 p90 -80.81 137.68 36.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.826 2.05 . . . . 0.0 113.735 177.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 40.9 mm -67.67 125.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 119.462 -2.024 . . . . 0.0 107.646 171.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 212' ' ' SER . . . . . . . . . . . . 0.255 40.2 m -87.09 156.88 19.54 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 124.082 3.128 . . . . 0.0 110.81 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -56.65 151.88 13.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 131.096 3.758 . . . . 0.0 118.168 171.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -114.93 156.95 24.07 Favored 'General case' 0 N--CA 1.447 -0.579 0 O-C-N 117.44 -3.288 . . . . 0.0 110.012 159.267 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . 0.283 12.5 pt20 -69.27 154.53 41.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 119.916 1.235 . . . . 0.0 112.95 -175.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -86.09 -154.08 23.51 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 130.361 3.839 . . . . 0.0 117.497 160.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . 0.306 1.4 pp -127.33 -7.82 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 129.985 3.314 . . . . 0.0 113.268 -178.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -60.07 126.31 27.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -111.66 -146.2 0.4 Allowed 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 131.501 3.92 . . . . 0.0 114.228 175.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.66 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -177.361 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 116.149 -1.882 . . . . 0.0 114.411 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -66.9 -176.54 0.77 Allowed 'Trans proline' 0 N--CA 1.449 -1.118 1 C-N-CA 126.438 4.758 . . . . 0.0 115.166 155.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 2.6 p -158.51 154.81 27.34 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 123.064 1.411 . . . . 0.0 112.941 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.81 -53.18 60.96 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 112.605 -2.089 . . . . 0.0 112.725 -165.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 16.8 mp0 -48.61 -20.86 0.49 Allowed 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 129.416 3.086 . . . . 0.0 118.741 177.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 16' ' ' HIS . . . . . 0.442 ' C ' ' HE2' ' L' ' 102' ' ' LYS . 14.4 m80 -117.2 -54.79 2.38 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 127.976 2.511 . . . . 0.0 109.923 -170.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 17' ' ' SER . . . . . . . . . . . . 0.721 0.5 OUTLIER -67.1 149.87 49.96 Favored 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.84 -4.913 . . . . 0.0 112.642 -165.154 . . . . . . . . 4 3 . 1 . 003 nuclear orig core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 22.0 p90 -163.09 172.52 14.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 128.093 2.557 . . . . 0.0 108.883 -164.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -139.51 147.89 41.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 128.018 2.527 . . . . 0.0 110.387 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -149.98 144.18 25.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 125.423 1.702 . . . . 0.0 115.41 -175.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.527 0 CA-C-O 124.597 2.221 . . . . 0.0 115.066 168.49 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.451 -0.404 0 CA-C-O 121.588 0.709 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -162.87 92.54 0.78 Allowed 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 124.649 2.166 . . . . 0.0 115.614 -160.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 27' ' ' VAL . . . . . . . . . . . . 0.305 12.8 p -147.78 147.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 O-C-N 119.467 -2.02 . . . . 0.0 113.836 179.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -137.1 -170.89 2.81 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 -170.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -86.09 -44.68 12.06 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 117.994 -2.942 . . . . 0.0 113.324 -175.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 47.5 p-10 -106.28 30.62 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 123.589 1.661 . . . . 0.0 111.456 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.87 125.06 2.42 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 115.933 -1.984 . . . . 0.0 114.693 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -85.44 175.35 6.31 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 123.803 3.002 . . . . 0.0 113.762 -175.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -148.39 170.67 17.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 177.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -142.31 155.06 45.17 Favored 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 128.235 2.614 . . . . 0.0 116.025 -170.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -163.14 166.02 23.9 Favored 'General case' 0 N--CA 1.448 -0.533 1 O-C-N 114.688 -5.007 . . . . 0.0 108.79 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 21.3 m -131.82 133.82 45.11 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.397 1.628 . . . . 0.0 115.397 -162.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.267 8.6 mt -81.52 104.29 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 127.056 2.142 . . . . 0.0 110.498 174.398 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -81.36 121.0 25.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 118.696 -1.201 . . . . 0.0 107.988 168.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -73.96 120.5 19.63 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.509 3.123 . . . . 0.0 107.262 173.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 1.8 t -149.91 141.34 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 123.69 1.71 . . . . 0.0 107.567 176.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t0 . . . . . 0 N--CA 1.448 -0.548 0 CA-C-N 111.287 -2.688 . . . . 0.0 110.87 -174.678 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.541 0 CA-C-O 124.632 2.158 . . . . 0.0 111.911 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 16.6 mmm-85 -70.65 164.1 25.67 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 112.263 -2.244 . . . . 0.0 108.551 164.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 71.0 p -117.32 21.63 12.99 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 126.819 2.048 . . . . 0.0 111.987 -169.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -167.96 147.47 4.81 Favored 'General case' 0 N--CA 1.448 -0.535 1 C-N-CA 134.1 4.96 . . . . 0.0 118.489 -178.559 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -91.49 -131.84 5.33 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 126.598 2.047 . . . . 0.0 116.646 -174.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.62 -18.86 1.24 Allowed Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 119.63 2.612 . . . . 0.0 119.63 173.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -63.29 150.44 89.3 Favored Pre-proline 0 N--CA 1.448 -0.564 0 CA-C-N 119.522 1.661 . . . . 0.0 113.799 175.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -78.84 109.04 2.52 Favored 'Trans proline' 0 N--CA 1.449 -1.107 1 C-N-CA 125.337 4.024 . . . . 0.0 111.847 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -117.42 174.78 5.95 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 116.512 -1.708 . . . . 0.0 114.514 177.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -161.35 150.49 16.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 124.866 2.27 . . . . 0.0 112.004 -174.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 11.6 p -127.7 143.08 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.033 -2.292 . . . . 0.0 108.89 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -139.61 111.42 7.32 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-O 116.131 -1.89 . . . . 0.0 108.85 168.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . 0.279 29.3 mt -116.91 142.77 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 128.476 2.71 . . . . 0.0 107.69 175.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -134.41 148.14 50.58 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.354 3.462 . . . . 0.0 116.0 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -130.83 -148.19 6.24 Favored Glycine 0 N--CA 1.449 -0.498 0 O-C-N 119.01 -2.306 . . . . 0.0 109.769 -171.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . 0.304 51.8 Cg_endo -71.3 138.03 32.22 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.685 2.924 . . . . 0.0 114.557 -169.421 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 19.0 t70 81.99 -52.27 0.24 Allowed 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 128.814 2.846 . . . . 0.0 109.388 163.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.4 -22.2 0.03 OUTLIER Glycine 0 C--N 1.337 0.608 0 C-N-CA 129.791 3.567 . . . . 0.0 113.525 175.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 55.8 tp -45.52 104.06 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 131.149 3.779 . . . . 0.0 115.394 -165.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.94 117.59 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-O 124.646 2.165 . . . . 0.0 107.651 165.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.52 125.79 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -65.68 130.07 41.99 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 117.466 -1.254 . . . . 0.0 108.583 172.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -135.92 138.59 42.54 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 126.538 2.399 . . . . 0.0 105.701 -175.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 58.0 mttp -118.06 116.38 26.75 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 126.755 2.022 . . . . 0.0 113.335 -165.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 39.6 t -94.6 143.0 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 97.6 m -142.65 120.68 12.1 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 118.405 -2.684 . . . . 0.0 106.81 166.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . 0.293 40.0 t0 -68.42 133.23 48.34 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 125.885 1.99 . . . . 0.0 110.165 170.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 -93.91 -2.65 52.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 118.256 2.687 . . . . 0.0 118.256 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 82.25 -33.02 0.09 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 128.673 2.789 . . . . 0.0 109.223 172.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -78.97 -18.09 54.31 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 116.265 -1.826 . . . . 0.0 114.149 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 136.53 8.51 1.49 Allowed Glycine 0 C--N 1.336 0.583 0 CA-C-N 121.881 2.128 . . . . 0.0 115.125 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 76.4 p -138.39 160.06 40.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 126.456 1.902 . . . . 0.0 113.728 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -128.08 118.32 23.25 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 127.083 2.153 . . . . 0.0 107.178 177.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -75.12 132.57 13.67 Favored Glycine 0 CA--C 1.523 0.564 0 CA-C-O 117.476 -1.736 . . . . 0.0 112.603 165.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.52 130.42 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 124.283 1.992 . . . . 0.0 108.921 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 t -130.62 140.77 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 114.282 -1.326 . . . . 0.0 113.398 -167.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . 0.339 5.6 p90 -159.43 163.56 35.31 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 126.42 3.009 . . . . 0.0 115.877 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.16 139.33 12.07 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 109.687 -3.415 . . . . 0.0 110.705 -170.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 84' ' ' ALA . . . . . . . . . . . . . . . -147.73 149.23 32.97 Favored Pre-proline 0 N--CA 1.45 -0.456 0 CA-C-N 114.091 -1.413 . . . . 0.0 114.207 155.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 85' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -91.04 44.27 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.106 1 C-N-CA 125.319 4.013 . . . . 0.0 112.558 -169.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -141.92 167.31 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 112.096 -3.812 . . . . 0.0 116.302 -157.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -134.58 123.08 23.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 121.937 2.153 . . . . 0.0 109.325 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 171.94 -106.28 0.23 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 125.981 1.753 . . . . 0.0 112.617 -178.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -149.7 125.7 10.59 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 128.985 2.914 . . . . 0.0 118.153 177.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 90' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -87.17 139.04 30.97 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 126.563 1.945 . . . . 0.0 107.71 169.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -130.69 106.83 8.73 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 127.66 3.1 . . . . 0.0 105.685 -171.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 32.3 t -112.02 138.18 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 127.33 2.894 . . . . 0.0 112.521 -166.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -140.78 136.27 32.31 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.366 2.266 . . . . 0.0 114.454 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 10.1 t -122.24 147.43 26.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 O-C-N 119.299 -2.126 . . . . 0.0 107.849 174.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 95' ' ' THR . . . . . 0.454 ' C ' ' H ' ' L' ' 97' ' ' ARG . 16.5 p -157.13 149.87 23.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 117.446 -1.264 . . . . 0.0 111.113 -175.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 21.2 mt -72.94 32.5 0.07 Allowed 'General case' 0 N--CA 1.449 -0.518 1 C-N-CA 135.199 5.4 . . . . 0.0 111.594 -177.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 97' ' ' ARG . . . . . 0.454 ' H ' ' C ' ' L' ' 95' ' ' THR . 11.7 tpp85 65.61 -47.35 0.39 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.14 1.776 . . . . 0.0 109.311 -170.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -123.56 -5.47 7.74 Favored Glycine 0 C--N 1.335 0.519 1 C-N-CA 131.475 4.369 . . . . 0.0 114.731 -171.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -145.54 139.72 15.14 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 119.984 1.892 . . . . 0.0 113.483 -172.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -84.15 164.72 13.16 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 N-CA-C 116.923 1.855 . . . . 0.0 116.923 -173.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.13 -176.54 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 O-C-N 119.277 -2.139 . . . . 0.0 107.699 -176.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 102' ' ' LYS . . . . . 0.442 ' HE2' ' C ' ' L' ' 16' ' ' HIS . 53.9 mtmt -83.35 139.39 33.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.34 1.856 . . . . 0.0 113.206 -165.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 t30 63.51 27.82 15.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 126.685 2.491 . . . . 0.0 115.264 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 11.7 mmt -119.86 129.44 25.35 Favored Pre-proline 0 N--CA 1.448 -0.573 0 C-N-CA 130.765 3.626 . . . . 0.0 104.418 -172.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -79.94 169.04 71.39 Favored 'Cis proline' 0 N--CA 1.448 -1.155 0 CA-C-N 122.543 1.944 . . . . 0.0 116.66 -15.058 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 106' ' ' ILE . . . . . 0.413 HD11 ' H ' ' L' ' 107' ' ' ASP . 5.3 tp -158.85 162.0 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 O-C-N 119.405 -2.059 . . . . 0.0 110.408 -166.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 107' ' ' ASP . . . . . 0.413 ' H ' HD11 ' L' ' 106' ' ' ILE . 12.9 m-20 -132.73 146.29 51.74 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.632 1.973 . . . . 0.0 111.249 -161.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 15.2 t -138.42 118.53 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 129.201 3.0 . . . . 0.0 108.498 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -74.58 136.02 42.06 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.248 2.219 . . . . 0.0 107.294 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 38.6 t -106.28 111.69 24.39 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.918 -1.037 . . . . 0.0 113.001 167.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 15.2 tt . . . . . 0 N--CA 1.448 -0.543 0 C-N-CA 129.302 3.041 . . . . 0.0 110.461 -179.406 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 46.7 t80 . . . . . 0 N--CA 1.447 -0.598 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 28.0 p -158.69 162.11 37.17 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.508 3.123 . . . . 0.0 103.241 -171.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.262 51.8 p90 -154.94 162.51 41.07 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 125.021 1.328 . . . . 0.0 113.958 -174.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 3.0 m -81.64 126.58 31.93 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 119.674 -1.891 . . . . 0.0 110.769 175.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 N--CA 1.45 -0.457 0 CA-C-N 113.569 -1.651 . . . . 0.0 106.981 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.485 0 N-CA-C 112.743 0.646 . . . . 0.0 112.743 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -149.68 143.69 25.64 Favored 'General case' 0 N--CA 1.45 -0.439 1 O-C-N 116.14 -4.1 . . . . 0.0 109.738 -176.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -159.5 80.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 125.07 1.481 . . . . 0.0 108.584 -175.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 33.1 pt -105.45 166.76 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 126.71 2.004 . . . . 0.0 114.782 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 80.5 p -69.06 -5.68 23.49 Favored 'General case' 0 N--CA 1.451 -0.405 1 O-C-N 116.059 -4.151 . . . . 0.0 112.744 176.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 52.5 mt -91.61 68.14 5.58 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 122.212 2.278 . . . . 0.0 110.135 170.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -74.5 120.72 20.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 111.199 -2.728 . . . . 0.0 106.036 -169.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -70.39 132.2 45.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 123.012 1.386 . . . . 0.0 107.851 -177.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 34.2 pt . . . . . 0 N--CA 1.448 -0.569 0 N-CA-C 120.189 3.403 . . . . 0.0 120.189 -167.021 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 19.7 p . . . . . 0 N--CA 1.447 -0.599 0 CA-C-O 122.724 1.25 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . 126.1 169.14 12.77 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 128.764 3.078 . . . . 0.0 113.893 -172.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 184' ' ' VAL . . . . . . . . . . . . 0.327 11.2 p -131.28 30.48 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 1 CA-C-O 128.786 4.136 . . . . 0.0 115.839 171.104 . . . . . . . . 3 2 . 1 . 003 nuclear orig core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -110.08 -23.33 11.35 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 117.323 -3.361 . . . . 0.0 109.655 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 46.1 tp -137.44 148.76 46.36 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.07 2.948 . . . . 0.0 108.586 175.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -45.65 120.33 2.55 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.134 0.973 . . . . 0.0 113.187 168.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -72.2 -13.67 76.58 Favored Glycine 0 N--CA 1.447 -0.597 0 O-C-N 117.751 -3.093 . . . . 0.0 113.959 -174.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 20.1 tptp -59.69 -26.58 65.69 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 120.606 2.203 . . . . 0.0 116.053 175.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -75.4 157.26 34.44 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 116.926 -1.511 . . . . 0.0 108.39 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 10.0 tp -148.86 164.97 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 125.773 2.701 . . . . 0.0 107.967 -170.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -74.08 122.54 22.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 128.041 2.537 . . . . 0.0 110.121 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 122.33 -179.14 16.27 Favored Glycine 0 C--N 1.335 0.487 0 C-N-CA 126.247 1.879 . . . . 0.0 115.351 174.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 41.3 t -93.49 119.9 66.87 Favored Pre-proline 0 N--CA 1.45 -0.45 0 CA-C-O 118.768 -0.634 . . . . 0.0 110.793 173.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -81.18 138.94 11.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 CA-C-O 124.405 1.752 . . . . 0.0 110.26 176.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -179.96 -13.22 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 115.296 -2.288 . . . . 0.0 114.031 -171.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 69.7 tttt -59.51 -23.24 62.64 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 125.83 2.728 . . . . 0.0 117.505 166.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -78.1 109.84 12.54 Favored 'General case' 0 N--CA 1.45 -0.464 1 O-C-N 116.245 -4.034 . . . . 0.0 111.749 153.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 86.4 t -77.88 109.83 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 118.824 -2.422 . . . . 0.0 104.585 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 66.9 mt -88.39 173.91 8.45 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 167.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . -69.55 144.31 40.28 Favored Glycine 0 C--N 1.336 0.552 0 CA-C-N 121.536 1.971 . . . . 0.0 111.665 -171.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -148.8 152.78 37.12 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 126.0 1.647 . . . . 0.0 110.597 -171.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -38.3 127.77 1.37 Allowed 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 126.547 2.405 . . . . 0.0 109.346 161.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 4.8 tp -77.67 143.76 37.89 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.542 3.137 . . . . 0.0 110.363 0.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -101.54 -64.0 1.09 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 170.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 2.5 p -132.6 128.49 37.27 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.318 1.847 . . . . 0.0 110.572 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 25.4 m -45.3 125.6 5.8 Favored Pre-proline 0 N--CA 1.45 -0.459 0 CA-C-N 111.523 -2.58 . . . . 0.0 111.289 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -63.24 169.73 8.92 Favored 'Trans proline' 0 N--CA 1.448 -1.15 1 C-N-CA 126.057 4.505 . . . . 0.0 112.755 168.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.14 -175.15 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 126.012 1.725 . . . . 0.0 108.648 -171.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -90.31 163.98 14.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 114.885 1.439 . . . . 0.0 114.885 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.08 109.0 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-O 128.445 3.974 . . . . 0.0 113.873 165.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 30.4 m -71.84 94.01 1.37 Allowed 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 118.888 -2.383 . . . . 0.0 112.115 178.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -145.46 134.14 22.22 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 121.246 -0.909 . . . . 0.0 111.796 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -62.35 149.71 41.53 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 115.286 1.587 . . . . 0.0 115.286 -176.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -155.89 136.35 13.2 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 126.182 2.176 . . . . 0.0 113.351 178.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -113.44 150.45 18.51 Favored Glycine 0 C--N 1.337 0.592 0 N-CA-C 106.586 -2.605 . . . . 0.0 106.586 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 8.2 tp -154.43 -25.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -174.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -105.5 136.39 45.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 125.676 2.655 . . . . 0.0 113.029 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . 0.273 . . -84.72 164.65 18.43 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 113.647 -1.615 . . . . 0.0 112.827 -174.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.515 0 O-C-N 117.573 -3.204 . . . . 0.0 115.353 -171.736 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 1' ' ' HIS . . . . . 0.452 ' HA ' ' OD1' ' L' ' 74' ' ' ASN . 2.5 t-80 . . . . . 0 N--CA 1.47 0.566 0 CA-C-O 121.412 0.625 . . . . 0.0 112.686 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -94.09 141.35 28.64 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.424 -2.672 . . . . 0.0 110.662 -171.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -146.61 0.11 0.76 Allowed 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 114.534 -2.651 . . . . 0.0 112.858 -177.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 78.1 m-70 -86.4 1.89 49.61 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 125.937 3.971 . . . . 0.0 110.061 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . 0.267 0.2 OUTLIER -169.91 169.27 8.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.217 2.607 . . . . 0.0 109.795 176.425 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -147.4 103.9 3.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 123.392 1.568 . . . . 0.0 111.292 152.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . 0.331 . . -159.32 -26.63 0.07 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 173.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 3.2 m -154.92 122.15 5.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 120.036 -1.665 . . . . 0.0 114.597 -176.118 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 43.4 pttt -141.8 145.62 37.55 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 164.392 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo -57.02 141.53 94.07 Favored 'Trans proline' 0 N--CA 1.448 -1.193 1 C-N-CA 125.38 4.054 . . . . 0.0 117.796 166.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.1 123.54 71.65 Favored Pre-proline 0 N--CA 1.449 -0.513 0 O-C-N 119.709 -1.869 . . . . 0.0 109.275 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -51.72 164.73 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 124.505 3.47 . . . . 0.0 113.339 -173.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 59.7 m -89.34 121.42 31.59 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.183 2.993 . . . . 0.0 110.546 169.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.83 -14.42 61.09 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.924 2.09 . . . . 0.0 112.138 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -65.54 -26.91 68.09 Favored 'General case' 0 N--CA 1.45 -0.459 1 C-N-CA 131.724 4.01 . . . . 0.0 108.729 167.25 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 31.9 m170 -134.42 -25.11 1.53 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.989 2.177 . . . . 0.0 112.047 -166.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 14.6 m -79.78 145.07 33.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 O-C-N 117.532 -3.23 . . . . 0.0 110.507 173.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . 0.53 6.8 p90 -167.25 -172.0 1.88 Allowed 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 114.912 -2.471 . . . . 0.0 117.042 -176.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . 0.254 . . -150.09 139.04 20.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 116.253 -2.179 . . . . 0.0 110.79 -148.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -147.4 144.11 28.44 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 119.061 -1.055 . . . . 0.0 113.54 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.42 -95.48 0.12 Allowed Glycine 0 C--N 1.336 0.531 0 CA-C-O 118.462 -1.188 . . . . 0.0 112.633 156.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . 0.426 36.3 tt0 -161.33 86.82 0.68 Allowed 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 129.389 3.641 . . . . 0.0 105.936 166.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.42 -143.73 19.5 Favored Glycine 0 C--N 1.336 0.557 0 O-C-N 126.121 2.138 . . . . 0.0 114.992 -151.268 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 59.7 mt -101.97 152.38 21.01 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 119.73 3.233 . . . . 0.0 119.73 -177.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 23.1 m -42.39 140.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-O 125.985 2.802 . . . . 0.0 117.95 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -163.15 121.72 2.04 Favored 'General case' 0 N--CA 1.449 -0.508 1 O-C-N 115.763 -4.335 . . . . 0.0 109.662 -177.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -142.35 144.09 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 O-C-N 128.657 3.723 . . . . 0.0 112.885 -157.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -135.3 157.81 45.96 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 122.008 2.185 . . . . 0.0 112.15 -150.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -76.91 -30.28 56.08 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 122.16 2.255 . . . . 0.0 111.541 175.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 22.0 p-10 -107.69 9.51 29.15 Favored 'General case' 0 N--CA 1.448 -0.571 0 CA-C-N 112.569 -2.105 . . . . 0.0 113.604 -172.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.85 153.49 28.79 Favored Pre-proline 0 N--CA 1.451 -0.409 0 CA-C-N 122.798 2.545 . . . . 0.0 113.199 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.9 172.66 8.08 Favored 'Trans proline' 0 N--CA 1.45 -1.069 2 C-N-CA 127.566 5.51 . . . . 0.0 107.248 159.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -127.66 160.16 32.5 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 127.49 2.993 . . . . 0.0 108.877 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -134.36 156.88 47.71 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 115.958 -1.972 . . . . 0.0 111.888 -172.22 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 35' ' ' PHE . . . . . 0.402 ' CE1' ' HE2' ' L' ' 104' ' ' MET . 9.1 p90 -160.08 172.84 16.76 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 126.767 2.027 . . . . 0.0 106.042 178.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 36' ' ' THR . . . . . . . . . . . . 0.253 8.2 m -135.03 142.62 46.43 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 124.172 1.939 . . . . 0.0 115.446 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . . 57.6 mt -108.67 114.93 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 O-C-N 118.404 -2.685 . . . . 0.0 111.211 -175.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -87.97 138.13 31.72 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 170.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -117.51 134.49 54.8 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 113.772 -1.558 . . . . 0.0 109.312 -166.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 79.7 t -150.17 141.61 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 C-N-CA 128.933 2.893 . . . . 0.0 110.974 -174.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -115.56 -146.27 0.4 Allowed 'General case' 0 N--CA 1.449 -0.518 0 O-C-N 118.232 -2.792 . . . . 0.0 108.149 -174.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 66.3 p -70.91 -23.52 62.29 Favored 'General case' 0 N--CA 1.448 -0.546 1 O-C-N 116.13 -4.106 . . . . 0.0 116.795 -145.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . . 22.0 ttmt -116.93 8.64 13.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 120.838 -1.164 . . . . 0.0 110.836 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.41 3.62 90.47 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 120.914 3.126 . . . . 0.0 120.914 -171.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -77.74 123.89 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 125.676 1.59 . . . . 0.0 108.894 164.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . -38.03 152.54 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 119.076 2.991 . . . . 0.0 119.076 169.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -60.51 135.44 57.75 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.269 -2.769 . . . . 0.0 116.145 176.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 40.6 p -89.03 7.12 36.47 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.038 2.236 . . . . 0.0 117.038 -172.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -169.3 -149.78 0.08 Allowed 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.674 2.79 . . . . 0.0 106.635 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -155.2 -153.51 6.55 Favored Glycine 0 C--N 1.335 0.496 0 N-CA-C 121.009 3.164 . . . . 0.0 121.009 -172.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.92 44.38 97.5 Favored Glycine 0 CA--C 1.522 0.486 0 O-C-N 120.412 -1.64 . . . . 0.0 111.167 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -87.09 163.76 38.93 Favored Pre-proline 0 N--CA 1.449 -0.489 0 CA-C-N 121.556 2.678 . . . . 0.0 105.212 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -90.97 78.83 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 CA-C-O 127.642 3.101 . . . . 0.0 117.69 177.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -84.68 163.11 19.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.03 2.932 . . . . 0.0 110.643 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -156.88 144.82 19.31 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.993 0.901 . . . . 0.0 111.968 166.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.07 136.3 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 128.63 2.772 . . . . 0.0 114.977 174.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -143.11 125.4 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 130.201 3.401 . . . . 0.0 112.359 -165.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 37.6 mm -121.7 103.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 1 O-C-N 116.149 -4.094 . . . . 0.0 110.493 -164.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -96.63 137.85 35.09 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.768 2.027 . . . . 0.0 111.635 -174.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.2 -159.98 16.26 Favored Glycine 0 C--N 1.336 0.559 0 O-C-N 118.677 -2.515 . . . . 0.0 115.262 169.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -69.76 150.61 68.43 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 N-CA-C 119.241 2.747 . . . . 0.0 119.241 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t70 70.09 -95.75 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 127.989 2.516 . . . . 0.0 111.312 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.05 29.23 3.24 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-O 117.334 -1.815 . . . . 0.0 114.488 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 36.4 mt -90.12 124.79 35.11 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 122.52 3.16 . . . . 0.0 117.88 -175.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 10.0 t -146.53 136.27 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 115.656 1.724 . . . . 0.0 115.656 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 17.5 t -135.77 132.64 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 124.068 0.947 . . . . 0.0 109.007 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.84 123.95 27.73 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-O 116.005 -1.95 . . . . 0.0 115.639 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -93.57 150.33 20.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.403 2.281 . . . . 0.0 114.131 -170.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . 0.551 42.1 tttm -76.15 94.8 3.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 124.193 0.997 . . . . 0.0 111.962 -179.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 14.2 t -64.95 143.97 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 O-C-N 118.211 -2.805 . . . . 0.0 104.425 154.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 27.8 m -141.8 133.99 27.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 124.404 2.05 . . . . 0.0 110.278 159.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -68.93 125.06 25.44 Favored 'General case' 0 N--CA 1.449 -0.505 1 O-C-N 116.249 -4.032 . . . . 0.0 113.559 172.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -69.91 -16.69 63.27 Favored 'General case' 0 N--CA 1.449 -0.506 1 C-N-CA 131.745 4.018 . . . . 0.0 118.348 174.49 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 74' ' ' ASN . . . . . 0.452 ' OD1' ' HA ' ' L' ' 1' ' ' HIS 0.263 57.7 t30 67.07 45.34 1.75 Allowed 'General case' 0 N--CA 1.448 -0.54 0 O-C-N 118.851 -2.406 . . . . 0.0 112.248 -168.614 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -159.14 -2.86 0.08 Allowed 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 118.634 -2.541 . . . . 0.0 116.837 -177.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 101.39 -5.66 55.25 Favored Glycine 0 C--N 1.335 0.516 0 CA-C-O 115.494 -2.837 . . . . 0.0 112.025 -167.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 31.3 p -123.37 164.99 17.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 123.465 3.633 . . . . 0.0 115.577 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -132.86 137.74 46.79 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 126.568 2.418 . . . . 0.0 109.755 -175.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -91.52 150.83 20.59 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 108.597 -1.801 . . . . 0.0 108.597 168.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -141.36 146.73 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 O-C-N 127.4 2.47 . . . . 0.0 110.531 177.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.8 p -132.11 143.67 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 126.652 1.981 . . . . 0.0 106.346 -175.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 10.3 p90 -161.97 167.43 24.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 117.681 -3.137 . . . . 0.0 115.979 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -142.82 162.67 34.85 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 116.459 -1.734 . . . . 0.0 111.509 -170.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 84' ' ' ALA . . . . . 0.449 ' HB2' ' CD1' ' L' ' 90' ' ' TYR . . . -125.12 78.01 66.94 Favored Pre-proline 0 N--CA 1.449 -0.502 0 C-N-CA 125.671 1.589 . . . . 0.0 111.22 -178.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 85' ' ' PRO . . . . . 0.463 ' HD2' ' CE2' ' L' ' 90' ' ' TYR 0.417 73.5 Cg_exo -40.1 -23.37 0.12 Allowed 'Trans proline' 0 N--CA 1.449 -1.142 1 C-N-CA 128.38 6.053 . . . . 0.0 119.596 178.621 . . . . . . . . 4 3 . 1 . 001 nuclear orig full ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 85.6 t -123.32 132.52 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-O 117.368 -1.301 . . . . 0.0 108.867 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -60.59 85.29 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 131.024 3.73 . . . . 0.0 109.365 163.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 172.88 -171.72 44.59 Favored Glycine 0 CA--C 1.523 0.536 1 C-N-CA 132.56 4.886 . . . . 0.0 112.895 -160.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -71.5 140.26 49.88 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.059 1.744 . . . . 0.0 112.834 167.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 90' ' ' TYR . . . . . 0.463 ' CE2' ' HD2' ' L' ' 85' ' ' PRO . 14.1 m-85 -112.1 168.75 9.36 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 120.164 -1.585 . . . . 0.0 109.955 150.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -133.31 133.91 43.17 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.833 3.253 . . . . 0.0 112.39 -177.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.67 121.9 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 CA-C-O 125.448 2.547 . . . . 0.0 105.716 -169.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -135.75 118.72 16.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.937 2.495 . . . . 0.0 115.873 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.53 142.93 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 CA-C-N 113.16 -1.836 . . . . 0.0 112.718 -169.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -142.79 151.28 41.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 125.042 1.464 . . . . 0.0 108.712 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 4.0 tt -133.83 116.74 16.04 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 127.656 2.383 . . . . 0.0 106.412 173.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? 62.83 -49.7 0.19 Allowed 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 127.495 2.318 . . . . 0.0 116.864 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -170.43 16.64 0.06 OUTLIER Glycine 0 CA--C 1.523 0.535 0 C-N-CA 129.608 3.48 . . . . 0.0 114.495 162.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 21.6 m120 -128.05 149.23 70.42 Favored Pre-proline 0 N--CA 1.451 -0.397 0 C-N-CA 127.943 2.497 . . . . 0.0 111.538 -163.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -80.49 -176.24 3.09 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 121.138 1.225 . . . . 0.0 113.94 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 4.1 pt -139.17 -155.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 C-N-CA 129.809 3.244 . . . . 0.0 108.444 -177.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 9.0 pttm -136.17 172.75 12.55 Favored 'General case' 0 N--CA 1.45 -0.469 1 O-C-N 115.365 -4.584 . . . . 0.0 111.009 170.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 49.0 t30 80.28 -57.68 0.34 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 130.365 3.466 . . . . 0.0 106.799 -160.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 104' ' ' MET . . . . . 0.402 ' HE2' ' CE1' ' L' ' 35' ' ' PHE . 0.9 OUTLIER -83.06 154.35 67.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 126.403 2.314 . . . . 0.0 109.745 164.166 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -77.71 163.66 87.63 Favored 'Cis proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.666 -2.223 . . . . 0.0 113.359 -5.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 9.3 tp -162.98 147.68 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 113.24 -1.8 . . . . 0.0 113.941 -161.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.49 150.87 40.14 Favored 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 120.072 -1.643 . . . . 0.0 109.295 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 9.0 p -158.46 125.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 O-C-N 126.151 2.157 . . . . 0.0 111.019 -163.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -81.73 148.58 28.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 118.339 -0.838 . . . . 0.0 112.931 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 5.3 t -101.24 117.67 35.44 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 128.779 2.832 . . . . 0.0 108.125 -170.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 20.2 tt -133.95 163.04 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-O 116.205 -1.855 . . . . 0.0 114.631 178.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -77.49 75.52 4.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 121.601 2.001 . . . . 0.0 112.657 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.65 -116.1 5.91 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 107.066 -2.414 . . . . 0.0 107.066 171.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.11 1.84 50.48 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 167.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 65.4 t30 -73.52 124.79 26.55 Favored 'General case' 0 N--CA 1.449 -0.486 0 O-C-N 117.717 -3.115 . . . . 0.0 107.494 -172.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.94 23.87 70.87 Favored Glycine 0 CA--C 1.523 0.55 0 O-C-N 120.248 -1.533 . . . . 0.0 115.297 -172.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -76.15 172.47 12.77 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 121.6 2.7 . . . . 0.0 113.597 160.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 118' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -64.4 139.03 58.72 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 129.705 3.202 . . . . 0.0 111.764 160.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 5.7 m -98.89 9.54 43.27 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 116.578 -3.827 . . . . 0.0 109.41 -11.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 60.0 p -65.05 -15.9 62.86 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.968 2.951 . . . . 0.0 118.968 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -69.66 -20.9 63.57 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.041 2.536 . . . . 0.0 111.302 171.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.52 18.12 57.43 Favored Glycine 0 C--N 1.335 0.521 0 O-C-N 127.867 3.23 . . . . 0.0 114.11 -177.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 123' ' ' SER . . . . . . . . . . . . . 47.7 m -74.42 136.57 42.37 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 127.861 2.464 . . . . 0.0 114.47 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 9.1 m-30 -62.14 146.59 50.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 128.556 2.742 . . . . 0.0 108.977 -168.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 73.2 p -162.19 143.82 10.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 128.238 2.615 . . . . 0.0 111.282 177.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.259 11.6 m-85 -61.59 143.32 56.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 114.679 -2.582 . . . . 0.0 110.128 149.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 20.3 m -68.67 105.7 2.37 Favored 'General case' 0 N--CA 1.449 -0.515 0 O-C-N 126.155 2.16 . . . . 0.0 106.623 148.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 14.5 p -150.36 140.31 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 127.511 2.324 . . . . 0.0 110.12 -178.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . 68.0 5.83 4.81 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.053 2.242 . . . . 0.0 117.053 170.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -168.47 157.11 8.65 Favored 'General case' 0 N--CA 1.447 -0.579 1 C-N-CA 134.768 5.227 . . . . 0.0 111.025 -171.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . 0.376 5.8 ptpt -59.21 -26.17 64.62 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.632 2.086 . . . . 0.0 116.632 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -148.42 146.23 28.36 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 126.669 3.128 . . . . 0.0 110.593 167.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . 0.297 46.3 mttm 68.95 -155.1 0.16 Allowed 'General case' 0 N--CA 1.449 -0.518 0 O-C-N 118.703 -2.498 . . . . 0.0 113.948 170.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . 0.332 51.7 pttt -49.0 156.04 0.55 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 120.921 3.675 . . . . 0.0 120.921 163.015 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . -81.13 153.34 33.88 Favored Glycine 0 C--N 1.335 0.501 0 O-C-N 116.903 -3.623 . . . . 0.0 109.698 159.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -73.12 -9.97 59.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 120.089 3.366 . . . . 0.0 120.089 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 74.0 t -71.48 132.06 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.504 2.321 . . . . 0.0 112.952 160.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -49.56 -51.06 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 117.822 2.527 . . . . 0.0 117.822 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 6.7 m -107.31 87.5 2.52 Favored 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 126.22 2.2 . . . . 0.0 112.294 174.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 35.0 p90 -83.49 10.29 9.25 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 116.231 -1.842 . . . . 0.0 113.245 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 146.17 -155.77 26.67 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -169.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . -105.5 -9.26 33.71 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 128.622 3.01 . . . . 0.0 113.864 -164.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -153.81 136.02 14.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 120.148 1.974 . . . . 0.0 109.469 -176.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 144' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -69.68 -31.51 69.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 116.036 1.865 . . . . 0.0 116.036 173.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -162.84 176.11 10.56 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 116.38 -3.95 . . . . 0.0 108.79 -173.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 146' ' ' GLU . . . . . 0.556 ' CD ' HH11 ' L' ' 179' ' ' ARG . 33.7 tt0 -130.58 136.52 48.98 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 160.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 2.5 p -80.12 140.4 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 112.508 -2.133 . . . . 0.0 113.345 -161.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 148' ' ' SER . . . . . . . . . . . . . 70.4 m -120.8 -12.23 8.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 113.775 -1.557 . . . . 0.0 113.379 175.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 tp -82.92 155.77 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 O-C-N 117.652 -3.155 . . . . 0.0 113.638 165.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 150' ' ' THR . . . . . . . . . . . . . 21.8 p -93.36 174.02 7.42 Favored 'General case' 0 N--CA 1.45 -0.443 1 O-C-N 116.053 -4.155 . . . . 0.0 108.746 175.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . 70.54 170.59 9.28 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 128.02 2.724 . . . . 0.0 118.449 -176.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -77.54 169.72 20.51 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.546 3.497 . . . . 0.0 114.087 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -76.0 -12.24 60.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 118.397 -2.69 . . . . 0.0 117.501 -176.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -50.29 -40.26 47.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 123.541 0.737 . . . . 0.0 110.195 164.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -101.04 6.42 43.41 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.778 -1.826 . . . . 0.0 114.206 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 57.3 mt -108.51 135.24 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 116.642 -3.786 . . . . 0.0 107.016 177.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 55.0 m -86.82 134.31 33.56 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -109.39 140.27 43.3 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 124.972 2.32 . . . . 0.0 112.975 165.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -158.86 119.26 3.22 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 119.722 -1.861 . . . . 0.0 108.309 -170.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -153.03 158.62 42.25 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.406 0.891 . . . . 0.0 113.406 -165.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 6.0 pt -71.24 -22.19 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-O 114.745 -2.55 . . . . 0.0 110.009 163.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -163.23 140.67 7.64 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 129.428 3.091 . . . . 0.0 109.262 162.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -66.26 -13.4 60.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 130.036 3.334 . . . . 0.0 110.301 -168.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 2.9 mp0 -107.3 -14.61 14.84 Favored 'General case' 0 N--CA 1.447 -0.613 0 O-C-N 117.687 -3.133 . . . . 0.0 110.145 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -100.94 -45.1 5.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 118.442 2.756 . . . . 0.0 118.442 171.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . -70.49 -165.81 5.87 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 129.323 3.344 . . . . 0.0 113.275 167.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 1.5 t -169.52 177.29 4.67 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -52.06 170.09 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 127.126 2.17 . . . . 0.0 114.826 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 169' ' ' THR . . . . . . . . . . . . . 11.3 t -155.29 153.93 31.33 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 127.703 2.401 . . . . 0.0 109.387 -176.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -168.69 145.45 3.74 Favored 'General case' 0 N--CA 1.45 -0.426 1 C-N-CA 133.911 4.884 . . . . 0.0 116.721 -178.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -127.34 -5.55 5.98 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 114.493 -1.231 . . . . 0.0 113.971 -172.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -76.31 135.97 39.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 128.232 2.613 . . . . 0.0 116.163 172.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 3.6 m -161.31 150.91 16.77 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 123.29 2.768 . . . . 0.0 108.862 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 20.2 mt -95.0 171.13 8.95 Favored 'General case' 0 N--CA 1.449 -0.513 1 C-N-CA 131.868 4.067 . . . . 0.0 109.601 167.358 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 35.8 t -77.83 118.19 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 126.33 1.852 . . . . 0.0 106.398 167.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . 160.44 -163.01 33.76 Favored Glycine 0 C--N 1.336 0.544 0 O-C-N 118.052 -2.905 . . . . 0.0 114.642 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -143.14 77.99 1.59 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 131.24 3.816 . . . . 0.0 106.949 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 178' ' ' GLY . . . . . . . . . . . . . . . -102.35 160.57 17.41 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 128.258 2.837 . . . . 0.0 110.495 174.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 179' ' ' ARG . . . . . 0.556 HH11 ' CD ' ' L' ' 146' ' ' GLU . 6.6 ptm180 -167.89 162.53 13.6 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 130.203 3.401 . . . . 0.0 117.313 177.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -128.52 141.09 51.49 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 114.994 -2.432 . . . . 0.0 109.634 163.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 181' ' ' SER . . . . . . . . . . . . . 30.0 m -68.81 66.55 0.13 Allowed 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 123.991 3.087 . . . . 0.0 113.695 -176.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 1.3 t -173.01 170.97 4.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 117.523 2.416 . . . . 0.0 117.523 174.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -156.77 -132.12 1.45 Allowed Glycine 0 C--N 1.335 0.473 1 C-N-CA 132.711 4.958 . . . . 0.0 109.963 175.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 5.0 t -132.69 101.08 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 117.585 -3.303 . . . . 0.0 110.317 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -52.37 117.31 2.75 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-O 117.706 -1.14 . . . . 0.0 110.265 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 11.1 tp -84.52 -38.57 19.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 128.982 3.926 . . . . 0.0 107.864 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -155.36 149.65 25.94 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.414 3.085 . . . . 0.0 107.956 179.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . 86.99 156.09 28.79 Favored Glycine 0 CA--C 1.522 0.52 0 CA-C-O 124.912 2.395 . . . . 0.0 113.668 173.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -55.64 113.9 1.64 Allowed 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 110.33 -2.935 . . . . 0.0 117.682 -175.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -71.35 125.71 27.72 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.255 174.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 16.8 mm 44.73 120.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 130.583 3.553 . . . . 0.0 111.049 -160.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -98.19 139.6 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 113.218 -1.81 . . . . 0.0 110.951 -164.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 111.5 -149.7 18.0 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 114.344 -1.298 . . . . 0.0 113.509 -175.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 1.1 t -151.15 142.01 15.01 Favored Pre-proline 0 N--CA 1.449 -0.5 0 C-N-CA 131.591 3.956 . . . . 0.0 112.583 -171.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -89.82 150.33 4.98 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 120.436 0.758 . . . . 0.0 110.956 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -157.2 145.96 19.78 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 120.964 3.69 . . . . 0.0 120.964 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -92.78 150.06 20.89 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 120.483 -1.386 . . . . 0.0 112.058 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -83.19 135.48 34.77 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 120.433 -1.417 . . . . 0.0 111.14 -173.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 63.0 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 115.265 1.58 . . . . 0.0 115.265 155.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 49.8 mt -110.71 137.56 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 120.626 -1.296 . . . . 0.0 111.323 162.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 126.17 144.47 6.15 Favored Glycine 0 CA--C 1.523 0.555 0 C-N-CA 125.332 1.444 . . . . 0.0 115.228 -169.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -156.16 165.45 36.37 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 123.224 1.488 . . . . 0.0 108.925 176.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -92.98 150.59 20.44 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 117.441 -3.287 . . . . 0.0 107.842 175.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 16.1 mt -91.78 167.0 12.47 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 128.656 2.783 . . . . 0.0 106.739 2.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -139.55 -13.21 1.14 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.079 1.352 . . . . 0.0 114.459 162.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 5.6 t -100.45 138.89 36.91 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.601 1.96 . . . . 0.0 113.303 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 66.5 p -123.47 166.78 17.02 Favored Pre-proline 0 N--CA 1.448 -0.541 0 C-N-CA 129.494 3.118 . . . . 0.0 112.328 -173.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -50.12 149.48 11.91 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 124.576 3.517 . . . . 0.0 116.803 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.61 -19.67 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 O-C-N 125.559 1.787 . . . . 0.0 112.055 -176.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -159.75 159.47 32.83 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 127.185 2.194 . . . . 0.0 106.572 157.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 29.2 mm -82.18 119.72 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 126.84 2.056 . . . . 0.0 107.196 169.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 3.2 m -78.98 148.19 32.66 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 126.019 2.074 . . . . 0.0 115.21 -172.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -70.54 117.68 12.38 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 170.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -72.15 -20.42 61.61 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.464 2.394 . . . . 0.0 117.464 175.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -151.16 172.27 16.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.617 1.567 . . . . 0.0 109.907 -170.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -118.82 -41.18 0.61 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-O 125.055 2.475 . . . . 0.0 115.313 161.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 29.5 mm 85.74 -66.09 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.47 1 C-N-CA 132.124 4.17 . . . . 0.0 111.437 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -49.7 122.14 6.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 129.478 3.111 . . . . 0.0 108.263 -162.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.98 -167.42 1.39 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 114.624 -2.608 . . . . 0.0 116.115 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -57.47 127.45 44.98 Favored Glycine 0 CA--C 1.522 0.471 0 O-C-N 126.348 2.28 . . . . 0.0 110.855 -173.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo . . . . . 0 C--O 1.251 1.135 1 C-N-CA 127.641 5.561 . . . . 0.0 114.577 179.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 1' ' ' HIS . . . . . . . . . . . . . 22.8 t-80 . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 117.507 -1.235 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 33.7 m-70 -128.04 155.2 44.71 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 124.909 1.381 . . . . 0.0 108.871 159.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -70.72 162.72 28.56 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 124.272 1.987 . . . . 0.0 113.818 160.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 24.5 m-70 -59.23 154.29 16.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 O-C-N 118.234 -2.791 . . . . 0.0 111.49 166.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -71.16 135.31 47.53 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 118.971 -2.331 . . . . 0.0 109.562 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 4.9 m-70 -138.85 129.82 26.57 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 110.923 -2.853 . . . . 0.0 111.632 173.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.61 28.77 4.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 131.297 3.839 . . . . 0.0 113.776 -178.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 2.2 p -166.91 150.01 6.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.999 2.12 . . . . 0.0 110.199 -172.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -107.96 102.03 43.8 Favored Pre-proline 0 N--CA 1.451 -0.412 0 N-CA-C 115.887 1.81 . . . . 0.0 115.887 172.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . 0.271 53.1 Cg_exo -38.13 140.54 0.31 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 123.013 2.475 . . . . 0.0 118.257 161.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -90.33 169.85 11.35 Favored Pre-proline 0 N--CA 1.451 -0.387 0 O-C-N 126.395 2.31 . . . . 0.0 109.507 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -62.91 137.61 63.63 Favored 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 122.606 2.204 . . . . 0.0 117.757 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 5.5 t -81.78 115.36 20.96 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 127.9 3.25 . . . . 0.0 111.349 155.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -50.05 -37.49 33.61 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 129.061 2.944 . . . . 0.0 112.919 166.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -63.77 -49.98 70.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 128.314 2.646 . . . . 0.0 111.6 176.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -113.53 -23.63 9.69 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.45 1.9 . . . . 0.0 113.452 -151.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 73.0 m -70.18 146.11 51.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 120.327 -1.483 . . . . 0.0 109.023 173.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 24.8 p90 -154.94 176.53 12.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.571 1.948 . . . . 0.0 111.492 -164.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -142.47 140.72 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 125.595 1.81 . . . . 0.0 110.748 172.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -147.26 134.92 21.05 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 125.884 2.754 . . . . 0.0 110.351 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.99 -168.11 41.08 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 125.306 2.615 . . . . 0.0 112.528 157.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -54.24 -34.37 60.56 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-N 112.428 -1.886 . . . . 0.0 110.526 178.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -46.41 -16.77 0.19 Allowed Glycine 0 C--N 1.335 0.482 0 C-N-CA 127.801 2.62 . . . . 0.0 118.901 166.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 13.5 mt -119.26 21.59 12.17 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.149 2.18 . . . . 0.0 114.236 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -133.19 -58.42 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-O 121.737 0.779 . . . . 0.0 110.525 -171.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 35.1 tttt -149.23 98.89 2.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.624 1.202 . . . . 0.0 108.659 -154.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 37.9 t -141.52 131.92 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 114.278 -2.773 . . . . 0.0 111.344 -152.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -127.2 149.54 49.94 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 119.58 3.178 . . . . 0.0 119.58 -158.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -63.35 -14.18 47.16 Favored 'General case' 0 N--CA 1.448 -0.542 0 O-C-N 124.694 1.246 . . . . 0.0 113.114 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . 0.263 14.4 p-10 -113.02 3.33 16.12 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.741 2.126 . . . . 0.0 116.741 169.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.41 137.91 11.32 Favored Pre-proline 0 N--CA 1.45 -0.441 1 N-CA-C 122.177 4.14 . . . . 0.0 122.177 -167.537 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -77.78 160.49 30.97 Favored 'Trans proline' 0 N--CA 1.447 -1.22 1 C-N-CA 128.078 5.852 . . . . 0.0 111.178 -172.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -141.35 152.38 44.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 126.206 2.191 . . . . 0.0 113.795 -173.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 34' ' ' GLU . . . . . 0.459 ' HA ' ' O ' ' L' ' 80' ' ' VAL . 11.3 mt-10 -128.0 152.32 48.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 124.912 1.285 . . . . 0.0 111.583 -167.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . 0.305 4.1 p90 -160.44 153.86 22.12 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.692 2.397 . . . . 0.0 106.735 -173.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 1.2 m -121.53 129.04 52.65 Favored 'General case' 0 N--CA 1.448 -0.535 0 O-C-N 123.626 0.579 . . . . 0.0 110.269 -169.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.314 4.1 mt -73.93 104.79 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 166.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -91.92 115.28 27.93 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 124.284 1.993 . . . . 0.0 108.923 168.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.14 145.71 28.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 118.347 -2.721 . . . . 0.0 109.009 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t -140.02 129.05 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 110.292 -3.14 . . . . 0.0 110.552 -175.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 35.2 p30 -75.31 176.05 7.79 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 127.84 3.686 . . . . 0.0 117.856 -177.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 12.1 p -50.83 -12.35 0.1 Allowed 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 110.32 -3.127 . . . . 0.0 117.717 173.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . 0.264 21.6 pttm -114.27 4.09 15.33 Favored 'General case' 0 N--CA 1.449 -0.516 0 O-C-N 125.307 1.629 . . . . 0.0 111.464 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.59 12.56 62.51 Favored Glycine 0 CA--C 1.523 0.541 0 C-N-CA 127.517 2.484 . . . . 0.0 117.972 -175.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . . 3.1 t -115.79 119.15 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 126.272 1.829 . . . . 0.0 113.095 -174.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . -24.43 139.73 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 117.996 2.591 . . . . 0.0 117.996 167.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . 0.271 11.1 mmm180 -76.83 153.37 34.91 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.252 1.821 . . . . 0.0 110.603 -177.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 43.2 p -124.41 -1.53 8.09 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 128.513 2.725 . . . . 0.0 115.265 -165.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -161.52 167.29 25.72 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -168.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.63 175.56 40.53 Favored Glycine 0 C--N 1.335 0.498 1 N-CA-C 125.415 4.926 . . . . 0.0 125.415 175.145 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 66.4 49.08 59.07 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 125.745 1.641 . . . . 0.0 112.544 161.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -83.38 150.38 60.25 Favored Pre-proline 0 N--CA 1.449 -0.512 0 CA-C-O 115.014 -2.422 . . . . 0.0 116.948 151.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -91.7 59.74 0.96 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 106.833 -2.026 . . . . 0.0 106.833 -164.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -69.7 155.7 40.11 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 117.929 2.566 . . . . 0.0 117.929 156.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.98 146.78 31.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 116.516 -1.707 . . . . 0.0 109.78 178.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -125.64 140.26 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 119.979 1.263 . . . . 0.0 111.882 -173.28 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.96 29.55 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 114.272 -2.775 . . . . 0.0 111.956 -176.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 15.7 mt -135.75 134.04 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 1 C-N-CA 131.898 4.079 . . . . 0.0 110.13 -178.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -120.91 148.69 43.71 Favored 'General case' 0 N--CA 1.45 -0.444 1 C-N-CA 133.445 4.698 . . . . 0.0 110.901 -178.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -148.63 -162.61 10.34 Favored Glycine 0 CA--C 1.522 0.504 0 CA-C-O 124.714 2.285 . . . . 0.0 114.931 -171.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.42 149.37 86.63 Favored 'Trans proline' 0 N--CA 1.448 -1.153 1 C-N-CA 125.403 4.069 . . . . 0.0 110.892 -178.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.83 -125.61 0.95 Allowed 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.724 2.41 . . . . 0.0 109.461 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -89.83 -9.26 66.34 Favored Glycine 0 C--N 1.335 0.506 1 O-C-N 114.457 -5.152 . . . . 0.0 111.314 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 8.8 tp -62.32 124.58 21.28 Favored 'General case' 0 N--CA 1.447 -0.593 0 O-C-N 118.358 -2.848 . . . . 0.0 113.467 -155.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 15.4 m -108.51 156.49 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 150.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 89.0 t -122.64 136.22 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 125.609 1.818 . . . . 0.0 110.084 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -89.96 118.04 29.23 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -63.22 147.04 52.07 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 118.564 -2.585 . . . . 0.0 116.922 172.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -116.92 119.94 36.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 64.2 t -112.62 143.99 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 CA-C-O 123.55 1.643 . . . . 0.0 108.434 -173.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -139.77 117.53 11.63 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 114.47 -1.241 . . . . 0.0 112.253 170.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -81.27 121.88 26.73 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 129.052 2.941 . . . . 0.0 109.456 178.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -77.61 -5.38 50.08 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 115.704 -2.093 . . . . 0.0 115.274 175.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 71.22 24.3 3.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 125.628 3.831 . . . . 0.0 112.092 -175.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -149.16 -12.52 0.31 Allowed 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 117.103 -3.498 . . . . 0.0 111.028 -160.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 115.86 5.34 18.07 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 120.103 2.801 . . . . 0.0 120.103 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 18.8 p -136.15 157.34 47.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.342 3.057 . . . . 0.0 111.391 170.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -130.43 140.1 50.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 116.666 -1.635 . . . . 0.0 108.956 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -77.32 132.89 12.49 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 127.346 2.403 . . . . 0.0 114.86 160.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 80' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' L' ' 34' ' ' GLU . 2.6 t -126.14 128.52 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 127.733 2.666 . . . . 0.0 115.65 174.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -136.4 143.04 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 120.645 -1.284 . . . . 0.0 113.225 174.444 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -151.04 -178.94 6.9 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 114.79 -1.096 . . . . 0.0 111.607 175.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -137.27 107.22 6.29 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.56 1.944 . . . . 0.0 111.338 178.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 84' ' ' ALA . . . . . . . . . . . . 0.28 . . -68.63 110.43 5.87 Favored Pre-proline 0 N--CA 1.45 -0.453 0 C-N-CA 124.843 1.257 . . . . 0.0 109.54 164.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 85' ' ' PRO . . . . . . . . . . . . 0.264 50.0 Cg_endo -67.29 -10.02 27.22 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 126.546 4.831 . . . . 0.0 117.866 -167.987 . . . . . . . . 3 2 . 1 . 002 nuclear orig full ' L' L ' 86' ' ' VAL . . . . . 0.425 HG23 ' HH ' ' L' ' 90' ' ' TYR . 0.0 OUTLIER -153.61 154.16 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-N 119.827 1.194 . . . . 0.0 110.209 -175.923 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -43.97 130.15 5.88 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 150.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 145.37 -149.65 21.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 127.618 2.532 . . . . 0.0 111.643 -174.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -121.98 153.93 37.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 127.033 2.133 . . . . 0.0 113.391 -178.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 90' ' ' TYR . . . . . 0.425 ' HH ' HG23 ' L' ' 86' ' ' VAL . 52.6 m-85 -152.27 156.39 39.59 Favored 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.332 1.853 . . . . 0.0 108.398 -172.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . 0.325 2.9 t30 -133.55 114.32 13.43 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.007 1.323 . . . . 0.0 111.512 -165.021 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 20.5 t -108.55 139.17 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-N 112.972 -1.922 . . . . 0.0 110.246 -164.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -155.1 106.49 2.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.659 2.784 . . . . 0.0 117.162 -173.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 33.1 t -94.56 142.63 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 111.899 -2.41 . . . . 0.0 108.873 159.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 35.0 p -137.42 -144.36 0.19 Allowed 'General case' 0 N--CA 1.451 -0.384 0 O-C-N 128.946 3.903 . . . . 0.0 117.431 -173.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 6.0 tp -150.72 154.52 37.54 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 123.667 2.94 . . . . 0.0 115.016 168.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 33.3 ttm180 -64.36 94.88 0.12 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 124.202 1.953 . . . . 0.0 109.856 142.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . 121.41 -153.16 16.71 Favored Glycine 0 N--CA 1.448 -0.504 1 C-N-CA 131.032 4.158 . . . . 0.0 110.295 -171.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -71.47 113.87 23.21 Favored Pre-proline 0 N--CA 1.449 -0.487 0 CA-C-O 113.358 -3.21 . . . . 0.0 108.551 -170.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -74.63 160.29 41.4 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 O-C-N 127.079 3.147 . . . . 0.0 114.23 -165.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.7 pt -90.07 138.81 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 O-C-N 117.064 -3.522 . . . . 0.0 112.071 -159.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 23.0 mmtt -92.59 -178.73 4.97 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-O 117.352 -1.309 . . . . 0.0 109.396 -173.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 72.64 -44.44 0.59 Allowed 'General case' 0 N--CA 1.448 -0.537 0 CA-C-O 126.797 3.189 . . . . 0.0 110.894 -154.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 28.0 mmt -69.74 155.25 93.84 Favored Pre-proline 0 N--CA 1.448 -0.541 0 CA-C-O 112.347 -3.692 . . . . 0.0 107.741 153.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -75.13 159.92 97.19 Favored 'Cis proline' 0 N--CA 1.447 -1.213 0 O-C-N 125.453 2.291 . . . . 0.0 110.481 -18.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 12.5 tt -151.55 141.05 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.163 -1.38 . . . . 0.0 112.709 -174.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -95.62 136.14 36.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.659 3.183 . . . . 0.0 113.692 173.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.27 143.25 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 128.979 2.911 . . . . 0.0 103.284 -163.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -111.75 147.4 35.72 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 126.321 1.848 . . . . 0.0 113.807 177.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 41.0 t -127.43 138.96 53.11 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 125.747 1.905 . . . . 0.0 106.356 -172.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 1.3 pp -136.19 158.84 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 128.125 2.57 . . . . 0.0 110.413 -177.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . 0.252 14.5 tt0 -56.72 125.42 22.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -177.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . -108.3 141.64 15.83 Favored Glycine 0 C--N 1.336 0.544 0 CA-C-O 117.534 -1.703 . . . . 0.0 111.593 147.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.61 129.41 41.94 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 116.46 2.022 . . . . 0.0 116.46 -177.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -56.62 -54.59 44.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 O-C-N 125.548 1.78 . . . . 0.0 115.53 174.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . -105.51 -151.78 20.38 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 126.882 2.182 . . . . 0.0 112.541 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -80.11 156.37 27.06 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-O 118.647 -0.692 . . . . 0.0 112.347 157.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 118' ' ' ASP . . . . . . . . . . . . 0.252 35.3 t70 -160.96 142.14 11.73 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.087 -166.589 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 51.1 m -63.88 -43.51 95.82 Favored 'General case' 0 N--CA 1.45 -0.444 1 O-C-N 113.808 -5.558 . . . . 0.0 112.356 1.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 90.0 p 179.43 169.1 1.07 Allowed 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.132 -2.23 . . . . 0.0 108.283 -163.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -92.59 130.17 38.31 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 122.785 2.539 . . . . 0.0 108.772 161.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . -169.96 -152.07 7.76 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 127.282 2.372 . . . . 0.0 116.538 -172.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 123' ' ' SER . . . . . . . . . . . . . 61.6 p -157.43 -103.82 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 126.292 1.819 . . . . 0.0 113.408 -174.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . 0.32 26.3 p90 -145.2 150.03 35.99 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 119.554 3.168 . . . . 0.0 119.554 -176.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 3.4 p -135.9 153.56 51.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 118.077 -2.89 . . . . 0.0 112.684 -166.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.338 56.9 t80 -66.22 154.51 39.64 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -174.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 12.9 t -60.42 149.24 34.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 130.256 3.422 . . . . 0.0 112.574 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 21.6 m -71.21 135.79 27.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 CA-C-N 112.599 -2.091 . . . . 0.0 110.093 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . -163.19 157.39 20.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.405 1.482 . . . . 0.0 111.902 173.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -78.31 153.55 31.65 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 121.976 0.893 . . . . 0.0 111.667 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -52.46 -24.26 7.6 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 120.291 -1.505 . . . . 0.0 112.277 -172.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -85.19 -16.19 41.16 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 120.592 -1.318 . . . . 0.0 113.444 -176.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -89.32 134.25 34.14 Favored 'General case' 0 N--CA 1.449 -0.516 0 O-C-N 119.446 -2.034 . . . . 0.0 113.843 178.093 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . . 48.9 tptt -68.3 125.03 25.13 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 123.92 1.819 . . . . 0.0 112.601 -179.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . -104.75 165.62 14.67 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 112.364 -2.198 . . . . 0.0 117.411 167.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -110.04 134.31 52.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 126.411 1.884 . . . . 0.0 111.393 -175.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 4.3 t -109.2 -34.54 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 127.062 2.145 . . . . 0.0 116.374 -176.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 59.6 mttt -71.04 -20.4 62.39 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 118.915 2.932 . . . . 0.0 118.915 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 17.8 m -107.32 145.53 32.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.11 3.364 . . . . 0.0 110.346 -178.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 79.4 t80 -142.27 131.78 23.81 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 125.403 2.525 . . . . 0.0 109.396 179.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.08 -163.84 51.01 Favored Glycine 0 CA--C 1.523 0.54 0 O-C-N 119.961 -1.712 . . . . 0.0 108.943 -170.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . 70.89 -135.57 24.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 118.022 1.969 . . . . 0.0 118.022 -165.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -91.31 -44.26 9.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 112.245 -1.977 . . . . 0.0 111.118 -160.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 144' ' ' LYS . . . . . 0.422 ' HE2' ' O ' ' L' ' 183' ' ' GLY . 89.4 mttt -80.05 31.7 0.27 Allowed 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 118.397 -2.689 . . . . 0.0 113.965 175.191 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -117.41 150.5 38.78 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 117.877 -3.015 . . . . 0.0 113.808 172.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 146' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -100.11 140.06 34.88 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 117.594 -3.191 . . . . 0.0 105.816 162.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 2.3 t -117.69 97.13 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-N 121.671 2.032 . . . . 0.0 107.07 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 148' ' ' SER . . . . . . . . . . . . 0.295 20.1 m -78.85 -7.63 58.08 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 127.193 2.197 . . . . 0.0 116.288 175.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . . 32.5 pt -92.44 167.88 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 119.519 -1.988 . . . . 0.0 113.464 164.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 150' ' ' THR . . . . . . . . . . . . . 22.3 m -94.53 95.89 9.1 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.16 -2.904 . . . . 0.0 103.16 169.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . 164.85 170.06 29.3 Favored Glycine 0 C--N 1.335 0.524 0 O-C-N 126.45 2.344 . . . . 0.0 115.502 -175.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -85.41 166.27 10.69 Favored 'Trans proline' 0 N--CA 1.449 -1.135 1 C-N-CA 126.125 4.55 . . . . 0.0 111.59 -170.118 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -133.01 80.0 1.87 Allowed 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 112.374 -2.194 . . . . 0.0 112.445 173.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -68.08 131.09 44.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 O-C-N 118.093 -2.879 . . . . 0.0 110.426 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -63.52 121.98 15.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 118.28 2.696 . . . . 0.0 118.28 176.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 4.8 tt -138.65 160.14 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-O 124.004 1.859 . . . . 0.0 114.167 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 28.6 m -78.89 131.3 36.37 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 115.025 -2.417 . . . . 0.0 108.833 173.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 22.4 tp -61.8 142.62 57.2 Favored 'General case' 0 N--CA 1.451 -0.406 1 C-N-CA 132.264 4.226 . . . . 0.0 109.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -151.66 142.49 22.92 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 127.113 2.165 . . . . 0.0 110.336 178.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -75.54 69.75 2.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.43 3.492 . . . . 0.0 113.831 175.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 15.1 pt -78.44 162.05 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 130.52 3.528 . . . . 0.0 111.279 -171.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -64.69 143.36 57.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 124.948 1.405 . . . . 0.0 114.21 163.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 10.7 t-20 -62.38 -18.12 60.77 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 112.606 -3.568 . . . . 0.0 114.079 173.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 -140.49 -29.54 0.68 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 125.549 3.795 . . . . 0.0 119.157 -177.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -75.35 111.19 10.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 114.247 1.203 . . . . 0.0 114.247 167.294 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . 98.99 -15.2 60.9 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 117.797 1.879 . . . . 0.0 117.797 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 6.7 m -46.89 -27.3 1.2 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 129.771 3.229 . . . . 0.0 117.396 177.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 7.4 p90 -55.08 -24.87 27.61 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 121.348 3.833 . . . . 0.0 121.348 170.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 169' ' ' THR . . . . . . . . . . . . . 59.0 p -75.33 -41.82 55.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 121.458 1.935 . . . . 0.0 115.798 176.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -62.44 174.48 0.96 Allowed 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 131.114 3.766 . . . . 0.0 117.028 173.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -107.52 125.63 51.52 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 111.853 -2.431 . . . . 0.0 104.781 -170.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 70.9 t80 -154.6 111.1 3.27 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.597 1.544 . . . . 0.0 110.308 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 85.0 p -159.5 -176.13 5.59 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 130.22 3.408 . . . . 0.0 110.285 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 12.3 tp -70.38 115.32 9.43 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 112.668 -2.06 . . . . 0.0 113.818 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.86 135.26 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.347 1.459 . . . . 0.0 110.315 172.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . -138.25 -145.01 4.76 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 129.944 3.64 . . . . 0.0 111.884 173.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -72.11 132.16 43.81 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 124.6 2.143 . . . . 0.0 114.024 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 178' ' ' GLY . . . . . . . . . . . . . . . -53.22 130.78 41.52 Favored Glycine 0 CA--C 1.523 0.569 0 C-N-CA 129.19 3.281 . . . . 0.0 114.099 174.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 179' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -132.43 147.59 52.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 O-C-N 128.009 2.829 . . . . 0.0 111.757 172.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 74.55 154.68 0.15 Allowed 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 119.579 -1.951 . . . . 0.0 111.901 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 181' ' ' SER . . . . . . . . . . . . 0.253 23.2 t 150.96 132.65 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 129.418 3.087 . . . . 0.0 112.305 163.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 38.1 m -95.19 151.74 18.96 Favored 'General case' 0 N--CA 1.449 -0.493 1 C-N-CA 131.739 4.015 . . . . 0.0 108.104 161.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 183' ' ' GLY . . . . . 0.422 ' O ' ' HE2' ' L' ' 144' ' ' LYS . . . -88.25 -175.04 47.68 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.911 -176.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 13.5 m -83.68 144.9 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 O-C-N 126.735 2.08 . . . . 0.0 111.732 155.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 53.5 tttp -69.05 130.26 42.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.703 2.401 . . . . 0.0 114.987 168.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 37.6 mt -100.42 -41.2 7.11 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 117.684 2.475 . . . . 0.0 117.684 -176.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -78.64 171.8 14.61 Favored 'General case' 0 N--CA 1.449 -0.509 1 C-N-CA 133.488 4.715 . . . . 0.0 113.457 -173.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -85.94 -154.79 24.59 Favored Glycine 0 C--N 1.336 0.534 0 C-N-CA 126.455 1.978 . . . . 0.0 109.592 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 18.2 ttmt -79.22 0.13 29.77 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 116.743 -1.599 . . . . 0.0 110.937 -174.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -62.35 148.04 46.47 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 122.478 2.399 . . . . 0.0 109.286 171.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 4.7 mt -131.28 129.43 62.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 1 C-N-CA 133.797 4.839 . . . . 0.0 106.997 178.02 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -100.16 141.67 32.67 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 127.356 2.91 . . . . 0.0 111.554 156.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 102.54 9.21 41.58 Favored Glycine 0 CA--C 1.523 0.588 0 CA-C-N 122.202 2.274 . . . . 0.0 117.964 166.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 46.2 m -65.39 134.23 95.6 Favored Pre-proline 0 N--CA 1.448 -0.557 1 CA-C-O 111.53 -4.081 . . . . 0.0 111.985 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -36.28 122.61 0.3 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 1 C-N-CA 128.439 6.092 . . . . 0.0 113.412 167.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -98.21 162.4 13.22 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.369 1.467 . . . . 0.0 109.668 172.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -64.72 148.41 51.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -164.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 91.6 mm-40 -117.56 143.27 46.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 O-C-N 119.545 -1.972 . . . . 0.0 109.242 163.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.1 139.91 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 119.031 -2.293 . . . . 0.0 111.331 -168.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 57.8 tp -146.42 117.5 7.79 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 110.474 -3.057 . . . . 0.0 108.872 168.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 81.12 173.93 48.28 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 127.195 2.331 . . . . 0.0 114.627 175.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 27.2 t30 -110.97 134.6 52.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -146.28 150.11 35.15 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 115.411 -2.233 . . . . 0.0 112.178 -170.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 55.6 mt -67.45 161.51 25.18 Favored 'General case' 0 N--CA 1.449 -0.483 1 C-N-CA 134.181 4.993 . . . . 0.0 109.836 0.279 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 55.7 t80 -62.51 137.82 58.34 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 126.13 2.871 . . . . 0.0 107.529 -177.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.98 119.56 33.7 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 117.356 -3.34 . . . . 0.0 112.201 -171.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 4.3 m -79.17 130.18 70.17 Favored Pre-proline 0 N--CA 1.451 -0.415 0 O-C-N 117.571 -3.206 . . . . 0.0 109.646 -162.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -64.3 125.17 14.59 Favored 'Trans proline' 0 N--CA 1.448 -1.185 1 C-N-CA 125.327 4.018 . . . . 0.0 109.267 173.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 6.9 p -163.07 159.36 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 130.171 3.388 . . . . 0.0 111.353 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 9.1 p90 -80.81 137.68 36.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.826 2.05 . . . . 0.0 113.735 177.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 40.9 mm -67.67 125.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 119.462 -2.024 . . . . 0.0 107.646 171.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 212' ' ' SER . . . . . . . . . . . . 0.255 40.2 m -87.09 156.88 19.54 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 124.082 3.128 . . . . 0.0 110.81 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -56.65 151.88 13.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 131.096 3.758 . . . . 0.0 118.168 171.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -114.93 156.95 24.07 Favored 'General case' 0 N--CA 1.447 -0.579 0 O-C-N 117.44 -3.288 . . . . 0.0 110.012 159.267 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . 0.283 12.5 pt20 -69.27 154.53 41.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 119.916 1.235 . . . . 0.0 112.95 -175.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -86.09 -154.08 23.51 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 130.361 3.839 . . . . 0.0 117.497 160.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . 0.306 1.4 pp -127.33 -7.82 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 129.985 3.314 . . . . 0.0 113.268 -178.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -60.07 126.31 27.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -111.66 -146.2 0.4 Allowed 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 131.501 3.92 . . . . 0.0 114.228 175.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -96.96 134.11 11.64 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -177.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.449 -1.127 1 C-N-CA 129.827 7.018 . . . . 0.0 112.234 169.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 1' ' ' HIS . . . . . . . . . . . . . 52.4 t-80 . . . . . 0 N--CA 1.471 0.6 0 CA-C-O 122.688 1.232 . . . . 0.0 113.152 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -67.8 137.95 55.78 Favored 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 117.594 -3.191 . . . . 0.0 115.475 178.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 126.903 2.081 . . . . 0.0 109.87 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 48.3 t60 -85.44 -46.7 10.66 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 166.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -75.16 172.29 12.65 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.22 -2.175 . . . . 0.0 113.13 -174.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 3.9 t60 -75.09 -54.73 6.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 120.414 -1.429 . . . . 0.0 109.044 -165.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.42 140.03 37.52 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.415 2.686 . . . . 0.0 110.737 -173.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 86.9 p -176.53 147.58 0.67 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 117.386 2.365 . . . . 0.0 117.386 -155.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -128.06 124.5 23.13 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 128.628 2.771 . . . . 0.0 113.056 -173.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -57.65 157.53 22.98 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 124.204 3.27 . . . . 0.0 115.401 -177.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.54 -10.19 0.11 Allowed Pre-proline 0 N--CA 1.45 -0.441 0 CA-C-O 116.149 -1.882 . . . . 0.0 114.411 165.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -66.9 -176.54 0.77 Allowed 'Trans proline' 0 N--CA 1.449 -1.118 1 C-N-CA 126.438 4.758 . . . . 0.0 115.166 155.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 2.6 p -158.51 154.81 27.34 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 123.064 1.411 . . . . 0.0 112.941 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.81 -53.18 60.96 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 112.605 -2.089 . . . . 0.0 112.725 -165.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 16.8 mp0 -48.61 -20.86 0.49 Allowed 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 129.416 3.086 . . . . 0.0 118.741 177.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 16' ' ' HIS . . . . . 0.442 ' C ' ' HE2' ' L' ' 102' ' ' LYS . 14.4 m80 -117.2 -54.79 2.38 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 127.976 2.511 . . . . 0.0 109.923 -170.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 17' ' ' SER . . . . . . . . . . . . 0.721 0.5 OUTLIER -67.1 149.87 49.96 Favored 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.84 -4.913 . . . . 0.0 112.642 -165.154 . . . . . . . . 4 3 . 1 . 003 nuclear orig full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 22.0 p90 -163.09 172.52 14.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 128.093 2.557 . . . . 0.0 108.883 -164.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -139.51 147.89 41.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 128.018 2.527 . . . . 0.0 110.387 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -149.98 144.18 25.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 125.423 1.702 . . . . 0.0 115.41 -175.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . 138.03 -166.19 25.23 Favored Glycine 0 C--N 1.335 0.527 0 CA-C-O 124.597 2.221 . . . . 0.0 115.066 168.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . 0.285 55.2 tt0 -42.46 -62.97 0.84 Allowed 'General case' 0 N--CA 1.448 -0.54 1 C-N-CA 131.948 4.099 . . . . 0.0 109.72 -178.732 . . . . . . . . 3 2 . 1 . 003 nuclear orig full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.73 14.98 0.07 OUTLIER Glycine 0 C--N 1.336 0.572 0 N-CA-C 120.404 2.922 . . . . 0.0 120.404 178.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 75.3 mt -122.57 0.92 9.45 Favored 'General case' 0 N--CA 1.449 -0.512 1 C-N-CA 132.246 4.218 . . . . 0.0 112.572 167.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 1.4 p -141.4 -15.26 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 124.405 3.275 . . . . 0.0 112.466 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -162.87 92.54 0.78 Allowed 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 124.649 2.166 . . . . 0.0 115.614 -160.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 27' ' ' VAL . . . . . . . . . . . . 0.305 12.8 p -147.78 147.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 O-C-N 119.467 -2.02 . . . . 0.0 113.836 179.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -137.1 -170.89 2.81 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 -170.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -86.09 -44.68 12.06 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 117.994 -2.942 . . . . 0.0 113.324 -175.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 47.5 p-10 -106.28 30.62 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 123.589 1.661 . . . . 0.0 111.456 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.87 125.06 2.42 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 115.933 -1.984 . . . . 0.0 114.693 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -85.44 175.35 6.31 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 123.803 3.002 . . . . 0.0 113.762 -175.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -148.39 170.67 17.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 177.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -142.31 155.06 45.17 Favored 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 128.235 2.614 . . . . 0.0 116.025 -170.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -163.14 166.02 23.9 Favored 'General case' 0 N--CA 1.448 -0.533 1 O-C-N 114.688 -5.007 . . . . 0.0 108.79 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 21.3 m -131.82 133.82 45.11 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.397 1.628 . . . . 0.0 115.397 -162.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.267 8.6 mt -81.52 104.29 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 127.056 2.142 . . . . 0.0 110.498 174.398 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -81.36 121.0 25.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 118.696 -1.201 . . . . 0.0 107.988 168.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -73.96 120.5 19.63 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.509 3.123 . . . . 0.0 107.262 173.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 1.8 t -149.91 141.34 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 123.69 1.71 . . . . 0.0 107.567 176.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -119.1 -2.26 10.78 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 111.287 -2.688 . . . . 0.0 110.87 -174.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 62.1 p -157.91 175.48 13.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 116.814 -3.679 . . . . 0.0 107.699 -161.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . . 26.7 mtpt -70.74 8.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 115.504 1.668 . . . . 0.0 115.504 175.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . -125.6 -146.89 6.83 Favored Glycine 0 C--N 1.336 0.581 0 CA-C-N 120.388 1.449 . . . . 0.0 114.791 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . 0.31 14.3 m -51.78 160.2 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 129.104 2.962 . . . . 0.0 113.936 -178.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.87 174.49 1.44 Allowed 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 124.632 2.158 . . . . 0.0 111.911 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 16.6 mmm-85 -70.65 164.1 25.67 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 112.263 -2.244 . . . . 0.0 108.551 164.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 71.0 p -117.32 21.63 12.99 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 126.819 2.048 . . . . 0.0 111.987 -169.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -167.96 147.47 4.81 Favored 'General case' 0 N--CA 1.448 -0.535 1 C-N-CA 134.1 4.96 . . . . 0.0 118.489 -178.559 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -91.49 -131.84 5.33 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 126.598 2.047 . . . . 0.0 116.646 -174.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.62 -18.86 1.24 Allowed Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 119.63 2.612 . . . . 0.0 119.63 173.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -63.29 150.44 89.3 Favored Pre-proline 0 N--CA 1.448 -0.564 0 CA-C-N 119.522 1.661 . . . . 0.0 113.799 175.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -78.84 109.04 2.52 Favored 'Trans proline' 0 N--CA 1.449 -1.107 1 C-N-CA 125.337 4.024 . . . . 0.0 111.847 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -117.42 174.78 5.95 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 116.512 -1.708 . . . . 0.0 114.514 177.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -161.35 150.49 16.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 124.866 2.27 . . . . 0.0 112.004 -174.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 11.6 p -127.7 143.08 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.033 -2.292 . . . . 0.0 108.89 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -139.61 111.42 7.32 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-O 116.131 -1.89 . . . . 0.0 108.85 168.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . 0.279 29.3 mt -116.91 142.77 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 128.476 2.71 . . . . 0.0 107.69 175.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -134.41 148.14 50.58 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.354 3.462 . . . . 0.0 116.0 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -130.83 -148.19 6.24 Favored Glycine 0 N--CA 1.449 -0.498 0 O-C-N 119.01 -2.306 . . . . 0.0 109.769 -171.075 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . 0.304 51.8 Cg_endo -71.3 138.03 32.22 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.685 2.924 . . . . 0.0 114.557 -169.421 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 19.0 t70 81.99 -52.27 0.24 Allowed 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 128.814 2.846 . . . . 0.0 109.388 163.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -159.4 -22.2 0.03 OUTLIER Glycine 0 C--N 1.337 0.608 0 C-N-CA 129.791 3.567 . . . . 0.0 113.525 175.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 55.8 tp -45.52 104.06 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 131.149 3.779 . . . . 0.0 115.394 -165.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.94 117.59 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-O 124.646 2.165 . . . . 0.0 107.651 165.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.52 125.79 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -65.68 130.07 41.99 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 117.466 -1.254 . . . . 0.0 108.583 172.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -135.92 138.59 42.54 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 126.538 2.399 . . . . 0.0 105.701 -175.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 58.0 mttp -118.06 116.38 26.75 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 126.755 2.022 . . . . 0.0 113.335 -165.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 39.6 t -94.6 143.0 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 97.6 m -142.65 120.68 12.1 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 118.405 -2.684 . . . . 0.0 106.81 166.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . 0.293 40.0 t0 -68.42 133.23 48.34 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 125.885 1.99 . . . . 0.0 110.165 170.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 -93.91 -2.65 52.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 118.256 2.687 . . . . 0.0 118.256 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 82.25 -33.02 0.09 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 128.673 2.789 . . . . 0.0 109.223 172.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -78.97 -18.09 54.31 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 116.265 -1.826 . . . . 0.0 114.149 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 136.53 8.51 1.49 Allowed Glycine 0 C--N 1.336 0.583 0 CA-C-N 121.881 2.128 . . . . 0.0 115.125 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 76.4 p -138.39 160.06 40.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 126.456 1.902 . . . . 0.0 113.728 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -128.08 118.32 23.25 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 127.083 2.153 . . . . 0.0 107.178 177.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -75.12 132.57 13.67 Favored Glycine 0 CA--C 1.523 0.564 0 CA-C-O 117.476 -1.736 . . . . 0.0 112.603 165.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.52 130.42 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 124.283 1.992 . . . . 0.0 108.921 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 t -130.62 140.77 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 114.282 -1.326 . . . . 0.0 113.398 -167.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . 0.339 5.6 p90 -159.43 163.56 35.31 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 126.42 3.009 . . . . 0.0 115.877 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.16 139.33 12.07 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 109.687 -3.415 . . . . 0.0 110.705 -170.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 84' ' ' ALA . . . . . . . . . . . . . . . -147.73 149.23 32.97 Favored Pre-proline 0 N--CA 1.45 -0.456 0 CA-C-N 114.091 -1.413 . . . . 0.0 114.207 155.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 85' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -91.04 44.27 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.106 1 C-N-CA 125.319 4.013 . . . . 0.0 112.558 -169.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -141.92 167.31 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 112.096 -3.812 . . . . 0.0 116.302 -157.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -134.58 123.08 23.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 121.937 2.153 . . . . 0.0 109.325 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 171.94 -106.28 0.23 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 125.981 1.753 . . . . 0.0 112.617 -178.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -149.7 125.7 10.59 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 128.985 2.914 . . . . 0.0 118.153 177.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 90' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -87.17 139.04 30.97 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 126.563 1.945 . . . . 0.0 107.71 169.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -130.69 106.83 8.73 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 127.66 3.1 . . . . 0.0 105.685 -171.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 32.3 t -112.02 138.18 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 127.33 2.894 . . . . 0.0 112.521 -166.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -140.78 136.27 32.31 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.366 2.266 . . . . 0.0 114.454 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 10.1 t -122.24 147.43 26.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 O-C-N 119.299 -2.126 . . . . 0.0 107.849 174.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 95' ' ' THR . . . . . 0.454 ' C ' ' H ' ' L' ' 97' ' ' ARG . 16.5 p -157.13 149.87 23.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 117.446 -1.264 . . . . 0.0 111.113 -175.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 21.2 mt -72.94 32.5 0.07 Allowed 'General case' 0 N--CA 1.449 -0.518 1 C-N-CA 135.199 5.4 . . . . 0.0 111.594 -177.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 97' ' ' ARG . . . . . 0.454 ' H ' ' C ' ' L' ' 95' ' ' THR . 11.7 tpp85 65.61 -47.35 0.39 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.14 1.776 . . . . 0.0 109.311 -170.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -123.56 -5.47 7.74 Favored Glycine 0 C--N 1.335 0.519 1 C-N-CA 131.475 4.369 . . . . 0.0 114.731 -171.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -145.54 139.72 15.14 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 119.984 1.892 . . . . 0.0 113.483 -172.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -84.15 164.72 13.16 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 N-CA-C 116.923 1.855 . . . . 0.0 116.923 -173.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.13 -176.54 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 O-C-N 119.277 -2.139 . . . . 0.0 107.699 -176.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 102' ' ' LYS . . . . . 0.442 ' HE2' ' C ' ' L' ' 16' ' ' HIS . 53.9 mtmt -83.35 139.39 33.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.34 1.856 . . . . 0.0 113.206 -165.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 t30 63.51 27.82 15.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 126.685 2.491 . . . . 0.0 115.264 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 11.7 mmt -119.86 129.44 25.35 Favored Pre-proline 0 N--CA 1.448 -0.573 0 C-N-CA 130.765 3.626 . . . . 0.0 104.418 -172.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -79.94 169.04 71.39 Favored 'Cis proline' 0 N--CA 1.448 -1.155 0 CA-C-N 122.543 1.944 . . . . 0.0 116.66 -15.058 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 106' ' ' ILE . . . . . 0.413 HD11 ' H ' ' L' ' 107' ' ' ASP . 5.3 tp -158.85 162.0 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 O-C-N 119.405 -2.059 . . . . 0.0 110.408 -166.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 107' ' ' ASP . . . . . 0.413 ' H ' HD11 ' L' ' 106' ' ' ILE . 12.9 m-20 -132.73 146.29 51.74 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.632 1.973 . . . . 0.0 111.249 -161.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 15.2 t -138.42 118.53 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 129.201 3.0 . . . . 0.0 108.498 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -74.58 136.02 42.06 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.248 2.219 . . . . 0.0 107.294 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 38.6 t -106.28 111.69 24.39 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.918 -1.037 . . . . 0.0 113.001 167.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 15.2 tt -156.74 152.49 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.302 3.041 . . . . 0.0 110.461 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -75.19 108.29 7.84 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 115.241 1.571 . . . . 0.0 115.241 -161.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . -64.03 108.69 2.37 Favored Glycine 0 C--N 1.336 0.547 0 CA-C-O 115.034 -3.092 . . . . 0.0 110.305 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -52.69 169.2 0.09 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 119.346 3.091 . . . . 0.0 119.346 -171.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -59.56 149.55 29.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 120.048 3.351 . . . . 0.0 120.048 -169.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.52 143.54 37.26 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 126.029 1.776 . . . . 0.0 111.419 172.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -139.08 163.64 31.87 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.788 1.635 . . . . 0.0 115.105 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 118' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -150.89 142.18 23.28 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 160.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 68.7 m -78.39 -26.31 46.49 Favored 'General case' 0 N--CA 1.45 -0.438 2 O-C-N 116.015 -4.178 . . . . 0.0 112.732 -2.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 4.2 t -173.02 150.97 2.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.462 2.305 . . . . 0.0 116.516 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -68.24 -7.05 27.21 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 116.935 2.198 . . . . 0.0 116.935 178.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . 140.17 -174.22 22.59 Favored Glycine 0 C--N 1.335 0.493 1 C-N-CA 132.475 4.845 . . . . 0.0 118.074 -175.408 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 123' ' ' SER . . . . . . . . . . . . 0.259 0.1 OUTLIER -74.0 -2.57 24.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 127.81 2.444 . . . . 0.0 115.149 -158.107 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -65.31 135.22 55.06 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 129.192 2.997 . . . . 0.0 108.457 -172.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 28.0 p -158.69 162.11 37.17 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.508 3.123 . . . . 0.0 103.241 -171.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.262 51.8 p90 -154.94 162.51 41.07 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 125.021 1.328 . . . . 0.0 113.958 -174.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 3.0 m -81.64 126.58 31.93 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 119.674 -1.891 . . . . 0.0 110.769 175.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 25.2 t -140.2 103.57 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 113.569 -1.651 . . . . 0.0 106.981 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.5 -37.54 62.84 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 129.331 3.052 . . . . 0.0 108.861 -174.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.39 -28.94 67.54 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.254 -1.529 . . . . 0.0 114.548 -174.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -71.81 -50.14 32.39 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 115.405 1.632 . . . . 0.0 115.405 166.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -167.9 148.46 5.1 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 129.477 3.111 . . . . 0.0 109.377 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -105.8 145.18 31.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.06 2.144 . . . . 0.0 109.607 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . 0.328 30.6 mmmt -82.65 21.76 0.96 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 129.682 3.193 . . . . 0.0 113.635 -157.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.39 -174.8 55.21 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 127.259 2.361 . . . . 0.0 114.685 -173.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -64.98 122.4 16.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 128.595 2.758 . . . . 0.0 108.715 166.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 57.2 t -93.91 111.49 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 -175.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -106.76 170.11 8.14 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 116.939 2.2 . . . . 0.0 116.939 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 47.6 p -47.31 -56.23 7.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.899 -1.751 . . . . 0.0 115.722 162.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 22.3 p90 -64.63 -20.3 66.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 119.275 3.065 . . . . 0.0 119.275 -170.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.76 163.76 31.42 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 170.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . -115.53 -169.38 15.74 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 126.154 1.835 . . . . 0.0 114.528 164.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -74.08 145.97 43.99 Favored 'General case' 0 N--CA 1.448 -0.534 0 O-C-N 117.07 -3.606 . . . . 0.0 112.978 -172.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 144' ' ' LYS . . . . . . . . . . . . . 76.2 mttt -91.65 -17.44 25.5 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -168.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -59.93 -43.48 94.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 121.269 1.849 . . . . 0.0 114.791 -167.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 146' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -97.87 167.24 11.04 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 127.611 3.576 . . . . 0.0 108.157 166.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -147.11 132.59 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 1 O-C-N 113.982 -5.449 . . . . 0.0 114.866 -176.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 148' ' ' SER . . . . . . . . . . . . . 35.3 m -66.37 -11.25 50.2 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 117.367 2.358 . . . . 0.0 117.367 -169.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . 0.276 2.0 pp -67.45 -3.81 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 123.77 2.986 . . . . 0.0 114.225 172.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 150' ' ' THR . . . . . . . . . . . . 0.259 2.8 p -68.87 155.81 39.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 120.902 1.683 . . . . 0.0 111.732 -170.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . -156.94 -177.67 30.29 Favored Glycine 0 C--N 1.335 0.503 0 CA-C-N 114.436 -1.256 . . . . 0.0 115.741 177.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -58.46 158.26 23.78 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 CA-C-O 125.179 2.075 . . . . 0.0 111.573 176.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -71.52 -9.14 57.73 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-N 112.402 -2.181 . . . . 0.0 112.743 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -149.68 143.69 25.64 Favored 'General case' 0 N--CA 1.45 -0.439 1 O-C-N 116.14 -4.1 . . . . 0.0 109.738 -176.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -159.5 80.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 125.07 1.481 . . . . 0.0 108.584 -175.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 33.1 pt -105.45 166.76 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 126.71 2.004 . . . . 0.0 114.782 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 80.5 p -69.06 -5.68 23.49 Favored 'General case' 0 N--CA 1.451 -0.405 1 O-C-N 116.059 -4.151 . . . . 0.0 112.744 176.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 52.5 mt -91.61 68.14 5.58 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 122.212 2.278 . . . . 0.0 110.135 170.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -74.5 120.72 20.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 111.199 -2.728 . . . . 0.0 106.036 -169.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -70.39 132.2 45.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 123.012 1.386 . . . . 0.0 107.851 -177.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 34.2 pt -88.44 -23.26 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 120.189 3.403 . . . . 0.0 120.189 -167.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . 0.257 24.5 t0 -101.26 127.64 47.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 113.561 -1.654 . . . . 0.0 110.894 157.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 37.2 t30 -89.4 115.95 27.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.296 -171.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -98.18 132.9 43.3 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-O 117.15 -1.405 . . . . 0.0 110.577 -167.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 30.6 t0 -119.47 155.66 31.66 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 128.425 3.964 . . . . 0.0 110.167 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.02 2.98 Favored Glycine 0 CA--C 1.523 0.59 0 O-C-N 117.59 -3.194 . . . . 0.0 115.802 -169.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 167' ' ' THR . . . . . . . . . . . . 0.252 6.6 m -73.63 127.29 32.37 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 116.825 -1.559 . . . . 0.0 115.17 -174.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -116.6 126.09 52.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 115.337 -2.268 . . . . 0.0 112.015 158.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 169' ' ' THR . . . . . . . . . . . . . 6.3 t -146.11 156.78 43.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 129.427 3.091 . . . . 0.0 110.338 169.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -153.27 171.1 19.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.851 2.06 . . . . 0.0 107.103 -175.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -59.87 -44.88 93.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 174.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -121.73 166.09 14.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.092 2.256 . . . . 0.0 117.092 -175.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 11.4 m -77.83 157.61 29.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 114.833 1.42 . . . . 0.0 114.833 170.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 7.4 mp -62.89 168.69 3.74 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.176 1.791 . . . . 0.0 107.837 -157.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 7.5 p -159.37 133.06 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 127.125 2.17 . . . . 0.0 109.415 166.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . -65.39 163.42 39.1 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 116.233 1.253 . . . . 0.0 116.233 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -67.09 111.51 3.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 115.962 -1.971 . . . . 0.0 109.836 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 178' ' ' GLY . . . . . . . . . . . . . . . -96.69 -137.98 9.74 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 129.024 3.953 . . . . 0.0 114.359 170.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 179' ' ' ARG . . . . . . . . . . . . . 13.8 ttt180 -90.73 75.62 6.52 Favored 'General case' 0 N--CA 1.447 -0.575 0 O-C-N 120.527 -1.572 . . . . 0.0 106.886 -175.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -157.46 128.64 6.73 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.462 3.505 . . . . 0.0 113.984 178.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 181' ' ' SER . . . . . . . . . . . . . 14.9 m -83.07 115.03 21.69 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 128.214 2.606 . . . . 0.0 112.145 -157.559 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 19.7 p -95.96 146.88 24.24 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 122.724 1.25 . . . . 0.0 111.093 -177.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . 126.1 169.14 12.77 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 128.764 3.078 . . . . 0.0 113.893 -172.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 184' ' ' VAL . . . . . . . . . . . . 0.327 11.2 p -131.28 30.48 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 1 CA-C-O 128.786 4.136 . . . . 0.0 115.839 171.104 . . . . . . . . 3 2 . 1 . 003 nuclear orig full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -110.08 -23.33 11.35 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 117.323 -3.361 . . . . 0.0 109.655 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 46.1 tp -137.44 148.76 46.36 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.07 2.948 . . . . 0.0 108.586 175.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -45.65 120.33 2.55 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.134 0.973 . . . . 0.0 113.187 168.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -72.2 -13.67 76.58 Favored Glycine 0 N--CA 1.447 -0.597 0 O-C-N 117.751 -3.093 . . . . 0.0 113.959 -174.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 20.1 tptp -59.69 -26.58 65.69 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 120.606 2.203 . . . . 0.0 116.053 175.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -75.4 157.26 34.44 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 116.926 -1.511 . . . . 0.0 108.39 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 10.0 tp -148.86 164.97 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 125.773 2.701 . . . . 0.0 107.967 -170.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -74.08 122.54 22.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 128.041 2.537 . . . . 0.0 110.121 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 122.33 -179.14 16.27 Favored Glycine 0 C--N 1.335 0.487 0 C-N-CA 126.247 1.879 . . . . 0.0 115.351 174.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 41.3 t -93.49 119.9 66.87 Favored Pre-proline 0 N--CA 1.45 -0.45 0 CA-C-O 118.768 -0.634 . . . . 0.0 110.793 173.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -81.18 138.94 11.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 CA-C-O 124.405 1.752 . . . . 0.0 110.26 176.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -179.96 -13.22 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 115.296 -2.288 . . . . 0.0 114.031 -171.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 69.7 tttt -59.51 -23.24 62.64 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 125.83 2.728 . . . . 0.0 117.505 166.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -78.1 109.84 12.54 Favored 'General case' 0 N--CA 1.45 -0.464 1 O-C-N 116.245 -4.034 . . . . 0.0 111.749 153.801 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 86.4 t -77.88 109.83 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 118.824 -2.422 . . . . 0.0 104.585 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 66.9 mt -88.39 173.91 8.45 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 167.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . -69.55 144.31 40.28 Favored Glycine 0 C--N 1.336 0.552 0 CA-C-N 121.536 1.971 . . . . 0.0 111.665 -171.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -148.8 152.78 37.12 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 126.0 1.647 . . . . 0.0 110.597 -171.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -38.3 127.77 1.37 Allowed 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 126.547 2.405 . . . . 0.0 109.346 161.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 4.8 tp -77.67 143.76 37.89 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.542 3.137 . . . . 0.0 110.363 0.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -101.54 -64.0 1.09 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 170.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 2.5 p -132.6 128.49 37.27 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.318 1.847 . . . . 0.0 110.572 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 25.4 m -45.3 125.6 5.8 Favored Pre-proline 0 N--CA 1.45 -0.459 0 CA-C-N 111.523 -2.58 . . . . 0.0 111.289 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -63.24 169.73 8.92 Favored 'Trans proline' 0 N--CA 1.448 -1.15 1 C-N-CA 126.057 4.505 . . . . 0.0 112.755 168.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.14 -175.15 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 126.012 1.725 . . . . 0.0 108.648 -171.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -90.31 163.98 14.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 114.885 1.439 . . . . 0.0 114.885 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.08 109.0 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-O 128.445 3.974 . . . . 0.0 113.873 165.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 30.4 m -71.84 94.01 1.37 Allowed 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 118.888 -2.383 . . . . 0.0 112.115 178.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -145.46 134.14 22.22 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 121.246 -0.909 . . . . 0.0 111.796 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -62.35 149.71 41.53 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 115.286 1.587 . . . . 0.0 115.286 -176.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -155.89 136.35 13.2 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 126.182 2.176 . . . . 0.0 113.351 178.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -113.44 150.45 18.51 Favored Glycine 0 C--N 1.337 0.592 0 N-CA-C 106.586 -2.605 . . . . 0.0 106.586 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 8.2 tp -154.43 -25.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -174.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -105.5 136.39 45.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 125.676 2.655 . . . . 0.0 113.029 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . 0.273 . . -84.72 164.65 18.43 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 113.647 -1.615 . . . . 0.0 112.827 -174.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -68.97 157.15 53.52 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 117.573 -3.204 . . . . 0.0 115.353 -171.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo . . . . . 0 C--O 1.251 1.162 1 C-N-CA 125.87 4.38 . . . . 0.0 116.991 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 12' ' ' PRO . . . . . 0.481 ' HB2' HD11 ' L' ' 96' ' ' LEU . 32.6 Cg_exo -51.72 164.73 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 124.505 3.47 . . . . 0.0 113.339 -173.223 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 59.7 m -89.34 121.42 31.59 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.183 2.993 . . . . 0.0 110.546 169.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.83 -14.42 61.09 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.924 2.09 . . . . 0.0 112.138 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -65.54 -26.91 68.09 Favored 'General case' 0 N--CA 1.45 -0.459 1 C-N-CA 131.724 4.01 . . . . 0.0 108.729 167.25 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 31.9 m170 -134.42 -25.11 1.53 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.989 2.177 . . . . 0.0 112.047 -166.342 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 14.6 m -79.78 145.07 33.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 O-C-N 117.532 -3.23 . . . . 0.0 110.507 173.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . 0.53 6.8 p90 -167.25 -172.0 1.88 Allowed 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 114.912 -2.471 . . . . 0.0 117.042 -176.051 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . 0.254 . . -150.09 139.04 20.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 116.253 -2.179 . . . . 0.0 110.79 -148.044 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -147.4 144.11 28.44 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 119.061 -1.055 . . . . 0.0 113.54 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.531 0 CA-C-O 118.462 -1.188 . . . . 0.0 112.633 156.956 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 23.1 m . . . . . 0 N--CA 1.448 -0.544 0 CA-C-O 125.985 2.802 . . . . 0.0 117.95 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -163.15 121.72 2.04 Favored 'General case' 0 N--CA 1.449 -0.508 1 O-C-N 115.763 -4.335 . . . . 0.0 109.662 -177.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -142.35 144.09 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 O-C-N 128.657 3.723 . . . . 0.0 112.885 -157.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -135.3 157.81 45.96 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 122.008 2.185 . . . . 0.0 112.15 -150.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -76.91 -30.28 56.08 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 122.16 2.255 . . . . 0.0 111.541 175.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 22.0 p-10 -107.69 9.51 29.15 Favored 'General case' 0 N--CA 1.448 -0.571 0 CA-C-N 112.569 -2.105 . . . . 0.0 113.604 -172.026 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.85 153.49 28.79 Favored Pre-proline 0 N--CA 1.451 -0.409 0 CA-C-N 122.798 2.545 . . . . 0.0 113.199 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.9 172.66 8.08 Favored 'Trans proline' 0 N--CA 1.45 -1.069 2 C-N-CA 127.566 5.51 . . . . 0.0 107.248 159.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -127.66 160.16 32.5 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 127.49 2.993 . . . . 0.0 108.877 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -134.36 156.88 47.71 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 115.958 -1.972 . . . . 0.0 111.888 -172.22 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -160.08 172.84 16.76 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 126.767 2.027 . . . . 0.0 106.042 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 36' ' ' THR . . . . . . . . . . . . 0.253 8.2 m -135.03 142.62 46.43 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 124.172 1.939 . . . . 0.0 115.446 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . . 57.6 mt -108.67 114.93 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 O-C-N 118.404 -2.685 . . . . 0.0 111.211 -175.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -87.97 138.13 31.72 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 170.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -117.51 134.49 54.8 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 113.772 -1.558 . . . . 0.0 109.312 -166.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.428 ' HA ' ' HA ' ' L' ' 46' ' ' ALA . 79.7 t -150.17 141.61 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 C-N-CA 128.933 2.893 . . . . 0.0 110.974 -174.237 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.518 0 O-C-N 118.232 -2.792 . . . . 0.0 108.149 -174.045 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 46' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' L' ' 40' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.453 0 N-CA-C 119.076 2.991 . . . . 0.0 119.076 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -60.51 135.44 57.75 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.269 -2.769 . . . . 0.0 116.145 176.374 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 40.6 p -89.03 7.12 36.47 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.038 2.236 . . . . 0.0 117.038 -172.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -169.3 -149.78 0.08 Allowed 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.674 2.79 . . . . 0.0 106.635 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -155.2 -153.51 6.55 Favored Glycine 0 C--N 1.335 0.496 0 N-CA-C 121.009 3.164 . . . . 0.0 121.009 -172.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.92 44.38 97.5 Favored Glycine 0 CA--C 1.522 0.486 0 O-C-N 120.412 -1.64 . . . . 0.0 111.167 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -87.09 163.76 38.93 Favored Pre-proline 0 N--CA 1.449 -0.489 0 CA-C-N 121.556 2.678 . . . . 0.0 105.212 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -90.97 78.83 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 CA-C-O 127.642 3.101 . . . . 0.0 117.69 177.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -84.68 163.11 19.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.03 2.932 . . . . 0.0 110.643 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -156.88 144.82 19.31 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.993 0.901 . . . . 0.0 111.968 166.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.07 136.3 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 128.63 2.772 . . . . 0.0 114.977 174.324 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -143.11 125.4 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 130.201 3.401 . . . . 0.0 112.359 -165.227 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 37.6 mm -121.7 103.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 1 O-C-N 116.149 -4.094 . . . . 0.0 110.493 -164.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -96.63 137.85 35.09 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.768 2.027 . . . . 0.0 111.635 -174.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.2 -159.98 16.26 Favored Glycine 0 C--N 1.336 0.559 0 O-C-N 118.677 -2.515 . . . . 0.0 115.262 169.008 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -69.76 150.61 68.43 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 N-CA-C 119.241 2.747 . . . . 0.0 119.241 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t70 70.09 -95.75 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 127.989 2.516 . . . . 0.0 111.312 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.05 29.23 3.24 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-O 117.334 -1.815 . . . . 0.0 114.488 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 36.4 mt -90.12 124.79 35.11 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 122.52 3.16 . . . . 0.0 117.88 -175.211 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 10.0 t -146.53 136.27 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 115.656 1.724 . . . . 0.0 115.656 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 17.5 t -135.77 132.64 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 124.068 0.947 . . . . 0.0 109.007 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.84 123.95 27.73 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-O 116.005 -1.95 . . . . 0.0 115.639 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -93.57 150.33 20.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.403 2.281 . . . . 0.0 114.131 -170.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . 0.551 42.1 tttm -76.15 94.8 3.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 124.193 0.997 . . . . 0.0 111.962 -179.137 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 14.2 t -64.95 143.97 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 O-C-N 118.211 -2.805 . . . . 0.0 104.425 154.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 27.8 m -141.8 133.99 27.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 124.404 2.05 . . . . 0.0 110.278 159.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -68.93 125.06 25.44 Favored 'General case' 0 N--CA 1.449 -0.505 1 O-C-N 116.249 -4.032 . . . . 0.0 113.559 172.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -69.91 -16.69 63.27 Favored 'General case' 0 N--CA 1.449 -0.506 1 C-N-CA 131.745 4.018 . . . . 0.0 118.348 174.49 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . 0.263 57.7 t30 67.07 45.34 1.75 Allowed 'General case' 0 N--CA 1.448 -0.54 0 O-C-N 118.851 -2.406 . . . . 0.0 112.248 -168.614 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -159.14 -2.86 0.08 Allowed 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 118.634 -2.541 . . . . 0.0 116.837 -177.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 101.39 -5.66 55.25 Favored Glycine 0 C--N 1.335 0.516 0 CA-C-O 115.494 -2.837 . . . . 0.0 112.025 -167.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 31.3 p -123.37 164.99 17.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 123.465 3.633 . . . . 0.0 115.577 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -132.86 137.74 46.79 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 126.568 2.418 . . . . 0.0 109.755 -175.49 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -91.52 150.83 20.59 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 108.597 -1.801 . . . . 0.0 108.597 168.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -141.36 146.73 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 O-C-N 127.4 2.47 . . . . 0.0 110.531 177.516 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.8 p -132.11 143.67 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 126.652 1.981 . . . . 0.0 106.346 -175.502 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 10.3 p90 -161.97 167.43 24.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 117.681 -3.137 . . . . 0.0 115.979 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -142.82 162.67 34.85 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 116.459 -1.734 . . . . 0.0 111.509 -170.296 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 84' ' ' ALA . . . . . 0.611 ' HB1' ' CD1' ' L' ' 90' ' ' TYR . . . -125.12 78.01 66.94 Favored Pre-proline 0 N--CA 1.449 -0.502 0 C-N-CA 125.671 1.589 . . . . 0.0 111.22 -178.178 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 85' ' ' PRO . . . . . 0.498 ' HD2' ' CE2' ' L' ' 90' ' ' TYR 0.417 73.5 Cg_exo -40.1 -23.37 0.12 Allowed 'Trans proline' 0 N--CA 1.449 -1.142 1 C-N-CA 128.38 6.053 . . . . 0.0 119.596 178.621 . . . . . . . . 4 3 . 1 . 001 nuclear build core ' L' L ' 86' ' ' VAL . . . . . 0.565 ' H ' ' HE1' ' L' ' 90' ' ' TYR . 85.6 t -123.32 132.52 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-O 117.368 -1.301 . . . . 0.0 108.867 -174.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -60.59 85.29 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 131.024 3.73 . . . . 0.0 109.365 163.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 172.88 -171.72 44.59 Favored Glycine 0 CA--C 1.523 0.536 1 C-N-CA 132.56 4.886 . . . . 0.0 112.895 -160.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -71.5 140.26 49.88 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.059 1.744 . . . . 0.0 112.834 167.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 90' ' ' TYR . . . . . 0.611 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 14.1 m-85 -112.1 168.75 9.36 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 120.164 -1.585 . . . . 0.0 109.955 150.081 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -133.31 133.91 43.17 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.833 3.253 . . . . 0.0 112.39 -177.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.67 121.9 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 CA-C-O 125.448 2.547 . . . . 0.0 105.716 -169.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -135.75 118.72 16.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.937 2.495 . . . . 0.0 115.873 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.53 142.93 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 CA-C-N 113.16 -1.836 . . . . 0.0 112.718 -169.164 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -142.79 151.28 41.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 125.042 1.464 . . . . 0.0 108.712 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 96' ' ' LEU . . . . . 0.481 HD11 ' HB2' ' L' ' 12' ' ' PRO . 4.0 tt -133.83 116.74 16.04 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 127.656 2.383 . . . . 0.0 106.412 173.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? 62.83 -49.7 0.19 Allowed 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 127.495 2.318 . . . . 0.0 116.864 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -170.43 16.64 0.06 OUTLIER Glycine 0 CA--C 1.523 0.535 0 C-N-CA 129.608 3.48 . . . . 0.0 114.495 162.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 21.6 m120 -128.05 149.23 70.42 Favored Pre-proline 0 N--CA 1.451 -0.397 0 C-N-CA 127.943 2.497 . . . . 0.0 111.538 -163.151 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -80.49 -176.24 3.09 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 121.138 1.225 . . . . 0.0 113.94 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 4.1 pt -139.17 -155.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 C-N-CA 129.809 3.244 . . . . 0.0 108.444 -177.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 9.0 pttm -136.17 172.75 12.55 Favored 'General case' 0 N--CA 1.45 -0.469 1 O-C-N 115.365 -4.584 . . . . 0.0 111.009 170.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 49.0 t30 80.28 -57.68 0.34 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 130.365 3.466 . . . . 0.0 106.799 -160.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -83.06 154.35 67.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 126.403 2.314 . . . . 0.0 109.745 164.166 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -77.71 163.66 87.63 Favored 'Cis proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.666 -2.223 . . . . 0.0 113.359 -5.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 9.3 tp -162.98 147.68 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 113.24 -1.8 . . . . 0.0 113.941 -161.272 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.49 150.87 40.14 Favored 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 120.072 -1.643 . . . . 0.0 109.295 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 9.0 p -158.46 125.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 O-C-N 126.151 2.157 . . . . 0.0 111.019 -163.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -81.73 148.58 28.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 118.339 -0.838 . . . . 0.0 112.931 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 5.3 t -101.24 117.67 35.44 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 128.779 2.832 . . . . 0.0 108.125 -170.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 111' ' ' ILE . . . . . 0.42 HD13 HG21 ' L' ' 111' ' ' ILE . 20.2 tt . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 116.205 -1.855 . . . . 0.0 114.631 178.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 9.1 m-30 . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 73.2 p -162.19 143.82 10.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 128.238 2.615 . . . . 0.0 111.282 177.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.259 11.6 m-85 -61.59 143.32 56.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 114.679 -2.582 . . . . 0.0 110.128 149.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 20.3 m -68.67 105.7 2.37 Favored 'General case' 0 N--CA 1.449 -0.515 0 O-C-N 126.155 2.16 . . . . 0.0 106.623 148.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.449 -0.507 0 C-N-CA 127.511 2.324 . . . . 0.0 110.12 -178.456 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 117.501 2.408 . . . . 0.0 117.501 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -50.29 -40.26 47.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 123.541 0.737 . . . . 0.0 110.195 164.098 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -101.04 6.42 43.41 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.778 -1.826 . . . . 0.0 114.206 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 57.3 mt -108.51 135.24 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 116.642 -3.786 . . . . 0.0 107.016 177.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 55.0 m -86.82 134.31 33.56 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 158' ' ' LEU . . . . . 0.412 HD23 ' H ' ' L' ' 159' ' ' ASP . 0.9 OUTLIER -109.39 140.27 43.3 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 124.972 2.32 . . . . 0.0 112.975 165.418 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' L' L ' 159' ' ' ASP . . . . . 0.412 ' H ' HD23 ' L' ' 158' ' ' LEU . 58.5 t0 -158.86 119.26 3.22 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 119.722 -1.861 . . . . 0.0 108.309 -170.394 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -153.03 158.62 42.25 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.406 0.891 . . . . 0.0 113.406 -165.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 6.0 pt . . . . . 0 N--CA 1.451 -0.408 0 CA-C-O 114.745 -2.55 . . . . 0.0 110.009 163.24 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 1.3 t . . . . . 0 N--CA 1.448 -0.56 0 N-CA-C 117.523 2.416 . . . . 0.0 117.523 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -156.77 -132.12 1.45 Allowed Glycine 0 C--N 1.335 0.473 1 C-N-CA 132.711 4.958 . . . . 0.0 109.963 175.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 184' ' ' VAL . . . . . 0.466 HG12 ' O ' ' L' ' 184' ' ' VAL . 5.0 t -132.69 101.08 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 117.585 -3.303 . . . . 0.0 110.317 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -52.37 117.31 2.75 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-O 117.706 -1.14 . . . . 0.0 110.265 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 11.1 tp -84.52 -38.57 19.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 128.982 3.926 . . . . 0.0 107.864 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -155.36 149.65 25.94 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.414 3.085 . . . . 0.0 107.956 179.167 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . 86.99 156.09 28.79 Favored Glycine 0 CA--C 1.522 0.52 0 CA-C-O 124.912 2.395 . . . . 0.0 113.668 173.128 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -55.64 113.9 1.64 Allowed 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 110.33 -2.935 . . . . 0.0 117.682 -175.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -71.35 125.71 27.72 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.255 174.054 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 16.8 mm 44.73 120.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 130.583 3.553 . . . . 0.0 111.049 -160.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -98.19 139.6 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 113.218 -1.81 . . . . 0.0 110.951 -164.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 111.5 -149.7 18.0 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 114.344 -1.298 . . . . 0.0 113.509 -175.007 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 1.1 t -151.15 142.01 15.01 Favored Pre-proline 0 N--CA 1.449 -0.5 0 C-N-CA 131.591 3.956 . . . . 0.0 112.583 -171.119 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -89.82 150.33 4.98 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 120.436 0.758 . . . . 0.0 110.956 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -157.2 145.96 19.78 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 120.964 3.69 . . . . 0.0 120.964 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -92.78 150.06 20.89 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 120.483 -1.386 . . . . 0.0 112.058 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -83.19 135.48 34.77 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 120.433 -1.417 . . . . 0.0 111.14 -173.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 63.0 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 115.265 1.58 . . . . 0.0 115.265 155.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 49.8 mt -110.71 137.56 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 120.626 -1.296 . . . . 0.0 111.323 162.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 126.17 144.47 6.15 Favored Glycine 0 CA--C 1.523 0.555 0 C-N-CA 125.332 1.444 . . . . 0.0 115.228 -169.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -156.16 165.45 36.37 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 123.224 1.488 . . . . 0.0 108.925 176.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -92.98 150.59 20.44 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 117.441 -3.287 . . . . 0.0 107.842 175.452 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 16.1 mt -91.78 167.0 12.47 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 128.656 2.783 . . . . 0.0 106.739 2.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -139.55 -13.21 1.14 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.079 1.352 . . . . 0.0 114.459 162.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 5.6 t -100.45 138.89 36.91 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.601 1.96 . . . . 0.0 113.303 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 66.5 p -123.47 166.78 17.02 Favored Pre-proline 0 N--CA 1.448 -0.541 0 C-N-CA 129.494 3.118 . . . . 0.0 112.328 -173.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -50.12 149.48 11.91 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 124.576 3.517 . . . . 0.0 116.803 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.61 -19.67 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 O-C-N 125.559 1.787 . . . . 0.0 112.055 -176.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -159.75 159.47 32.83 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 127.185 2.194 . . . . 0.0 106.572 157.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 29.2 mm -82.18 119.72 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 126.84 2.056 . . . . 0.0 107.196 169.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 3.2 m -78.98 148.19 32.66 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 126.019 2.074 . . . . 0.0 115.21 -172.229 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -70.54 117.68 12.38 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 170.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -72.15 -20.42 61.61 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.464 2.394 . . . . 0.0 117.464 175.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -151.16 172.27 16.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.617 1.567 . . . . 0.0 109.907 -170.079 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -118.82 -41.18 0.61 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-O 125.055 2.475 . . . . 0.0 115.313 161.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 29.5 mm 85.74 -66.09 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.47 1 C-N-CA 132.124 4.17 . . . . 0.0 111.437 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -49.7 122.14 6.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 129.478 3.111 . . . . 0.0 108.263 -162.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.98 -167.42 1.39 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 114.624 -2.608 . . . . 0.0 116.115 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.471 0 O-C-N 126.348 2.28 . . . . 0.0 110.855 -173.793 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.387 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -62.91 137.61 63.63 Favored 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 122.606 2.204 . . . . 0.0 117.757 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 5.5 t -81.78 115.36 20.96 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 127.9 3.25 . . . . 0.0 111.349 155.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -50.05 -37.49 33.61 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 129.061 2.944 . . . . 0.0 112.919 166.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -63.77 -49.98 70.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 128.314 2.646 . . . . 0.0 111.6 176.111 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -113.53 -23.63 9.69 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.45 1.9 . . . . 0.0 113.452 -151.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 73.0 m -70.18 146.11 51.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 120.327 -1.483 . . . . 0.0 109.023 173.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 24.8 p90 -154.94 176.53 12.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.571 1.948 . . . . 0.0 111.492 -164.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -142.47 140.72 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 125.595 1.81 . . . . 0.0 110.748 172.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -147.26 134.92 21.05 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 125.884 2.754 . . . . 0.0 110.351 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.601 0 CA-C-O 125.306 2.615 . . . . 0.0 112.528 157.54 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t . . . . . 0 N--CA 1.447 -0.618 0 CA-C-O 121.737 0.779 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 35.1 tttt -149.23 98.89 2.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.624 1.202 . . . . 0.0 108.659 -154.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 37.9 t -141.52 131.92 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 114.278 -2.773 . . . . 0.0 111.344 -152.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -127.2 149.54 49.94 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 119.58 3.178 . . . . 0.0 119.58 -158.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -63.35 -14.18 47.16 Favored 'General case' 0 N--CA 1.448 -0.542 0 O-C-N 124.694 1.246 . . . . 0.0 113.114 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . 0.263 14.4 p-10 -113.02 3.33 16.12 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.741 2.126 . . . . 0.0 116.741 169.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.41 137.91 11.32 Favored Pre-proline 0 N--CA 1.45 -0.441 1 N-CA-C 122.177 4.14 . . . . 0.0 122.177 -167.537 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -77.78 160.49 30.97 Favored 'Trans proline' 0 N--CA 1.447 -1.22 1 C-N-CA 128.078 5.852 . . . . 0.0 111.178 -172.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -141.35 152.38 44.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 126.206 2.191 . . . . 0.0 113.795 -173.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 34' ' ' GLU . . . . . 0.522 ' HA ' ' O ' ' L' ' 80' ' ' VAL . 11.3 mt-10 -128.0 152.32 48.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 124.912 1.285 . . . . 0.0 111.583 -167.732 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . 0.305 4.1 p90 -160.44 153.86 22.12 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.692 2.397 . . . . 0.0 106.735 -173.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 1.2 m -121.53 129.04 52.65 Favored 'General case' 0 N--CA 1.448 -0.535 0 O-C-N 123.626 0.579 . . . . 0.0 110.269 -169.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.314 4.1 mt -73.93 104.79 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 166.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -91.92 115.28 27.93 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 124.284 1.993 . . . . 0.0 108.923 168.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.14 145.71 28.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 118.347 -2.721 . . . . 0.0 109.009 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t -140.02 129.05 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 110.292 -3.14 . . . . 0.0 110.552 -175.574 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 35.2 p30 . . . . . 0 N--CA 1.448 -0.54 0 CA-C-O 127.84 3.686 . . . . 0.0 117.856 -177.109 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 117.996 2.591 . . . . 0.0 117.996 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . 0.271 11.1 mmm180 -76.83 153.37 34.91 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.252 1.821 . . . . 0.0 110.603 -177.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 43.2 p -124.41 -1.53 8.09 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 128.513 2.725 . . . . 0.0 115.265 -165.307 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -161.52 167.29 25.72 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -168.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.63 175.56 40.53 Favored Glycine 0 C--N 1.335 0.498 1 N-CA-C 125.415 4.926 . . . . 0.0 125.415 175.145 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 66.4 49.08 59.07 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 125.745 1.641 . . . . 0.0 112.544 161.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -83.38 150.38 60.25 Favored Pre-proline 0 N--CA 1.449 -0.512 0 CA-C-O 115.014 -2.422 . . . . 0.0 116.948 151.795 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -91.7 59.74 0.96 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 106.833 -2.026 . . . . 0.0 106.833 -164.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -69.7 155.7 40.11 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 117.929 2.566 . . . . 0.0 117.929 156.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.98 146.78 31.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 116.516 -1.707 . . . . 0.0 109.78 178.435 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -125.64 140.26 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 119.979 1.263 . . . . 0.0 111.882 -173.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.96 29.55 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 114.272 -2.775 . . . . 0.0 111.956 -176.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 15.7 mt -135.75 134.04 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 1 C-N-CA 131.898 4.079 . . . . 0.0 110.13 -178.695 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -120.91 148.69 43.71 Favored 'General case' 0 N--CA 1.45 -0.444 1 C-N-CA 133.445 4.698 . . . . 0.0 110.901 -178.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -148.63 -162.61 10.34 Favored Glycine 0 CA--C 1.522 0.504 0 CA-C-O 124.714 2.285 . . . . 0.0 114.931 -171.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.42 149.37 86.63 Favored 'Trans proline' 0 N--CA 1.448 -1.153 1 C-N-CA 125.403 4.069 . . . . 0.0 110.892 -178.101 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.83 -125.61 0.95 Allowed 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.724 2.41 . . . . 0.0 109.461 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -89.83 -9.26 66.34 Favored Glycine 0 C--N 1.335 0.506 1 O-C-N 114.457 -5.152 . . . . 0.0 111.314 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 8.8 tp -62.32 124.58 21.28 Favored 'General case' 0 N--CA 1.447 -0.593 0 O-C-N 118.358 -2.848 . . . . 0.0 113.467 -155.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 15.4 m -108.51 156.49 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 150.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 89.0 t -122.64 136.22 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 125.609 1.818 . . . . 0.0 110.084 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -89.96 118.04 29.23 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -63.22 147.04 52.07 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 118.564 -2.585 . . . . 0.0 116.922 172.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -116.92 119.94 36.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 64.2 t -112.62 143.99 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 CA-C-O 123.55 1.643 . . . . 0.0 108.434 -173.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -139.77 117.53 11.63 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 114.47 -1.241 . . . . 0.0 112.253 170.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -81.27 121.88 26.73 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 129.052 2.941 . . . . 0.0 109.456 178.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -77.61 -5.38 50.08 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 115.704 -2.093 . . . . 0.0 115.274 175.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 71.22 24.3 3.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 125.628 3.831 . . . . 0.0 112.092 -175.007 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -149.16 -12.52 0.31 Allowed 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 117.103 -3.498 . . . . 0.0 111.028 -160.48 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 115.86 5.34 18.07 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 120.103 2.801 . . . . 0.0 120.103 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 18.8 p -136.15 157.34 47.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.342 3.057 . . . . 0.0 111.391 170.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -130.43 140.1 50.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 116.666 -1.635 . . . . 0.0 108.956 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -77.32 132.89 12.49 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 127.346 2.403 . . . . 0.0 114.86 160.124 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 80' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' L' ' 34' ' ' GLU . 2.6 t -126.14 128.52 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 127.733 2.666 . . . . 0.0 115.65 174.336 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -136.4 143.04 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 120.645 -1.284 . . . . 0.0 113.225 174.444 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -151.04 -178.94 6.9 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 114.79 -1.096 . . . . 0.0 111.607 175.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -137.27 107.22 6.29 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.56 1.944 . . . . 0.0 111.338 178.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 84' ' ' ALA . . . . . 0.549 ' HB1' ' CD1' ' L' ' 90' ' ' TYR 0.28 . . -68.63 110.43 5.87 Favored Pre-proline 0 N--CA 1.45 -0.453 0 C-N-CA 124.843 1.257 . . . . 0.0 109.54 164.204 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' L' L ' 85' ' ' PRO . . . . . . . . . . . . 0.264 50.0 Cg_endo -67.29 -10.02 27.22 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 126.546 4.831 . . . . 0.0 117.866 -167.987 . . . . . . . . 3 2 . 1 . 002 nuclear build core ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.61 154.16 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-N 119.827 1.194 . . . . 0.0 110.209 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -43.97 130.15 5.88 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 150.693 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 145.37 -149.65 21.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 127.618 2.532 . . . . 0.0 111.643 -174.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -121.98 153.93 37.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 127.033 2.133 . . . . 0.0 113.391 -178.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 90' ' ' TYR . . . . . 0.549 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 52.6 m-85 -152.27 156.39 39.59 Favored 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.332 1.853 . . . . 0.0 108.398 -172.234 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . 0.325 2.9 t30 -133.55 114.32 13.43 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.007 1.323 . . . . 0.0 111.512 -165.021 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 20.5 t -108.55 139.17 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-N 112.972 -1.922 . . . . 0.0 110.246 -164.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -155.1 106.49 2.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.659 2.784 . . . . 0.0 117.162 -173.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 94' ' ' VAL . . . . . 0.461 ' HB ' ' HG3' ' L' ' 104' ' ' MET . 33.1 t -94.56 142.63 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 111.899 -2.41 . . . . 0.0 108.873 159.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 95' ' ' THR . . . . . 0.409 ' HB ' ' H ' ' L' ' 96' ' ' LEU . 35.0 p -137.42 -144.36 0.19 Allowed 'General case' 0 N--CA 1.451 -0.384 0 O-C-N 128.946 3.903 . . . . 0.0 117.431 -173.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 96' ' ' LEU . . . . . 0.409 ' H ' ' HB ' ' L' ' 95' ' ' THR . 6.0 tp -150.72 154.52 37.54 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 123.667 2.94 . . . . 0.0 115.016 168.232 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 33.3 ttm180 -64.36 94.88 0.12 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 124.202 1.953 . . . . 0.0 109.856 142.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . 121.41 -153.16 16.71 Favored Glycine 0 N--CA 1.448 -0.504 1 C-N-CA 131.032 4.158 . . . . 0.0 110.295 -171.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -71.47 113.87 23.21 Favored Pre-proline 0 N--CA 1.449 -0.487 0 CA-C-O 113.358 -3.21 . . . . 0.0 108.551 -170.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -74.63 160.29 41.4 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 O-C-N 127.079 3.147 . . . . 0.0 114.23 -165.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.7 pt -90.07 138.81 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 O-C-N 117.064 -3.522 . . . . 0.0 112.071 -159.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 23.0 mmtt -92.59 -178.73 4.97 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-O 117.352 -1.309 . . . . 0.0 109.396 -173.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 72.64 -44.44 0.59 Allowed 'General case' 0 N--CA 1.448 -0.537 0 CA-C-O 126.797 3.189 . . . . 0.0 110.894 -154.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 104' ' ' MET . . . . . 0.461 ' HG3' ' HB ' ' L' ' 94' ' ' VAL . 28.0 mmt -69.74 155.25 93.84 Favored Pre-proline 0 N--CA 1.448 -0.541 0 CA-C-O 112.347 -3.692 . . . . 0.0 107.741 153.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -75.13 159.92 97.19 Favored 'Cis proline' 0 N--CA 1.447 -1.213 0 O-C-N 125.453 2.291 . . . . 0.0 110.481 -18.636 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 12.5 tt -151.55 141.05 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.163 -1.38 . . . . 0.0 112.709 -174.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -95.62 136.14 36.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.659 3.183 . . . . 0.0 113.692 173.603 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.27 143.25 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 128.979 2.911 . . . . 0.0 103.284 -163.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -111.75 147.4 35.72 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 126.321 1.848 . . . . 0.0 113.807 177.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 41.0 t -127.43 138.96 53.11 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 125.747 1.905 . . . . 0.0 106.356 -172.398 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 1.3 pp . . . . . 0 N--CA 1.449 -0.48 0 C-N-CA 128.125 2.57 . . . . 0.0 110.413 -177.482 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . 0.32 26.3 p90 . . . . . 0 N--CA 1.45 -0.442 0 N-CA-C 119.554 3.168 . . . . 0.0 119.554 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 3.4 p -135.9 153.56 51.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 118.077 -2.89 . . . . 0.0 112.684 -166.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.338 56.9 t80 -66.22 154.51 39.64 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -174.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 12.9 t -60.42 149.24 34.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 130.256 3.422 . . . . 0.0 112.574 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 21.6 m . . . . . 0 N--CA 1.449 -0.52 0 CA-C-N 112.599 -2.091 . . . . 0.0 110.093 178.915 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.518 0 CA-C-O 123.067 1.413 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -68.08 131.09 44.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 O-C-N 118.093 -2.879 . . . . 0.0 110.426 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -63.52 121.98 15.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 118.28 2.696 . . . . 0.0 118.28 176.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 4.8 tt -138.65 160.14 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-O 124.004 1.859 . . . . 0.0 114.167 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 28.6 m -78.89 131.3 36.37 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 115.025 -2.417 . . . . 0.0 108.833 173.088 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 22.4 tp -61.8 142.62 57.2 Favored 'General case' 0 N--CA 1.451 -0.406 1 C-N-CA 132.264 4.226 . . . . 0.0 109.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -151.66 142.49 22.92 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 127.113 2.165 . . . . 0.0 110.336 178.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -75.54 69.75 2.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.43 3.492 . . . . 0.0 113.831 175.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 15.1 pt . . . . . 0 N--CA 1.448 -0.528 0 C-N-CA 130.52 3.528 . . . . 0.0 111.279 -171.927 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 38.1 m . . . . . 0 N--CA 1.449 -0.493 0 CA-C-O 124.175 1.94 . . . . 0.0 108.104 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -88.25 -175.04 47.68 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.911 -176.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 13.5 m -83.68 144.9 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 O-C-N 126.735 2.08 . . . . 0.0 111.732 155.272 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 53.5 tttp -69.05 130.26 42.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.703 2.401 . . . . 0.0 114.987 168.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 37.6 mt -100.42 -41.2 7.11 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 117.684 2.475 . . . . 0.0 117.684 -176.53 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -78.64 171.8 14.61 Favored 'General case' 0 N--CA 1.449 -0.509 1 C-N-CA 133.488 4.715 . . . . 0.0 113.457 -173.28 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -85.94 -154.79 24.59 Favored Glycine 0 C--N 1.336 0.534 0 C-N-CA 126.455 1.978 . . . . 0.0 109.592 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 18.2 ttmt -79.22 0.13 29.77 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 116.743 -1.599 . . . . 0.0 110.937 -174.253 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -62.35 148.04 46.47 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 122.478 2.399 . . . . 0.0 109.286 171.312 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 4.7 mt -131.28 129.43 62.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 1 C-N-CA 133.797 4.839 . . . . 0.0 106.997 178.02 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -100.16 141.67 32.67 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 127.356 2.91 . . . . 0.0 111.554 156.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 102.54 9.21 41.58 Favored Glycine 0 CA--C 1.523 0.588 0 CA-C-N 122.202 2.274 . . . . 0.0 117.964 166.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 46.2 m -65.39 134.23 95.6 Favored Pre-proline 0 N--CA 1.448 -0.557 1 CA-C-O 111.53 -4.081 . . . . 0.0 111.985 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -36.28 122.61 0.3 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 1 C-N-CA 128.439 6.092 . . . . 0.0 113.412 167.312 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -98.21 162.4 13.22 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.369 1.467 . . . . 0.0 109.668 172.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -64.72 148.41 51.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -164.459 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 91.6 mm-40 -117.56 143.27 46.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 O-C-N 119.545 -1.972 . . . . 0.0 109.242 163.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.1 139.91 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 119.031 -2.293 . . . . 0.0 111.331 -168.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 57.8 tp -146.42 117.5 7.79 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 110.474 -3.057 . . . . 0.0 108.872 168.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 81.12 173.93 48.28 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 127.195 2.331 . . . . 0.0 114.627 175.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 27.2 t30 -110.97 134.6 52.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -146.28 150.11 35.15 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 115.411 -2.233 . . . . 0.0 112.178 -170.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 55.6 mt -67.45 161.51 25.18 Favored 'General case' 0 N--CA 1.449 -0.483 1 C-N-CA 134.181 4.993 . . . . 0.0 109.836 0.279 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 55.7 t80 -62.51 137.82 58.34 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 126.13 2.871 . . . . 0.0 107.529 -177.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.98 119.56 33.7 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 117.356 -3.34 . . . . 0.0 112.201 -171.504 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 4.3 m -79.17 130.18 70.17 Favored Pre-proline 0 N--CA 1.451 -0.415 0 O-C-N 117.571 -3.206 . . . . 0.0 109.646 -162.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -64.3 125.17 14.59 Favored 'Trans proline' 0 N--CA 1.448 -1.185 1 C-N-CA 125.327 4.018 . . . . 0.0 109.267 173.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 6.9 p -163.07 159.36 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 130.171 3.388 . . . . 0.0 111.353 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 9.1 p90 -80.81 137.68 36.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.826 2.05 . . . . 0.0 113.735 177.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 40.9 mm -67.67 125.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 119.462 -2.024 . . . . 0.0 107.646 171.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 212' ' ' SER . . . . . . . . . . . . 0.255 40.2 m -87.09 156.88 19.54 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 124.082 3.128 . . . . 0.0 110.81 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -56.65 151.88 13.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 131.096 3.758 . . . . 0.0 118.168 171.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -114.93 156.95 24.07 Favored 'General case' 0 N--CA 1.447 -0.579 0 O-C-N 117.44 -3.288 . . . . 0.0 110.012 159.267 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . 0.283 12.5 pt20 -69.27 154.53 41.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 119.916 1.235 . . . . 0.0 112.95 -175.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -86.09 -154.08 23.51 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 130.361 3.839 . . . . 0.0 117.497 160.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . 0.306 1.4 pp -127.33 -7.82 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 129.985 3.314 . . . . 0.0 113.268 -178.468 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -60.07 126.31 27.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -111.66 -146.2 0.4 Allowed 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 131.501 3.92 . . . . 0.0 114.228 175.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.66 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -177.361 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 116.149 -1.882 . . . . 0.0 114.411 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -66.9 -176.54 0.77 Allowed 'Trans proline' 0 N--CA 1.449 -1.118 1 C-N-CA 126.438 4.758 . . . . 0.0 115.166 155.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 2.6 p -158.51 154.81 27.34 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 123.064 1.411 . . . . 0.0 112.941 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.81 -53.18 60.96 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 112.605 -2.089 . . . . 0.0 112.725 -165.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 16.8 mp0 -48.61 -20.86 0.49 Allowed 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 129.416 3.086 . . . . 0.0 118.741 177.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -117.2 -54.79 2.38 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 127.976 2.511 . . . . 0.0 109.923 -170.529 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 17' ' ' SER . . . . . . . . . . . . 0.721 0.5 OUTLIER -67.1 149.87 49.96 Favored 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.84 -4.913 . . . . 0.0 112.642 -165.154 . . . . . . . . 4 3 . 1 . 003 nuclear build core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 22.0 p90 -163.09 172.52 14.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 128.093 2.557 . . . . 0.0 108.883 -164.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -139.51 147.89 41.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 128.018 2.527 . . . . 0.0 110.387 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -149.98 144.18 25.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 125.423 1.702 . . . . 0.0 115.41 -175.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.527 0 CA-C-O 124.597 2.221 . . . . 0.0 115.066 168.49 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.451 -0.404 0 CA-C-O 121.588 0.709 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -162.87 92.54 0.78 Allowed 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 124.649 2.166 . . . . 0.0 115.614 -160.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 27' ' ' VAL . . . . . 0.471 HG13 ' CD1' ' L' ' 90' ' ' TYR 0.305 12.8 p -147.78 147.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 O-C-N 119.467 -2.02 . . . . 0.0 113.836 179.055 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' L' L ' 28' ' ' PHE . . . . . 0.488 ' HA ' ' SG ' ' L' ' 110' ' ' CYS . 12.9 t80 -137.1 -170.89 2.81 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 -170.098 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -86.09 -44.68 12.06 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 117.994 -2.942 . . . . 0.0 113.324 -175.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 47.5 p-10 -106.28 30.62 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 123.589 1.661 . . . . 0.0 111.456 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.87 125.06 2.42 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 115.933 -1.984 . . . . 0.0 114.693 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -85.44 175.35 6.31 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 123.803 3.002 . . . . 0.0 113.762 -175.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -148.39 170.67 17.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 177.543 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -142.31 155.06 45.17 Favored 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 128.235 2.614 . . . . 0.0 116.025 -170.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -163.14 166.02 23.9 Favored 'General case' 0 N--CA 1.448 -0.533 1 O-C-N 114.688 -5.007 . . . . 0.0 108.79 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 36' ' ' THR . . . . . 0.443 ' HA ' ' O ' ' L' ' 78' ' ' TYR . 21.3 m -131.82 133.82 45.11 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.397 1.628 . . . . 0.0 115.397 -162.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.267 8.6 mt -81.52 104.29 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 127.056 2.142 . . . . 0.0 110.498 174.398 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -81.36 121.0 25.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 118.696 -1.201 . . . . 0.0 107.988 168.623 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -73.96 120.5 19.63 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.509 3.123 . . . . 0.0 107.262 173.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 1.8 t -149.91 141.34 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 123.69 1.71 . . . . 0.0 107.567 176.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t0 . . . . . 0 N--CA 1.448 -0.548 0 CA-C-N 111.287 -2.688 . . . . 0.0 110.87 -174.678 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.541 0 CA-C-O 124.632 2.158 . . . . 0.0 111.911 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 16.6 mmm-85 -70.65 164.1 25.67 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 112.263 -2.244 . . . . 0.0 108.551 164.392 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 71.0 p -117.32 21.63 12.99 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 126.819 2.048 . . . . 0.0 111.987 -169.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -167.96 147.47 4.81 Favored 'General case' 0 N--CA 1.448 -0.535 1 C-N-CA 134.1 4.96 . . . . 0.0 118.489 -178.559 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -91.49 -131.84 5.33 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 126.598 2.047 . . . . 0.0 116.646 -174.637 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.62 -18.86 1.24 Allowed Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 119.63 2.612 . . . . 0.0 119.63 173.252 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -63.29 150.44 89.3 Favored Pre-proline 0 N--CA 1.448 -0.564 0 CA-C-N 119.522 1.661 . . . . 0.0 113.799 175.299 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -78.84 109.04 2.52 Favored 'Trans proline' 0 N--CA 1.449 -1.107 1 C-N-CA 125.337 4.024 . . . . 0.0 111.847 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -117.42 174.78 5.95 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 116.512 -1.708 . . . . 0.0 114.514 177.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -161.35 150.49 16.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 124.866 2.27 . . . . 0.0 112.004 -174.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 11.6 p -127.7 143.08 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.033 -2.292 . . . . 0.0 108.89 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -139.61 111.42 7.32 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-O 116.131 -1.89 . . . . 0.0 108.85 168.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . 0.279 29.3 mt -116.91 142.77 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 128.476 2.71 . . . . 0.0 107.69 175.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -134.41 148.14 50.58 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.354 3.462 . . . . 0.0 116.0 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -130.83 -148.19 6.24 Favored Glycine 0 N--CA 1.449 -0.498 0 O-C-N 119.01 -2.306 . . . . 0.0 109.769 -171.075 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . 0.304 51.8 Cg_endo -71.3 138.03 32.22 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.685 2.924 . . . . 0.0 114.557 -169.421 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 19.0 t70 81.99 -52.27 0.24 Allowed 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 128.814 2.846 . . . . 0.0 109.388 163.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 63' ' ' GLY . . . . . 0.401 ' H ' ' H ' ' L' ' 64' ' ' LEU . . . -159.4 -22.2 0.03 OUTLIER Glycine 0 C--N 1.337 0.608 0 C-N-CA 129.791 3.567 . . . . 0.0 113.525 175.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 64' ' ' LEU . . . . . 0.401 ' H ' ' H ' ' L' ' 63' ' ' GLY . 55.8 tp -45.52 104.06 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 131.149 3.779 . . . . 0.0 115.394 -165.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.94 117.59 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-O 124.646 2.165 . . . . 0.0 107.651 165.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.52 125.79 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -65.68 130.07 41.99 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 117.466 -1.254 . . . . 0.0 108.583 172.63 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -135.92 138.59 42.54 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 126.538 2.399 . . . . 0.0 105.701 -175.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 58.0 mttp -118.06 116.38 26.75 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 126.755 2.022 . . . . 0.0 113.335 -165.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 39.6 t -94.6 143.0 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 97.6 m -142.65 120.68 12.1 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 118.405 -2.684 . . . . 0.0 106.81 166.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . 0.293 40.0 t0 -68.42 133.23 48.34 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 125.885 1.99 . . . . 0.0 110.165 170.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 -93.91 -2.65 52.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 118.256 2.687 . . . . 0.0 118.256 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 82.25 -33.02 0.09 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 128.673 2.789 . . . . 0.0 109.223 172.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -78.97 -18.09 54.31 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 116.265 -1.826 . . . . 0.0 114.149 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 136.53 8.51 1.49 Allowed Glycine 0 C--N 1.336 0.583 0 CA-C-N 121.881 2.128 . . . . 0.0 115.125 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 76.4 p -138.39 160.06 40.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 126.456 1.902 . . . . 0.0 113.728 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 78' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' L' ' 36' ' ' THR . 1.4 m-85 -128.08 118.32 23.25 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 127.083 2.153 . . . . 0.0 107.178 177.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -75.12 132.57 13.67 Favored Glycine 0 CA--C 1.523 0.564 0 CA-C-O 117.476 -1.736 . . . . 0.0 112.603 165.621 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.52 130.42 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 124.283 1.992 . . . . 0.0 108.921 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 t -130.62 140.77 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 114.282 -1.326 . . . . 0.0 113.398 -167.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . 0.339 5.6 p90 -159.43 163.56 35.31 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 126.42 3.009 . . . . 0.0 115.877 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.16 139.33 12.07 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 109.687 -3.415 . . . . 0.0 110.705 -170.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 84' ' ' ALA . . . . . . . . . . . . . . . -147.73 149.23 32.97 Favored Pre-proline 0 N--CA 1.45 -0.456 0 CA-C-N 114.091 -1.413 . . . . 0.0 114.207 155.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 85' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -91.04 44.27 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.106 1 C-N-CA 125.319 4.013 . . . . 0.0 112.558 -169.491 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -141.92 167.31 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 112.096 -3.812 . . . . 0.0 116.302 -157.529 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -134.58 123.08 23.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 121.937 2.153 . . . . 0.0 109.325 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 171.94 -106.28 0.23 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 125.981 1.753 . . . . 0.0 112.617 -178.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -149.7 125.7 10.59 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 128.985 2.914 . . . . 0.0 118.153 177.233 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 90' ' ' TYR . . . . . 0.471 ' CD1' HG13 ' L' ' 27' ' ' VAL . 84.6 m-85 -87.17 139.04 30.97 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 126.563 1.945 . . . . 0.0 107.71 169.603 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -130.69 106.83 8.73 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 127.66 3.1 . . . . 0.0 105.685 -171.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 32.3 t -112.02 138.18 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 127.33 2.894 . . . . 0.0 112.521 -166.29 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -140.78 136.27 32.31 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.366 2.266 . . . . 0.0 114.454 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 10.1 t -122.24 147.43 26.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 O-C-N 119.299 -2.126 . . . . 0.0 107.849 174.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 16.5 p -157.13 149.87 23.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 117.446 -1.264 . . . . 0.0 111.113 -175.36 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 21.2 mt -72.94 32.5 0.07 Allowed 'General case' 0 N--CA 1.449 -0.518 1 C-N-CA 135.199 5.4 . . . . 0.0 111.594 -177.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 65.61 -47.35 0.39 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.14 1.776 . . . . 0.0 109.311 -170.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -123.56 -5.47 7.74 Favored Glycine 0 C--N 1.335 0.519 1 C-N-CA 131.475 4.369 . . . . 0.0 114.731 -171.76 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -145.54 139.72 15.14 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 119.984 1.892 . . . . 0.0 113.483 -172.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -84.15 164.72 13.16 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 N-CA-C 116.923 1.855 . . . . 0.0 116.923 -173.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.13 -176.54 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 O-C-N 119.277 -2.139 . . . . 0.0 107.699 -176.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -83.35 139.39 33.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.34 1.856 . . . . 0.0 113.206 -165.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 t30 63.51 27.82 15.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 126.685 2.491 . . . . 0.0 115.264 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 11.7 mmt -119.86 129.44 25.35 Favored Pre-proline 0 N--CA 1.448 -0.573 0 C-N-CA 130.765 3.626 . . . . 0.0 104.418 -172.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -79.94 169.04 71.39 Favored 'Cis proline' 0 N--CA 1.448 -1.155 0 CA-C-N 122.543 1.944 . . . . 0.0 116.66 -15.058 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 106' ' ' ILE . . . . . 0.501 HD12 ' H ' ' L' ' 107' ' ' ASP . 5.3 tp -158.85 162.0 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 O-C-N 119.405 -2.059 . . . . 0.0 110.408 -166.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 107' ' ' ASP . . . . . 0.501 ' H ' HD12 ' L' ' 106' ' ' ILE . 12.9 m-20 -132.73 146.29 51.74 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.632 1.973 . . . . 0.0 111.249 -161.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 15.2 t -138.42 118.53 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 129.201 3.0 . . . . 0.0 108.498 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -74.58 136.02 42.06 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.248 2.219 . . . . 0.0 107.294 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 110' ' ' CYS . . . . . 0.488 ' SG ' ' HA ' ' L' ' 28' ' ' PHE . 38.6 t -106.28 111.69 24.39 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.918 -1.037 . . . . 0.0 113.001 167.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 15.2 tt . . . . . 0 N--CA 1.448 -0.543 0 C-N-CA 129.302 3.041 . . . . 0.0 110.461 -179.406 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 46.7 t80 . . . . . 0 N--CA 1.447 -0.598 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 28.0 p -158.69 162.11 37.17 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.508 3.123 . . . . 0.0 103.241 -171.089 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.262 51.8 p90 -154.94 162.51 41.07 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 125.021 1.328 . . . . 0.0 113.958 -174.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 3.0 m -81.64 126.58 31.93 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 119.674 -1.891 . . . . 0.0 110.769 175.418 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 N--CA 1.45 -0.457 0 CA-C-N 113.569 -1.651 . . . . 0.0 106.981 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.485 0 N-CA-C 112.743 0.646 . . . . 0.0 112.743 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -149.68 143.69 25.64 Favored 'General case' 0 N--CA 1.45 -0.439 1 O-C-N 116.14 -4.1 . . . . 0.0 109.738 -176.134 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -159.5 80.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 125.07 1.481 . . . . 0.0 108.584 -175.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 33.1 pt -105.45 166.76 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 126.71 2.004 . . . . 0.0 114.782 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 80.5 p -69.06 -5.68 23.49 Favored 'General case' 0 N--CA 1.451 -0.405 1 O-C-N 116.059 -4.151 . . . . 0.0 112.744 176.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 52.5 mt -91.61 68.14 5.58 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 122.212 2.278 . . . . 0.0 110.135 170.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -74.5 120.72 20.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 111.199 -2.728 . . . . 0.0 106.036 -169.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -70.39 132.2 45.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 123.012 1.386 . . . . 0.0 107.851 -177.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 161' ' ' ILE . . . . . 0.41 HD13 HG21 ' L' ' 161' ' ' ILE . 34.2 pt . . . . . 0 N--CA 1.448 -0.569 0 N-CA-C 120.189 3.403 . . . . 0.0 120.189 -167.021 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 19.7 p . . . . . 0 N--CA 1.447 -0.599 0 CA-C-O 122.724 1.25 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . 126.1 169.14 12.77 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 128.764 3.078 . . . . 0.0 113.893 -172.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 184' ' ' VAL . . . . . . . . . . . . 0.327 11.2 p -131.28 30.48 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 1 CA-C-O 128.786 4.136 . . . . 0.0 115.839 171.104 . . . . . . . . 3 2 . 1 . 003 nuclear build core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -110.08 -23.33 11.35 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 117.323 -3.361 . . . . 0.0 109.655 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 46.1 tp -137.44 148.76 46.36 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.07 2.948 . . . . 0.0 108.586 175.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -45.65 120.33 2.55 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.134 0.973 . . . . 0.0 113.187 168.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -72.2 -13.67 76.58 Favored Glycine 0 N--CA 1.447 -0.597 0 O-C-N 117.751 -3.093 . . . . 0.0 113.959 -174.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 20.1 tptp -59.69 -26.58 65.69 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 120.606 2.203 . . . . 0.0 116.053 175.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -75.4 157.26 34.44 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 116.926 -1.511 . . . . 0.0 108.39 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 10.0 tp -148.86 164.97 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 125.773 2.701 . . . . 0.0 107.967 -170.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -74.08 122.54 22.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 128.041 2.537 . . . . 0.0 110.121 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 122.33 -179.14 16.27 Favored Glycine 0 C--N 1.335 0.487 0 C-N-CA 126.247 1.879 . . . . 0.0 115.351 174.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 41.3 t -93.49 119.9 66.87 Favored Pre-proline 0 N--CA 1.45 -0.45 0 CA-C-O 118.768 -0.634 . . . . 0.0 110.793 173.334 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -81.18 138.94 11.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 CA-C-O 124.405 1.752 . . . . 0.0 110.26 176.11 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -179.96 -13.22 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 115.296 -2.288 . . . . 0.0 114.031 -171.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 69.7 tttt -59.51 -23.24 62.64 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 125.83 2.728 . . . . 0.0 117.505 166.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -78.1 109.84 12.54 Favored 'General case' 0 N--CA 1.45 -0.464 1 O-C-N 116.245 -4.034 . . . . 0.0 111.749 153.801 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 86.4 t -77.88 109.83 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 118.824 -2.422 . . . . 0.0 104.585 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 66.9 mt -88.39 173.91 8.45 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 167.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . -69.55 144.31 40.28 Favored Glycine 0 C--N 1.336 0.552 0 CA-C-N 121.536 1.971 . . . . 0.0 111.665 -171.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -148.8 152.78 37.12 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 126.0 1.647 . . . . 0.0 110.597 -171.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -38.3 127.77 1.37 Allowed 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 126.547 2.405 . . . . 0.0 109.346 161.218 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 4.8 tp -77.67 143.76 37.89 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.542 3.137 . . . . 0.0 110.363 0.043 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -101.54 -64.0 1.09 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 170.441 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 2.5 p -132.6 128.49 37.27 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.318 1.847 . . . . 0.0 110.572 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 25.4 m -45.3 125.6 5.8 Favored Pre-proline 0 N--CA 1.45 -0.459 0 CA-C-N 111.523 -2.58 . . . . 0.0 111.289 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -63.24 169.73 8.92 Favored 'Trans proline' 0 N--CA 1.448 -1.15 1 C-N-CA 126.057 4.505 . . . . 0.0 112.755 168.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.14 -175.15 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 126.012 1.725 . . . . 0.0 108.648 -171.188 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -90.31 163.98 14.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 114.885 1.439 . . . . 0.0 114.885 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.08 109.0 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-O 128.445 3.974 . . . . 0.0 113.873 165.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 30.4 m -71.84 94.01 1.37 Allowed 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 118.888 -2.383 . . . . 0.0 112.115 178.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -145.46 134.14 22.22 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 121.246 -0.909 . . . . 0.0 111.796 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -62.35 149.71 41.53 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 115.286 1.587 . . . . 0.0 115.286 -176.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -155.89 136.35 13.2 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 126.182 2.176 . . . . 0.0 113.351 178.157 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -113.44 150.45 18.51 Favored Glycine 0 C--N 1.337 0.592 0 N-CA-C 106.586 -2.605 . . . . 0.0 106.586 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 8.2 tp -154.43 -25.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -174.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -105.5 136.39 45.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 125.676 2.655 . . . . 0.0 113.029 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . 0.273 . . -84.72 164.65 18.43 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 113.647 -1.615 . . . . 0.0 112.827 -174.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.515 0 O-C-N 117.573 -3.204 . . . . 0.0 115.353 -171.736 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 1' ' ' HIS . . . . . 0.453 ' HA ' ' OD1' ' L' ' 74' ' ' ASN . 2.5 t-80 . . . . . 0 N--CA 1.47 0.566 0 CA-C-O 121.412 0.625 . . . . 0.0 112.686 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -94.09 141.35 28.64 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.424 -2.672 . . . . 0.0 110.662 -171.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -146.61 0.11 0.76 Allowed 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 114.534 -2.651 . . . . 0.0 112.858 -177.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 78.1 m-70 -86.4 1.89 49.61 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 125.937 3.971 . . . . 0.0 110.061 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . 0.267 0.2 OUTLIER -169.91 169.27 8.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.217 2.607 . . . . 0.0 109.795 176.425 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -147.4 103.9 3.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 123.392 1.568 . . . . 0.0 111.292 152.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . 0.331 . . -159.32 -26.63 0.07 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 173.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 3.2 m -154.92 122.15 5.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 120.036 -1.665 . . . . 0.0 114.597 -176.118 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 43.4 pttt -141.8 145.62 37.55 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 164.392 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo -57.02 141.53 94.07 Favored 'Trans proline' 0 N--CA 1.448 -1.193 1 C-N-CA 125.38 4.054 . . . . 0.0 117.796 166.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.1 123.54 71.65 Favored Pre-proline 0 N--CA 1.449 -0.513 0 O-C-N 119.709 -1.869 . . . . 0.0 109.275 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 12' ' ' PRO . . . . . 0.481 ' HB2' HD11 ' L' ' 96' ' ' LEU . 32.6 Cg_exo -51.72 164.73 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 124.505 3.47 . . . . 0.0 113.339 -173.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 59.7 m -89.34 121.42 31.59 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.183 2.993 . . . . 0.0 110.546 169.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.83 -14.42 61.09 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.924 2.09 . . . . 0.0 112.138 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -65.54 -26.91 68.09 Favored 'General case' 0 N--CA 1.45 -0.459 1 C-N-CA 131.724 4.01 . . . . 0.0 108.729 167.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 31.9 m170 -134.42 -25.11 1.53 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.989 2.177 . . . . 0.0 112.047 -166.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 14.6 m -79.78 145.07 33.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 O-C-N 117.532 -3.23 . . . . 0.0 110.507 173.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . 0.53 6.8 p90 -167.25 -172.0 1.88 Allowed 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 114.912 -2.471 . . . . 0.0 117.042 -176.051 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . 0.254 . . -150.09 139.04 20.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 116.253 -2.179 . . . . 0.0 110.79 -148.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -147.4 144.11 28.44 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 119.061 -1.055 . . . . 0.0 113.54 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.42 -95.48 0.12 Allowed Glycine 0 C--N 1.336 0.531 0 CA-C-O 118.462 -1.188 . . . . 0.0 112.633 156.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . 0.426 36.3 tt0 -161.33 86.82 0.68 Allowed 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 129.389 3.641 . . . . 0.0 105.936 166.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.42 -143.73 19.5 Favored Glycine 0 C--N 1.336 0.557 0 O-C-N 126.121 2.138 . . . . 0.0 114.992 -151.268 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 59.7 mt -101.97 152.38 21.01 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 119.73 3.233 . . . . 0.0 119.73 -177.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 23.1 m -42.39 140.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-O 125.985 2.802 . . . . 0.0 117.95 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -163.15 121.72 2.04 Favored 'General case' 0 N--CA 1.449 -0.508 1 O-C-N 115.763 -4.335 . . . . 0.0 109.662 -177.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -142.35 144.09 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 O-C-N 128.657 3.723 . . . . 0.0 112.885 -157.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -135.3 157.81 45.96 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 122.008 2.185 . . . . 0.0 112.15 -150.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -76.91 -30.28 56.08 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 122.16 2.255 . . . . 0.0 111.541 175.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 22.0 p-10 -107.69 9.51 29.15 Favored 'General case' 0 N--CA 1.448 -0.571 0 CA-C-N 112.569 -2.105 . . . . 0.0 113.604 -172.026 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.85 153.49 28.79 Favored Pre-proline 0 N--CA 1.451 -0.409 0 CA-C-N 122.798 2.545 . . . . 0.0 113.199 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.9 172.66 8.08 Favored 'Trans proline' 0 N--CA 1.45 -1.069 2 C-N-CA 127.566 5.51 . . . . 0.0 107.248 159.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -127.66 160.16 32.5 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 127.49 2.993 . . . . 0.0 108.877 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -134.36 156.88 47.71 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 115.958 -1.972 . . . . 0.0 111.888 -172.22 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -160.08 172.84 16.76 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 126.767 2.027 . . . . 0.0 106.042 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 36' ' ' THR . . . . . . . . . . . . 0.253 8.2 m -135.03 142.62 46.43 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 124.172 1.939 . . . . 0.0 115.446 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . . 57.6 mt -108.67 114.93 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 O-C-N 118.404 -2.685 . . . . 0.0 111.211 -175.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -87.97 138.13 31.72 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 170.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -117.51 134.49 54.8 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 113.772 -1.558 . . . . 0.0 109.312 -166.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.428 ' HA ' ' HA ' ' L' ' 46' ' ' ALA . 79.7 t -150.17 141.61 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 C-N-CA 128.933 2.893 . . . . 0.0 110.974 -174.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -115.56 -146.27 0.4 Allowed 'General case' 0 N--CA 1.449 -0.518 0 O-C-N 118.232 -2.792 . . . . 0.0 108.149 -174.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 66.3 p -70.91 -23.52 62.29 Favored 'General case' 0 N--CA 1.448 -0.546 1 O-C-N 116.13 -4.106 . . . . 0.0 116.795 -145.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . . 22.0 ttmt -116.93 8.64 13.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 120.838 -1.164 . . . . 0.0 110.836 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.41 3.62 90.47 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 120.914 3.126 . . . . 0.0 120.914 -171.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -77.74 123.89 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 125.676 1.59 . . . . 0.0 108.894 164.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 46' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' L' ' 40' ' ' VAL . . . -38.03 152.54 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 119.076 2.991 . . . . 0.0 119.076 169.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -60.51 135.44 57.75 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.269 -2.769 . . . . 0.0 116.145 176.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 40.6 p -89.03 7.12 36.47 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.038 2.236 . . . . 0.0 117.038 -172.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -169.3 -149.78 0.08 Allowed 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.674 2.79 . . . . 0.0 106.635 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -155.2 -153.51 6.55 Favored Glycine 0 C--N 1.335 0.496 0 N-CA-C 121.009 3.164 . . . . 0.0 121.009 -172.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.92 44.38 97.5 Favored Glycine 0 CA--C 1.522 0.486 0 O-C-N 120.412 -1.64 . . . . 0.0 111.167 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -87.09 163.76 38.93 Favored Pre-proline 0 N--CA 1.449 -0.489 0 CA-C-N 121.556 2.678 . . . . 0.0 105.212 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -90.97 78.83 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 CA-C-O 127.642 3.101 . . . . 0.0 117.69 177.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -84.68 163.11 19.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.03 2.932 . . . . 0.0 110.643 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -156.88 144.82 19.31 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.993 0.901 . . . . 0.0 111.968 166.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.07 136.3 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 128.63 2.772 . . . . 0.0 114.977 174.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -143.11 125.4 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 130.201 3.401 . . . . 0.0 112.359 -165.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 37.6 mm -121.7 103.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 1 O-C-N 116.149 -4.094 . . . . 0.0 110.493 -164.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -96.63 137.85 35.09 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.768 2.027 . . . . 0.0 111.635 -174.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.2 -159.98 16.26 Favored Glycine 0 C--N 1.336 0.559 0 O-C-N 118.677 -2.515 . . . . 0.0 115.262 169.008 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -69.76 150.61 68.43 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 N-CA-C 119.241 2.747 . . . . 0.0 119.241 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t70 70.09 -95.75 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 127.989 2.516 . . . . 0.0 111.312 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.05 29.23 3.24 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-O 117.334 -1.815 . . . . 0.0 114.488 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 36.4 mt -90.12 124.79 35.11 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 122.52 3.16 . . . . 0.0 117.88 -175.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 10.0 t -146.53 136.27 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 115.656 1.724 . . . . 0.0 115.656 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 17.5 t -135.77 132.64 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 124.068 0.947 . . . . 0.0 109.007 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.84 123.95 27.73 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-O 116.005 -1.95 . . . . 0.0 115.639 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -93.57 150.33 20.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.403 2.281 . . . . 0.0 114.131 -170.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . 0.551 42.1 tttm -76.15 94.8 3.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 124.193 0.997 . . . . 0.0 111.962 -179.137 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 14.2 t -64.95 143.97 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 O-C-N 118.211 -2.805 . . . . 0.0 104.425 154.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 27.8 m -141.8 133.99 27.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 124.404 2.05 . . . . 0.0 110.278 159.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -68.93 125.06 25.44 Favored 'General case' 0 N--CA 1.449 -0.505 1 O-C-N 116.249 -4.032 . . . . 0.0 113.559 172.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -69.91 -16.69 63.27 Favored 'General case' 0 N--CA 1.449 -0.506 1 C-N-CA 131.745 4.018 . . . . 0.0 118.348 174.49 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 74' ' ' ASN . . . . . 0.453 ' OD1' ' HA ' ' L' ' 1' ' ' HIS 0.263 57.7 t30 67.07 45.34 1.75 Allowed 'General case' 0 N--CA 1.448 -0.54 0 O-C-N 118.851 -2.406 . . . . 0.0 112.248 -168.614 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -159.14 -2.86 0.08 Allowed 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 118.634 -2.541 . . . . 0.0 116.837 -177.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 101.39 -5.66 55.25 Favored Glycine 0 C--N 1.335 0.516 0 CA-C-O 115.494 -2.837 . . . . 0.0 112.025 -167.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 31.3 p -123.37 164.99 17.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 123.465 3.633 . . . . 0.0 115.577 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -132.86 137.74 46.79 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 126.568 2.418 . . . . 0.0 109.755 -175.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -91.52 150.83 20.59 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 108.597 -1.801 . . . . 0.0 108.597 168.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -141.36 146.73 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 O-C-N 127.4 2.47 . . . . 0.0 110.531 177.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.8 p -132.11 143.67 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 126.652 1.981 . . . . 0.0 106.346 -175.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 10.3 p90 -161.97 167.43 24.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 117.681 -3.137 . . . . 0.0 115.979 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -142.82 162.67 34.85 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 116.459 -1.734 . . . . 0.0 111.509 -170.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 84' ' ' ALA . . . . . 0.611 ' HB1' ' CD1' ' L' ' 90' ' ' TYR . . . -125.12 78.01 66.94 Favored Pre-proline 0 N--CA 1.449 -0.502 0 C-N-CA 125.671 1.589 . . . . 0.0 111.22 -178.178 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 85' ' ' PRO . . . . . 0.498 ' HD2' ' CE2' ' L' ' 90' ' ' TYR 0.417 73.5 Cg_exo -40.1 -23.37 0.12 Allowed 'Trans proline' 0 N--CA 1.449 -1.142 1 C-N-CA 128.38 6.053 . . . . 0.0 119.596 178.621 . . . . . . . . 4 3 . 1 . 001 nuclear build full ' L' L ' 86' ' ' VAL . . . . . 0.565 ' H ' ' HE1' ' L' ' 90' ' ' TYR . 85.6 t -123.32 132.52 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-O 117.368 -1.301 . . . . 0.0 108.867 -174.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -60.59 85.29 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 131.024 3.73 . . . . 0.0 109.365 163.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 172.88 -171.72 44.59 Favored Glycine 0 CA--C 1.523 0.536 1 C-N-CA 132.56 4.886 . . . . 0.0 112.895 -160.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -71.5 140.26 49.88 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.059 1.744 . . . . 0.0 112.834 167.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 90' ' ' TYR . . . . . 0.611 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 14.1 m-85 -112.1 168.75 9.36 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 120.164 -1.585 . . . . 0.0 109.955 150.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -133.31 133.91 43.17 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.833 3.253 . . . . 0.0 112.39 -177.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.67 121.9 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 CA-C-O 125.448 2.547 . . . . 0.0 105.716 -169.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -135.75 118.72 16.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.937 2.495 . . . . 0.0 115.873 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.53 142.93 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 CA-C-N 113.16 -1.836 . . . . 0.0 112.718 -169.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -142.79 151.28 41.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 125.042 1.464 . . . . 0.0 108.712 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 96' ' ' LEU . . . . . 0.481 HD11 ' HB2' ' L' ' 12' ' ' PRO . 4.0 tt -133.83 116.74 16.04 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 127.656 2.383 . . . . 0.0 106.412 173.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? 62.83 -49.7 0.19 Allowed 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 127.495 2.318 . . . . 0.0 116.864 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -170.43 16.64 0.06 OUTLIER Glycine 0 CA--C 1.523 0.535 0 C-N-CA 129.608 3.48 . . . . 0.0 114.495 162.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 21.6 m120 -128.05 149.23 70.42 Favored Pre-proline 0 N--CA 1.451 -0.397 0 C-N-CA 127.943 2.497 . . . . 0.0 111.538 -163.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -80.49 -176.24 3.09 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 121.138 1.225 . . . . 0.0 113.94 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 4.1 pt -139.17 -155.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 C-N-CA 129.809 3.244 . . . . 0.0 108.444 -177.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 9.0 pttm -136.17 172.75 12.55 Favored 'General case' 0 N--CA 1.45 -0.469 1 O-C-N 115.365 -4.584 . . . . 0.0 111.009 170.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 49.0 t30 80.28 -57.68 0.34 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 130.365 3.466 . . . . 0.0 106.799 -160.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -83.06 154.35 67.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 126.403 2.314 . . . . 0.0 109.745 164.166 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -77.71 163.66 87.63 Favored 'Cis proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.666 -2.223 . . . . 0.0 113.359 -5.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 9.3 tp -162.98 147.68 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 113.24 -1.8 . . . . 0.0 113.941 -161.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.49 150.87 40.14 Favored 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 120.072 -1.643 . . . . 0.0 109.295 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 9.0 p -158.46 125.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 O-C-N 126.151 2.157 . . . . 0.0 111.019 -163.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -81.73 148.58 28.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 118.339 -0.838 . . . . 0.0 112.931 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 5.3 t -101.24 117.67 35.44 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 128.779 2.832 . . . . 0.0 108.125 -170.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 111' ' ' ILE . . . . . 0.42 HD13 HG21 ' L' ' 111' ' ' ILE . 20.2 tt -133.95 163.04 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-O 116.205 -1.855 . . . . 0.0 114.631 178.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -77.49 75.52 4.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 121.601 2.001 . . . . 0.0 112.657 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.65 -116.1 5.91 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 107.066 -2.414 . . . . 0.0 107.066 171.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.11 1.84 50.48 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 167.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 65.4 t30 -73.52 124.79 26.55 Favored 'General case' 0 N--CA 1.449 -0.486 0 O-C-N 117.717 -3.115 . . . . 0.0 107.494 -172.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.94 23.87 70.87 Favored Glycine 0 CA--C 1.523 0.55 0 O-C-N 120.248 -1.533 . . . . 0.0 115.297 -172.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -76.15 172.47 12.77 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 121.6 2.7 . . . . 0.0 113.597 160.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 118' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' L' ' 119' ' ' SER . 14.2 t70 -64.4 139.03 58.72 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 129.705 3.202 . . . . 0.0 111.764 160.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 119' ' ' SER . . . . . 0.408 ' HB3' HG21 ' L' ' 169' ' ' THR . 5.7 m -98.89 9.54 43.27 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 116.578 -3.827 . . . . 0.0 109.41 -11.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 60.0 p -65.05 -15.9 62.86 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.968 2.951 . . . . 0.0 118.968 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -69.66 -20.9 63.57 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.041 2.536 . . . . 0.0 111.302 171.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.52 18.12 57.43 Favored Glycine 0 C--N 1.335 0.521 0 O-C-N 127.867 3.23 . . . . 0.0 114.11 -177.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 123' ' ' SER . . . . . . . . . . . . . 47.7 m -74.42 136.57 42.37 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 127.861 2.464 . . . . 0.0 114.47 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 9.1 m-30 -62.14 146.59 50.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 128.556 2.742 . . . . 0.0 108.977 -168.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 73.2 p -162.19 143.82 10.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 128.238 2.615 . . . . 0.0 111.282 177.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.259 11.6 m-85 -61.59 143.32 56.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 114.679 -2.582 . . . . 0.0 110.128 149.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 20.3 m -68.67 105.7 2.37 Favored 'General case' 0 N--CA 1.449 -0.515 0 O-C-N 126.155 2.16 . . . . 0.0 106.623 148.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 14.5 p -150.36 140.31 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 127.511 2.324 . . . . 0.0 110.12 -178.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . 68.0 5.83 4.81 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.053 2.242 . . . . 0.0 117.053 170.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -168.47 157.11 8.65 Favored 'General case' 0 N--CA 1.447 -0.579 1 C-N-CA 134.768 5.227 . . . . 0.0 111.025 -171.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . 0.376 5.8 ptpt -59.21 -26.17 64.62 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.632 2.086 . . . . 0.0 116.632 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -148.42 146.23 28.36 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 126.669 3.128 . . . . 0.0 110.593 167.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . 0.297 46.3 mttm 68.95 -155.1 0.16 Allowed 'General case' 0 N--CA 1.449 -0.518 0 O-C-N 118.703 -2.498 . . . . 0.0 113.948 170.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . 0.332 51.7 pttt -49.0 156.04 0.55 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 120.921 3.675 . . . . 0.0 120.921 163.015 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . -81.13 153.34 33.88 Favored Glycine 0 C--N 1.335 0.501 0 O-C-N 116.903 -3.623 . . . . 0.0 109.698 159.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -73.12 -9.97 59.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 120.089 3.366 . . . . 0.0 120.089 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 74.0 t -71.48 132.06 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.504 2.321 . . . . 0.0 112.952 160.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -49.56 -51.06 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 117.822 2.527 . . . . 0.0 117.822 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 6.7 m -107.31 87.5 2.52 Favored 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 126.22 2.2 . . . . 0.0 112.294 174.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 35.0 p90 -83.49 10.29 9.25 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 116.231 -1.842 . . . . 0.0 113.245 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 146.17 -155.77 26.67 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -169.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . -105.5 -9.26 33.71 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 128.622 3.01 . . . . 0.0 113.864 -164.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -153.81 136.02 14.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 120.148 1.974 . . . . 0.0 109.469 -176.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 144' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -69.68 -31.51 69.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 116.036 1.865 . . . . 0.0 116.036 173.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -162.84 176.11 10.56 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 116.38 -3.95 . . . . 0.0 108.79 -173.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 146' ' ' GLU . . . . . 0.565 ' CD ' HH11 ' L' ' 179' ' ' ARG . 33.7 tt0 -130.58 136.52 48.98 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 160.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 2.5 p -80.12 140.4 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 112.508 -2.133 . . . . 0.0 113.345 -161.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 148' ' ' SER . . . . . . . . . . . . . 70.4 m -120.8 -12.23 8.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 113.775 -1.557 . . . . 0.0 113.379 175.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 tp -82.92 155.77 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 O-C-N 117.652 -3.155 . . . . 0.0 113.638 165.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 150' ' ' THR . . . . . . . . . . . . . 21.8 p -93.36 174.02 7.42 Favored 'General case' 0 N--CA 1.45 -0.443 1 O-C-N 116.053 -4.155 . . . . 0.0 108.746 175.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . 70.54 170.59 9.28 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 128.02 2.724 . . . . 0.0 118.449 -176.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -77.54 169.72 20.51 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.546 3.497 . . . . 0.0 114.087 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -76.0 -12.24 60.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 118.397 -2.69 . . . . 0.0 117.501 -176.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -50.29 -40.26 47.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 123.541 0.737 . . . . 0.0 110.195 164.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -101.04 6.42 43.41 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.778 -1.826 . . . . 0.0 114.206 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 57.3 mt -108.51 135.24 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 116.642 -3.786 . . . . 0.0 107.016 177.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 55.0 m -86.82 134.31 33.56 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 158' ' ' LEU . . . . . 0.412 HD23 ' H ' ' L' ' 159' ' ' ASP . 0.9 OUTLIER -109.39 140.27 43.3 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 124.972 2.32 . . . . 0.0 112.975 165.418 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 159' ' ' ASP . . . . . 0.412 ' H ' HD23 ' L' ' 158' ' ' LEU . 58.5 t0 -158.86 119.26 3.22 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 119.722 -1.861 . . . . 0.0 108.309 -170.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -153.03 158.62 42.25 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.406 0.891 . . . . 0.0 113.406 -165.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 6.0 pt -71.24 -22.19 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-O 114.745 -2.55 . . . . 0.0 110.009 163.24 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -163.23 140.67 7.64 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 129.428 3.091 . . . . 0.0 109.262 162.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -66.26 -13.4 60.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 130.036 3.334 . . . . 0.0 110.301 -168.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 2.9 mp0 -107.3 -14.61 14.84 Favored 'General case' 0 N--CA 1.447 -0.613 0 O-C-N 117.687 -3.133 . . . . 0.0 110.145 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -100.94 -45.1 5.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 118.442 2.756 . . . . 0.0 118.442 171.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . -70.49 -165.81 5.87 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 129.323 3.344 . . . . 0.0 113.275 167.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 1.5 t -169.52 177.29 4.67 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -52.06 170.09 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 127.126 2.17 . . . . 0.0 114.826 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 169' ' ' THR . . . . . 0.408 HG21 ' HB3' ' L' ' 119' ' ' SER . 11.3 t -155.29 153.93 31.33 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 127.703 2.401 . . . . 0.0 109.387 -176.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -168.69 145.45 3.74 Favored 'General case' 0 N--CA 1.45 -0.426 1 C-N-CA 133.911 4.884 . . . . 0.0 116.721 -178.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -127.34 -5.55 5.98 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 114.493 -1.231 . . . . 0.0 113.971 -172.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -76.31 135.97 39.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 128.232 2.613 . . . . 0.0 116.163 172.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 3.6 m -161.31 150.91 16.77 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 123.29 2.768 . . . . 0.0 108.862 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 20.2 mt -95.0 171.13 8.95 Favored 'General case' 0 N--CA 1.449 -0.513 1 C-N-CA 131.868 4.067 . . . . 0.0 109.601 167.358 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 35.8 t -77.83 118.19 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 126.33 1.852 . . . . 0.0 106.398 167.158 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . 160.44 -163.01 33.76 Favored Glycine 0 C--N 1.336 0.544 0 O-C-N 118.052 -2.905 . . . . 0.0 114.642 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -143.14 77.99 1.59 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 131.24 3.816 . . . . 0.0 106.949 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 178' ' ' GLY . . . . . . . . . . . . . . . -102.35 160.57 17.41 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 128.258 2.837 . . . . 0.0 110.495 174.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 179' ' ' ARG . . . . . 0.565 HH11 ' CD ' ' L' ' 146' ' ' GLU . 6.6 ptm180 -167.89 162.53 13.6 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 130.203 3.401 . . . . 0.0 117.313 177.319 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -128.52 141.09 51.49 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 114.994 -2.432 . . . . 0.0 109.634 163.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 181' ' ' SER . . . . . . . . . . . . . 30.0 m -68.81 66.55 0.13 Allowed 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 123.991 3.087 . . . . 0.0 113.695 -176.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 1.3 t -173.01 170.97 4.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 117.523 2.416 . . . . 0.0 117.523 174.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -156.77 -132.12 1.45 Allowed Glycine 0 C--N 1.335 0.473 1 C-N-CA 132.711 4.958 . . . . 0.0 109.963 175.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 184' ' ' VAL . . . . . 0.466 HG12 ' O ' ' L' ' 184' ' ' VAL . 5.0 t -132.69 101.08 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 117.585 -3.303 . . . . 0.0 110.317 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -52.37 117.31 2.75 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-O 117.706 -1.14 . . . . 0.0 110.265 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 11.1 tp -84.52 -38.57 19.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 128.982 3.926 . . . . 0.0 107.864 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -155.36 149.65 25.94 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.414 3.085 . . . . 0.0 107.956 179.167 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . 86.99 156.09 28.79 Favored Glycine 0 CA--C 1.522 0.52 0 CA-C-O 124.912 2.395 . . . . 0.0 113.668 173.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -55.64 113.9 1.64 Allowed 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 110.33 -2.935 . . . . 0.0 117.682 -175.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -71.35 125.71 27.72 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.255 174.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 16.8 mm 44.73 120.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 130.583 3.553 . . . . 0.0 111.049 -160.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -98.19 139.6 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 113.218 -1.81 . . . . 0.0 110.951 -164.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 111.5 -149.7 18.0 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 114.344 -1.298 . . . . 0.0 113.509 -175.007 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 1.1 t -151.15 142.01 15.01 Favored Pre-proline 0 N--CA 1.449 -0.5 0 C-N-CA 131.591 3.956 . . . . 0.0 112.583 -171.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -89.82 150.33 4.98 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 120.436 0.758 . . . . 0.0 110.956 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -157.2 145.96 19.78 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 120.964 3.69 . . . . 0.0 120.964 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -92.78 150.06 20.89 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 120.483 -1.386 . . . . 0.0 112.058 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -83.19 135.48 34.77 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 120.433 -1.417 . . . . 0.0 111.14 -173.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 63.0 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 115.265 1.58 . . . . 0.0 115.265 155.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 49.8 mt -110.71 137.56 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 120.626 -1.296 . . . . 0.0 111.323 162.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 126.17 144.47 6.15 Favored Glycine 0 CA--C 1.523 0.555 0 C-N-CA 125.332 1.444 . . . . 0.0 115.228 -169.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -156.16 165.45 36.37 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 123.224 1.488 . . . . 0.0 108.925 176.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -92.98 150.59 20.44 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 117.441 -3.287 . . . . 0.0 107.842 175.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 16.1 mt -91.78 167.0 12.47 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 128.656 2.783 . . . . 0.0 106.739 2.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -139.55 -13.21 1.14 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.079 1.352 . . . . 0.0 114.459 162.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 5.6 t -100.45 138.89 36.91 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.601 1.96 . . . . 0.0 113.303 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 66.5 p -123.47 166.78 17.02 Favored Pre-proline 0 N--CA 1.448 -0.541 0 C-N-CA 129.494 3.118 . . . . 0.0 112.328 -173.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -50.12 149.48 11.91 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 124.576 3.517 . . . . 0.0 116.803 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.61 -19.67 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 O-C-N 125.559 1.787 . . . . 0.0 112.055 -176.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -159.75 159.47 32.83 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 127.185 2.194 . . . . 0.0 106.572 157.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 29.2 mm -82.18 119.72 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 126.84 2.056 . . . . 0.0 107.196 169.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 3.2 m -78.98 148.19 32.66 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 126.019 2.074 . . . . 0.0 115.21 -172.229 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -70.54 117.68 12.38 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 170.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -72.15 -20.42 61.61 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.464 2.394 . . . . 0.0 117.464 175.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -151.16 172.27 16.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.617 1.567 . . . . 0.0 109.907 -170.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -118.82 -41.18 0.61 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-O 125.055 2.475 . . . . 0.0 115.313 161.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 29.5 mm 85.74 -66.09 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.47 1 C-N-CA 132.124 4.17 . . . . 0.0 111.437 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -49.7 122.14 6.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 129.478 3.111 . . . . 0.0 108.263 -162.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.98 -167.42 1.39 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 114.624 -2.608 . . . . 0.0 116.115 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -57.47 127.45 44.98 Favored Glycine 0 CA--C 1.522 0.471 0 O-C-N 126.348 2.28 . . . . 0.0 110.855 -173.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo . . . . . 0 C--O 1.251 1.135 1 C-N-CA 127.641 5.561 . . . . 0.0 114.577 179.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 1' ' ' HIS . . . . . . . . . . . . . 44.7 t60 . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 117.507 -1.235 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 33.7 m-70 -128.04 155.2 44.71 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 124.909 1.381 . . . . 0.0 108.871 159.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -70.72 162.72 28.56 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 124.272 1.987 . . . . 0.0 113.818 160.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 24.5 m-70 -59.23 154.29 16.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 O-C-N 118.234 -2.791 . . . . 0.0 111.49 166.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -71.16 135.31 47.53 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 118.971 -2.331 . . . . 0.0 109.562 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 4.9 m-70 -138.85 129.82 26.57 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 110.923 -2.853 . . . . 0.0 111.632 173.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.61 28.77 4.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 131.297 3.839 . . . . 0.0 113.776 -178.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 2.2 p -166.91 150.01 6.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.999 2.12 . . . . 0.0 110.199 -172.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -107.96 102.03 43.8 Favored Pre-proline 0 N--CA 1.451 -0.412 0 N-CA-C 115.887 1.81 . . . . 0.0 115.887 172.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . 0.271 53.1 Cg_exo -38.13 140.54 0.31 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 123.013 2.475 . . . . 0.0 118.257 161.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -90.33 169.85 11.35 Favored Pre-proline 0 N--CA 1.451 -0.387 0 O-C-N 126.395 2.31 . . . . 0.0 109.507 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -62.91 137.61 63.63 Favored 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 122.606 2.204 . . . . 0.0 117.757 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 5.5 t -81.78 115.36 20.96 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 127.9 3.25 . . . . 0.0 111.349 155.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -50.05 -37.49 33.61 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 129.061 2.944 . . . . 0.0 112.919 166.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -63.77 -49.98 70.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 128.314 2.646 . . . . 0.0 111.6 176.111 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -113.53 -23.63 9.69 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.45 1.9 . . . . 0.0 113.452 -151.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 73.0 m -70.18 146.11 51.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 120.327 -1.483 . . . . 0.0 109.023 173.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 24.8 p90 -154.94 176.53 12.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.571 1.948 . . . . 0.0 111.492 -164.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -142.47 140.72 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 125.595 1.81 . . . . 0.0 110.748 172.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -147.26 134.92 21.05 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 125.884 2.754 . . . . 0.0 110.351 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.99 -168.11 41.08 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 125.306 2.615 . . . . 0.0 112.528 157.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -54.24 -34.37 60.56 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-N 112.428 -1.886 . . . . 0.0 110.526 178.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -46.41 -16.77 0.19 Allowed Glycine 0 C--N 1.335 0.482 0 C-N-CA 127.801 2.62 . . . . 0.0 118.901 166.466 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 13.5 mt -119.26 21.59 12.17 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.149 2.18 . . . . 0.0 114.236 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -133.19 -58.42 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-O 121.737 0.779 . . . . 0.0 110.525 -171.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 35.1 tttt -149.23 98.89 2.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.624 1.202 . . . . 0.0 108.659 -154.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 37.9 t -141.52 131.92 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 114.278 -2.773 . . . . 0.0 111.344 -152.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -127.2 149.54 49.94 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 119.58 3.178 . . . . 0.0 119.58 -158.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -63.35 -14.18 47.16 Favored 'General case' 0 N--CA 1.448 -0.542 0 O-C-N 124.694 1.246 . . . . 0.0 113.114 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . 0.263 14.4 p-10 -113.02 3.33 16.12 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.741 2.126 . . . . 0.0 116.741 169.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.41 137.91 11.32 Favored Pre-proline 0 N--CA 1.45 -0.441 1 N-CA-C 122.177 4.14 . . . . 0.0 122.177 -167.537 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -77.78 160.49 30.97 Favored 'Trans proline' 0 N--CA 1.447 -1.22 1 C-N-CA 128.078 5.852 . . . . 0.0 111.178 -172.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -141.35 152.38 44.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 126.206 2.191 . . . . 0.0 113.795 -173.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 34' ' ' GLU . . . . . 0.522 ' HA ' ' O ' ' L' ' 80' ' ' VAL . 11.3 mt-10 -128.0 152.32 48.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 124.912 1.285 . . . . 0.0 111.583 -167.732 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . 0.305 4.1 p90 -160.44 153.86 22.12 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.692 2.397 . . . . 0.0 106.735 -173.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 1.2 m -121.53 129.04 52.65 Favored 'General case' 0 N--CA 1.448 -0.535 0 O-C-N 123.626 0.579 . . . . 0.0 110.269 -169.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.314 4.1 mt -73.93 104.79 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 166.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -91.92 115.28 27.93 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 124.284 1.993 . . . . 0.0 108.923 168.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.14 145.71 28.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 118.347 -2.721 . . . . 0.0 109.009 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t -140.02 129.05 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 110.292 -3.14 . . . . 0.0 110.552 -175.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 35.2 p30 -75.31 176.05 7.79 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 127.84 3.686 . . . . 0.0 117.856 -177.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 12.1 p -50.83 -12.35 0.1 Allowed 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 110.32 -3.127 . . . . 0.0 117.717 173.147 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . 0.264 21.6 pttm -114.27 4.09 15.33 Favored 'General case' 0 N--CA 1.449 -0.516 0 O-C-N 125.307 1.629 . . . . 0.0 111.464 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.59 12.56 62.51 Favored Glycine 0 CA--C 1.523 0.541 0 C-N-CA 127.517 2.484 . . . . 0.0 117.972 -175.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . . 3.1 t -115.79 119.15 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 126.272 1.829 . . . . 0.0 113.095 -174.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . -24.43 139.73 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 117.996 2.591 . . . . 0.0 117.996 167.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . 0.271 11.1 mmm180 -76.83 153.37 34.91 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.252 1.821 . . . . 0.0 110.603 -177.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 43.2 p -124.41 -1.53 8.09 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 128.513 2.725 . . . . 0.0 115.265 -165.307 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -161.52 167.29 25.72 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -168.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.63 175.56 40.53 Favored Glycine 0 C--N 1.335 0.498 1 N-CA-C 125.415 4.926 . . . . 0.0 125.415 175.145 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 66.4 49.08 59.07 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 125.745 1.641 . . . . 0.0 112.544 161.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -83.38 150.38 60.25 Favored Pre-proline 0 N--CA 1.449 -0.512 0 CA-C-O 115.014 -2.422 . . . . 0.0 116.948 151.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -91.7 59.74 0.96 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 106.833 -2.026 . . . . 0.0 106.833 -164.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -69.7 155.7 40.11 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 117.929 2.566 . . . . 0.0 117.929 156.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.98 146.78 31.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 116.516 -1.707 . . . . 0.0 109.78 178.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -125.64 140.26 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 119.979 1.263 . . . . 0.0 111.882 -173.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.96 29.55 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 114.272 -2.775 . . . . 0.0 111.956 -176.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 15.7 mt -135.75 134.04 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 1 C-N-CA 131.898 4.079 . . . . 0.0 110.13 -178.695 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -120.91 148.69 43.71 Favored 'General case' 0 N--CA 1.45 -0.444 1 C-N-CA 133.445 4.698 . . . . 0.0 110.901 -178.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -148.63 -162.61 10.34 Favored Glycine 0 CA--C 1.522 0.504 0 CA-C-O 124.714 2.285 . . . . 0.0 114.931 -171.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.42 149.37 86.63 Favored 'Trans proline' 0 N--CA 1.448 -1.153 1 C-N-CA 125.403 4.069 . . . . 0.0 110.892 -178.101 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.83 -125.61 0.95 Allowed 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.724 2.41 . . . . 0.0 109.461 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -89.83 -9.26 66.34 Favored Glycine 0 C--N 1.335 0.506 1 O-C-N 114.457 -5.152 . . . . 0.0 111.314 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 8.8 tp -62.32 124.58 21.28 Favored 'General case' 0 N--CA 1.447 -0.593 0 O-C-N 118.358 -2.848 . . . . 0.0 113.467 -155.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 15.4 m -108.51 156.49 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 150.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 89.0 t -122.64 136.22 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 125.609 1.818 . . . . 0.0 110.084 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -89.96 118.04 29.23 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -63.22 147.04 52.07 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 118.564 -2.585 . . . . 0.0 116.922 172.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -116.92 119.94 36.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 64.2 t -112.62 143.99 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 CA-C-O 123.55 1.643 . . . . 0.0 108.434 -173.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -139.77 117.53 11.63 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 114.47 -1.241 . . . . 0.0 112.253 170.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -81.27 121.88 26.73 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 129.052 2.941 . . . . 0.0 109.456 178.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -77.61 -5.38 50.08 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 115.704 -2.093 . . . . 0.0 115.274 175.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 71.22 24.3 3.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 125.628 3.831 . . . . 0.0 112.092 -175.007 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -149.16 -12.52 0.31 Allowed 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 117.103 -3.498 . . . . 0.0 111.028 -160.48 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 115.86 5.34 18.07 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 120.103 2.801 . . . . 0.0 120.103 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 18.8 p -136.15 157.34 47.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.342 3.057 . . . . 0.0 111.391 170.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -130.43 140.1 50.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 116.666 -1.635 . . . . 0.0 108.956 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -77.32 132.89 12.49 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 127.346 2.403 . . . . 0.0 114.86 160.124 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 80' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' L' ' 34' ' ' GLU . 2.6 t -126.14 128.52 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 127.733 2.666 . . . . 0.0 115.65 174.336 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -136.4 143.04 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 120.645 -1.284 . . . . 0.0 113.225 174.444 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -151.04 -178.94 6.9 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 114.79 -1.096 . . . . 0.0 111.607 175.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -137.27 107.22 6.29 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.56 1.944 . . . . 0.0 111.338 178.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 84' ' ' ALA . . . . . 0.549 ' HB1' ' CD1' ' L' ' 90' ' ' TYR 0.28 . . -68.63 110.43 5.87 Favored Pre-proline 0 N--CA 1.45 -0.453 0 C-N-CA 124.843 1.257 . . . . 0.0 109.54 164.204 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 85' ' ' PRO . . . . . . . . . . . . 0.264 50.0 Cg_endo -67.29 -10.02 27.22 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 126.546 4.831 . . . . 0.0 117.866 -167.987 . . . . . . . . 3 2 . 1 . 002 nuclear build full ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.61 154.16 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-N 119.827 1.194 . . . . 0.0 110.209 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -43.97 130.15 5.88 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 150.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 145.37 -149.65 21.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 127.618 2.532 . . . . 0.0 111.643 -174.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -121.98 153.93 37.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 127.033 2.133 . . . . 0.0 113.391 -178.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 90' ' ' TYR . . . . . 0.549 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 52.6 m-85 -152.27 156.39 39.59 Favored 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.332 1.853 . . . . 0.0 108.398 -172.234 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . 0.325 2.9 t30 -133.55 114.32 13.43 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.007 1.323 . . . . 0.0 111.512 -165.021 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 20.5 t -108.55 139.17 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-N 112.972 -1.922 . . . . 0.0 110.246 -164.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -155.1 106.49 2.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.659 2.784 . . . . 0.0 117.162 -173.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 94' ' ' VAL . . . . . 0.461 ' HB ' ' HG3' ' L' ' 104' ' ' MET . 33.1 t -94.56 142.63 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 111.899 -2.41 . . . . 0.0 108.873 159.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 95' ' ' THR . . . . . 0.409 ' HB ' ' H ' ' L' ' 96' ' ' LEU . 35.0 p -137.42 -144.36 0.19 Allowed 'General case' 0 N--CA 1.451 -0.384 0 O-C-N 128.946 3.903 . . . . 0.0 117.431 -173.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 96' ' ' LEU . . . . . 0.409 ' H ' ' HB ' ' L' ' 95' ' ' THR . 6.0 tp -150.72 154.52 37.54 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 123.667 2.94 . . . . 0.0 115.016 168.232 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 33.3 ttm180 -64.36 94.88 0.12 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 124.202 1.953 . . . . 0.0 109.856 142.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . 121.41 -153.16 16.71 Favored Glycine 0 N--CA 1.448 -0.504 1 C-N-CA 131.032 4.158 . . . . 0.0 110.295 -171.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -71.47 113.87 23.21 Favored Pre-proline 0 N--CA 1.449 -0.487 0 CA-C-O 113.358 -3.21 . . . . 0.0 108.551 -170.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -74.63 160.29 41.4 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 O-C-N 127.079 3.147 . . . . 0.0 114.23 -165.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.7 pt -90.07 138.81 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 O-C-N 117.064 -3.522 . . . . 0.0 112.071 -159.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 23.0 mmtt -92.59 -178.73 4.97 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-O 117.352 -1.309 . . . . 0.0 109.396 -173.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 72.64 -44.44 0.59 Allowed 'General case' 0 N--CA 1.448 -0.537 0 CA-C-O 126.797 3.189 . . . . 0.0 110.894 -154.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 104' ' ' MET . . . . . 0.461 ' HG3' ' HB ' ' L' ' 94' ' ' VAL . 28.0 mmt -69.74 155.25 93.84 Favored Pre-proline 0 N--CA 1.448 -0.541 0 CA-C-O 112.347 -3.692 . . . . 0.0 107.741 153.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -75.13 159.92 97.19 Favored 'Cis proline' 0 N--CA 1.447 -1.213 0 O-C-N 125.453 2.291 . . . . 0.0 110.481 -18.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 12.5 tt -151.55 141.05 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.163 -1.38 . . . . 0.0 112.709 -174.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -95.62 136.14 36.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.659 3.183 . . . . 0.0 113.692 173.603 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.27 143.25 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 128.979 2.911 . . . . 0.0 103.284 -163.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -111.75 147.4 35.72 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 126.321 1.848 . . . . 0.0 113.807 177.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 41.0 t -127.43 138.96 53.11 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 125.747 1.905 . . . . 0.0 106.356 -172.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 1.3 pp -136.19 158.84 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 128.125 2.57 . . . . 0.0 110.413 -177.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . 0.252 14.5 tt0 -56.72 125.42 22.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -177.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . -108.3 141.64 15.83 Favored Glycine 0 C--N 1.336 0.544 0 CA-C-O 117.534 -1.703 . . . . 0.0 111.593 147.494 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.61 129.41 41.94 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 116.46 2.022 . . . . 0.0 116.46 -177.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -56.62 -54.59 44.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 O-C-N 125.548 1.78 . . . . 0.0 115.53 174.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . -105.51 -151.78 20.38 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 126.882 2.182 . . . . 0.0 112.541 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -80.11 156.37 27.06 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-O 118.647 -0.692 . . . . 0.0 112.347 157.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 118' ' ' ASP . . . . . . . . . . . . 0.252 35.3 t70 -160.96 142.14 11.73 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.087 -166.589 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 51.1 m -63.88 -43.51 95.82 Favored 'General case' 0 N--CA 1.45 -0.444 1 O-C-N 113.808 -5.558 . . . . 0.0 112.356 1.055 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 90.0 p 179.43 169.1 1.07 Allowed 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.132 -2.23 . . . . 0.0 108.283 -163.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -92.59 130.17 38.31 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 122.785 2.539 . . . . 0.0 108.772 161.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . -169.96 -152.07 7.76 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 127.282 2.372 . . . . 0.0 116.538 -172.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 123' ' ' SER . . . . . . . . . . . . . 61.6 p -157.43 -103.82 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 126.292 1.819 . . . . 0.0 113.408 -174.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . 0.32 26.3 p90 -145.2 150.03 35.99 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 119.554 3.168 . . . . 0.0 119.554 -176.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 3.4 p -135.9 153.56 51.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 118.077 -2.89 . . . . 0.0 112.684 -166.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.338 56.9 t80 -66.22 154.51 39.64 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -174.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 12.9 t -60.42 149.24 34.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 130.256 3.422 . . . . 0.0 112.574 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 21.6 m -71.21 135.79 27.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 CA-C-N 112.599 -2.091 . . . . 0.0 110.093 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . -163.19 157.39 20.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.405 1.482 . . . . 0.0 111.902 173.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -78.31 153.55 31.65 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 121.976 0.893 . . . . 0.0 111.667 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -52.46 -24.26 7.6 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 120.291 -1.505 . . . . 0.0 112.277 -172.111 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -85.19 -16.19 41.16 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 120.592 -1.318 . . . . 0.0 113.444 -176.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -89.32 134.25 34.14 Favored 'General case' 0 N--CA 1.449 -0.516 0 O-C-N 119.446 -2.034 . . . . 0.0 113.843 178.093 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . . 48.9 tptt -68.3 125.03 25.13 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 123.92 1.819 . . . . 0.0 112.601 -179.227 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . -104.75 165.62 14.67 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 112.364 -2.198 . . . . 0.0 117.411 167.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -110.04 134.31 52.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 126.411 1.884 . . . . 0.0 111.393 -175.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 4.3 t -109.2 -34.54 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 127.062 2.145 . . . . 0.0 116.374 -176.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 59.6 mttt -71.04 -20.4 62.39 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 118.915 2.932 . . . . 0.0 118.915 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 17.8 m -107.32 145.53 32.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.11 3.364 . . . . 0.0 110.346 -178.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 79.4 t80 -142.27 131.78 23.81 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 125.403 2.525 . . . . 0.0 109.396 179.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.08 -163.84 51.01 Favored Glycine 0 CA--C 1.523 0.54 0 O-C-N 119.961 -1.712 . . . . 0.0 108.943 -170.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . 70.89 -135.57 24.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 118.022 1.969 . . . . 0.0 118.022 -165.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -91.31 -44.26 9.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 112.245 -1.977 . . . . 0.0 111.118 -160.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 144' ' ' LYS . . . . . 0.446 ' HE2' ' O ' ' L' ' 183' ' ' GLY . 89.4 mttt -80.05 31.7 0.27 Allowed 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 118.397 -2.689 . . . . 0.0 113.965 175.191 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -117.41 150.5 38.78 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 117.877 -3.015 . . . . 0.0 113.808 172.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 146' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -100.11 140.06 34.88 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 117.594 -3.191 . . . . 0.0 105.816 162.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 2.3 t -117.69 97.13 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-N 121.671 2.032 . . . . 0.0 107.07 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 148' ' ' SER . . . . . 0.406 ' HA ' ' HA2' ' L' ' 178' ' ' GLY 0.295 20.1 m -78.85 -7.63 58.08 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 127.193 2.197 . . . . 0.0 116.288 175.872 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . . 32.5 pt -92.44 167.88 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 119.519 -1.988 . . . . 0.0 113.464 164.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 150' ' ' THR . . . . . . . . . . . . . 22.3 m -94.53 95.89 9.1 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.16 -2.904 . . . . 0.0 103.16 169.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . 164.85 170.06 29.3 Favored Glycine 0 C--N 1.335 0.524 0 O-C-N 126.45 2.344 . . . . 0.0 115.502 -175.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -85.41 166.27 10.69 Favored 'Trans proline' 0 N--CA 1.449 -1.135 1 C-N-CA 126.125 4.55 . . . . 0.0 111.59 -170.118 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -133.01 80.0 1.87 Allowed 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 112.374 -2.194 . . . . 0.0 112.445 173.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -68.08 131.09 44.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 O-C-N 118.093 -2.879 . . . . 0.0 110.426 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -63.52 121.98 15.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 118.28 2.696 . . . . 0.0 118.28 176.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 4.8 tt -138.65 160.14 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-O 124.004 1.859 . . . . 0.0 114.167 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 28.6 m -78.89 131.3 36.37 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 115.025 -2.417 . . . . 0.0 108.833 173.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 22.4 tp -61.8 142.62 57.2 Favored 'General case' 0 N--CA 1.451 -0.406 1 C-N-CA 132.264 4.226 . . . . 0.0 109.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -151.66 142.49 22.92 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 127.113 2.165 . . . . 0.0 110.336 178.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -75.54 69.75 2.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.43 3.492 . . . . 0.0 113.831 175.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 15.1 pt -78.44 162.05 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 130.52 3.528 . . . . 0.0 111.279 -171.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -64.69 143.36 57.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 124.948 1.405 . . . . 0.0 114.21 163.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 10.7 t-20 -62.38 -18.12 60.77 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 112.606 -3.568 . . . . 0.0 114.079 173.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 -140.49 -29.54 0.68 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 125.549 3.795 . . . . 0.0 119.157 -177.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -75.35 111.19 10.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 114.247 1.203 . . . . 0.0 114.247 167.294 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . 98.99 -15.2 60.9 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 117.797 1.879 . . . . 0.0 117.797 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 6.7 m -46.89 -27.3 1.2 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 129.771 3.229 . . . . 0.0 117.396 177.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 7.4 p90 -55.08 -24.87 27.61 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 121.348 3.833 . . . . 0.0 121.348 170.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 169' ' ' THR . . . . . . . . . . . . . 59.0 p -75.33 -41.82 55.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 121.458 1.935 . . . . 0.0 115.798 176.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -62.44 174.48 0.96 Allowed 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 131.114 3.766 . . . . 0.0 117.028 173.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -107.52 125.63 51.52 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 111.853 -2.431 . . . . 0.0 104.781 -170.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 70.9 t80 -154.6 111.1 3.27 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.597 1.544 . . . . 0.0 110.308 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 85.0 p -159.5 -176.13 5.59 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 130.22 3.408 . . . . 0.0 110.285 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 12.3 tp -70.38 115.32 9.43 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 112.668 -2.06 . . . . 0.0 113.818 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.86 135.26 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.347 1.459 . . . . 0.0 110.315 172.057 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . -138.25 -145.01 4.76 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 129.944 3.64 . . . . 0.0 111.884 173.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -72.11 132.16 43.81 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 124.6 2.143 . . . . 0.0 114.024 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 178' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' L' ' 148' ' ' SER . . . -53.22 130.78 41.52 Favored Glycine 0 CA--C 1.523 0.569 0 C-N-CA 129.19 3.281 . . . . 0.0 114.099 174.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 179' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -132.43 147.59 52.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 O-C-N 128.009 2.829 . . . . 0.0 111.757 172.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 74.55 154.68 0.15 Allowed 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 119.579 -1.951 . . . . 0.0 111.901 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 181' ' ' SER . . . . . . . . . . . . 0.253 23.2 t 150.96 132.65 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 129.418 3.087 . . . . 0.0 112.305 163.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 38.1 m -95.19 151.74 18.96 Favored 'General case' 0 N--CA 1.449 -0.493 1 C-N-CA 131.739 4.015 . . . . 0.0 108.104 161.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 183' ' ' GLY . . . . . 0.446 ' O ' ' HE2' ' L' ' 144' ' ' LYS . . . -88.25 -175.04 47.68 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.911 -176.033 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 13.5 m -83.68 144.9 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 O-C-N 126.735 2.08 . . . . 0.0 111.732 155.272 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 53.5 tttp -69.05 130.26 42.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.703 2.401 . . . . 0.0 114.987 168.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 37.6 mt -100.42 -41.2 7.11 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 117.684 2.475 . . . . 0.0 117.684 -176.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -78.64 171.8 14.61 Favored 'General case' 0 N--CA 1.449 -0.509 1 C-N-CA 133.488 4.715 . . . . 0.0 113.457 -173.28 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -85.94 -154.79 24.59 Favored Glycine 0 C--N 1.336 0.534 0 C-N-CA 126.455 1.978 . . . . 0.0 109.592 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 18.2 ttmt -79.22 0.13 29.77 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 116.743 -1.599 . . . . 0.0 110.937 -174.253 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -62.35 148.04 46.47 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 122.478 2.399 . . . . 0.0 109.286 171.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 4.7 mt -131.28 129.43 62.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 1 C-N-CA 133.797 4.839 . . . . 0.0 106.997 178.02 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -100.16 141.67 32.67 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 127.356 2.91 . . . . 0.0 111.554 156.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 102.54 9.21 41.58 Favored Glycine 0 CA--C 1.523 0.588 0 CA-C-N 122.202 2.274 . . . . 0.0 117.964 166.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 46.2 m -65.39 134.23 95.6 Favored Pre-proline 0 N--CA 1.448 -0.557 1 CA-C-O 111.53 -4.081 . . . . 0.0 111.985 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -36.28 122.61 0.3 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 1 C-N-CA 128.439 6.092 . . . . 0.0 113.412 167.312 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -98.21 162.4 13.22 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.369 1.467 . . . . 0.0 109.668 172.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -64.72 148.41 51.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -164.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 91.6 mm-40 -117.56 143.27 46.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 O-C-N 119.545 -1.972 . . . . 0.0 109.242 163.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.1 139.91 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 119.031 -2.293 . . . . 0.0 111.331 -168.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 57.8 tp -146.42 117.5 7.79 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 110.474 -3.057 . . . . 0.0 108.872 168.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 81.12 173.93 48.28 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 127.195 2.331 . . . . 0.0 114.627 175.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 27.2 t30 -110.97 134.6 52.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -146.28 150.11 35.15 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 115.411 -2.233 . . . . 0.0 112.178 -170.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 55.6 mt -67.45 161.51 25.18 Favored 'General case' 0 N--CA 1.449 -0.483 1 C-N-CA 134.181 4.993 . . . . 0.0 109.836 0.279 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 55.7 t80 -62.51 137.82 58.34 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 126.13 2.871 . . . . 0.0 107.529 -177.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.98 119.56 33.7 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 117.356 -3.34 . . . . 0.0 112.201 -171.504 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 4.3 m -79.17 130.18 70.17 Favored Pre-proline 0 N--CA 1.451 -0.415 0 O-C-N 117.571 -3.206 . . . . 0.0 109.646 -162.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -64.3 125.17 14.59 Favored 'Trans proline' 0 N--CA 1.448 -1.185 1 C-N-CA 125.327 4.018 . . . . 0.0 109.267 173.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 6.9 p -163.07 159.36 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 130.171 3.388 . . . . 0.0 111.353 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 9.1 p90 -80.81 137.68 36.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.826 2.05 . . . . 0.0 113.735 177.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 40.9 mm -67.67 125.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 119.462 -2.024 . . . . 0.0 107.646 171.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 212' ' ' SER . . . . . . . . . . . . 0.255 40.2 m -87.09 156.88 19.54 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 124.082 3.128 . . . . 0.0 110.81 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -56.65 151.88 13.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 131.096 3.758 . . . . 0.0 118.168 171.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -114.93 156.95 24.07 Favored 'General case' 0 N--CA 1.447 -0.579 0 O-C-N 117.44 -3.288 . . . . 0.0 110.012 159.267 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . 0.283 12.5 pt20 -69.27 154.53 41.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 119.916 1.235 . . . . 0.0 112.95 -175.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -86.09 -154.08 23.51 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 130.361 3.839 . . . . 0.0 117.497 160.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . 0.306 1.4 pp -127.33 -7.82 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 129.985 3.314 . . . . 0.0 113.268 -178.468 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -60.07 126.31 27.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -111.66 -146.2 0.4 Allowed 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 131.501 3.92 . . . . 0.0 114.228 175.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -96.96 134.11 11.64 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -177.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.449 -1.127 1 C-N-CA 129.827 7.018 . . . . 0.0 112.234 169.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 1' ' ' HIS . . . . . . . . . . . . . 52.4 t-80 . . . . . 0 N--CA 1.471 0.6 0 CA-C-O 122.688 1.232 . . . . 0.0 113.152 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -67.8 137.95 55.78 Favored 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 117.594 -3.191 . . . . 0.0 115.475 178.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 126.903 2.081 . . . . 0.0 109.87 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 48.3 t60 -85.44 -46.7 10.66 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 166.173 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -75.16 172.29 12.65 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.22 -2.175 . . . . 0.0 113.13 -174.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 3.9 t60 -75.09 -54.73 6.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 120.414 -1.429 . . . . 0.0 109.044 -165.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.42 140.03 37.52 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.415 2.686 . . . . 0.0 110.737 -173.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 86.9 p -176.53 147.58 0.67 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 117.386 2.365 . . . . 0.0 117.386 -155.642 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -128.06 124.5 23.13 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 128.628 2.771 . . . . 0.0 113.056 -173.457 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -57.65 157.53 22.98 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 124.204 3.27 . . . . 0.0 115.401 -177.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.54 -10.19 0.11 Allowed Pre-proline 0 N--CA 1.45 -0.441 0 CA-C-O 116.149 -1.882 . . . . 0.0 114.411 165.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -66.9 -176.54 0.77 Allowed 'Trans proline' 0 N--CA 1.449 -1.118 1 C-N-CA 126.438 4.758 . . . . 0.0 115.166 155.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 2.6 p -158.51 154.81 27.34 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 123.064 1.411 . . . . 0.0 112.941 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.81 -53.18 60.96 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 112.605 -2.089 . . . . 0.0 112.725 -165.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 16.8 mp0 -48.61 -20.86 0.49 Allowed 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 129.416 3.086 . . . . 0.0 118.741 177.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -117.2 -54.79 2.38 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 127.976 2.511 . . . . 0.0 109.923 -170.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 17' ' ' SER . . . . . . . . . . . . 0.721 0.5 OUTLIER -67.1 149.87 49.96 Favored 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.84 -4.913 . . . . 0.0 112.642 -165.154 . . . . . . . . 4 3 . 1 . 003 nuclear build full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 22.0 p90 -163.09 172.52 14.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 128.093 2.557 . . . . 0.0 108.883 -164.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -139.51 147.89 41.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 128.018 2.527 . . . . 0.0 110.387 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -149.98 144.18 25.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 125.423 1.702 . . . . 0.0 115.41 -175.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . 138.03 -166.19 25.23 Favored Glycine 0 C--N 1.335 0.527 0 CA-C-O 124.597 2.221 . . . . 0.0 115.066 168.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . 0.285 55.2 tt0 -42.46 -62.97 0.84 Allowed 'General case' 0 N--CA 1.448 -0.54 1 C-N-CA 131.948 4.099 . . . . 0.0 109.72 -178.732 . . . . . . . . 3 2 . 1 . 003 nuclear build full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.73 14.98 0.07 OUTLIER Glycine 0 C--N 1.336 0.572 0 N-CA-C 120.404 2.922 . . . . 0.0 120.404 178.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 75.3 mt -122.57 0.92 9.45 Favored 'General case' 0 N--CA 1.449 -0.512 1 C-N-CA 132.246 4.218 . . . . 0.0 112.572 167.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 1.4 p -141.4 -15.26 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 124.405 3.275 . . . . 0.0 112.466 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -162.87 92.54 0.78 Allowed 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 124.649 2.166 . . . . 0.0 115.614 -160.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 27' ' ' VAL . . . . . 0.471 HG13 ' CD1' ' L' ' 90' ' ' TYR 0.305 12.8 p -147.78 147.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 O-C-N 119.467 -2.02 . . . . 0.0 113.836 179.055 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' L' L ' 28' ' ' PHE . . . . . 0.488 ' HA ' ' SG ' ' L' ' 110' ' ' CYS . 12.9 t80 -137.1 -170.89 2.81 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 -170.098 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -86.09 -44.68 12.06 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 117.994 -2.942 . . . . 0.0 113.324 -175.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 47.5 p-10 -106.28 30.62 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 123.589 1.661 . . . . 0.0 111.456 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.87 125.06 2.42 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 115.933 -1.984 . . . . 0.0 114.693 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -85.44 175.35 6.31 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 123.803 3.002 . . . . 0.0 113.762 -175.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -148.39 170.67 17.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 177.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -142.31 155.06 45.17 Favored 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 128.235 2.614 . . . . 0.0 116.025 -170.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -163.14 166.02 23.9 Favored 'General case' 0 N--CA 1.448 -0.533 1 O-C-N 114.688 -5.007 . . . . 0.0 108.79 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 36' ' ' THR . . . . . 0.443 ' HA ' ' O ' ' L' ' 78' ' ' TYR . 21.3 m -131.82 133.82 45.11 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.397 1.628 . . . . 0.0 115.397 -162.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.267 8.6 mt -81.52 104.29 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 127.056 2.142 . . . . 0.0 110.498 174.398 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -81.36 121.0 25.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 118.696 -1.201 . . . . 0.0 107.988 168.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -73.96 120.5 19.63 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.509 3.123 . . . . 0.0 107.262 173.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 1.8 t -149.91 141.34 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 123.69 1.71 . . . . 0.0 107.567 176.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -119.1 -2.26 10.78 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 111.287 -2.688 . . . . 0.0 110.87 -174.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 62.1 p -157.91 175.48 13.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 116.814 -3.679 . . . . 0.0 107.699 -161.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . . 26.7 mtpt -70.74 8.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 115.504 1.668 . . . . 0.0 115.504 175.098 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . -125.6 -146.89 6.83 Favored Glycine 0 C--N 1.336 0.581 0 CA-C-N 120.388 1.449 . . . . 0.0 114.791 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . 0.31 14.3 m -51.78 160.2 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 129.104 2.962 . . . . 0.0 113.936 -178.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.87 174.49 1.44 Allowed 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 124.632 2.158 . . . . 0.0 111.911 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 16.6 mmm-85 -70.65 164.1 25.67 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 112.263 -2.244 . . . . 0.0 108.551 164.392 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 71.0 p -117.32 21.63 12.99 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 126.819 2.048 . . . . 0.0 111.987 -169.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -167.96 147.47 4.81 Favored 'General case' 0 N--CA 1.448 -0.535 1 C-N-CA 134.1 4.96 . . . . 0.0 118.489 -178.559 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -91.49 -131.84 5.33 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 126.598 2.047 . . . . 0.0 116.646 -174.637 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.62 -18.86 1.24 Allowed Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 119.63 2.612 . . . . 0.0 119.63 173.252 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -63.29 150.44 89.3 Favored Pre-proline 0 N--CA 1.448 -0.564 0 CA-C-N 119.522 1.661 . . . . 0.0 113.799 175.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -78.84 109.04 2.52 Favored 'Trans proline' 0 N--CA 1.449 -1.107 1 C-N-CA 125.337 4.024 . . . . 0.0 111.847 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -117.42 174.78 5.95 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 116.512 -1.708 . . . . 0.0 114.514 177.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -161.35 150.49 16.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 124.866 2.27 . . . . 0.0 112.004 -174.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 11.6 p -127.7 143.08 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.033 -2.292 . . . . 0.0 108.89 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -139.61 111.42 7.32 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-O 116.131 -1.89 . . . . 0.0 108.85 168.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . 0.279 29.3 mt -116.91 142.77 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 128.476 2.71 . . . . 0.0 107.69 175.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -134.41 148.14 50.58 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.354 3.462 . . . . 0.0 116.0 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -130.83 -148.19 6.24 Favored Glycine 0 N--CA 1.449 -0.498 0 O-C-N 119.01 -2.306 . . . . 0.0 109.769 -171.075 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . 0.304 51.8 Cg_endo -71.3 138.03 32.22 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.685 2.924 . . . . 0.0 114.557 -169.421 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 19.0 t70 81.99 -52.27 0.24 Allowed 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 128.814 2.846 . . . . 0.0 109.388 163.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 63' ' ' GLY . . . . . 0.401 ' H ' ' H ' ' L' ' 64' ' ' LEU . . . -159.4 -22.2 0.03 OUTLIER Glycine 0 C--N 1.337 0.608 0 C-N-CA 129.791 3.567 . . . . 0.0 113.525 175.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 64' ' ' LEU . . . . . 0.401 ' H ' ' H ' ' L' ' 63' ' ' GLY . 55.8 tp -45.52 104.06 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 131.149 3.779 . . . . 0.0 115.394 -165.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.94 117.59 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-O 124.646 2.165 . . . . 0.0 107.651 165.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.52 125.79 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -65.68 130.07 41.99 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 117.466 -1.254 . . . . 0.0 108.583 172.63 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -135.92 138.59 42.54 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 126.538 2.399 . . . . 0.0 105.701 -175.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 58.0 mttp -118.06 116.38 26.75 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 126.755 2.022 . . . . 0.0 113.335 -165.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 39.6 t -94.6 143.0 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 97.6 m -142.65 120.68 12.1 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 118.405 -2.684 . . . . 0.0 106.81 166.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . 0.293 40.0 t0 -68.42 133.23 48.34 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 125.885 1.99 . . . . 0.0 110.165 170.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 -93.91 -2.65 52.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 118.256 2.687 . . . . 0.0 118.256 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 82.25 -33.02 0.09 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 128.673 2.789 . . . . 0.0 109.223 172.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -78.97 -18.09 54.31 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 116.265 -1.826 . . . . 0.0 114.149 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 136.53 8.51 1.49 Allowed Glycine 0 C--N 1.336 0.583 0 CA-C-N 121.881 2.128 . . . . 0.0 115.125 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 76.4 p -138.39 160.06 40.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 126.456 1.902 . . . . 0.0 113.728 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 78' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' L' ' 36' ' ' THR . 1.4 m-85 -128.08 118.32 23.25 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 127.083 2.153 . . . . 0.0 107.178 177.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -75.12 132.57 13.67 Favored Glycine 0 CA--C 1.523 0.564 0 CA-C-O 117.476 -1.736 . . . . 0.0 112.603 165.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.52 130.42 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 124.283 1.992 . . . . 0.0 108.921 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 t -130.62 140.77 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 114.282 -1.326 . . . . 0.0 113.398 -167.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . 0.339 5.6 p90 -159.43 163.56 35.31 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 126.42 3.009 . . . . 0.0 115.877 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.16 139.33 12.07 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 109.687 -3.415 . . . . 0.0 110.705 -170.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 84' ' ' ALA . . . . . . . . . . . . . . . -147.73 149.23 32.97 Favored Pre-proline 0 N--CA 1.45 -0.456 0 CA-C-N 114.091 -1.413 . . . . 0.0 114.207 155.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 85' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -91.04 44.27 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.106 1 C-N-CA 125.319 4.013 . . . . 0.0 112.558 -169.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -141.92 167.31 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 112.096 -3.812 . . . . 0.0 116.302 -157.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -134.58 123.08 23.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 121.937 2.153 . . . . 0.0 109.325 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 171.94 -106.28 0.23 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 125.981 1.753 . . . . 0.0 112.617 -178.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -149.7 125.7 10.59 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 128.985 2.914 . . . . 0.0 118.153 177.233 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 90' ' ' TYR . . . . . 0.471 ' CD1' HG13 ' L' ' 27' ' ' VAL . 84.6 m-85 -87.17 139.04 30.97 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 126.563 1.945 . . . . 0.0 107.71 169.603 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -130.69 106.83 8.73 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 127.66 3.1 . . . . 0.0 105.685 -171.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 32.3 t -112.02 138.18 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 127.33 2.894 . . . . 0.0 112.521 -166.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -140.78 136.27 32.31 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.366 2.266 . . . . 0.0 114.454 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 10.1 t -122.24 147.43 26.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 O-C-N 119.299 -2.126 . . . . 0.0 107.849 174.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 16.5 p -157.13 149.87 23.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 117.446 -1.264 . . . . 0.0 111.113 -175.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 21.2 mt -72.94 32.5 0.07 Allowed 'General case' 0 N--CA 1.449 -0.518 1 C-N-CA 135.199 5.4 . . . . 0.0 111.594 -177.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 65.61 -47.35 0.39 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.14 1.776 . . . . 0.0 109.311 -170.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -123.56 -5.47 7.74 Favored Glycine 0 C--N 1.335 0.519 1 C-N-CA 131.475 4.369 . . . . 0.0 114.731 -171.76 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -145.54 139.72 15.14 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 119.984 1.892 . . . . 0.0 113.483 -172.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -84.15 164.72 13.16 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 N-CA-C 116.923 1.855 . . . . 0.0 116.923 -173.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.13 -176.54 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 O-C-N 119.277 -2.139 . . . . 0.0 107.699 -176.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -83.35 139.39 33.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.34 1.856 . . . . 0.0 113.206 -165.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 t30 63.51 27.82 15.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 126.685 2.491 . . . . 0.0 115.264 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 11.7 mmt -119.86 129.44 25.35 Favored Pre-proline 0 N--CA 1.448 -0.573 0 C-N-CA 130.765 3.626 . . . . 0.0 104.418 -172.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -79.94 169.04 71.39 Favored 'Cis proline' 0 N--CA 1.448 -1.155 0 CA-C-N 122.543 1.944 . . . . 0.0 116.66 -15.058 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 106' ' ' ILE . . . . . 0.501 HD12 ' H ' ' L' ' 107' ' ' ASP . 5.3 tp -158.85 162.0 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 O-C-N 119.405 -2.059 . . . . 0.0 110.408 -166.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 107' ' ' ASP . . . . . 0.501 ' H ' HD12 ' L' ' 106' ' ' ILE . 12.9 m-20 -132.73 146.29 51.74 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.632 1.973 . . . . 0.0 111.249 -161.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 15.2 t -138.42 118.53 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 129.201 3.0 . . . . 0.0 108.498 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -74.58 136.02 42.06 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.248 2.219 . . . . 0.0 107.294 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 110' ' ' CYS . . . . . 0.488 ' SG ' ' HA ' ' L' ' 28' ' ' PHE . 38.6 t -106.28 111.69 24.39 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.918 -1.037 . . . . 0.0 113.001 167.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 15.2 tt -156.74 152.49 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.302 3.041 . . . . 0.0 110.461 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -75.19 108.29 7.84 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 115.241 1.571 . . . . 0.0 115.241 -161.175 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . -64.03 108.69 2.37 Favored Glycine 0 C--N 1.336 0.547 0 CA-C-O 115.034 -3.092 . . . . 0.0 110.305 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -52.69 169.2 0.09 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 119.346 3.091 . . . . 0.0 119.346 -171.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -59.56 149.55 29.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 120.048 3.351 . . . . 0.0 120.048 -169.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.52 143.54 37.26 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 126.029 1.776 . . . . 0.0 111.419 172.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -139.08 163.64 31.87 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.788 1.635 . . . . 0.0 115.105 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 118' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -150.89 142.18 23.28 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 160.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 68.7 m -78.39 -26.31 46.49 Favored 'General case' 0 N--CA 1.45 -0.438 2 O-C-N 116.015 -4.178 . . . . 0.0 112.732 -2.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 4.2 t -173.02 150.97 2.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.462 2.305 . . . . 0.0 116.516 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -68.24 -7.05 27.21 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 116.935 2.198 . . . . 0.0 116.935 178.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . 140.17 -174.22 22.59 Favored Glycine 0 C--N 1.335 0.493 1 C-N-CA 132.475 4.845 . . . . 0.0 118.074 -175.408 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 123' ' ' SER . . . . . . . . . . . . 0.259 0.1 OUTLIER -74.0 -2.57 24.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 127.81 2.444 . . . . 0.0 115.149 -158.107 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -65.31 135.22 55.06 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 129.192 2.997 . . . . 0.0 108.457 -172.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 28.0 p -158.69 162.11 37.17 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.508 3.123 . . . . 0.0 103.241 -171.089 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.262 51.8 p90 -154.94 162.51 41.07 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 125.021 1.328 . . . . 0.0 113.958 -174.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 3.0 m -81.64 126.58 31.93 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 119.674 -1.891 . . . . 0.0 110.769 175.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 25.2 t -140.2 103.57 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 113.569 -1.651 . . . . 0.0 106.981 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.5 -37.54 62.84 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 129.331 3.052 . . . . 0.0 108.861 -174.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.39 -28.94 67.54 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.254 -1.529 . . . . 0.0 114.548 -174.265 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -71.81 -50.14 32.39 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 115.405 1.632 . . . . 0.0 115.405 166.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -167.9 148.46 5.1 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 129.477 3.111 . . . . 0.0 109.377 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -105.8 145.18 31.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.06 2.144 . . . . 0.0 109.607 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . 0.328 30.6 mmmt -82.65 21.76 0.96 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 129.682 3.193 . . . . 0.0 113.635 -157.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.39 -174.8 55.21 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 127.259 2.361 . . . . 0.0 114.685 -173.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -64.98 122.4 16.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 128.595 2.758 . . . . 0.0 108.715 166.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 57.2 t -93.91 111.49 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 -175.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -106.76 170.11 8.14 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 116.939 2.2 . . . . 0.0 116.939 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 47.6 p -47.31 -56.23 7.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.899 -1.751 . . . . 0.0 115.722 162.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 22.3 p90 -64.63 -20.3 66.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 119.275 3.065 . . . . 0.0 119.275 -170.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.76 163.76 31.42 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 170.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . -115.53 -169.38 15.74 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 126.154 1.835 . . . . 0.0 114.528 164.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -74.08 145.97 43.99 Favored 'General case' 0 N--CA 1.448 -0.534 0 O-C-N 117.07 -3.606 . . . . 0.0 112.978 -172.174 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 144' ' ' LYS . . . . . . . . . . . . . 76.2 mttt -91.65 -17.44 25.5 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -168.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -59.93 -43.48 94.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 121.269 1.849 . . . . 0.0 114.791 -167.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 146' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -97.87 167.24 11.04 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 127.611 3.576 . . . . 0.0 108.157 166.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -147.11 132.59 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 1 O-C-N 113.982 -5.449 . . . . 0.0 114.866 -176.498 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 148' ' ' SER . . . . . . . . . . . . . 35.3 m -66.37 -11.25 50.2 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 117.367 2.358 . . . . 0.0 117.367 -169.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . 0.276 2.0 pp -67.45 -3.81 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 123.77 2.986 . . . . 0.0 114.225 172.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 150' ' ' THR . . . . . . . . . . . . 0.259 2.8 p -68.87 155.81 39.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 120.902 1.683 . . . . 0.0 111.732 -170.341 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . -156.94 -177.67 30.29 Favored Glycine 0 C--N 1.335 0.503 0 CA-C-N 114.436 -1.256 . . . . 0.0 115.741 177.348 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -58.46 158.26 23.78 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 CA-C-O 125.179 2.075 . . . . 0.0 111.573 176.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -71.52 -9.14 57.73 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-N 112.402 -2.181 . . . . 0.0 112.743 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -149.68 143.69 25.64 Favored 'General case' 0 N--CA 1.45 -0.439 1 O-C-N 116.14 -4.1 . . . . 0.0 109.738 -176.134 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -159.5 80.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 125.07 1.481 . . . . 0.0 108.584 -175.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 33.1 pt -105.45 166.76 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 126.71 2.004 . . . . 0.0 114.782 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 80.5 p -69.06 -5.68 23.49 Favored 'General case' 0 N--CA 1.451 -0.405 1 O-C-N 116.059 -4.151 . . . . 0.0 112.744 176.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 52.5 mt -91.61 68.14 5.58 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 122.212 2.278 . . . . 0.0 110.135 170.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -74.5 120.72 20.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 111.199 -2.728 . . . . 0.0 106.036 -169.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -70.39 132.2 45.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 123.012 1.386 . . . . 0.0 107.851 -177.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 161' ' ' ILE . . . . . 0.41 HD13 HG21 ' L' ' 161' ' ' ILE . 34.2 pt -88.44 -23.26 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 120.189 3.403 . . . . 0.0 120.189 -167.021 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . 0.257 24.5 t0 -101.26 127.64 47.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 113.561 -1.654 . . . . 0.0 110.894 157.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 37.2 t30 -89.4 115.95 27.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.296 -171.571 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -98.18 132.9 43.3 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-O 117.15 -1.405 . . . . 0.0 110.577 -167.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 30.6 t0 -119.47 155.66 31.66 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 128.425 3.964 . . . . 0.0 110.167 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.02 2.98 Favored Glycine 0 CA--C 1.523 0.59 0 O-C-N 117.59 -3.194 . . . . 0.0 115.802 -169.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 167' ' ' THR . . . . . . . . . . . . 0.252 6.6 m -73.63 127.29 32.37 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 116.825 -1.559 . . . . 0.0 115.17 -174.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -116.6 126.09 52.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 115.337 -2.268 . . . . 0.0 112.015 158.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 169' ' ' THR . . . . . . . . . . . . . 6.3 t -146.11 156.78 43.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 129.427 3.091 . . . . 0.0 110.338 169.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -153.27 171.1 19.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.851 2.06 . . . . 0.0 107.103 -175.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -59.87 -44.88 93.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 174.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -121.73 166.09 14.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.092 2.256 . . . . 0.0 117.092 -175.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 11.4 m -77.83 157.61 29.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 114.833 1.42 . . . . 0.0 114.833 170.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 7.4 mp -62.89 168.69 3.74 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.176 1.791 . . . . 0.0 107.837 -157.225 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 7.5 p -159.37 133.06 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 127.125 2.17 . . . . 0.0 109.415 166.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . -65.39 163.42 39.1 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 116.233 1.253 . . . . 0.0 116.233 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -67.09 111.51 3.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 115.962 -1.971 . . . . 0.0 109.836 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 178' ' ' GLY . . . . . . . . . . . . . . . -96.69 -137.98 9.74 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 129.024 3.953 . . . . 0.0 114.359 170.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 179' ' ' ARG . . . . . . . . . . . . . 13.8 ttt180 -90.73 75.62 6.52 Favored 'General case' 0 N--CA 1.447 -0.575 0 O-C-N 120.527 -1.572 . . . . 0.0 106.886 -175.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -157.46 128.64 6.73 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.462 3.505 . . . . 0.0 113.984 178.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 181' ' ' SER . . . . . . . . . . . . . 14.9 m -83.07 115.03 21.69 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 128.214 2.606 . . . . 0.0 112.145 -157.559 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 19.7 p -95.96 146.88 24.24 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 122.724 1.25 . . . . 0.0 111.093 -177.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . 126.1 169.14 12.77 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 128.764 3.078 . . . . 0.0 113.893 -172.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 184' ' ' VAL . . . . . . . . . . . . 0.327 11.2 p -131.28 30.48 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 1 CA-C-O 128.786 4.136 . . . . 0.0 115.839 171.104 . . . . . . . . 3 2 . 1 . 003 nuclear build full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -110.08 -23.33 11.35 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 117.323 -3.361 . . . . 0.0 109.655 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 46.1 tp -137.44 148.76 46.36 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.07 2.948 . . . . 0.0 108.586 175.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -45.65 120.33 2.55 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.134 0.973 . . . . 0.0 113.187 168.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -72.2 -13.67 76.58 Favored Glycine 0 N--CA 1.447 -0.597 0 O-C-N 117.751 -3.093 . . . . 0.0 113.959 -174.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 20.1 tptp -59.69 -26.58 65.69 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 120.606 2.203 . . . . 0.0 116.053 175.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -75.4 157.26 34.44 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 116.926 -1.511 . . . . 0.0 108.39 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 10.0 tp -148.86 164.97 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 125.773 2.701 . . . . 0.0 107.967 -170.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -74.08 122.54 22.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 128.041 2.537 . . . . 0.0 110.121 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 122.33 -179.14 16.27 Favored Glycine 0 C--N 1.335 0.487 0 C-N-CA 126.247 1.879 . . . . 0.0 115.351 174.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 41.3 t -93.49 119.9 66.87 Favored Pre-proline 0 N--CA 1.45 -0.45 0 CA-C-O 118.768 -0.634 . . . . 0.0 110.793 173.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -81.18 138.94 11.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 CA-C-O 124.405 1.752 . . . . 0.0 110.26 176.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -179.96 -13.22 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 115.296 -2.288 . . . . 0.0 114.031 -171.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 69.7 tttt -59.51 -23.24 62.64 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 125.83 2.728 . . . . 0.0 117.505 166.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -78.1 109.84 12.54 Favored 'General case' 0 N--CA 1.45 -0.464 1 O-C-N 116.245 -4.034 . . . . 0.0 111.749 153.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 86.4 t -77.88 109.83 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 118.824 -2.422 . . . . 0.0 104.585 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 66.9 mt -88.39 173.91 8.45 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 167.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . -69.55 144.31 40.28 Favored Glycine 0 C--N 1.336 0.552 0 CA-C-N 121.536 1.971 . . . . 0.0 111.665 -171.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -148.8 152.78 37.12 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 126.0 1.647 . . . . 0.0 110.597 -171.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -38.3 127.77 1.37 Allowed 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 126.547 2.405 . . . . 0.0 109.346 161.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 4.8 tp -77.67 143.76 37.89 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.542 3.137 . . . . 0.0 110.363 0.043 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -101.54 -64.0 1.09 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 170.441 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 2.5 p -132.6 128.49 37.27 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.318 1.847 . . . . 0.0 110.572 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 25.4 m -45.3 125.6 5.8 Favored Pre-proline 0 N--CA 1.45 -0.459 0 CA-C-N 111.523 -2.58 . . . . 0.0 111.289 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -63.24 169.73 8.92 Favored 'Trans proline' 0 N--CA 1.448 -1.15 1 C-N-CA 126.057 4.505 . . . . 0.0 112.755 168.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.14 -175.15 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 126.012 1.725 . . . . 0.0 108.648 -171.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -90.31 163.98 14.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 114.885 1.439 . . . . 0.0 114.885 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.08 109.0 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-O 128.445 3.974 . . . . 0.0 113.873 165.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 30.4 m -71.84 94.01 1.37 Allowed 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 118.888 -2.383 . . . . 0.0 112.115 178.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -145.46 134.14 22.22 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 121.246 -0.909 . . . . 0.0 111.796 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -62.35 149.71 41.53 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 115.286 1.587 . . . . 0.0 115.286 -176.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -155.89 136.35 13.2 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 126.182 2.176 . . . . 0.0 113.351 178.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -113.44 150.45 18.51 Favored Glycine 0 C--N 1.337 0.592 0 N-CA-C 106.586 -2.605 . . . . 0.0 106.586 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 8.2 tp -154.43 -25.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -174.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -105.5 136.39 45.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 125.676 2.655 . . . . 0.0 113.029 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . 0.273 . . -84.72 164.65 18.43 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 113.647 -1.615 . . . . 0.0 112.827 -174.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -68.97 157.15 53.52 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 117.573 -3.204 . . . . 0.0 115.353 -171.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo . . . . . 0 C--O 1.251 1.162 1 C-N-CA 125.87 4.38 . . . . 0.0 116.991 170.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 12' ' ' PRO . . . . . 0.481 ' HB2' HD11 ' L' ' 96' ' ' LEU . 32.6 Cg_exo -51.72 164.73 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 124.505 3.47 . . . . 0.0 113.339 -173.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 59.7 m -89.34 121.42 31.59 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.183 2.993 . . . . 0.0 110.546 169.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.83 -14.42 61.09 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.924 2.09 . . . . 0.0 112.138 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -65.54 -26.91 68.09 Favored 'General case' 0 N--CA 1.45 -0.459 1 C-N-CA 131.724 4.01 . . . . 0.0 108.729 167.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 31.9 m170 -134.42 -25.11 1.53 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.989 2.177 . . . . 0.0 112.047 -166.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 14.6 m -79.78 145.07 33.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 O-C-N 117.532 -3.23 . . . . 0.0 110.507 173.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . 0.53 6.8 p90 -167.25 -172.0 1.88 Allowed 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 114.912 -2.471 . . . . 0.0 117.042 -176.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . 0.254 . . -150.09 139.04 20.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 116.253 -2.179 . . . . 0.0 110.79 -148.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -147.4 144.11 28.44 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 119.061 -1.055 . . . . 0.0 113.54 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.336 0.531 0 CA-C-O 118.462 -1.188 . . . . 0.0 112.633 156.956 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 23.1 m . . . . . 0 N--CA 1.448 -0.544 0 CA-C-O 125.985 2.802 . . . . 0.0 117.95 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -163.15 121.72 2.04 Favored 'General case' 0 N--CA 1.449 -0.508 1 O-C-N 115.763 -4.335 . . . . 0.0 109.662 -177.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -142.35 144.09 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 O-C-N 128.657 3.723 . . . . 0.0 112.885 -157.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -135.3 157.81 45.96 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 122.008 2.185 . . . . 0.0 112.15 -150.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -76.91 -30.28 56.08 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 122.16 2.255 . . . . 0.0 111.541 175.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 22.0 p-10 -107.69 9.51 29.15 Favored 'General case' 0 N--CA 1.448 -0.571 0 CA-C-N 112.569 -2.105 . . . . 0.0 113.604 -172.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.85 153.49 28.79 Favored Pre-proline 0 N--CA 1.451 -0.409 0 CA-C-N 122.798 2.545 . . . . 0.0 113.199 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.9 172.66 8.08 Favored 'Trans proline' 0 N--CA 1.45 -1.069 2 C-N-CA 127.566 5.51 . . . . 0.0 107.248 159.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -127.66 160.16 32.5 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 127.49 2.993 . . . . 0.0 108.877 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -134.36 156.88 47.71 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 115.958 -1.972 . . . . 0.0 111.888 -172.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -160.08 172.84 16.76 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 126.767 2.027 . . . . 0.0 106.042 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 36' ' ' THR . . . . . . . . . . . . 0.253 8.2 m -135.03 142.62 46.43 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 124.172 1.939 . . . . 0.0 115.446 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . . 57.6 mt -108.67 114.93 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 O-C-N 118.404 -2.685 . . . . 0.0 111.211 -175.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -87.97 138.13 31.72 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 170.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -117.51 134.49 54.8 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 113.772 -1.558 . . . . 0.0 109.312 -166.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.428 ' HA ' ' HA ' ' L' ' 46' ' ' ALA . 79.7 t -150.17 141.61 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 C-N-CA 128.933 2.893 . . . . 0.0 110.974 -174.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.449 -0.518 0 O-C-N 118.232 -2.792 . . . . 0.0 108.149 -174.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 46' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' L' ' 40' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.453 0 N-CA-C 119.076 2.991 . . . . 0.0 119.076 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -60.51 135.44 57.75 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.269 -2.769 . . . . 0.0 116.145 176.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 40.6 p -89.03 7.12 36.47 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.038 2.236 . . . . 0.0 117.038 -172.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -169.3 -149.78 0.08 Allowed 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.674 2.79 . . . . 0.0 106.635 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -155.2 -153.51 6.55 Favored Glycine 0 C--N 1.335 0.496 0 N-CA-C 121.009 3.164 . . . . 0.0 121.009 -172.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.92 44.38 97.5 Favored Glycine 0 CA--C 1.522 0.486 0 O-C-N 120.412 -1.64 . . . . 0.0 111.167 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -87.09 163.76 38.93 Favored Pre-proline 0 N--CA 1.449 -0.489 0 CA-C-N 121.556 2.678 . . . . 0.0 105.212 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -90.97 78.83 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 CA-C-O 127.642 3.101 . . . . 0.0 117.69 177.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -84.68 163.11 19.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.03 2.932 . . . . 0.0 110.643 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -156.88 144.82 19.31 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.993 0.901 . . . . 0.0 111.968 166.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.07 136.3 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 128.63 2.772 . . . . 0.0 114.977 174.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -143.11 125.4 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 130.201 3.401 . . . . 0.0 112.359 -165.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 37.6 mm -121.7 103.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 1 O-C-N 116.149 -4.094 . . . . 0.0 110.493 -164.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -96.63 137.85 35.09 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.768 2.027 . . . . 0.0 111.635 -174.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.2 -159.98 16.26 Favored Glycine 0 C--N 1.336 0.559 0 O-C-N 118.677 -2.515 . . . . 0.0 115.262 169.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -69.76 150.61 68.43 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 N-CA-C 119.241 2.747 . . . . 0.0 119.241 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t70 70.09 -95.75 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 127.989 2.516 . . . . 0.0 111.312 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.05 29.23 3.24 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-O 117.334 -1.815 . . . . 0.0 114.488 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 36.4 mt -90.12 124.79 35.11 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 122.52 3.16 . . . . 0.0 117.88 -175.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 10.0 t -146.53 136.27 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 115.656 1.724 . . . . 0.0 115.656 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 17.5 t -135.77 132.64 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 124.068 0.947 . . . . 0.0 109.007 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.84 123.95 27.73 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-O 116.005 -1.95 . . . . 0.0 115.639 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -93.57 150.33 20.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.403 2.281 . . . . 0.0 114.131 -170.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . 0.551 42.1 tttm -76.15 94.8 3.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 124.193 0.997 . . . . 0.0 111.962 -179.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 14.2 t -64.95 143.97 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 O-C-N 118.211 -2.805 . . . . 0.0 104.425 154.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 27.8 m -141.8 133.99 27.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 124.404 2.05 . . . . 0.0 110.278 159.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -68.93 125.06 25.44 Favored 'General case' 0 N--CA 1.449 -0.505 1 O-C-N 116.249 -4.032 . . . . 0.0 113.559 172.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -69.91 -16.69 63.27 Favored 'General case' 0 N--CA 1.449 -0.506 1 C-N-CA 131.745 4.018 . . . . 0.0 118.348 174.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . 0.263 57.7 t30 67.07 45.34 1.75 Allowed 'General case' 0 N--CA 1.448 -0.54 0 O-C-N 118.851 -2.406 . . . . 0.0 112.248 -168.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -159.14 -2.86 0.08 Allowed 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 118.634 -2.541 . . . . 0.0 116.837 -177.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 101.39 -5.66 55.25 Favored Glycine 0 C--N 1.335 0.516 0 CA-C-O 115.494 -2.837 . . . . 0.0 112.025 -167.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 31.3 p -123.37 164.99 17.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 123.465 3.633 . . . . 0.0 115.577 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -132.86 137.74 46.79 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 126.568 2.418 . . . . 0.0 109.755 -175.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -91.52 150.83 20.59 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 108.597 -1.801 . . . . 0.0 108.597 168.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -141.36 146.73 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 O-C-N 127.4 2.47 . . . . 0.0 110.531 177.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.8 p -132.11 143.67 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 126.652 1.981 . . . . 0.0 106.346 -175.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 10.3 p90 -161.97 167.43 24.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 117.681 -3.137 . . . . 0.0 115.979 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -142.82 162.67 34.85 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 116.459 -1.734 . . . . 0.0 111.509 -170.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 84' ' ' ALA . . . . . 0.611 ' HB1' ' CD1' ' L' ' 90' ' ' TYR . . . -125.12 78.01 66.94 Favored Pre-proline 0 N--CA 1.449 -0.502 0 C-N-CA 125.671 1.589 . . . . 0.0 111.22 -178.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 85' ' ' PRO . . . . . 0.498 ' HD2' ' CE2' ' L' ' 90' ' ' TYR 0.417 73.5 Cg_exo -40.1 -23.37 0.12 Allowed 'Trans proline' 0 N--CA 1.449 -1.142 1 C-N-CA 128.38 6.053 . . . . 0.0 119.596 178.621 . . . . . . . . 4 3 . 1 . 001 nuclear nobuild core ' L' L ' 86' ' ' VAL . . . . . 0.565 ' H ' ' HE1' ' L' ' 90' ' ' TYR . 85.6 t -123.32 132.52 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-O 117.368 -1.301 . . . . 0.0 108.867 -174.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -60.59 85.29 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 131.024 3.73 . . . . 0.0 109.365 163.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 172.88 -171.72 44.59 Favored Glycine 0 CA--C 1.523 0.536 1 C-N-CA 132.56 4.886 . . . . 0.0 112.895 -160.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -71.5 140.26 49.88 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.059 1.744 . . . . 0.0 112.834 167.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 90' ' ' TYR . . . . . 0.611 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 14.1 m-85 -112.1 168.75 9.36 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 120.164 -1.585 . . . . 0.0 109.955 150.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -133.31 133.91 43.17 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.833 3.253 . . . . 0.0 112.39 -177.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.67 121.9 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 CA-C-O 125.448 2.547 . . . . 0.0 105.716 -169.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -135.75 118.72 16.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.937 2.495 . . . . 0.0 115.873 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.53 142.93 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 CA-C-N 113.16 -1.836 . . . . 0.0 112.718 -169.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -142.79 151.28 41.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 125.042 1.464 . . . . 0.0 108.712 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 96' ' ' LEU . . . . . 0.481 HD11 ' HB2' ' L' ' 12' ' ' PRO . 4.0 tt -133.83 116.74 16.04 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 127.656 2.383 . . . . 0.0 106.412 173.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? 62.83 -49.7 0.19 Allowed 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 127.495 2.318 . . . . 0.0 116.864 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -170.43 16.64 0.06 OUTLIER Glycine 0 CA--C 1.523 0.535 0 C-N-CA 129.608 3.48 . . . . 0.0 114.495 162.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 21.6 m120 -128.05 149.23 70.42 Favored Pre-proline 0 N--CA 1.451 -0.397 0 C-N-CA 127.943 2.497 . . . . 0.0 111.538 -163.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -80.49 -176.24 3.09 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 121.138 1.225 . . . . 0.0 113.94 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 4.1 pt -139.17 -155.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 C-N-CA 129.809 3.244 . . . . 0.0 108.444 -177.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 9.0 pttm -136.17 172.75 12.55 Favored 'General case' 0 N--CA 1.45 -0.469 1 O-C-N 115.365 -4.584 . . . . 0.0 111.009 170.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 49.0 t30 80.28 -57.68 0.34 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 130.365 3.466 . . . . 0.0 106.799 -160.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -83.06 154.35 67.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 126.403 2.314 . . . . 0.0 109.745 164.166 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -77.71 163.66 87.63 Favored 'Cis proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.666 -2.223 . . . . 0.0 113.359 -5.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 9.3 tp -162.98 147.68 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 113.24 -1.8 . . . . 0.0 113.941 -161.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.49 150.87 40.14 Favored 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 120.072 -1.643 . . . . 0.0 109.295 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 9.0 p -158.46 125.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 O-C-N 126.151 2.157 . . . . 0.0 111.019 -163.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -81.73 148.58 28.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 118.339 -0.838 . . . . 0.0 112.931 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 5.3 t -101.24 117.67 35.44 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 128.779 2.832 . . . . 0.0 108.125 -170.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 111' ' ' ILE . . . . . 0.42 HD13 HG21 ' L' ' 111' ' ' ILE . 20.2 tt . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 116.205 -1.855 . . . . 0.0 114.631 178.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 9.1 m-30 . . . . . 0 N--CA 1.449 -0.486 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 73.2 p -162.19 143.82 10.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 128.238 2.615 . . . . 0.0 111.282 177.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.259 11.6 m-85 -61.59 143.32 56.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 114.679 -2.582 . . . . 0.0 110.128 149.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 20.3 m -68.67 105.7 2.37 Favored 'General case' 0 N--CA 1.449 -0.515 0 O-C-N 126.155 2.16 . . . . 0.0 106.623 148.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.449 -0.507 0 C-N-CA 127.511 2.324 . . . . 0.0 110.12 -178.456 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 117.501 2.408 . . . . 0.0 117.501 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -50.29 -40.26 47.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 123.541 0.737 . . . . 0.0 110.195 164.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -101.04 6.42 43.41 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.778 -1.826 . . . . 0.0 114.206 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 57.3 mt -108.51 135.24 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 116.642 -3.786 . . . . 0.0 107.016 177.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 55.0 m -86.82 134.31 33.56 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 158' ' ' LEU . . . . . 0.412 HD23 ' H ' ' L' ' 159' ' ' ASP . 0.9 OUTLIER -109.39 140.27 43.3 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 124.972 2.32 . . . . 0.0 112.975 165.418 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' L' L ' 159' ' ' ASP . . . . . 0.412 ' H ' HD23 ' L' ' 158' ' ' LEU . 58.5 t0 -158.86 119.26 3.22 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 119.722 -1.861 . . . . 0.0 108.309 -170.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -153.03 158.62 42.25 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.406 0.891 . . . . 0.0 113.406 -165.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 6.0 pt . . . . . 0 N--CA 1.451 -0.408 0 CA-C-O 114.745 -2.55 . . . . 0.0 110.009 163.24 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 1.3 t . . . . . 0 N--CA 1.448 -0.56 0 N-CA-C 117.523 2.416 . . . . 0.0 117.523 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -156.77 -132.12 1.45 Allowed Glycine 0 C--N 1.335 0.473 1 C-N-CA 132.711 4.958 . . . . 0.0 109.963 175.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 184' ' ' VAL . . . . . 0.466 HG12 ' O ' ' L' ' 184' ' ' VAL . 5.0 t -132.69 101.08 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 117.585 -3.303 . . . . 0.0 110.317 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -52.37 117.31 2.75 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-O 117.706 -1.14 . . . . 0.0 110.265 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 11.1 tp -84.52 -38.57 19.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 128.982 3.926 . . . . 0.0 107.864 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -155.36 149.65 25.94 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.414 3.085 . . . . 0.0 107.956 179.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . 86.99 156.09 28.79 Favored Glycine 0 CA--C 1.522 0.52 0 CA-C-O 124.912 2.395 . . . . 0.0 113.668 173.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -55.64 113.9 1.64 Allowed 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 110.33 -2.935 . . . . 0.0 117.682 -175.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -71.35 125.71 27.72 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.255 174.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 16.8 mm 44.73 120.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 130.583 3.553 . . . . 0.0 111.049 -160.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -98.19 139.6 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 113.218 -1.81 . . . . 0.0 110.951 -164.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 111.5 -149.7 18.0 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 114.344 -1.298 . . . . 0.0 113.509 -175.007 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 1.1 t -151.15 142.01 15.01 Favored Pre-proline 0 N--CA 1.449 -0.5 0 C-N-CA 131.591 3.956 . . . . 0.0 112.583 -171.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -89.82 150.33 4.98 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 120.436 0.758 . . . . 0.0 110.956 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -157.2 145.96 19.78 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 120.964 3.69 . . . . 0.0 120.964 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -92.78 150.06 20.89 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 120.483 -1.386 . . . . 0.0 112.058 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -83.19 135.48 34.77 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 120.433 -1.417 . . . . 0.0 111.14 -173.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 63.0 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 115.265 1.58 . . . . 0.0 115.265 155.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 49.8 mt -110.71 137.56 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 120.626 -1.296 . . . . 0.0 111.323 162.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 126.17 144.47 6.15 Favored Glycine 0 CA--C 1.523 0.555 0 C-N-CA 125.332 1.444 . . . . 0.0 115.228 -169.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -156.16 165.45 36.37 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 123.224 1.488 . . . . 0.0 108.925 176.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -92.98 150.59 20.44 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 117.441 -3.287 . . . . 0.0 107.842 175.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 16.1 mt -91.78 167.0 12.47 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 128.656 2.783 . . . . 0.0 106.739 2.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -139.55 -13.21 1.14 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.079 1.352 . . . . 0.0 114.459 162.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 5.6 t -100.45 138.89 36.91 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.601 1.96 . . . . 0.0 113.303 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 66.5 p -123.47 166.78 17.02 Favored Pre-proline 0 N--CA 1.448 -0.541 0 C-N-CA 129.494 3.118 . . . . 0.0 112.328 -173.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -50.12 149.48 11.91 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 124.576 3.517 . . . . 0.0 116.803 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.61 -19.67 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 O-C-N 125.559 1.787 . . . . 0.0 112.055 -176.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -159.75 159.47 32.83 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 127.185 2.194 . . . . 0.0 106.572 157.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 29.2 mm -82.18 119.72 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 126.84 2.056 . . . . 0.0 107.196 169.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 3.2 m -78.98 148.19 32.66 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 126.019 2.074 . . . . 0.0 115.21 -172.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -70.54 117.68 12.38 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 170.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -72.15 -20.42 61.61 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.464 2.394 . . . . 0.0 117.464 175.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -151.16 172.27 16.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.617 1.567 . . . . 0.0 109.907 -170.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -118.82 -41.18 0.61 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-O 125.055 2.475 . . . . 0.0 115.313 161.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 29.5 mm 85.74 -66.09 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.47 1 C-N-CA 132.124 4.17 . . . . 0.0 111.437 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -49.7 122.14 6.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 129.478 3.111 . . . . 0.0 108.263 -162.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.98 -167.42 1.39 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 114.624 -2.608 . . . . 0.0 116.115 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.471 0 O-C-N 126.348 2.28 . . . . 0.0 110.855 -173.793 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.387 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -62.91 137.61 63.63 Favored 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 122.606 2.204 . . . . 0.0 117.757 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 5.5 t -81.78 115.36 20.96 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 127.9 3.25 . . . . 0.0 111.349 155.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -50.05 -37.49 33.61 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 129.061 2.944 . . . . 0.0 112.919 166.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -63.77 -49.98 70.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 128.314 2.646 . . . . 0.0 111.6 176.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -113.53 -23.63 9.69 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.45 1.9 . . . . 0.0 113.452 -151.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 73.0 m -70.18 146.11 51.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 120.327 -1.483 . . . . 0.0 109.023 173.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 24.8 p90 -154.94 176.53 12.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.571 1.948 . . . . 0.0 111.492 -164.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -142.47 140.72 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 125.595 1.81 . . . . 0.0 110.748 172.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -147.26 134.92 21.05 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 125.884 2.754 . . . . 0.0 110.351 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.601 0 CA-C-O 125.306 2.615 . . . . 0.0 112.528 157.54 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t . . . . . 0 N--CA 1.447 -0.618 0 CA-C-O 121.737 0.779 . . . . 0.0 110.525 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 35.1 tttt -149.23 98.89 2.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.624 1.202 . . . . 0.0 108.659 -154.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 37.9 t -141.52 131.92 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 114.278 -2.773 . . . . 0.0 111.344 -152.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -127.2 149.54 49.94 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 119.58 3.178 . . . . 0.0 119.58 -158.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -63.35 -14.18 47.16 Favored 'General case' 0 N--CA 1.448 -0.542 0 O-C-N 124.694 1.246 . . . . 0.0 113.114 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . 0.263 14.4 p-10 -113.02 3.33 16.12 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.741 2.126 . . . . 0.0 116.741 169.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.41 137.91 11.32 Favored Pre-proline 0 N--CA 1.45 -0.441 1 N-CA-C 122.177 4.14 . . . . 0.0 122.177 -167.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -77.78 160.49 30.97 Favored 'Trans proline' 0 N--CA 1.447 -1.22 1 C-N-CA 128.078 5.852 . . . . 0.0 111.178 -172.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -141.35 152.38 44.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 126.206 2.191 . . . . 0.0 113.795 -173.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 34' ' ' GLU . . . . . 0.522 ' HA ' ' O ' ' L' ' 80' ' ' VAL . 11.3 mt-10 -128.0 152.32 48.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 124.912 1.285 . . . . 0.0 111.583 -167.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . 0.305 4.1 p90 -160.44 153.86 22.12 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.692 2.397 . . . . 0.0 106.735 -173.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 1.2 m -121.53 129.04 52.65 Favored 'General case' 0 N--CA 1.448 -0.535 0 O-C-N 123.626 0.579 . . . . 0.0 110.269 -169.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.314 4.1 mt -73.93 104.79 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 166.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -91.92 115.28 27.93 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 124.284 1.993 . . . . 0.0 108.923 168.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.14 145.71 28.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 118.347 -2.721 . . . . 0.0 109.009 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t -140.02 129.05 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 110.292 -3.14 . . . . 0.0 110.552 -175.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 35.2 p30 . . . . . 0 N--CA 1.448 -0.54 0 CA-C-O 127.84 3.686 . . . . 0.0 117.856 -177.109 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.499 0 N-CA-C 117.996 2.591 . . . . 0.0 117.996 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . 0.271 11.1 mmm180 -76.83 153.37 34.91 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.252 1.821 . . . . 0.0 110.603 -177.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 43.2 p -124.41 -1.53 8.09 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 128.513 2.725 . . . . 0.0 115.265 -165.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -161.52 167.29 25.72 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -168.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.63 175.56 40.53 Favored Glycine 0 C--N 1.335 0.498 1 N-CA-C 125.415 4.926 . . . . 0.0 125.415 175.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 66.4 49.08 59.07 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 125.745 1.641 . . . . 0.0 112.544 161.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -83.38 150.38 60.25 Favored Pre-proline 0 N--CA 1.449 -0.512 0 CA-C-O 115.014 -2.422 . . . . 0.0 116.948 151.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -91.7 59.74 0.96 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 106.833 -2.026 . . . . 0.0 106.833 -164.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -69.7 155.7 40.11 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 117.929 2.566 . . . . 0.0 117.929 156.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.98 146.78 31.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 116.516 -1.707 . . . . 0.0 109.78 178.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -125.64 140.26 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 119.979 1.263 . . . . 0.0 111.882 -173.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.96 29.55 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 114.272 -2.775 . . . . 0.0 111.956 -176.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 15.7 mt -135.75 134.04 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 1 C-N-CA 131.898 4.079 . . . . 0.0 110.13 -178.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -120.91 148.69 43.71 Favored 'General case' 0 N--CA 1.45 -0.444 1 C-N-CA 133.445 4.698 . . . . 0.0 110.901 -178.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -148.63 -162.61 10.34 Favored Glycine 0 CA--C 1.522 0.504 0 CA-C-O 124.714 2.285 . . . . 0.0 114.931 -171.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.42 149.37 86.63 Favored 'Trans proline' 0 N--CA 1.448 -1.153 1 C-N-CA 125.403 4.069 . . . . 0.0 110.892 -178.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.83 -125.61 0.95 Allowed 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.724 2.41 . . . . 0.0 109.461 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -89.83 -9.26 66.34 Favored Glycine 0 C--N 1.335 0.506 1 O-C-N 114.457 -5.152 . . . . 0.0 111.314 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 8.8 tp -62.32 124.58 21.28 Favored 'General case' 0 N--CA 1.447 -0.593 0 O-C-N 118.358 -2.848 . . . . 0.0 113.467 -155.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 15.4 m -108.51 156.49 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 150.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 89.0 t -122.64 136.22 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 125.609 1.818 . . . . 0.0 110.084 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -89.96 118.04 29.23 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -63.22 147.04 52.07 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 118.564 -2.585 . . . . 0.0 116.922 172.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -116.92 119.94 36.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 64.2 t -112.62 143.99 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 CA-C-O 123.55 1.643 . . . . 0.0 108.434 -173.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -139.77 117.53 11.63 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 114.47 -1.241 . . . . 0.0 112.253 170.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -81.27 121.88 26.73 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 129.052 2.941 . . . . 0.0 109.456 178.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -77.61 -5.38 50.08 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 115.704 -2.093 . . . . 0.0 115.274 175.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 71.22 24.3 3.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 125.628 3.831 . . . . 0.0 112.092 -175.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -149.16 -12.52 0.31 Allowed 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 117.103 -3.498 . . . . 0.0 111.028 -160.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 115.86 5.34 18.07 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 120.103 2.801 . . . . 0.0 120.103 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 18.8 p -136.15 157.34 47.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.342 3.057 . . . . 0.0 111.391 170.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -130.43 140.1 50.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 116.666 -1.635 . . . . 0.0 108.956 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -77.32 132.89 12.49 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 127.346 2.403 . . . . 0.0 114.86 160.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 80' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' L' ' 34' ' ' GLU . 2.6 t -126.14 128.52 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 127.733 2.666 . . . . 0.0 115.65 174.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -136.4 143.04 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 120.645 -1.284 . . . . 0.0 113.225 174.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -151.04 -178.94 6.9 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 114.79 -1.096 . . . . 0.0 111.607 175.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -137.27 107.22 6.29 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.56 1.944 . . . . 0.0 111.338 178.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 84' ' ' ALA . . . . . 0.549 ' HB1' ' CD1' ' L' ' 90' ' ' TYR 0.28 . . -68.63 110.43 5.87 Favored Pre-proline 0 N--CA 1.45 -0.453 0 C-N-CA 124.843 1.257 . . . . 0.0 109.54 164.204 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' L' L ' 85' ' ' PRO . . . . . . . . . . . . 0.264 50.0 Cg_endo -67.29 -10.02 27.22 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 126.546 4.831 . . . . 0.0 117.866 -167.987 . . . . . . . . 3 2 . 1 . 002 nuclear nobuild core ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.61 154.16 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-N 119.827 1.194 . . . . 0.0 110.209 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -43.97 130.15 5.88 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 150.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 145.37 -149.65 21.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 127.618 2.532 . . . . 0.0 111.643 -174.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -121.98 153.93 37.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 127.033 2.133 . . . . 0.0 113.391 -178.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 90' ' ' TYR . . . . . 0.549 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 52.6 m-85 -152.27 156.39 39.59 Favored 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.332 1.853 . . . . 0.0 108.398 -172.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . 0.325 2.9 t30 -133.55 114.32 13.43 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.007 1.323 . . . . 0.0 111.512 -165.021 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 20.5 t -108.55 139.17 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-N 112.972 -1.922 . . . . 0.0 110.246 -164.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -155.1 106.49 2.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.659 2.784 . . . . 0.0 117.162 -173.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 94' ' ' VAL . . . . . 0.461 ' HB ' ' HG3' ' L' ' 104' ' ' MET . 33.1 t -94.56 142.63 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 111.899 -2.41 . . . . 0.0 108.873 159.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 95' ' ' THR . . . . . 0.409 ' HB ' ' H ' ' L' ' 96' ' ' LEU . 35.0 p -137.42 -144.36 0.19 Allowed 'General case' 0 N--CA 1.451 -0.384 0 O-C-N 128.946 3.903 . . . . 0.0 117.431 -173.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 96' ' ' LEU . . . . . 0.409 ' H ' ' HB ' ' L' ' 95' ' ' THR . 6.0 tp -150.72 154.52 37.54 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 123.667 2.94 . . . . 0.0 115.016 168.232 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 33.3 ttm180 -64.36 94.88 0.12 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 124.202 1.953 . . . . 0.0 109.856 142.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . 121.41 -153.16 16.71 Favored Glycine 0 N--CA 1.448 -0.504 1 C-N-CA 131.032 4.158 . . . . 0.0 110.295 -171.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -71.47 113.87 23.21 Favored Pre-proline 0 N--CA 1.449 -0.487 0 CA-C-O 113.358 -3.21 . . . . 0.0 108.551 -170.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -74.63 160.29 41.4 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 O-C-N 127.079 3.147 . . . . 0.0 114.23 -165.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.7 pt -90.07 138.81 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 O-C-N 117.064 -3.522 . . . . 0.0 112.071 -159.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 23.0 mmtt -92.59 -178.73 4.97 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-O 117.352 -1.309 . . . . 0.0 109.396 -173.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 72.64 -44.44 0.59 Allowed 'General case' 0 N--CA 1.448 -0.537 0 CA-C-O 126.797 3.189 . . . . 0.0 110.894 -154.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 104' ' ' MET . . . . . 0.461 ' HG3' ' HB ' ' L' ' 94' ' ' VAL . 28.0 mmt -69.74 155.25 93.84 Favored Pre-proline 0 N--CA 1.448 -0.541 0 CA-C-O 112.347 -3.692 . . . . 0.0 107.741 153.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -75.13 159.92 97.19 Favored 'Cis proline' 0 N--CA 1.447 -1.213 0 O-C-N 125.453 2.291 . . . . 0.0 110.481 -18.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 12.5 tt -151.55 141.05 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.163 -1.38 . . . . 0.0 112.709 -174.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -95.62 136.14 36.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.659 3.183 . . . . 0.0 113.692 173.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.27 143.25 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 128.979 2.911 . . . . 0.0 103.284 -163.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -111.75 147.4 35.72 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 126.321 1.848 . . . . 0.0 113.807 177.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 41.0 t -127.43 138.96 53.11 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 125.747 1.905 . . . . 0.0 106.356 -172.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 1.3 pp . . . . . 0 N--CA 1.449 -0.48 0 C-N-CA 128.125 2.57 . . . . 0.0 110.413 -177.482 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . 0.32 26.3 p90 . . . . . 0 N--CA 1.45 -0.442 0 N-CA-C 119.554 3.168 . . . . 0.0 119.554 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 3.4 p -135.9 153.56 51.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 118.077 -2.89 . . . . 0.0 112.684 -166.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.338 56.9 t80 -66.22 154.51 39.64 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -174.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 12.9 t -60.42 149.24 34.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 130.256 3.422 . . . . 0.0 112.574 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 21.6 m . . . . . 0 N--CA 1.449 -0.52 0 CA-C-N 112.599 -2.091 . . . . 0.0 110.093 178.915 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.518 0 CA-C-O 123.067 1.413 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -68.08 131.09 44.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 O-C-N 118.093 -2.879 . . . . 0.0 110.426 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -63.52 121.98 15.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 118.28 2.696 . . . . 0.0 118.28 176.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 4.8 tt -138.65 160.14 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-O 124.004 1.859 . . . . 0.0 114.167 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 28.6 m -78.89 131.3 36.37 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 115.025 -2.417 . . . . 0.0 108.833 173.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 22.4 tp -61.8 142.62 57.2 Favored 'General case' 0 N--CA 1.451 -0.406 1 C-N-CA 132.264 4.226 . . . . 0.0 109.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -151.66 142.49 22.92 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 127.113 2.165 . . . . 0.0 110.336 178.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -75.54 69.75 2.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.43 3.492 . . . . 0.0 113.831 175.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 15.1 pt . . . . . 0 N--CA 1.448 -0.528 0 C-N-CA 130.52 3.528 . . . . 0.0 111.279 -171.927 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 38.1 m . . . . . 0 N--CA 1.449 -0.493 0 CA-C-O 124.175 1.94 . . . . 0.0 108.104 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -88.25 -175.04 47.68 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.911 -176.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 13.5 m -83.68 144.9 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 O-C-N 126.735 2.08 . . . . 0.0 111.732 155.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 53.5 tttp -69.05 130.26 42.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.703 2.401 . . . . 0.0 114.987 168.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 37.6 mt -100.42 -41.2 7.11 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 117.684 2.475 . . . . 0.0 117.684 -176.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -78.64 171.8 14.61 Favored 'General case' 0 N--CA 1.449 -0.509 1 C-N-CA 133.488 4.715 . . . . 0.0 113.457 -173.28 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -85.94 -154.79 24.59 Favored Glycine 0 C--N 1.336 0.534 0 C-N-CA 126.455 1.978 . . . . 0.0 109.592 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 18.2 ttmt -79.22 0.13 29.77 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 116.743 -1.599 . . . . 0.0 110.937 -174.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -62.35 148.04 46.47 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 122.478 2.399 . . . . 0.0 109.286 171.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 4.7 mt -131.28 129.43 62.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 1 C-N-CA 133.797 4.839 . . . . 0.0 106.997 178.02 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -100.16 141.67 32.67 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 127.356 2.91 . . . . 0.0 111.554 156.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 102.54 9.21 41.58 Favored Glycine 0 CA--C 1.523 0.588 0 CA-C-N 122.202 2.274 . . . . 0.0 117.964 166.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 46.2 m -65.39 134.23 95.6 Favored Pre-proline 0 N--CA 1.448 -0.557 1 CA-C-O 111.53 -4.081 . . . . 0.0 111.985 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -36.28 122.61 0.3 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 1 C-N-CA 128.439 6.092 . . . . 0.0 113.412 167.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -98.21 162.4 13.22 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.369 1.467 . . . . 0.0 109.668 172.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -64.72 148.41 51.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -164.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 91.6 mm-40 -117.56 143.27 46.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 O-C-N 119.545 -1.972 . . . . 0.0 109.242 163.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.1 139.91 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 119.031 -2.293 . . . . 0.0 111.331 -168.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 57.8 tp -146.42 117.5 7.79 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 110.474 -3.057 . . . . 0.0 108.872 168.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 81.12 173.93 48.28 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 127.195 2.331 . . . . 0.0 114.627 175.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 27.2 t30 -110.97 134.6 52.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -146.28 150.11 35.15 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 115.411 -2.233 . . . . 0.0 112.178 -170.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 55.6 mt -67.45 161.51 25.18 Favored 'General case' 0 N--CA 1.449 -0.483 1 C-N-CA 134.181 4.993 . . . . 0.0 109.836 0.279 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 55.7 t80 -62.51 137.82 58.34 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 126.13 2.871 . . . . 0.0 107.529 -177.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.98 119.56 33.7 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 117.356 -3.34 . . . . 0.0 112.201 -171.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 4.3 m -79.17 130.18 70.17 Favored Pre-proline 0 N--CA 1.451 -0.415 0 O-C-N 117.571 -3.206 . . . . 0.0 109.646 -162.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -64.3 125.17 14.59 Favored 'Trans proline' 0 N--CA 1.448 -1.185 1 C-N-CA 125.327 4.018 . . . . 0.0 109.267 173.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 6.9 p -163.07 159.36 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 130.171 3.388 . . . . 0.0 111.353 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 9.1 p90 -80.81 137.68 36.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.826 2.05 . . . . 0.0 113.735 177.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 40.9 mm -67.67 125.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 119.462 -2.024 . . . . 0.0 107.646 171.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 212' ' ' SER . . . . . . . . . . . . 0.255 40.2 m -87.09 156.88 19.54 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 124.082 3.128 . . . . 0.0 110.81 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -56.65 151.88 13.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 131.096 3.758 . . . . 0.0 118.168 171.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -114.93 156.95 24.07 Favored 'General case' 0 N--CA 1.447 -0.579 0 O-C-N 117.44 -3.288 . . . . 0.0 110.012 159.267 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . 0.283 12.5 pt20 -69.27 154.53 41.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 119.916 1.235 . . . . 0.0 112.95 -175.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -86.09 -154.08 23.51 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 130.361 3.839 . . . . 0.0 117.497 160.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . 0.306 1.4 pp -127.33 -7.82 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 129.985 3.314 . . . . 0.0 113.268 -178.468 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -60.07 126.31 27.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -111.66 -146.2 0.4 Allowed 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 131.501 3.92 . . . . 0.0 114.228 175.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.66 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -177.361 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.441 0 CA-C-O 116.149 -1.882 . . . . 0.0 114.411 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -66.9 -176.54 0.77 Allowed 'Trans proline' 0 N--CA 1.449 -1.118 1 C-N-CA 126.438 4.758 . . . . 0.0 115.166 155.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 2.6 p -158.51 154.81 27.34 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 123.064 1.411 . . . . 0.0 112.941 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.81 -53.18 60.96 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 112.605 -2.089 . . . . 0.0 112.725 -165.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 16.8 mp0 -48.61 -20.86 0.49 Allowed 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 129.416 3.086 . . . . 0.0 118.741 177.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -117.2 -54.79 2.38 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 127.976 2.511 . . . . 0.0 109.923 -170.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 17' ' ' SER . . . . . . . . . . . . 0.721 0.5 OUTLIER -67.1 149.87 49.96 Favored 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.84 -4.913 . . . . 0.0 112.642 -165.154 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild core ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 22.0 p90 -163.09 172.52 14.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 128.093 2.557 . . . . 0.0 108.883 -164.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -139.51 147.89 41.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 128.018 2.527 . . . . 0.0 110.387 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -149.98 144.18 25.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 125.423 1.702 . . . . 0.0 115.41 -175.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.527 0 CA-C-O 124.597 2.221 . . . . 0.0 115.066 168.49 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.451 -0.404 0 CA-C-O 121.588 0.709 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -162.87 92.54 0.78 Allowed 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 124.649 2.166 . . . . 0.0 115.614 -160.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 27' ' ' VAL . . . . . 0.471 HG13 ' CD1' ' L' ' 90' ' ' TYR 0.305 12.8 p -147.78 147.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 O-C-N 119.467 -2.02 . . . . 0.0 113.836 179.055 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' L' L ' 28' ' ' PHE . . . . . 0.488 ' HA ' ' SG ' ' L' ' 110' ' ' CYS . 12.9 t80 -137.1 -170.89 2.81 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 -170.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -86.09 -44.68 12.06 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 117.994 -2.942 . . . . 0.0 113.324 -175.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 47.5 p-10 -106.28 30.62 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 123.589 1.661 . . . . 0.0 111.456 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.87 125.06 2.42 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 115.933 -1.984 . . . . 0.0 114.693 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -85.44 175.35 6.31 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 123.803 3.002 . . . . 0.0 113.762 -175.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -148.39 170.67 17.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 177.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -142.31 155.06 45.17 Favored 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 128.235 2.614 . . . . 0.0 116.025 -170.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -163.14 166.02 23.9 Favored 'General case' 0 N--CA 1.448 -0.533 1 O-C-N 114.688 -5.007 . . . . 0.0 108.79 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 36' ' ' THR . . . . . 0.443 ' HA ' ' O ' ' L' ' 78' ' ' TYR . 21.3 m -131.82 133.82 45.11 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.397 1.628 . . . . 0.0 115.397 -162.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.267 8.6 mt -81.52 104.29 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 127.056 2.142 . . . . 0.0 110.498 174.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -81.36 121.0 25.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 118.696 -1.201 . . . . 0.0 107.988 168.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -73.96 120.5 19.63 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.509 3.123 . . . . 0.0 107.262 173.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 1.8 t -149.91 141.34 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 123.69 1.71 . . . . 0.0 107.567 176.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t0 . . . . . 0 N--CA 1.448 -0.548 0 CA-C-N 111.287 -2.688 . . . . 0.0 110.87 -174.678 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.541 0 CA-C-O 124.632 2.158 . . . . 0.0 111.911 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 16.6 mmm-85 -70.65 164.1 25.67 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 112.263 -2.244 . . . . 0.0 108.551 164.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 71.0 p -117.32 21.63 12.99 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 126.819 2.048 . . . . 0.0 111.987 -169.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -167.96 147.47 4.81 Favored 'General case' 0 N--CA 1.448 -0.535 1 C-N-CA 134.1 4.96 . . . . 0.0 118.489 -178.559 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -91.49 -131.84 5.33 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 126.598 2.047 . . . . 0.0 116.646 -174.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.62 -18.86 1.24 Allowed Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 119.63 2.612 . . . . 0.0 119.63 173.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -63.29 150.44 89.3 Favored Pre-proline 0 N--CA 1.448 -0.564 0 CA-C-N 119.522 1.661 . . . . 0.0 113.799 175.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -78.84 109.04 2.52 Favored 'Trans proline' 0 N--CA 1.449 -1.107 1 C-N-CA 125.337 4.024 . . . . 0.0 111.847 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -117.42 174.78 5.95 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 116.512 -1.708 . . . . 0.0 114.514 177.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -161.35 150.49 16.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 124.866 2.27 . . . . 0.0 112.004 -174.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 11.6 p -127.7 143.08 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.033 -2.292 . . . . 0.0 108.89 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -139.61 111.42 7.32 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-O 116.131 -1.89 . . . . 0.0 108.85 168.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 58' ' ' ILE . . . . . . . . . . . . 0.279 29.3 mt -116.91 142.77 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 128.476 2.71 . . . . 0.0 107.69 175.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -134.41 148.14 50.58 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.354 3.462 . . . . 0.0 116.0 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -130.83 -148.19 6.24 Favored Glycine 0 N--CA 1.449 -0.498 0 O-C-N 119.01 -2.306 . . . . 0.0 109.769 -171.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 61' ' ' PRO . . . . . . . . . . . . 0.304 51.8 Cg_endo -71.3 138.03 32.22 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.685 2.924 . . . . 0.0 114.557 -169.421 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 19.0 t70 81.99 -52.27 0.24 Allowed 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 128.814 2.846 . . . . 0.0 109.388 163.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 63' ' ' GLY . . . . . 0.401 ' H ' ' H ' ' L' ' 64' ' ' LEU . . . -159.4 -22.2 0.03 OUTLIER Glycine 0 C--N 1.337 0.608 0 C-N-CA 129.791 3.567 . . . . 0.0 113.525 175.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 64' ' ' LEU . . . . . 0.401 ' H ' ' H ' ' L' ' 63' ' ' GLY . 55.8 tp -45.52 104.06 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 131.149 3.779 . . . . 0.0 115.394 -165.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.94 117.59 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-O 124.646 2.165 . . . . 0.0 107.651 165.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.52 125.79 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -65.68 130.07 41.99 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 117.466 -1.254 . . . . 0.0 108.583 172.63 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -135.92 138.59 42.54 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 126.538 2.399 . . . . 0.0 105.701 -175.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 58.0 mttp -118.06 116.38 26.75 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 126.755 2.022 . . . . 0.0 113.335 -165.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 39.6 t -94.6 143.0 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 97.6 m -142.65 120.68 12.1 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 118.405 -2.684 . . . . 0.0 106.81 166.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 72' ' ' ASP . . . . . . . . . . . . 0.293 40.0 t0 -68.42 133.23 48.34 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 125.885 1.99 . . . . 0.0 110.165 170.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 -93.91 -2.65 52.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 118.256 2.687 . . . . 0.0 118.256 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 82.25 -33.02 0.09 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 128.673 2.789 . . . . 0.0 109.223 172.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -78.97 -18.09 54.31 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 116.265 -1.826 . . . . 0.0 114.149 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 136.53 8.51 1.49 Allowed Glycine 0 C--N 1.336 0.583 0 CA-C-N 121.881 2.128 . . . . 0.0 115.125 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 76.4 p -138.39 160.06 40.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 126.456 1.902 . . . . 0.0 113.728 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 78' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' L' ' 36' ' ' THR . 1.4 m-85 -128.08 118.32 23.25 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 127.083 2.153 . . . . 0.0 107.178 177.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -75.12 132.57 13.67 Favored Glycine 0 CA--C 1.523 0.564 0 CA-C-O 117.476 -1.736 . . . . 0.0 112.603 165.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.52 130.42 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 124.283 1.992 . . . . 0.0 108.921 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 t -130.62 140.77 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 114.282 -1.326 . . . . 0.0 113.398 -167.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 82' ' ' TYR . . . . . . . . . . . . 0.339 5.6 p90 -159.43 163.56 35.31 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 126.42 3.009 . . . . 0.0 115.877 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.16 139.33 12.07 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 109.687 -3.415 . . . . 0.0 110.705 -170.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 84' ' ' ALA . . . . . . . . . . . . . . . -147.73 149.23 32.97 Favored Pre-proline 0 N--CA 1.45 -0.456 0 CA-C-N 114.091 -1.413 . . . . 0.0 114.207 155.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 85' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -91.04 44.27 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.106 1 C-N-CA 125.319 4.013 . . . . 0.0 112.558 -169.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -141.92 167.31 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 112.096 -3.812 . . . . 0.0 116.302 -157.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -134.58 123.08 23.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 121.937 2.153 . . . . 0.0 109.325 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 171.94 -106.28 0.23 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 125.981 1.753 . . . . 0.0 112.617 -178.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -149.7 125.7 10.59 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 128.985 2.914 . . . . 0.0 118.153 177.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 90' ' ' TYR . . . . . 0.471 ' CD1' HG13 ' L' ' 27' ' ' VAL . 84.6 m-85 -87.17 139.04 30.97 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 126.563 1.945 . . . . 0.0 107.71 169.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -130.69 106.83 8.73 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 127.66 3.1 . . . . 0.0 105.685 -171.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 32.3 t -112.02 138.18 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 127.33 2.894 . . . . 0.0 112.521 -166.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -140.78 136.27 32.31 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.366 2.266 . . . . 0.0 114.454 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 10.1 t -122.24 147.43 26.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 O-C-N 119.299 -2.126 . . . . 0.0 107.849 174.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 16.5 p -157.13 149.87 23.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 117.446 -1.264 . . . . 0.0 111.113 -175.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 21.2 mt -72.94 32.5 0.07 Allowed 'General case' 0 N--CA 1.449 -0.518 1 C-N-CA 135.199 5.4 . . . . 0.0 111.594 -177.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 65.61 -47.35 0.39 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.14 1.776 . . . . 0.0 109.311 -170.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -123.56 -5.47 7.74 Favored Glycine 0 C--N 1.335 0.519 1 C-N-CA 131.475 4.369 . . . . 0.0 114.731 -171.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -145.54 139.72 15.14 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 119.984 1.892 . . . . 0.0 113.483 -172.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -84.15 164.72 13.16 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 N-CA-C 116.923 1.855 . . . . 0.0 116.923 -173.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.13 -176.54 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 O-C-N 119.277 -2.139 . . . . 0.0 107.699 -176.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -83.35 139.39 33.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.34 1.856 . . . . 0.0 113.206 -165.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 t30 63.51 27.82 15.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 126.685 2.491 . . . . 0.0 115.264 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 11.7 mmt -119.86 129.44 25.35 Favored Pre-proline 0 N--CA 1.448 -0.573 0 C-N-CA 130.765 3.626 . . . . 0.0 104.418 -172.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -79.94 169.04 71.39 Favored 'Cis proline' 0 N--CA 1.448 -1.155 0 CA-C-N 122.543 1.944 . . . . 0.0 116.66 -15.058 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 106' ' ' ILE . . . . . 0.501 HD12 ' H ' ' L' ' 107' ' ' ASP . 5.3 tp -158.85 162.0 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 O-C-N 119.405 -2.059 . . . . 0.0 110.408 -166.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 107' ' ' ASP . . . . . 0.501 ' H ' HD12 ' L' ' 106' ' ' ILE . 12.9 m-20 -132.73 146.29 51.74 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.632 1.973 . . . . 0.0 111.249 -161.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 15.2 t -138.42 118.53 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 129.201 3.0 . . . . 0.0 108.498 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -74.58 136.02 42.06 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.248 2.219 . . . . 0.0 107.294 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 110' ' ' CYS . . . . . 0.488 ' SG ' ' HA ' ' L' ' 28' ' ' PHE . 38.6 t -106.28 111.69 24.39 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.918 -1.037 . . . . 0.0 113.001 167.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 15.2 tt . . . . . 0 N--CA 1.448 -0.543 0 C-N-CA 129.302 3.041 . . . . 0.0 110.461 -179.406 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 46.7 t80 . . . . . 0 N--CA 1.447 -0.598 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 28.0 p -158.69 162.11 37.17 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.508 3.123 . . . . 0.0 103.241 -171.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.262 51.8 p90 -154.94 162.51 41.07 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 125.021 1.328 . . . . 0.0 113.958 -174.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 3.0 m -81.64 126.58 31.93 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 119.674 -1.891 . . . . 0.0 110.769 175.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 N--CA 1.45 -0.457 0 CA-C-N 113.569 -1.651 . . . . 0.0 106.981 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.485 0 N-CA-C 112.743 0.646 . . . . 0.0 112.743 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -149.68 143.69 25.64 Favored 'General case' 0 N--CA 1.45 -0.439 1 O-C-N 116.14 -4.1 . . . . 0.0 109.738 -176.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -159.5 80.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 125.07 1.481 . . . . 0.0 108.584 -175.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 33.1 pt -105.45 166.76 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 126.71 2.004 . . . . 0.0 114.782 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 80.5 p -69.06 -5.68 23.49 Favored 'General case' 0 N--CA 1.451 -0.405 1 O-C-N 116.059 -4.151 . . . . 0.0 112.744 176.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 52.5 mt -91.61 68.14 5.58 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 122.212 2.278 . . . . 0.0 110.135 170.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -74.5 120.72 20.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 111.199 -2.728 . . . . 0.0 106.036 -169.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -70.39 132.2 45.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 123.012 1.386 . . . . 0.0 107.851 -177.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 161' ' ' ILE . . . . . 0.41 HD13 HG21 ' L' ' 161' ' ' ILE . 34.2 pt . . . . . 0 N--CA 1.448 -0.569 0 N-CA-C 120.189 3.403 . . . . 0.0 120.189 -167.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 19.7 p . . . . . 0 N--CA 1.447 -0.599 0 CA-C-O 122.724 1.25 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . 126.1 169.14 12.77 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 128.764 3.078 . . . . 0.0 113.893 -172.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 184' ' ' VAL . . . . . . . . . . . . 0.327 11.2 p -131.28 30.48 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 1 CA-C-O 128.786 4.136 . . . . 0.0 115.839 171.104 . . . . . . . . 3 2 . 1 . 003 nuclear nobuild core ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -110.08 -23.33 11.35 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 117.323 -3.361 . . . . 0.0 109.655 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 46.1 tp -137.44 148.76 46.36 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.07 2.948 . . . . 0.0 108.586 175.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -45.65 120.33 2.55 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.134 0.973 . . . . 0.0 113.187 168.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -72.2 -13.67 76.58 Favored Glycine 0 N--CA 1.447 -0.597 0 O-C-N 117.751 -3.093 . . . . 0.0 113.959 -174.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 20.1 tptp -59.69 -26.58 65.69 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 120.606 2.203 . . . . 0.0 116.053 175.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -75.4 157.26 34.44 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 116.926 -1.511 . . . . 0.0 108.39 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 10.0 tp -148.86 164.97 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 125.773 2.701 . . . . 0.0 107.967 -170.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -74.08 122.54 22.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 128.041 2.537 . . . . 0.0 110.121 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 122.33 -179.14 16.27 Favored Glycine 0 C--N 1.335 0.487 0 C-N-CA 126.247 1.879 . . . . 0.0 115.351 174.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 41.3 t -93.49 119.9 66.87 Favored Pre-proline 0 N--CA 1.45 -0.45 0 CA-C-O 118.768 -0.634 . . . . 0.0 110.793 173.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -81.18 138.94 11.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 CA-C-O 124.405 1.752 . . . . 0.0 110.26 176.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -179.96 -13.22 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 115.296 -2.288 . . . . 0.0 114.031 -171.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 69.7 tttt -59.51 -23.24 62.64 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 125.83 2.728 . . . . 0.0 117.505 166.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -78.1 109.84 12.54 Favored 'General case' 0 N--CA 1.45 -0.464 1 O-C-N 116.245 -4.034 . . . . 0.0 111.749 153.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 86.4 t -77.88 109.83 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 118.824 -2.422 . . . . 0.0 104.585 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 66.9 mt -88.39 173.91 8.45 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 167.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . -69.55 144.31 40.28 Favored Glycine 0 C--N 1.336 0.552 0 CA-C-N 121.536 1.971 . . . . 0.0 111.665 -171.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -148.8 152.78 37.12 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 126.0 1.647 . . . . 0.0 110.597 -171.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -38.3 127.77 1.37 Allowed 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 126.547 2.405 . . . . 0.0 109.346 161.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 4.8 tp -77.67 143.76 37.89 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.542 3.137 . . . . 0.0 110.363 0.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -101.54 -64.0 1.09 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 170.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 2.5 p -132.6 128.49 37.27 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.318 1.847 . . . . 0.0 110.572 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 25.4 m -45.3 125.6 5.8 Favored Pre-proline 0 N--CA 1.45 -0.459 0 CA-C-N 111.523 -2.58 . . . . 0.0 111.289 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -63.24 169.73 8.92 Favored 'Trans proline' 0 N--CA 1.448 -1.15 1 C-N-CA 126.057 4.505 . . . . 0.0 112.755 168.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.14 -175.15 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 126.012 1.725 . . . . 0.0 108.648 -171.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -90.31 163.98 14.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 114.885 1.439 . . . . 0.0 114.885 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.08 109.0 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-O 128.445 3.974 . . . . 0.0 113.873 165.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 30.4 m -71.84 94.01 1.37 Allowed 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 118.888 -2.383 . . . . 0.0 112.115 178.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -145.46 134.14 22.22 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 121.246 -0.909 . . . . 0.0 111.796 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -62.35 149.71 41.53 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 115.286 1.587 . . . . 0.0 115.286 -176.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -155.89 136.35 13.2 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 126.182 2.176 . . . . 0.0 113.351 178.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -113.44 150.45 18.51 Favored Glycine 0 C--N 1.337 0.592 0 N-CA-C 106.586 -2.605 . . . . 0.0 106.586 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 8.2 tp -154.43 -25.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -174.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -105.5 136.39 45.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 125.676 2.655 . . . . 0.0 113.029 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 219' ' ' ALA . . . . . . . . . . . . 0.273 . . -84.72 164.65 18.43 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 113.647 -1.615 . . . . 0.0 112.827 -174.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.335 0.515 0 O-C-N 117.573 -3.204 . . . . 0.0 115.353 -171.736 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 1' ' ' HIS . . . . . 0.453 ' HA ' ' OD1' ' L' ' 74' ' ' ASN . 2.5 t-80 . . . . . 0 N--CA 1.47 0.566 0 CA-C-O 121.412 0.625 . . . . 0.0 112.686 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 72.1 t60 -94.09 141.35 28.64 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 118.424 -2.672 . . . . 0.0 110.662 -171.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 32.0 p80 -146.61 0.11 0.76 Allowed 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 114.534 -2.651 . . . . 0.0 112.858 -177.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 78.1 m-70 -86.4 1.89 49.61 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 125.937 3.971 . . . . 0.0 110.061 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . 0.267 0.2 OUTLIER -169.91 169.27 8.31 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.217 2.607 . . . . 0.0 109.795 176.425 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -147.4 103.9 3.6 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 123.392 1.568 . . . . 0.0 111.292 152.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . 0.331 . . -159.32 -26.63 0.07 Allowed 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 118.699 2.851 . . . . 0.0 118.699 173.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 3.2 m -154.92 122.15 5.59 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 120.036 -1.665 . . . . 0.0 114.597 -176.118 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 43.4 pttt -141.8 145.62 37.55 Favored Pre-proline 0 N--CA 1.45 -0.473 0 N-CA-C 115.608 1.707 . . . . 0.0 115.608 164.392 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_exo -57.02 141.53 94.07 Favored 'Trans proline' 0 N--CA 1.448 -1.193 1 C-N-CA 125.38 4.054 . . . . 0.0 117.796 166.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -86.1 123.54 71.65 Favored Pre-proline 0 N--CA 1.449 -0.513 0 O-C-N 119.709 -1.869 . . . . 0.0 109.275 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 12' ' ' PRO . . . . . 0.481 ' HB2' HD11 ' L' ' 96' ' ' LEU . 32.6 Cg_exo -51.72 164.73 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.17 0 C-N-CA 124.505 3.47 . . . . 0.0 113.339 -173.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 59.7 m -89.34 121.42 31.59 Favored 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.183 2.993 . . . . 0.0 110.546 169.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -73.83 -14.42 61.09 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 126.924 2.09 . . . . 0.0 112.138 168.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 57.2 mp0 -65.54 -26.91 68.09 Favored 'General case' 0 N--CA 1.45 -0.459 1 C-N-CA 131.724 4.01 . . . . 0.0 108.729 167.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 31.9 m170 -134.42 -25.11 1.53 Allowed 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 121.989 2.177 . . . . 0.0 112.047 -166.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 14.6 m -79.78 145.07 33.03 Favored 'General case' 0 N--CA 1.449 -0.477 0 O-C-N 117.532 -3.23 . . . . 0.0 110.507 173.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . 0.53 6.8 p90 -167.25 -172.0 1.88 Allowed 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 114.912 -2.471 . . . . 0.0 117.042 -176.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . 0.254 . . -150.09 139.04 20.98 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 116.253 -2.179 . . . . 0.0 110.79 -148.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -147.4 144.11 28.44 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 119.061 -1.055 . . . . 0.0 113.54 174.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . -74.42 -95.48 0.12 Allowed Glycine 0 C--N 1.336 0.531 0 CA-C-O 118.462 -1.188 . . . . 0.0 112.633 156.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . 0.426 36.3 tt0 -161.33 86.82 0.68 Allowed 'General case' 0 N--CA 1.451 -0.423 0 O-C-N 129.389 3.641 . . . . 0.0 105.936 166.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . 86.42 -143.73 19.5 Favored Glycine 0 C--N 1.336 0.557 0 O-C-N 126.121 2.138 . . . . 0.0 114.992 -151.268 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 59.7 mt -101.97 152.38 21.01 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 119.73 3.233 . . . . 0.0 119.73 -177.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 23.1 m -42.39 140.2 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-O 125.985 2.802 . . . . 0.0 117.95 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 30.0 tttt -163.15 121.72 2.04 Favored 'General case' 0 N--CA 1.449 -0.508 1 O-C-N 115.763 -4.335 . . . . 0.0 109.662 -177.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -142.35 144.09 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 O-C-N 128.657 3.723 . . . . 0.0 112.885 -157.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -135.3 157.81 45.96 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 122.008 2.185 . . . . 0.0 112.15 -150.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 34.4 t0 -76.91 -30.28 56.08 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 122.16 2.255 . . . . 0.0 111.541 175.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 22.0 p-10 -107.69 9.51 29.15 Favored 'General case' 0 N--CA 1.448 -0.571 0 CA-C-N 112.569 -2.105 . . . . 0.0 113.604 -172.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -153.85 153.49 28.79 Favored Pre-proline 0 N--CA 1.451 -0.409 0 CA-C-N 122.798 2.545 . . . . 0.0 113.199 172.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.9 172.66 8.08 Favored 'Trans proline' 0 N--CA 1.45 -1.069 2 C-N-CA 127.566 5.51 . . . . 0.0 107.248 159.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -127.66 160.16 32.5 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 127.49 2.993 . . . . 0.0 108.877 173.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -134.36 156.88 47.71 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 115.958 -1.972 . . . . 0.0 111.888 -172.22 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 9.1 p90 -160.08 172.84 16.76 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 126.767 2.027 . . . . 0.0 106.042 178.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 36' ' ' THR . . . . . . . . . . . . 0.253 8.2 m -135.03 142.62 46.43 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 124.172 1.939 . . . . 0.0 115.446 -178.474 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . . 57.6 mt -108.67 114.93 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 O-C-N 118.404 -2.685 . . . . 0.0 111.211 -175.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -87.97 138.13 31.72 Favored 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 115.424 1.638 . . . . 0.0 115.424 170.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -117.51 134.49 54.8 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 113.772 -1.558 . . . . 0.0 109.312 -166.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.428 ' HA ' ' HA ' ' L' ' 46' ' ' ALA . 79.7 t -150.17 141.61 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 C-N-CA 128.933 2.893 . . . . 0.0 110.974 -174.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -115.56 -146.27 0.4 Allowed 'General case' 0 N--CA 1.449 -0.518 0 O-C-N 118.232 -2.792 . . . . 0.0 108.149 -174.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 66.3 p -70.91 -23.52 62.29 Favored 'General case' 0 N--CA 1.448 -0.546 1 O-C-N 116.13 -4.106 . . . . 0.0 116.795 -145.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . . 22.0 ttmt -116.93 8.64 13.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 120.838 -1.164 . . . . 0.0 110.836 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.41 3.62 90.47 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 120.914 3.126 . . . . 0.0 120.914 -171.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . . 12.5 t -77.74 123.89 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 125.676 1.59 . . . . 0.0 108.894 164.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 46' ' ' ALA . . . . . 0.428 ' HA ' ' HA ' ' L' ' 40' ' ' VAL . . . -38.03 152.54 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 119.076 2.991 . . . . 0.0 119.076 169.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -60.51 135.44 57.75 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.269 -2.769 . . . . 0.0 116.145 176.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 40.6 p -89.03 7.12 36.47 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.038 2.236 . . . . 0.0 117.038 -172.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -169.3 -149.78 0.08 Allowed 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.674 2.79 . . . . 0.0 106.635 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -155.2 -153.51 6.55 Favored Glycine 0 C--N 1.335 0.496 0 N-CA-C 121.009 3.164 . . . . 0.0 121.009 -172.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 62.92 44.38 97.5 Favored Glycine 0 CA--C 1.522 0.486 0 O-C-N 120.412 -1.64 . . . . 0.0 111.167 -173.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -87.09 163.76 38.93 Favored Pre-proline 0 N--CA 1.449 -0.489 0 CA-C-N 121.556 2.678 . . . . 0.0 105.212 -177.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -90.97 78.83 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 CA-C-O 127.642 3.101 . . . . 0.0 117.69 177.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -84.68 163.11 19.42 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.03 2.932 . . . . 0.0 110.643 169.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 19.7 tt0 -156.88 144.82 19.31 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.993 0.901 . . . . 0.0 111.968 166.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 40.3 t -124.07 136.3 60.81 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 C-N-CA 128.63 2.772 . . . . 0.0 114.977 174.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -143.11 125.4 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 C-N-CA 130.201 3.401 . . . . 0.0 112.359 -165.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 37.6 mm -121.7 103.38 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.478 1 O-C-N 116.149 -4.094 . . . . 0.0 110.493 -164.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -96.63 137.85 35.09 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 126.768 2.027 . . . . 0.0 111.635 -174.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.2 -159.98 16.26 Favored Glycine 0 C--N 1.336 0.559 0 O-C-N 118.677 -2.515 . . . . 0.0 115.262 169.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -69.76 150.61 68.43 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 N-CA-C 119.241 2.747 . . . . 0.0 119.241 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 38.9 t70 70.09 -95.75 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 127.989 2.516 . . . . 0.0 111.312 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -133.05 29.23 3.24 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-O 117.334 -1.815 . . . . 0.0 114.488 -178.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 36.4 mt -90.12 124.79 35.11 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 122.52 3.16 . . . . 0.0 117.88 -175.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 10.0 t -146.53 136.27 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 115.656 1.724 . . . . 0.0 115.656 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 17.5 t -135.77 132.64 51.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 124.068 0.947 . . . . 0.0 109.007 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.84 123.95 27.73 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-O 116.005 -1.95 . . . . 0.0 115.639 173.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -93.57 150.33 20.51 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 127.403 2.281 . . . . 0.0 114.131 -170.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . 0.551 42.1 tttm -76.15 94.8 3.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 124.193 0.997 . . . . 0.0 111.962 -179.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 14.2 t -64.95 143.97 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 O-C-N 118.211 -2.805 . . . . 0.0 104.425 154.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 27.8 m -141.8 133.99 27.77 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 124.404 2.05 . . . . 0.0 110.278 159.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 14.4 t0 -68.93 125.06 25.44 Favored 'General case' 0 N--CA 1.449 -0.505 1 O-C-N 116.249 -4.032 . . . . 0.0 113.559 172.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -69.91 -16.69 63.27 Favored 'General case' 0 N--CA 1.449 -0.506 1 C-N-CA 131.745 4.018 . . . . 0.0 118.348 174.49 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 74' ' ' ASN . . . . . 0.453 ' OD1' ' HA ' ' L' ' 1' ' ' HIS 0.263 57.7 t30 67.07 45.34 1.75 Allowed 'General case' 0 N--CA 1.448 -0.54 0 O-C-N 118.851 -2.406 . . . . 0.0 112.248 -168.614 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -159.14 -2.86 0.08 Allowed 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 118.634 -2.541 . . . . 0.0 116.837 -177.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 101.39 -5.66 55.25 Favored Glycine 0 C--N 1.335 0.516 0 CA-C-O 115.494 -2.837 . . . . 0.0 112.025 -167.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 31.3 p -123.37 164.99 17.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 123.465 3.633 . . . . 0.0 115.577 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -132.86 137.74 46.79 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 126.568 2.418 . . . . 0.0 109.755 -175.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -91.52 150.83 20.59 Favored Glycine 0 C--N 1.336 0.531 0 N-CA-C 108.597 -1.801 . . . . 0.0 108.597 168.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -141.36 146.73 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 O-C-N 127.4 2.47 . . . . 0.0 110.531 177.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.8 p -132.11 143.67 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 126.652 1.981 . . . . 0.0 106.346 -175.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 10.3 p90 -161.97 167.43 24.54 Favored 'General case' 0 N--CA 1.449 -0.501 0 O-C-N 117.681 -3.137 . . . . 0.0 115.979 175.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -142.82 162.67 34.85 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 116.459 -1.734 . . . . 0.0 111.509 -170.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 84' ' ' ALA . . . . . 0.611 ' HB1' ' CD1' ' L' ' 90' ' ' TYR . . . -125.12 78.01 66.94 Favored Pre-proline 0 N--CA 1.449 -0.502 0 C-N-CA 125.671 1.589 . . . . 0.0 111.22 -178.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 85' ' ' PRO . . . . . 0.498 ' HD2' ' CE2' ' L' ' 90' ' ' TYR 0.417 73.5 Cg_exo -40.1 -23.37 0.12 Allowed 'Trans proline' 0 N--CA 1.449 -1.142 1 C-N-CA 128.38 6.053 . . . . 0.0 119.596 178.621 . . . . . . . . 4 3 . 1 . 001 nuclear nobuild full ' L' L ' 86' ' ' VAL . . . . . 0.565 ' H ' ' HE1' ' L' ' 90' ' ' TYR . 85.6 t -123.32 132.52 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 CA-C-O 117.368 -1.301 . . . . 0.0 108.867 -174.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -60.59 85.29 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 131.024 3.73 . . . . 0.0 109.365 163.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 172.88 -171.72 44.59 Favored Glycine 0 CA--C 1.523 0.536 1 C-N-CA 132.56 4.886 . . . . 0.0 112.895 -160.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -71.5 140.26 49.88 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.059 1.744 . . . . 0.0 112.834 167.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 90' ' ' TYR . . . . . 0.611 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 14.1 m-85 -112.1 168.75 9.36 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 120.164 -1.585 . . . . 0.0 109.955 150.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -133.31 133.91 43.17 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.833 3.253 . . . . 0.0 112.39 -177.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 59.3 t -120.67 121.9 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.584 0 CA-C-O 125.448 2.547 . . . . 0.0 105.716 -169.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -135.75 118.72 16.35 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.937 2.495 . . . . 0.0 115.873 -176.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.53 142.93 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 CA-C-N 113.16 -1.836 . . . . 0.0 112.718 -169.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -142.79 151.28 41.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 O-C-N 125.042 1.464 . . . . 0.0 108.712 -168.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 96' ' ' LEU . . . . . 0.481 HD11 ' HB2' ' L' ' 12' ' ' PRO . 4.0 tt -133.83 116.74 16.04 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 127.656 2.383 . . . . 0.0 106.412 173.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 tmm_? 62.83 -49.7 0.19 Allowed 'General case' 0 N--CA 1.447 -0.603 0 C-N-CA 127.495 2.318 . . . . 0.0 116.864 178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -170.43 16.64 0.06 OUTLIER Glycine 0 CA--C 1.523 0.535 0 C-N-CA 129.608 3.48 . . . . 0.0 114.495 162.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 21.6 m120 -128.05 149.23 70.42 Favored Pre-proline 0 N--CA 1.451 -0.397 0 C-N-CA 127.943 2.497 . . . . 0.0 111.538 -163.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -80.49 -176.24 3.09 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 121.138 1.225 . . . . 0.0 113.94 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 4.1 pt -139.17 -155.13 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 C-N-CA 129.809 3.244 . . . . 0.0 108.444 -177.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 9.0 pttm -136.17 172.75 12.55 Favored 'General case' 0 N--CA 1.45 -0.469 1 O-C-N 115.365 -4.584 . . . . 0.0 111.009 170.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 49.0 t30 80.28 -57.68 0.34 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 130.365 3.466 . . . . 0.0 106.799 -160.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -83.06 154.35 67.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 O-C-N 126.403 2.314 . . . . 0.0 109.745 164.166 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -77.71 163.66 87.63 Favored 'Cis proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.666 -2.223 . . . . 0.0 113.359 -5.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 9.3 tp -162.98 147.68 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-N 113.24 -1.8 . . . . 0.0 113.941 -161.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -120.49 150.87 40.14 Favored 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 120.072 -1.643 . . . . 0.0 109.295 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 9.0 p -158.46 125.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 O-C-N 126.151 2.157 . . . . 0.0 111.019 -163.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 56.3 mtpt -81.73 148.58 28.87 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 118.339 -0.838 . . . . 0.0 112.931 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 5.3 t -101.24 117.67 35.44 Favored 'General case' 0 N--CA 1.449 -0.48 0 C-N-CA 128.779 2.832 . . . . 0.0 108.125 -170.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 111' ' ' ILE . . . . . 0.42 HD13 HG21 ' L' ' 111' ' ' ILE . 20.2 tt -133.95 163.04 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-O 116.205 -1.855 . . . . 0.0 114.631 178.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . . 10.0 tt0 -77.49 75.52 4.04 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 121.601 2.001 . . . . 0.0 112.657 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.65 -116.1 5.91 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 107.066 -2.414 . . . . 0.0 107.066 171.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.11 1.84 50.48 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 114.973 1.472 . . . . 0.0 114.973 167.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 65.4 t30 -73.52 124.79 26.55 Favored 'General case' 0 N--CA 1.449 -0.486 0 O-C-N 117.717 -3.115 . . . . 0.0 107.494 -172.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.94 23.87 70.87 Favored Glycine 0 CA--C 1.523 0.55 0 O-C-N 120.248 -1.533 . . . . 0.0 115.297 -172.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -76.15 172.47 12.77 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 121.6 2.7 . . . . 0.0 113.597 160.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 118' ' ' ASP . . . . . 0.401 ' HA ' ' HA ' ' L' ' 119' ' ' SER . 14.2 t70 -64.4 139.03 58.72 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 129.705 3.202 . . . . 0.0 111.764 160.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 119' ' ' SER . . . . . 0.408 ' HB3' HG21 ' L' ' 169' ' ' THR . 5.7 m -98.89 9.54 43.27 Favored 'General case' 0 N--CA 1.449 -0.508 0 O-C-N 116.578 -3.827 . . . . 0.0 109.41 -11.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 60.0 p -65.05 -15.9 62.86 Favored 'General case' 0 N--CA 1.451 -0.422 0 N-CA-C 118.968 2.951 . . . . 0.0 118.968 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -69.66 -20.9 63.57 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 128.041 2.536 . . . . 0.0 111.302 171.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . -98.52 18.12 57.43 Favored Glycine 0 C--N 1.335 0.521 0 O-C-N 127.867 3.23 . . . . 0.0 114.11 -177.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 123' ' ' SER . . . . . . . . . . . . . 47.7 m -74.42 136.57 42.37 Favored 'General case' 0 N--CA 1.448 -0.562 0 C-N-CA 127.861 2.464 . . . . 0.0 114.47 -172.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 9.1 m-30 -62.14 146.59 50.13 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 128.556 2.742 . . . . 0.0 108.977 -168.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 73.2 p -162.19 143.82 10.83 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 128.238 2.615 . . . . 0.0 111.282 177.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.259 11.6 m-85 -61.59 143.32 56.23 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 114.679 -2.582 . . . . 0.0 110.128 149.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 20.3 m -68.67 105.7 2.37 Favored 'General case' 0 N--CA 1.449 -0.515 0 O-C-N 126.155 2.16 . . . . 0.0 106.623 148.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 14.5 p -150.36 140.31 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 C-N-CA 127.511 2.324 . . . . 0.0 110.12 -178.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . 68.0 5.83 4.81 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.053 2.242 . . . . 0.0 117.053 170.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -168.47 157.11 8.65 Favored 'General case' 0 N--CA 1.447 -0.579 1 C-N-CA 134.768 5.227 . . . . 0.0 111.025 -171.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . 0.376 5.8 ptpt -59.21 -26.17 64.62 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.632 2.086 . . . . 0.0 116.632 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 22.4 m120 -148.42 146.23 28.36 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 126.669 3.128 . . . . 0.0 110.593 167.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . 0.297 46.3 mttm 68.95 -155.1 0.16 Allowed 'General case' 0 N--CA 1.449 -0.518 0 O-C-N 118.703 -2.498 . . . . 0.0 113.948 170.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . 0.332 51.7 pttt -49.0 156.04 0.55 Allowed 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 120.921 3.675 . . . . 0.0 120.921 163.015 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . -81.13 153.34 33.88 Favored Glycine 0 C--N 1.335 0.501 0 O-C-N 116.903 -3.623 . . . . 0.0 109.698 159.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -73.12 -9.97 59.28 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 120.089 3.366 . . . . 0.0 120.089 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 74.0 t -71.48 132.06 33.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 C-N-CA 127.504 2.321 . . . . 0.0 112.952 160.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -49.56 -51.06 39.45 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 117.822 2.527 . . . . 0.0 117.822 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 6.7 m -107.31 87.5 2.52 Favored 'General case' 0 N--CA 1.45 -0.45 0 O-C-N 126.22 2.2 . . . . 0.0 112.294 174.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 35.0 p90 -83.49 10.29 9.25 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 116.231 -1.842 . . . . 0.0 113.245 175.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 146.17 -155.77 26.67 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -169.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . -105.5 -9.26 33.71 Favored Glycine 0 CA--C 1.522 0.502 0 C-N-CA 128.622 3.01 . . . . 0.0 113.864 -164.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -153.81 136.02 14.84 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-N 120.148 1.974 . . . . 0.0 109.469 -176.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 144' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -69.68 -31.51 69.59 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 116.036 1.865 . . . . 0.0 116.036 173.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -162.84 176.11 10.56 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 116.38 -3.95 . . . . 0.0 108.79 -173.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 146' ' ' GLU . . . . . 0.565 ' CD ' HH11 ' L' ' 179' ' ' ARG . 33.7 tt0 -130.58 136.52 48.98 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 160.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 2.5 p -80.12 140.4 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.459 0 CA-C-N 112.508 -2.133 . . . . 0.0 113.345 -161.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 148' ' ' SER . . . . . . . . . . . . . 70.4 m -120.8 -12.23 8.86 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 113.775 -1.557 . . . . 0.0 113.379 175.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . . 5.4 tp -82.92 155.77 3.85 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 O-C-N 117.652 -3.155 . . . . 0.0 113.638 165.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 150' ' ' THR . . . . . . . . . . . . . 21.8 p -93.36 174.02 7.42 Favored 'General case' 0 N--CA 1.45 -0.443 1 O-C-N 116.053 -4.155 . . . . 0.0 108.746 175.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . 70.54 170.59 9.28 Favored Glycine 0 CA--C 1.523 0.542 0 C-N-CA 128.02 2.724 . . . . 0.0 118.449 -176.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -77.54 169.72 20.51 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 124.546 3.497 . . . . 0.0 114.087 177.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -76.0 -12.24 60.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 118.397 -2.69 . . . . 0.0 117.501 -176.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -50.29 -40.26 47.84 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 123.541 0.737 . . . . 0.0 110.195 164.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -101.04 6.42 43.41 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.778 -1.826 . . . . 0.0 114.206 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 57.3 mt -108.51 135.24 47.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 116.642 -3.786 . . . . 0.0 107.016 177.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 55.0 m -86.82 134.31 33.56 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 158' ' ' LEU . . . . . 0.412 HD23 ' H ' ' L' ' 159' ' ' ASP . 0.9 OUTLIER -109.39 140.27 43.3 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 124.972 2.32 . . . . 0.0 112.975 165.418 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 159' ' ' ASP . . . . . 0.412 ' H ' HD23 ' L' ' 158' ' ' LEU . 58.5 t0 -158.86 119.26 3.22 Favored 'General case' 0 N--CA 1.449 -0.522 0 O-C-N 119.722 -1.861 . . . . 0.0 108.309 -170.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -153.03 158.62 42.25 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 113.406 0.891 . . . . 0.0 113.406 -165.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 6.0 pt -71.24 -22.19 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 CA-C-O 114.745 -2.55 . . . . 0.0 110.009 163.24 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -163.23 140.67 7.64 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 129.428 3.091 . . . . 0.0 109.262 162.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -66.26 -13.4 60.35 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 130.036 3.334 . . . . 0.0 110.301 -168.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 2.9 mp0 -107.3 -14.61 14.84 Favored 'General case' 0 N--CA 1.447 -0.613 0 O-C-N 117.687 -3.133 . . . . 0.0 110.145 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -100.94 -45.1 5.53 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 118.442 2.756 . . . . 0.0 118.442 171.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . -70.49 -165.81 5.87 Favored Glycine 0 CA--C 1.523 0.564 0 C-N-CA 129.323 3.344 . . . . 0.0 113.275 167.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 1.5 t -169.52 177.29 4.67 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 106.93 -1.507 . . . . 0.0 106.93 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 83.3 m-85 -52.06 170.09 0.06 Allowed 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 127.126 2.17 . . . . 0.0 114.826 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 169' ' ' THR . . . . . 0.408 HG21 ' HB3' ' L' ' 119' ' ' SER . 11.3 t -155.29 153.93 31.33 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 127.703 2.401 . . . . 0.0 109.387 -176.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -168.69 145.45 3.74 Favored 'General case' 0 N--CA 1.45 -0.426 1 C-N-CA 133.911 4.884 . . . . 0.0 116.721 -178.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -127.34 -5.55 5.98 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 114.493 -1.231 . . . . 0.0 113.971 -172.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -76.31 135.97 39.59 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 128.232 2.613 . . . . 0.0 116.163 172.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 3.6 m -161.31 150.91 16.77 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 123.29 2.768 . . . . 0.0 108.862 174.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 20.2 mt -95.0 171.13 8.95 Favored 'General case' 0 N--CA 1.449 -0.513 1 C-N-CA 131.868 4.067 . . . . 0.0 109.601 167.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 35.8 t -77.83 118.19 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 C-N-CA 126.33 1.852 . . . . 0.0 106.398 167.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . 160.44 -163.01 33.76 Favored Glycine 0 C--N 1.336 0.544 0 O-C-N 118.052 -2.905 . . . . 0.0 114.642 177.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 5.4 t-20 -143.14 77.99 1.59 Allowed 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 131.24 3.816 . . . . 0.0 106.949 178.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 178' ' ' GLY . . . . . . . . . . . . . . . -102.35 160.57 17.41 Favored Glycine 0 C--N 1.336 0.557 0 C-N-CA 128.258 2.837 . . . . 0.0 110.495 174.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 179' ' ' ARG . . . . . 0.565 HH11 ' CD ' ' L' ' 146' ' ' GLU . 6.6 ptm180 -167.89 162.53 13.6 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 130.203 3.401 . . . . 0.0 117.313 177.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -128.52 141.09 51.49 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-O 114.994 -2.432 . . . . 0.0 109.634 163.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 181' ' ' SER . . . . . . . . . . . . . 30.0 m -68.81 66.55 0.13 Allowed 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 123.991 3.087 . . . . 0.0 113.695 -176.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 1.3 t -173.01 170.97 4.32 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 117.523 2.416 . . . . 0.0 117.523 174.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . -156.77 -132.12 1.45 Allowed Glycine 0 C--N 1.335 0.473 1 C-N-CA 132.711 4.958 . . . . 0.0 109.963 175.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 184' ' ' VAL . . . . . 0.466 HG12 ' O ' ' L' ' 184' ' ' VAL . 5.0 t -132.69 101.08 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 O-C-N 117.585 -3.303 . . . . 0.0 110.317 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -52.37 117.31 2.75 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-O 117.706 -1.14 . . . . 0.0 110.265 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 11.1 tp -84.52 -38.57 19.9 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 128.982 3.926 . . . . 0.0 107.864 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 58.2 t30 -155.36 149.65 25.94 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.414 3.085 . . . . 0.0 107.956 179.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . 86.99 156.09 28.79 Favored Glycine 0 CA--C 1.522 0.52 0 CA-C-O 124.912 2.395 . . . . 0.0 113.668 173.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -55.64 113.9 1.64 Allowed 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 110.33 -2.935 . . . . 0.0 117.682 -175.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -71.35 125.71 27.72 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 114.418 -1.265 . . . . 0.0 113.255 174.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 16.8 mm 44.73 120.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 130.583 3.553 . . . . 0.0 111.049 -160.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -98.19 139.6 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 113.218 -1.81 . . . . 0.0 110.951 -164.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 111.5 -149.7 18.0 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 114.344 -1.298 . . . . 0.0 113.509 -175.007 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 1.1 t -151.15 142.01 15.01 Favored Pre-proline 0 N--CA 1.449 -0.5 0 C-N-CA 131.591 3.956 . . . . 0.0 112.583 -171.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -89.82 150.33 4.98 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 120.436 0.758 . . . . 0.0 110.956 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -157.2 145.96 19.78 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 120.964 3.69 . . . . 0.0 120.964 -178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 89.7 mttt -92.78 150.06 20.89 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 120.483 -1.386 . . . . 0.0 112.058 -177.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 6.8 tt0 -83.19 135.48 34.77 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 120.433 -1.417 . . . . 0.0 111.14 -173.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 63.0 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 115.265 1.58 . . . . 0.0 115.265 155.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 49.8 mt -110.71 137.56 48.23 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 120.626 -1.296 . . . . 0.0 111.323 162.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 126.17 144.47 6.15 Favored Glycine 0 CA--C 1.523 0.555 0 C-N-CA 125.332 1.444 . . . . 0.0 115.228 -169.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -156.16 165.45 36.37 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-O 123.224 1.488 . . . . 0.0 108.925 176.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -92.98 150.59 20.44 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 117.441 -3.287 . . . . 0.0 107.842 175.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 16.1 mt -91.78 167.0 12.47 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 128.656 2.783 . . . . 0.0 106.739 2.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -139.55 -13.21 1.14 Allowed 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.079 1.352 . . . . 0.0 114.459 162.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 5.6 t -100.45 138.89 36.91 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 126.601 1.96 . . . . 0.0 113.303 -178.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 66.5 p -123.47 166.78 17.02 Favored Pre-proline 0 N--CA 1.448 -0.541 0 C-N-CA 129.494 3.118 . . . . 0.0 112.328 -173.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -50.12 149.48 11.91 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 124.576 3.517 . . . . 0.0 116.803 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.61 -19.67 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 O-C-N 125.559 1.787 . . . . 0.0 112.055 -176.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -159.75 159.47 32.83 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 127.185 2.194 . . . . 0.0 106.572 157.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 29.2 mm -82.18 119.72 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 126.84 2.056 . . . . 0.0 107.196 169.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 3.2 m -78.98 148.19 32.66 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 126.019 2.074 . . . . 0.0 115.21 -172.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 72.8 mm-40 -70.54 117.68 12.38 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 170.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -72.15 -20.42 61.61 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 117.464 2.394 . . . . 0.0 117.464 175.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -151.16 172.27 16.06 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 125.617 1.567 . . . . 0.0 109.907 -170.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -118.82 -41.18 0.61 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-O 125.055 2.475 . . . . 0.0 115.313 161.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 29.5 mm 85.74 -66.09 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.47 1 C-N-CA 132.124 4.17 . . . . 0.0 111.437 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -49.7 122.14 6.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 129.478 3.111 . . . . 0.0 108.263 -162.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -102.98 -167.42 1.39 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 114.624 -2.608 . . . . 0.0 116.115 177.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -57.47 127.45 44.98 Favored Glycine 0 CA--C 1.522 0.471 0 O-C-N 126.348 2.28 . . . . 0.0 110.855 -173.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo . . . . . 0 C--O 1.251 1.135 1 C-N-CA 127.641 5.561 . . . . 0.0 114.577 179.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 1' ' ' HIS . . . . . . . . . . . . . 22.8 t-80 . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 117.507 -1.235 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 33.7 m-70 -128.04 155.2 44.71 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 124.909 1.381 . . . . 0.0 108.871 159.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 36.6 m80 -70.72 162.72 28.56 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-O 124.272 1.987 . . . . 0.0 113.818 160.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 24.5 m-70 -59.23 154.29 16.64 Favored 'General case' 0 N--CA 1.448 -0.564 0 O-C-N 118.234 -2.791 . . . . 0.0 111.49 166.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -71.16 135.31 47.53 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 118.971 -2.331 . . . . 0.0 109.562 -176.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 4.9 m-70 -138.85 129.82 26.57 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 110.923 -2.853 . . . . 0.0 111.632 173.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.61 28.77 4.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 131.297 3.839 . . . . 0.0 113.776 -178.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 2.2 p -166.91 150.01 6.58 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.999 2.12 . . . . 0.0 110.199 -172.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 66.3 tttt -107.96 102.03 43.8 Favored Pre-proline 0 N--CA 1.451 -0.412 0 N-CA-C 115.887 1.81 . . . . 0.0 115.887 172.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . 0.271 53.1 Cg_exo -38.13 140.54 0.31 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 123.013 2.475 . . . . 0.0 118.257 161.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -90.33 169.85 11.35 Favored Pre-proline 0 N--CA 1.451 -0.387 0 O-C-N 126.395 2.31 . . . . 0.0 109.507 175.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_exo -62.91 137.61 63.63 Favored 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 122.606 2.204 . . . . 0.0 117.757 163.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 5.5 t -81.78 115.36 20.96 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 127.9 3.25 . . . . 0.0 111.349 155.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -50.05 -37.49 33.61 Favored 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 129.061 2.944 . . . . 0.0 112.919 166.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 -63.77 -49.98 70.84 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 128.314 2.646 . . . . 0.0 111.6 176.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 15.9 m170 -113.53 -23.63 9.69 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 126.45 1.9 . . . . 0.0 113.452 -151.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 17' ' ' SER . . . . . . . . . . . . . 73.0 m -70.18 146.11 51.0 Favored 'General case' 0 N--CA 1.448 -0.547 0 O-C-N 120.327 -1.483 . . . . 0.0 109.023 173.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 24.8 p90 -154.94 176.53 12.4 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.571 1.948 . . . . 0.0 111.492 -164.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -142.47 140.72 31.99 Favored 'General case' 0 N--CA 1.449 -0.485 0 O-C-N 125.595 1.81 . . . . 0.0 110.748 172.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 25.8 tt0 -147.26 134.92 21.05 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 125.884 2.754 . . . . 0.0 110.351 179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.99 -168.11 41.08 Favored Glycine 0 CA--C 1.524 0.601 0 CA-C-O 125.306 2.615 . . . . 0.0 112.528 157.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -54.24 -34.37 60.56 Favored 'General case' 0 N--CA 1.451 -0.425 0 CA-C-N 112.428 -1.886 . . . . 0.0 110.526 178.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -46.41 -16.77 0.19 Allowed Glycine 0 C--N 1.335 0.482 0 C-N-CA 127.801 2.62 . . . . 0.0 118.901 166.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 13.5 mt -119.26 21.59 12.17 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 127.149 2.18 . . . . 0.0 114.236 173.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 55.6 t -133.19 -58.42 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-O 121.737 0.779 . . . . 0.0 110.525 -171.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 35.1 tttt -149.23 98.89 2.87 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 122.624 1.202 . . . . 0.0 108.659 -154.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 27' ' ' VAL . . . . . . . . . . . . . 37.9 t -141.52 131.92 25.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 CA-C-O 114.278 -2.773 . . . . 0.0 111.344 -152.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 28' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -127.2 149.54 49.94 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 119.58 3.178 . . . . 0.0 119.58 -158.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -63.35 -14.18 47.16 Favored 'General case' 0 N--CA 1.448 -0.542 0 O-C-N 124.694 1.246 . . . . 0.0 113.114 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . 0.263 14.4 p-10 -113.02 3.33 16.12 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 116.741 2.126 . . . . 0.0 116.741 169.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -152.41 137.91 11.32 Favored Pre-proline 0 N--CA 1.45 -0.441 1 N-CA-C 122.177 4.14 . . . . 0.0 122.177 -167.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -77.78 160.49 30.97 Favored 'Trans proline' 0 N--CA 1.447 -1.22 1 C-N-CA 128.078 5.852 . . . . 0.0 111.178 -172.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -141.35 152.38 44.35 Favored 'General case' 0 N--CA 1.449 -0.496 0 O-C-N 126.206 2.191 . . . . 0.0 113.795 -173.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 34' ' ' GLU . . . . . 0.522 ' HA ' ' O ' ' L' ' 80' ' ' VAL . 11.3 mt-10 -128.0 152.32 48.07 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 124.912 1.285 . . . . 0.0 111.583 -167.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . 0.305 4.1 p90 -160.44 153.86 22.12 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.692 2.397 . . . . 0.0 106.735 -173.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 36' ' ' THR . . . . . . . . . . . . . 1.2 m -121.53 129.04 52.65 Favored 'General case' 0 N--CA 1.448 -0.535 0 O-C-N 123.626 0.579 . . . . 0.0 110.269 -169.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.314 4.1 mt -73.93 104.79 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 166.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -91.92 115.28 27.93 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 124.284 1.993 . . . . 0.0 108.923 168.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.14 145.71 28.97 Favored 'General case' 0 N--CA 1.448 -0.527 0 O-C-N 118.347 -2.721 . . . . 0.0 109.009 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t -140.02 129.05 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 110.292 -3.14 . . . . 0.0 110.552 -175.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 35.2 p30 -75.31 176.05 7.79 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-O 127.84 3.686 . . . . 0.0 117.856 -177.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 12.1 p -50.83 -12.35 0.1 Allowed 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 110.32 -3.127 . . . . 0.0 117.717 173.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . 0.264 21.6 pttm -114.27 4.09 15.33 Favored 'General case' 0 N--CA 1.449 -0.516 0 O-C-N 125.307 1.629 . . . . 0.0 111.464 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . 89.59 12.56 62.51 Favored Glycine 0 CA--C 1.523 0.541 0 C-N-CA 127.517 2.484 . . . . 0.0 117.972 -175.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . . 3.1 t -115.79 119.15 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 C-N-CA 126.272 1.829 . . . . 0.0 113.095 -174.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . -24.43 139.73 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 117.996 2.591 . . . . 0.0 117.996 167.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . 0.271 11.1 mmm180 -76.83 153.37 34.91 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.252 1.821 . . . . 0.0 110.603 -177.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 43.2 p -124.41 -1.53 8.09 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 128.513 2.725 . . . . 0.0 115.265 -165.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -161.52 167.29 25.72 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.771 1.026 . . . . 0.0 113.771 -168.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.63 175.56 40.53 Favored Glycine 0 C--N 1.335 0.498 1 N-CA-C 125.415 4.926 . . . . 0.0 125.415 175.145 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 66.4 49.08 59.07 Favored Glycine 0 C--N 1.335 0.509 0 C-N-CA 125.745 1.641 . . . . 0.0 112.544 161.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 -83.38 150.38 60.25 Favored Pre-proline 0 N--CA 1.449 -0.512 0 CA-C-O 115.014 -2.422 . . . . 0.0 116.948 151.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -91.7 59.74 0.96 Allowed 'Trans proline' 0 N--CA 1.451 -1.025 0 N-CA-C 106.833 -2.026 . . . . 0.0 106.833 -164.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -69.7 155.7 40.11 Favored 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 117.929 2.566 . . . . 0.0 117.929 156.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 28.8 tt0 -145.98 146.78 31.14 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-O 116.516 -1.707 . . . . 0.0 109.78 178.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 4.6 t -125.64 140.26 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 119.979 1.263 . . . . 0.0 111.882 -173.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.96 29.55 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 114.272 -2.775 . . . . 0.0 111.956 -176.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . . 15.7 mt -135.75 134.04 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 1 C-N-CA 131.898 4.079 . . . . 0.0 110.13 -178.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -120.91 148.69 43.71 Favored 'General case' 0 N--CA 1.45 -0.444 1 C-N-CA 133.445 4.698 . . . . 0.0 110.901 -178.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -148.63 -162.61 10.34 Favored Glycine 0 CA--C 1.522 0.504 0 CA-C-O 124.714 2.285 . . . . 0.0 114.931 -171.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.42 149.37 86.63 Favored 'Trans proline' 0 N--CA 1.448 -1.153 1 C-N-CA 125.403 4.069 . . . . 0.0 110.892 -178.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 24.9 t70 60.83 -125.61 0.95 Allowed 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 127.724 2.41 . . . . 0.0 109.461 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 63' ' ' GLY . . . . . . . . . . . . . . . -89.83 -9.26 66.34 Favored Glycine 0 C--N 1.335 0.506 1 O-C-N 114.457 -5.152 . . . . 0.0 111.314 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 64' ' ' LEU . . . . . . . . . . . . . 8.8 tp -62.32 124.58 21.28 Favored 'General case' 0 N--CA 1.447 -0.593 0 O-C-N 118.358 -2.848 . . . . 0.0 113.467 -155.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 15.4 m -108.51 156.49 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 N-CA-C 117.972 2.582 . . . . 0.0 117.972 150.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 89.0 t -122.64 136.22 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 125.609 1.818 . . . . 0.0 110.084 -168.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -89.96 118.04 29.23 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -176.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -63.22 147.04 52.07 Favored 'General case' 0 N--CA 1.45 -0.441 0 O-C-N 118.564 -2.585 . . . . 0.0 116.922 172.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 5.2 mptt -116.92 119.94 36.91 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 173.023 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 64.2 t -112.62 143.99 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 CA-C-O 123.55 1.643 . . . . 0.0 108.434 -173.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -139.77 117.53 11.63 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 114.47 -1.241 . . . . 0.0 112.253 170.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -81.27 121.88 26.73 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 129.052 2.941 . . . . 0.0 109.456 178.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -77.61 -5.38 50.08 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-O 115.704 -2.093 . . . . 0.0 115.274 175.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 71.22 24.3 3.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 125.628 3.831 . . . . 0.0 112.092 -175.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 35.5 t70 -149.16 -12.52 0.31 Allowed 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 117.103 -3.498 . . . . 0.0 111.028 -160.48 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 115.86 5.34 18.07 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 120.103 2.801 . . . . 0.0 120.103 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 18.8 p -136.15 157.34 47.06 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 129.342 3.057 . . . . 0.0 111.391 170.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 78' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -130.43 140.1 50.57 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 116.666 -1.635 . . . . 0.0 108.956 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -77.32 132.89 12.49 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 127.346 2.403 . . . . 0.0 114.86 160.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 80' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' L' ' 34' ' ' GLU . 2.6 t -126.14 128.52 71.78 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 127.733 2.666 . . . . 0.0 115.65 174.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 7.5 p -136.4 143.04 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 120.645 -1.284 . . . . 0.0 113.225 174.444 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . . 12.2 p90 -151.04 -178.94 6.9 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 114.79 -1.096 . . . . 0.0 111.607 175.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -137.27 107.22 6.29 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.56 1.944 . . . . 0.0 111.338 178.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 84' ' ' ALA . . . . . 0.549 ' HB1' ' CD1' ' L' ' 90' ' ' TYR 0.28 . . -68.63 110.43 5.87 Favored Pre-proline 0 N--CA 1.45 -0.453 0 C-N-CA 124.843 1.257 . . . . 0.0 109.54 164.204 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 85' ' ' PRO . . . . . . . . . . . . 0.264 50.0 Cg_endo -67.29 -10.02 27.22 Favored 'Trans proline' 0 N--CA 1.449 -1.145 1 C-N-CA 126.546 4.831 . . . . 0.0 117.866 -167.987 . . . . . . . . 3 2 . 1 . 002 nuclear nobuild full ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.61 154.16 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 CA-C-N 119.827 1.194 . . . . 0.0 110.209 -175.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -43.97 130.15 5.88 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 114.327 1.232 . . . . 0.0 114.327 150.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 145.37 -149.65 21.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 127.618 2.532 . . . . 0.0 111.643 -174.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 5.9 m120 -121.98 153.93 37.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 127.033 2.133 . . . . 0.0 113.391 -178.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 90' ' ' TYR . . . . . 0.549 ' CD1' ' HB1' ' L' ' 84' ' ' ALA . 52.6 m-85 -152.27 156.39 39.59 Favored 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.332 1.853 . . . . 0.0 108.398 -172.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . 0.325 2.9 t30 -133.55 114.32 13.43 Favored 'General case' 0 N--CA 1.448 -0.526 0 C-N-CA 125.007 1.323 . . . . 0.0 111.512 -165.021 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 20.5 t -108.55 139.17 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-N 112.972 -1.922 . . . . 0.0 110.246 -164.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -155.1 106.49 2.62 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 128.659 2.784 . . . . 0.0 117.162 -173.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 94' ' ' VAL . . . . . 0.461 ' HB ' ' HG3' ' L' ' 104' ' ' MET . 33.1 t -94.56 142.63 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 111.899 -2.41 . . . . 0.0 108.873 159.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 95' ' ' THR . . . . . 0.409 ' HB ' ' H ' ' L' ' 96' ' ' LEU . 35.0 p -137.42 -144.36 0.19 Allowed 'General case' 0 N--CA 1.451 -0.384 0 O-C-N 128.946 3.903 . . . . 0.0 117.431 -173.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 96' ' ' LEU . . . . . 0.409 ' H ' ' HB ' ' L' ' 95' ' ' THR . 6.0 tp -150.72 154.52 37.54 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 123.667 2.94 . . . . 0.0 115.016 168.232 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 33.3 ttm180 -64.36 94.88 0.12 Allowed 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 124.202 1.953 . . . . 0.0 109.856 142.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . 121.41 -153.16 16.71 Favored Glycine 0 N--CA 1.448 -0.504 1 C-N-CA 131.032 4.158 . . . . 0.0 110.295 -171.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -71.47 113.87 23.21 Favored Pre-proline 0 N--CA 1.449 -0.487 0 CA-C-O 113.358 -3.21 . . . . 0.0 108.551 -170.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -74.63 160.29 41.4 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 O-C-N 127.079 3.147 . . . . 0.0 114.23 -165.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.7 pt -90.07 138.81 18.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 O-C-N 117.064 -3.522 . . . . 0.0 112.071 -159.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 23.0 mmtt -92.59 -178.73 4.97 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-O 117.352 -1.309 . . . . 0.0 109.396 -173.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 72.64 -44.44 0.59 Allowed 'General case' 0 N--CA 1.448 -0.537 0 CA-C-O 126.797 3.189 . . . . 0.0 110.894 -154.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 104' ' ' MET . . . . . 0.461 ' HG3' ' HB ' ' L' ' 94' ' ' VAL . 28.0 mmt -69.74 155.25 93.84 Favored Pre-proline 0 N--CA 1.448 -0.541 0 CA-C-O 112.347 -3.692 . . . . 0.0 107.741 153.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -75.13 159.92 97.19 Favored 'Cis proline' 0 N--CA 1.447 -1.213 0 O-C-N 125.453 2.291 . . . . 0.0 110.481 -18.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 106' ' ' ILE . . . . . . . . . . . . . 12.5 tt -151.55 141.05 15.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-N 114.163 -1.38 . . . . 0.0 112.709 -174.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 107' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -95.62 136.14 36.4 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 129.659 3.183 . . . . 0.0 113.692 173.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.27 143.25 41.18 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 C-N-CA 128.979 2.911 . . . . 0.0 103.284 -163.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -111.75 147.4 35.72 Favored 'General case' 0 N--CA 1.448 -0.525 0 C-N-CA 126.321 1.848 . . . . 0.0 113.807 177.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 110' ' ' CYS . . . . . . . . . . . . . 41.0 t -127.43 138.96 53.11 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 125.747 1.905 . . . . 0.0 106.356 -172.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 1.3 pp -136.19 158.84 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 128.125 2.57 . . . . 0.0 110.413 -177.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . 0.252 14.5 tt0 -56.72 125.42 22.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -177.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . -108.3 141.64 15.83 Favored Glycine 0 C--N 1.336 0.544 0 CA-C-O 117.534 -1.703 . . . . 0.0 111.593 147.494 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -58.61 129.41 41.94 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 116.46 2.022 . . . . 0.0 116.46 -177.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -56.62 -54.59 44.23 Favored 'General case' 0 N--CA 1.448 -0.533 0 O-C-N 125.548 1.78 . . . . 0.0 115.53 174.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . -105.51 -151.78 20.38 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 126.882 2.182 . . . . 0.0 112.541 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -80.11 156.37 27.06 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-O 118.647 -0.692 . . . . 0.0 112.347 157.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 118' ' ' ASP . . . . . . . . . . . . 0.252 35.3 t70 -160.96 142.14 11.73 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.087 -166.589 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 51.1 m -63.88 -43.51 95.82 Favored 'General case' 0 N--CA 1.45 -0.444 1 O-C-N 113.808 -5.558 . . . . 0.0 112.356 1.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 90.0 p 179.43 169.1 1.07 Allowed 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.132 -2.23 . . . . 0.0 108.283 -163.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -92.59 130.17 38.31 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 122.785 2.539 . . . . 0.0 108.772 161.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . -169.96 -152.07 7.76 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 127.282 2.372 . . . . 0.0 116.538 -172.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 123' ' ' SER . . . . . . . . . . . . . 61.6 p -157.43 -103.82 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.487 0 O-C-N 126.292 1.819 . . . . 0.0 113.408 -174.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . 0.32 26.3 p90 -145.2 150.03 35.99 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 119.554 3.168 . . . . 0.0 119.554 -176.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 3.4 p -135.9 153.56 51.41 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 118.077 -2.89 . . . . 0.0 112.684 -166.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.338 56.9 t80 -66.22 154.51 39.64 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -174.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 12.9 t -60.42 149.24 34.68 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 130.256 3.422 . . . . 0.0 112.574 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 21.6 m -71.21 135.79 27.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 CA-C-N 112.599 -2.091 . . . . 0.0 110.093 178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . -163.19 157.39 20.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.405 1.482 . . . . 0.0 111.902 173.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -78.31 153.55 31.65 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 121.976 0.893 . . . . 0.0 111.667 178.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -52.46 -24.26 7.6 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 120.291 -1.505 . . . . 0.0 112.277 -172.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -85.19 -16.19 41.16 Favored 'General case' 0 N--CA 1.448 -0.574 0 O-C-N 120.592 -1.318 . . . . 0.0 113.444 -176.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . . 69.1 mmtt -89.32 134.25 34.14 Favored 'General case' 0 N--CA 1.449 -0.516 0 O-C-N 119.446 -2.034 . . . . 0.0 113.843 178.093 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . . 48.9 tptt -68.3 125.03 25.13 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 123.92 1.819 . . . . 0.0 112.601 -179.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . -104.75 165.62 14.67 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 112.364 -2.198 . . . . 0.0 117.411 167.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -110.04 134.31 52.28 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 126.411 1.884 . . . . 0.0 111.393 -175.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 4.3 t -109.2 -34.54 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 C-N-CA 127.062 2.145 . . . . 0.0 116.374 -176.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 59.6 mttt -71.04 -20.4 62.39 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 118.915 2.932 . . . . 0.0 118.915 -177.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 17.8 m -107.32 145.53 32.69 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.11 3.364 . . . . 0.0 110.346 -178.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 79.4 t80 -142.27 131.78 23.81 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 125.403 2.525 . . . . 0.0 109.396 179.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 78.08 -163.84 51.01 Favored Glycine 0 CA--C 1.523 0.54 0 O-C-N 119.961 -1.712 . . . . 0.0 108.943 -170.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . 70.89 -135.57 24.72 Favored Glycine 0 C--N 1.335 0.509 0 N-CA-C 118.022 1.969 . . . . 0.0 118.022 -165.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -91.31 -44.26 9.29 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 112.245 -1.977 . . . . 0.0 111.118 -160.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 144' ' ' LYS . . . . . 0.446 ' HE2' ' O ' ' L' ' 183' ' ' GLY . 89.4 mttt -80.05 31.7 0.27 Allowed 'General case' 0 N--CA 1.449 -0.493 0 O-C-N 118.397 -2.689 . . . . 0.0 113.965 175.191 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 -117.41 150.5 38.78 Favored 'General case' 0 N--CA 1.448 -0.543 0 O-C-N 117.877 -3.015 . . . . 0.0 113.808 172.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 146' ' ' GLU . . . . . . . . . . . . . 25.7 tt0 -100.11 140.06 34.88 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 117.594 -3.191 . . . . 0.0 105.816 162.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 2.3 t -117.69 97.13 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-N 121.671 2.032 . . . . 0.0 107.07 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 148' ' ' SER . . . . . 0.406 ' HA ' ' HA2' ' L' ' 178' ' ' GLY 0.295 20.1 m -78.85 -7.63 58.08 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 127.193 2.197 . . . . 0.0 116.288 175.872 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . . 32.5 pt -92.44 167.88 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 O-C-N 119.519 -1.988 . . . . 0.0 113.464 164.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 150' ' ' THR . . . . . . . . . . . . . 22.3 m -94.53 95.89 9.1 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 103.16 -2.904 . . . . 0.0 103.16 169.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . 164.85 170.06 29.3 Favored Glycine 0 C--N 1.335 0.524 0 O-C-N 126.45 2.344 . . . . 0.0 115.502 -175.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -85.41 166.27 10.69 Favored 'Trans proline' 0 N--CA 1.449 -1.135 1 C-N-CA 126.125 4.55 . . . . 0.0 111.59 -170.118 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -133.01 80.0 1.87 Allowed 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 112.374 -2.194 . . . . 0.0 112.445 173.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -68.08 131.09 44.8 Favored 'General case' 0 N--CA 1.449 -0.497 0 O-C-N 118.093 -2.879 . . . . 0.0 110.426 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 33.6 tt0 -63.52 121.98 15.17 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 118.28 2.696 . . . . 0.0 118.28 176.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 4.8 tt -138.65 160.14 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-O 124.004 1.859 . . . . 0.0 114.167 177.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 28.6 m -78.89 131.3 36.37 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 115.025 -2.417 . . . . 0.0 108.833 173.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 22.4 tp -61.8 142.62 57.2 Favored 'General case' 0 N--CA 1.451 -0.406 1 C-N-CA 132.264 4.226 . . . . 0.0 109.323 176.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 28.8 t0 -151.66 142.49 22.92 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 127.113 2.165 . . . . 0.0 110.336 178.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -75.54 69.75 2.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.43 3.492 . . . . 0.0 113.831 175.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 161' ' ' ILE . . . . . . . . . . . . . 15.1 pt -78.44 162.05 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 130.52 3.528 . . . . 0.0 111.279 -171.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -64.69 143.36 57.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 O-C-N 124.948 1.405 . . . . 0.0 114.21 163.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 10.7 t-20 -62.38 -18.12 60.77 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 112.606 -3.568 . . . . 0.0 114.079 173.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 92.9 mm-40 -140.49 -29.54 0.68 Allowed 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 125.549 3.795 . . . . 0.0 119.157 -177.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -75.35 111.19 10.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 114.247 1.203 . . . . 0.0 114.247 167.294 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . 98.99 -15.2 60.9 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 117.797 1.879 . . . . 0.0 117.797 -177.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 167' ' ' THR . . . . . . . . . . . . . 6.7 m -46.89 -27.3 1.2 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 129.771 3.229 . . . . 0.0 117.396 177.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 7.4 p90 -55.08 -24.87 27.61 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 121.348 3.833 . . . . 0.0 121.348 170.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 169' ' ' THR . . . . . . . . . . . . . 59.0 p -75.33 -41.82 55.84 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 121.458 1.935 . . . . 0.0 115.798 176.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -62.44 174.48 0.96 Allowed 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 131.114 3.766 . . . . 0.0 117.028 173.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -107.52 125.63 51.52 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-N 111.853 -2.431 . . . . 0.0 104.781 -170.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 70.9 t80 -154.6 111.1 3.27 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.597 1.544 . . . . 0.0 110.308 -175.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 85.0 p -159.5 -176.13 5.59 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 130.22 3.408 . . . . 0.0 110.285 -165.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 12.3 tp -70.38 115.32 9.43 Favored 'General case' 0 N--CA 1.448 -0.543 0 CA-C-N 112.668 -2.06 . . . . 0.0 113.818 179.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 47.2 t -72.86 135.26 28.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 C-N-CA 125.347 1.459 . . . . 0.0 110.315 172.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . -138.25 -145.01 4.76 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 129.944 3.64 . . . . 0.0 111.884 173.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -72.11 132.16 43.81 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 124.6 2.143 . . . . 0.0 114.024 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 178' ' ' GLY . . . . . 0.406 ' HA2' ' HA ' ' L' ' 148' ' ' SER . . . -53.22 130.78 41.52 Favored Glycine 0 CA--C 1.523 0.569 0 C-N-CA 129.19 3.281 . . . . 0.0 114.099 174.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 179' ' ' ARG . . . . . . . . . . . . . 50.1 ttt180 -132.43 147.59 52.38 Favored 'General case' 0 N--CA 1.449 -0.5 0 O-C-N 128.009 2.829 . . . . 0.0 111.757 172.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 74.55 154.68 0.15 Allowed 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 119.579 -1.951 . . . . 0.0 111.901 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 181' ' ' SER . . . . . . . . . . . . 0.253 23.2 t 150.96 132.65 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 129.418 3.087 . . . . 0.0 112.305 163.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 38.1 m -95.19 151.74 18.96 Favored 'General case' 0 N--CA 1.449 -0.493 1 C-N-CA 131.739 4.015 . . . . 0.0 108.104 161.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 183' ' ' GLY . . . . . 0.446 ' O ' ' HE2' ' L' ' 144' ' ' LYS . . . -88.25 -175.04 47.68 Favored Glycine 0 C--N 1.337 0.628 0 CA-C-N 113.868 -1.514 . . . . 0.0 114.911 -176.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 184' ' ' VAL . . . . . . . . . . . . . 13.5 m -83.68 144.9 9.09 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 O-C-N 126.735 2.08 . . . . 0.0 111.732 155.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 53.5 tttp -69.05 130.26 42.25 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.703 2.401 . . . . 0.0 114.987 168.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 37.6 mt -100.42 -41.2 7.11 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 117.684 2.475 . . . . 0.0 117.684 -176.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -78.64 171.8 14.61 Favored 'General case' 0 N--CA 1.449 -0.509 1 C-N-CA 133.488 4.715 . . . . 0.0 113.457 -173.28 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -85.94 -154.79 24.59 Favored Glycine 0 C--N 1.336 0.534 0 C-N-CA 126.455 1.978 . . . . 0.0 109.592 171.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 18.2 ttmt -79.22 0.13 29.77 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-O 116.743 -1.599 . . . . 0.0 110.937 -174.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 24.4 t-80 -62.35 148.04 46.47 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 122.478 2.399 . . . . 0.0 109.286 171.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 4.7 mt -131.28 129.43 62.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 1 C-N-CA 133.797 4.839 . . . . 0.0 106.997 178.02 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -100.16 141.67 32.67 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 127.356 2.91 . . . . 0.0 111.554 156.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 102.54 9.21 41.58 Favored Glycine 0 CA--C 1.523 0.588 0 CA-C-N 122.202 2.274 . . . . 0.0 117.964 166.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 46.2 m -65.39 134.23 95.6 Favored Pre-proline 0 N--CA 1.448 -0.557 1 CA-C-O 111.53 -4.081 . . . . 0.0 111.985 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -36.28 122.61 0.3 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 1 C-N-CA 128.439 6.092 . . . . 0.0 113.412 167.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -98.21 162.4 13.22 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 125.369 1.467 . . . . 0.0 109.668 172.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -64.72 148.41 51.16 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.363 1.616 . . . . 0.0 115.363 -164.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 91.6 mm-40 -117.56 143.27 46.27 Favored 'General case' 0 N--CA 1.45 -0.44 0 O-C-N 119.545 -1.972 . . . . 0.0 109.242 163.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 2.1 p -82.1 139.91 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 119.031 -2.293 . . . . 0.0 111.331 -168.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 57.8 tp -146.42 117.5 7.79 Favored 'General case' 0 N--CA 1.45 -0.44 0 CA-C-N 110.474 -3.057 . . . . 0.0 108.872 168.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . 81.12 173.93 48.28 Favored Glycine 0 C--N 1.335 0.495 0 C-N-CA 127.195 2.331 . . . . 0.0 114.627 175.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 27.2 t30 -110.97 134.6 52.46 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 177.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -146.28 150.11 35.15 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-O 115.411 -2.233 . . . . 0.0 112.178 -170.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 55.6 mt -67.45 161.51 25.18 Favored 'General case' 0 N--CA 1.449 -0.483 1 C-N-CA 134.181 4.993 . . . . 0.0 109.836 0.279 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 55.7 t80 -62.51 137.82 58.34 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 126.13 2.871 . . . . 0.0 107.529 -177.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.98 119.56 33.7 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 117.356 -3.34 . . . . 0.0 112.201 -171.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 4.3 m -79.17 130.18 70.17 Favored Pre-proline 0 N--CA 1.451 -0.415 0 O-C-N 117.571 -3.206 . . . . 0.0 109.646 -162.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -64.3 125.17 14.59 Favored 'Trans proline' 0 N--CA 1.448 -1.185 1 C-N-CA 125.327 4.018 . . . . 0.0 109.267 173.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 6.9 p -163.07 159.36 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 C-N-CA 130.171 3.388 . . . . 0.0 111.353 172.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 9.1 p90 -80.81 137.68 36.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 126.826 2.05 . . . . 0.0 113.735 177.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 40.9 mm -67.67 125.06 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 O-C-N 119.462 -2.024 . . . . 0.0 107.646 171.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 212' ' ' SER . . . . . . . . . . . . 0.255 40.2 m -87.09 156.88 19.54 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 124.082 3.128 . . . . 0.0 110.81 -178.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -56.65 151.88 13.08 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 131.096 3.758 . . . . 0.0 118.168 171.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -114.93 156.95 24.07 Favored 'General case' 0 N--CA 1.447 -0.579 0 O-C-N 117.44 -3.288 . . . . 0.0 110.012 159.267 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . 0.283 12.5 pt20 -69.27 154.53 41.89 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 119.916 1.235 . . . . 0.0 112.95 -175.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -86.09 -154.08 23.51 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 130.361 3.839 . . . . 0.0 117.497 160.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . 0.306 1.4 pp -127.33 -7.82 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 129.985 3.314 . . . . 0.0 113.268 -178.468 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 10.0 mmm-85 -60.07 126.31 27.03 Favored 'General case' 0 N--CA 1.452 -0.362 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . . . . -111.66 -146.2 0.4 Allowed 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 131.501 3.92 . . . . 0.0 114.228 175.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -96.96 134.11 11.64 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -177.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.449 -1.127 1 C-N-CA 129.827 7.018 . . . . 0.0 112.234 169.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 1' ' ' HIS . . . . . . . . . . . . . 52.4 t-80 . . . . . 0 N--CA 1.471 0.6 0 CA-C-O 122.688 1.232 . . . . 0.0 113.152 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 2' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -67.8 137.95 55.78 Favored 'General case' 0 N--CA 1.448 -0.572 0 O-C-N 117.594 -3.191 . . . . 0.0 115.475 178.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 3' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 126.903 2.081 . . . . 0.0 109.87 177.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 4' ' ' HIS . . . . . . . . . . . . . 48.3 t60 -85.44 -46.7 10.66 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 166.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 5' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -75.16 172.29 12.65 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.22 -2.175 . . . . 0.0 113.13 -174.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 6' ' ' HIS . . . . . . . . . . . . . 3.9 t60 -75.09 -54.73 6.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 O-C-N 120.414 -1.429 . . . . 0.0 109.044 -165.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.42 140.03 37.52 Favored 'General case' 0 N--CA 1.451 -0.406 0 C-N-CA 128.415 2.686 . . . . 0.0 110.737 -173.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 8' ' ' SER . . . . . . . . . . . . . 86.9 p -176.53 147.58 0.67 Allowed 'General case' 0 N--CA 1.449 -0.501 0 N-CA-C 117.386 2.365 . . . . 0.0 117.386 -155.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 9' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -128.06 124.5 23.13 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 128.628 2.771 . . . . 0.0 113.056 -173.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 10' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -57.65 157.53 22.98 Favored 'Trans proline' 0 N--CA 1.449 -1.1 0 C-N-CA 124.204 3.27 . . . . 0.0 115.401 -177.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.54 -10.19 0.11 Allowed Pre-proline 0 N--CA 1.45 -0.441 0 CA-C-O 116.149 -1.882 . . . . 0.0 114.411 165.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -66.9 -176.54 0.77 Allowed 'Trans proline' 0 N--CA 1.449 -1.118 1 C-N-CA 126.438 4.758 . . . . 0.0 115.166 155.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 13' ' ' SER . . . . . . . . . . . . . 2.6 p -158.51 154.81 27.34 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-O 123.064 1.411 . . . . 0.0 112.941 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 14' ' ' ALA . . . . . . . . . . . . . . . -59.81 -53.18 60.96 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 112.605 -2.089 . . . . 0.0 112.725 -165.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 15' ' ' GLU . . . . . . . . . . . . . 16.8 mp0 -48.61 -20.86 0.49 Allowed 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 129.416 3.086 . . . . 0.0 118.741 177.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 16' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -117.2 -54.79 2.38 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 127.976 2.511 . . . . 0.0 109.923 -170.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 17' ' ' SER . . . . . . . . . . . . 0.721 0.5 OUTLIER -67.1 149.87 49.96 Favored 'General case' 0 N--CA 1.449 -0.507 1 O-C-N 114.84 -4.913 . . . . 0.0 112.642 -165.154 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild full ' L' L ' 18' ' ' TYR . . . . . . . . . . . . . 22.0 p90 -163.09 172.52 14.79 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 128.093 2.557 . . . . 0.0 108.883 -164.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 19' ' ' ALA . . . . . . . . . . . . . . . -139.51 147.89 41.88 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 128.018 2.527 . . . . 0.0 110.387 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 20' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -149.98 144.18 25.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 125.423 1.702 . . . . 0.0 115.41 -175.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 21' ' ' GLY . . . . . . . . . . . . . . . 138.03 -166.19 25.23 Favored Glycine 0 C--N 1.335 0.527 0 CA-C-O 124.597 2.221 . . . . 0.0 115.066 168.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . 0.285 55.2 tt0 -42.46 -62.97 0.84 Allowed 'General case' 0 N--CA 1.448 -0.54 1 C-N-CA 131.948 4.099 . . . . 0.0 109.72 -178.732 . . . . . . . . 3 2 . 1 . 003 nuclear nobuild full ' L' L ' 23' ' ' GLY . . . . . . . . . . . . . . . -62.73 14.98 0.07 OUTLIER Glycine 0 C--N 1.336 0.572 0 N-CA-C 120.404 2.922 . . . . 0.0 120.404 178.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 24' ' ' LEU . . . . . . . . . . . . . 75.3 mt -122.57 0.92 9.45 Favored 'General case' 0 N--CA 1.449 -0.512 1 C-N-CA 132.246 4.218 . . . . 0.0 112.572 167.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 25' ' ' VAL . . . . . . . . . . . . . 1.4 p -141.4 -15.26 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 124.405 3.275 . . . . 0.0 112.466 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -162.87 92.54 0.78 Allowed 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 124.649 2.166 . . . . 0.0 115.614 -160.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 27' ' ' VAL . . . . . 0.471 HG13 ' CD1' ' L' ' 90' ' ' TYR 0.305 12.8 p -147.78 147.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 O-C-N 119.467 -2.02 . . . . 0.0 113.836 179.055 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' L' L ' 28' ' ' PHE . . . . . 0.488 ' HA ' ' SG ' ' L' ' 110' ' ' CYS . 12.9 t80 -137.1 -170.89 2.81 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 118.841 2.904 . . . . 0.0 118.841 -170.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 29' ' ' ASP . . . . . . . . . . . . . 6.2 t70 -86.09 -44.68 12.06 Favored 'General case' 0 N--CA 1.45 -0.433 0 O-C-N 117.994 -2.942 . . . . 0.0 113.324 -175.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 30' ' ' ASN . . . . . . . . . . . . . 47.5 p-10 -106.28 30.62 5.79 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 123.589 1.661 . . . . 0.0 111.456 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 31' ' ' ALA . . . . . . . . . . . . . . . -158.87 125.06 2.42 Favored Pre-proline 0 N--CA 1.448 -0.543 0 CA-C-O 115.933 -1.984 . . . . 0.0 114.693 -178.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 32' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -85.44 175.35 6.31 Favored 'Trans proline' 0 N--CA 1.448 -1.174 0 C-N-CA 123.803 3.002 . . . . 0.0 113.762 -175.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 33' ' ' ALA . . . . . . . . . . . . . . . -148.39 170.67 17.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 177.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 34' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -142.31 155.06 45.17 Favored 'General case' 0 N--CA 1.449 -0.517 0 C-N-CA 128.235 2.614 . . . . 0.0 116.025 -170.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 35' ' ' PHE . . . . . . . . . . . . . 19.8 p90 -163.14 166.02 23.9 Favored 'General case' 0 N--CA 1.448 -0.533 1 O-C-N 114.688 -5.007 . . . . 0.0 108.79 178.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 36' ' ' THR . . . . . 0.443 ' HA ' ' O ' ' L' ' 78' ' ' TYR . 21.3 m -131.82 133.82 45.11 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 115.397 1.628 . . . . 0.0 115.397 -162.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 37' ' ' ILE . . . . . . . . . . . . 0.267 8.6 mt -81.52 104.29 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.558 0 C-N-CA 127.056 2.142 . . . . 0.0 110.498 174.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 38' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -81.36 121.0 25.66 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 118.696 -1.201 . . . . 0.0 107.988 168.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 39' ' ' ALA . . . . . . . . . . . . . . . -73.96 120.5 19.63 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.509 3.123 . . . . 0.0 107.262 173.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 1.8 t -149.91 141.34 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 123.69 1.71 . . . . 0.0 107.567 176.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 41' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -119.1 -2.26 10.78 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 111.287 -2.688 . . . . 0.0 110.87 -174.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 42' ' ' THR . . . . . . . . . . . . . 62.1 p -157.91 175.48 13.79 Favored 'General case' 0 N--CA 1.449 -0.48 0 O-C-N 116.814 -3.679 . . . . 0.0 107.699 -161.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 43' ' ' LYS . . . . . . . . . . . . . 26.7 mtpt -70.74 8.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 115.504 1.668 . . . . 0.0 115.504 175.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 44' ' ' GLY . . . . . . . . . . . . . . . -125.6 -146.89 6.83 Favored Glycine 0 C--N 1.336 0.581 0 CA-C-N 120.388 1.449 . . . . 0.0 114.791 178.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 45' ' ' VAL . . . . . . . . . . . . 0.31 14.3 m -51.78 160.2 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 C-N-CA 129.104 2.962 . . . . 0.0 113.936 -178.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.87 174.49 1.44 Allowed 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 124.632 2.158 . . . . 0.0 111.911 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 47' ' ' ARG . . . . . . . . . . . . . 16.6 mmm-85 -70.65 164.1 25.67 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 112.263 -2.244 . . . . 0.0 108.551 164.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 48' ' ' THR . . . . . . . . . . . . . 71.0 p -117.32 21.63 12.99 Favored 'General case' 0 N--CA 1.448 -0.569 0 C-N-CA 126.819 2.048 . . . . 0.0 111.987 -169.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 49' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -167.96 147.47 4.81 Favored 'General case' 0 N--CA 1.448 -0.535 1 C-N-CA 134.1 4.96 . . . . 0.0 118.489 -178.559 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' L' L ' 50' ' ' GLY . . . . . . . . . . . . . . . -91.49 -131.84 5.33 Favored Glycine 0 C--N 1.336 0.582 0 C-N-CA 126.598 2.047 . . . . 0.0 116.646 -174.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 51' ' ' GLY . . . . . . . . . . . . . . . 72.62 -18.86 1.24 Allowed Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 119.63 2.612 . . . . 0.0 119.63 173.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 52' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -63.29 150.44 89.3 Favored Pre-proline 0 N--CA 1.448 -0.564 0 CA-C-N 119.522 1.661 . . . . 0.0 113.799 175.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 53' ' ' PRO . . . . . . . . . . . . . 63.4 Cg_endo -78.84 109.04 2.52 Favored 'Trans proline' 0 N--CA 1.449 -1.107 1 C-N-CA 125.337 4.024 . . . . 0.0 111.847 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 54' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -117.42 174.78 5.95 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 116.512 -1.708 . . . . 0.0 114.514 177.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 55' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -161.35 150.49 16.34 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 124.866 2.27 . . . . 0.0 112.004 -174.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 56' ' ' VAL . . . . . . . . . . . . . 11.6 p -127.7 143.08 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 119.033 -2.292 . . . . 0.0 108.89 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 57' ' ' ALA . . . . . . . . . . . . . . . -139.61 111.42 7.32 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-O 116.131 -1.89 . . . . 0.0 108.85 168.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 58' ' ' ILE . . . . . . . . . . . . 0.279 29.3 mt -116.91 142.77 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 C-N-CA 128.476 2.71 . . . . 0.0 107.69 175.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 59' ' ' ASN . . . . . . . . . . . . . 23.2 t-20 -134.41 148.14 50.58 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 130.354 3.462 . . . . 0.0 116.0 177.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 60' ' ' GLY . . . . . . . . . . . . . . . -130.83 -148.19 6.24 Favored Glycine 0 N--CA 1.449 -0.498 0 O-C-N 119.01 -2.306 . . . . 0.0 109.769 -171.075 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 61' ' ' PRO . . . . . . . . . . . . 0.304 51.8 Cg_endo -71.3 138.03 32.22 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.685 2.924 . . . . 0.0 114.557 -169.421 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 62' ' ' ASP . . . . . . . . . . . . . 19.0 t70 81.99 -52.27 0.24 Allowed 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 128.814 2.846 . . . . 0.0 109.388 163.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 63' ' ' GLY . . . . . 0.401 ' H ' ' H ' ' L' ' 64' ' ' LEU . . . -159.4 -22.2 0.03 OUTLIER Glycine 0 C--N 1.337 0.608 0 C-N-CA 129.791 3.567 . . . . 0.0 113.525 175.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 64' ' ' LEU . . . . . 0.401 ' H ' ' H ' ' L' ' 63' ' ' GLY . 55.8 tp -45.52 104.06 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 131.149 3.779 . . . . 0.0 115.394 -165.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 65' ' ' VAL . . . . . . . . . . . . . 52.8 t -67.94 117.59 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 CA-C-O 124.646 2.165 . . . . 0.0 107.651 165.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 66' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.52 125.79 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 N-CA-C 105.222 -2.14 . . . . 0.0 105.222 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 67' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -65.68 130.07 41.99 Favored 'General case' 0 N--CA 1.45 -0.448 0 CA-C-O 117.466 -1.254 . . . . 0.0 108.583 172.63 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 68' ' ' ALA . . . . . . . . . . . . . . . -135.92 138.59 42.54 Favored 'General case' 0 N--CA 1.45 -0.449 0 O-C-N 126.538 2.399 . . . . 0.0 105.701 -175.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 69' ' ' LYS . . . . . . . . . . . . . 58.0 mttp -118.06 116.38 26.75 Favored 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 126.755 2.022 . . . . 0.0 113.335 -165.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 70' ' ' VAL . . . . . . . . . . . . . 39.6 t -94.6 143.0 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 71' ' ' THR . . . . . . . . . . . . . 97.6 m -142.65 120.68 12.1 Favored 'General case' 0 N--CA 1.448 -0.528 0 O-C-N 118.405 -2.684 . . . . 0.0 106.81 166.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 72' ' ' ASP . . . . . . . . . . . . 0.293 40.0 t0 -68.42 133.23 48.34 Favored 'General case' 0 N--CA 1.449 -0.498 0 O-C-N 125.885 1.99 . . . . 0.0 110.165 170.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 73' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 -93.91 -2.65 52.97 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 118.256 2.687 . . . . 0.0 118.256 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 74' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 82.25 -33.02 0.09 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 128.673 2.789 . . . . 0.0 109.223 172.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 75' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -78.97 -18.09 54.31 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-O 116.265 -1.826 . . . . 0.0 114.149 -172.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 76' ' ' GLY . . . . . . . . . . . . . . . 136.53 8.51 1.49 Allowed Glycine 0 C--N 1.336 0.583 0 CA-C-N 121.881 2.128 . . . . 0.0 115.125 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 77' ' ' THR . . . . . . . . . . . . . 76.4 p -138.39 160.06 40.49 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 126.456 1.902 . . . . 0.0 113.728 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 78' ' ' TYR . . . . . 0.443 ' O ' ' HA ' ' L' ' 36' ' ' THR . 1.4 m-85 -128.08 118.32 23.25 Favored 'General case' 0 N--CA 1.447 -0.595 0 C-N-CA 127.083 2.153 . . . . 0.0 107.178 177.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 79' ' ' GLY . . . . . . . . . . . . . . . -75.12 132.57 13.67 Favored Glycine 0 CA--C 1.523 0.564 0 CA-C-O 117.476 -1.736 . . . . 0.0 112.603 165.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 80' ' ' VAL . . . . . . . . . . . . . 45.0 t -125.52 130.42 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-O 124.283 1.992 . . . . 0.0 108.921 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 81' ' ' VAL . . . . . . . . . . . . . 3.7 t -130.62 140.77 47.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 CA-C-N 114.282 -1.326 . . . . 0.0 113.398 -167.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 82' ' ' TYR . . . . . . . . . . . . 0.339 5.6 p90 -159.43 163.56 35.31 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 126.42 3.009 . . . . 0.0 115.877 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 83' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.16 139.33 12.07 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 109.687 -3.415 . . . . 0.0 110.705 -170.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 84' ' ' ALA . . . . . . . . . . . . . . . -147.73 149.23 32.97 Favored Pre-proline 0 N--CA 1.45 -0.456 0 CA-C-N 114.091 -1.413 . . . . 0.0 114.207 155.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 85' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -91.04 44.27 0.49 Allowed 'Trans proline' 0 N--CA 1.449 -1.106 1 C-N-CA 125.319 4.013 . . . . 0.0 112.558 -169.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 86' ' ' VAL . . . . . . . . . . . . . 22.0 m -141.92 167.31 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-O 112.096 -3.812 . . . . 0.0 116.302 -157.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 87' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -134.58 123.08 23.27 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 121.937 2.153 . . . . 0.0 109.325 -179.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 88' ' ' GLY . . . . . . . . . . . . . . . 171.94 -106.28 0.23 Allowed Glycine 0 C--N 1.336 0.582 0 C-N-CA 125.981 1.753 . . . . 0.0 112.617 -178.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 89' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -149.7 125.7 10.59 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 128.985 2.914 . . . . 0.0 118.153 177.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 90' ' ' TYR . . . . . 0.471 ' CD1' HG13 ' L' ' 27' ' ' VAL . 84.6 m-85 -87.17 139.04 30.97 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 126.563 1.945 . . . . 0.0 107.71 169.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 91' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -130.69 106.83 8.73 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 127.66 3.1 . . . . 0.0 105.685 -171.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 92' ' ' VAL . . . . . . . . . . . . . 32.3 t -112.02 138.18 41.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 O-C-N 127.33 2.894 . . . . 0.0 112.521 -166.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 93' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -140.78 136.27 32.31 Favored 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.366 2.266 . . . . 0.0 114.454 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 94' ' ' VAL . . . . . . . . . . . . . 10.1 t -122.24 147.43 26.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 O-C-N 119.299 -2.126 . . . . 0.0 107.849 174.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 95' ' ' THR . . . . . . . . . . . . . 16.5 p -157.13 149.87 23.43 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 117.446 -1.264 . . . . 0.0 111.113 -175.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 96' ' ' LEU . . . . . . . . . . . . . 21.2 mt -72.94 32.5 0.07 Allowed 'General case' 0 N--CA 1.449 -0.518 1 C-N-CA 135.199 5.4 . . . . 0.0 111.594 -177.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 97' ' ' ARG . . . . . . . . . . . . . 11.7 tpp85 65.61 -47.35 0.39 Allowed 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 126.14 1.776 . . . . 0.0 109.311 -170.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 98' ' ' GLY . . . . . . . . . . . . . . . -123.56 -5.47 7.74 Favored Glycine 0 C--N 1.335 0.519 1 C-N-CA 131.475 4.369 . . . . 0.0 114.731 -171.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 99' ' ' ASN . . . . . . . . . . . . . 53.2 t30 -145.54 139.72 15.14 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-N 119.984 1.892 . . . . 0.0 113.483 -172.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -84.15 164.72 13.16 Favored 'Trans proline' 0 N--CA 1.45 -1.056 0 N-CA-C 116.923 1.855 . . . . 0.0 116.923 -173.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 101' ' ' ILE . . . . . . . . . . . . . 10.0 pt -136.13 -176.54 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 O-C-N 119.277 -2.139 . . . . 0.0 107.699 -176.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 102' ' ' LYS . . . . . . . . . . . . . 53.9 mtmt -83.35 139.39 33.05 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.34 1.856 . . . . 0.0 113.206 -165.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 103' ' ' ASN . . . . . . . . . . . . . 1.8 t30 63.51 27.82 15.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 126.685 2.491 . . . . 0.0 115.264 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 104' ' ' MET . . . . . . . . . . . . . 11.7 mmt -119.86 129.44 25.35 Favored Pre-proline 0 N--CA 1.448 -0.573 0 C-N-CA 130.765 3.626 . . . . 0.0 104.418 -172.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 105' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -79.94 169.04 71.39 Favored 'Cis proline' 0 N--CA 1.448 -1.155 0 CA-C-N 122.543 1.944 . . . . 0.0 116.66 -15.058 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 106' ' ' ILE . . . . . 0.501 HD12 ' H ' ' L' ' 107' ' ' ASP . 5.3 tp -158.85 162.0 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 O-C-N 119.405 -2.059 . . . . 0.0 110.408 -166.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 107' ' ' ASP . . . . . 0.501 ' H ' HD12 ' L' ' 106' ' ' ILE . 12.9 m-20 -132.73 146.29 51.74 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 126.632 1.973 . . . . 0.0 111.249 -161.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 108' ' ' VAL . . . . . . . . . . . . . 15.2 t -138.42 118.53 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.548 0 C-N-CA 129.201 3.0 . . . . 0.0 108.498 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 109' ' ' LYS . . . . . . . . . . . . . 55.0 tttt -74.58 136.02 42.06 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 127.248 2.219 . . . . 0.0 107.294 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 110' ' ' CYS . . . . . 0.488 ' SG ' ' HA ' ' L' ' 28' ' ' PHE . 38.6 t -106.28 111.69 24.39 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 114.918 -1.037 . . . . 0.0 113.001 167.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 111' ' ' ILE . . . . . . . . . . . . . 15.2 tt -156.74 152.49 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 129.302 3.041 . . . . 0.0 110.461 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 112' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -75.19 108.29 7.84 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 115.241 1.571 . . . . 0.0 115.241 -161.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 113' ' ' GLY . . . . . . . . . . . . . . . -64.03 108.69 2.37 Favored Glycine 0 C--N 1.336 0.547 0 CA-C-O 115.034 -3.092 . . . . 0.0 110.305 168.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 114' ' ' ALA . . . . . . . . . . . . . . . -52.69 169.2 0.09 Allowed 'General case' 0 N--CA 1.45 -0.467 0 N-CA-C 119.346 3.091 . . . . 0.0 119.346 -171.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 115' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 -59.56 149.55 29.73 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 120.048 3.351 . . . . 0.0 120.048 -169.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 116' ' ' GLY . . . . . . . . . . . . . . . -70.52 143.54 37.26 Favored Glycine 0 C--N 1.334 0.438 0 C-N-CA 126.029 1.776 . . . . 0.0 111.419 172.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 117' ' ' GLU . . . . . . . . . . . . . 16.6 tp10 -139.08 163.64 31.87 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 125.788 1.635 . . . . 0.0 115.105 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 118' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -150.89 142.18 23.28 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 160.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 119' ' ' SER . . . . . . . . . . . . . 68.7 m -78.39 -26.31 46.49 Favored 'General case' 0 N--CA 1.45 -0.438 2 O-C-N 116.015 -4.178 . . . . 0.0 112.732 -2.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 120' ' ' SER . . . . . . . . . . . . . 4.2 t -173.02 150.97 2.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.462 2.305 . . . . 0.0 116.516 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 121' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -68.24 -7.05 27.21 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 116.935 2.198 . . . . 0.0 116.935 178.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 122' ' ' GLY . . . . . . . . . . . . . . . 140.17 -174.22 22.59 Favored Glycine 0 C--N 1.335 0.493 1 C-N-CA 132.475 4.845 . . . . 0.0 118.074 -175.408 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 123' ' ' SER . . . . . . . . . . . . 0.259 0.1 OUTLIER -74.0 -2.57 24.74 Favored 'General case' 0 N--CA 1.448 -0.534 0 C-N-CA 127.81 2.444 . . . . 0.0 115.149 -158.107 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' L' L ' 124' ' ' PHE . . . . . . . . . . . . . 46.7 t80 -65.31 135.22 55.06 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 129.192 2.997 . . . . 0.0 108.457 -172.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 125' ' ' THR . . . . . . . . . . . . . 28.0 p -158.69 162.11 37.17 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 129.508 3.123 . . . . 0.0 103.241 -171.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 126' ' ' PHE . . . . . . . . . . . . 0.262 51.8 p90 -154.94 162.51 41.07 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 125.021 1.328 . . . . 0.0 113.958 -174.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 127' ' ' THR . . . . . . . . . . . . . 3.0 m -81.64 126.58 31.93 Favored 'General case' 0 N--CA 1.448 -0.541 0 O-C-N 119.674 -1.891 . . . . 0.0 110.769 175.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 128' ' ' VAL . . . . . . . . . . . . . 25.2 t -140.2 103.57 1.62 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 113.569 -1.651 . . . . 0.0 106.981 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 129' ' ' ALA . . . . . . . . . . . . . . . -53.5 -37.54 62.84 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 129.331 3.052 . . . . 0.0 108.861 -174.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.39 -28.94 67.54 Favored 'General case' 0 N--CA 1.448 -0.571 0 O-C-N 120.254 -1.529 . . . . 0.0 114.548 -174.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 131' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -71.81 -50.14 32.39 Favored 'General case' 0 N--CA 1.449 -0.485 0 N-CA-C 115.405 1.632 . . . . 0.0 115.405 166.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 132' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -167.9 148.46 5.1 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 129.477 3.111 . . . . 0.0 109.377 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 133' ' ' LYS . . . . . . . . . . . . . 80.2 mttt -105.8 145.18 31.51 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.06 2.144 . . . . 0.0 109.607 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 134' ' ' LYS . . . . . . . . . . . . 0.328 30.6 mmmt -82.65 21.76 0.96 Allowed 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 129.682 3.193 . . . . 0.0 113.635 -157.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 135' ' ' GLY . . . . . . . . . . . . . . . 79.39 -174.8 55.21 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 127.259 2.361 . . . . 0.0 114.685 -173.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 136' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -64.98 122.4 16.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 128.595 2.758 . . . . 0.0 108.715 166.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 137' ' ' VAL . . . . . . . . . . . . . 57.2 t -93.91 111.49 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 104.391 -2.448 . . . . 0.0 104.391 -175.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 138' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp -106.76 170.11 8.14 Favored 'General case' 0 N--CA 1.45 -0.444 0 N-CA-C 116.939 2.2 . . . . 0.0 116.939 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 139' ' ' THR . . . . . . . . . . . . . 47.6 p -47.31 -56.23 7.22 Favored 'General case' 0 N--CA 1.449 -0.503 0 O-C-N 119.899 -1.751 . . . . 0.0 115.722 162.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 140' ' ' TYR . . . . . . . . . . . . . 22.3 p90 -64.63 -20.3 66.2 Favored 'General case' 0 N--CA 1.449 -0.522 0 N-CA-C 119.275 3.065 . . . . 0.0 119.275 -170.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.76 163.76 31.42 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 118.092 1.997 . . . . 0.0 118.092 170.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 142' ' ' GLY . . . . . . . . . . . . . . . -115.53 -169.38 15.74 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 126.154 1.835 . . . . 0.0 114.528 164.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 143' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -74.08 145.97 43.99 Favored 'General case' 0 N--CA 1.448 -0.534 0 O-C-N 117.07 -3.606 . . . . 0.0 112.978 -172.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 144' ' ' LYS . . . . . . . . . . . . . 76.2 mttt -91.65 -17.44 25.5 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -168.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 145' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -59.93 -43.48 94.9 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 121.269 1.849 . . . . 0.0 114.791 -167.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 146' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -97.87 167.24 11.04 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 127.611 3.576 . . . . 0.0 108.157 166.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 147' ' ' VAL . . . . . . . . . . . . . 7.4 p -147.11 132.59 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 1 O-C-N 113.982 -5.449 . . . . 0.0 114.866 -176.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 148' ' ' SER . . . . . . . . . . . . . 35.3 m -66.37 -11.25 50.2 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 117.367 2.358 . . . . 0.0 117.367 -169.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 149' ' ' ILE . . . . . . . . . . . . 0.276 2.0 pp -67.45 -3.81 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 123.77 2.986 . . . . 0.0 114.225 172.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 150' ' ' THR . . . . . . . . . . . . 0.259 2.8 p -68.87 155.81 39.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 120.902 1.683 . . . . 0.0 111.732 -170.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 151' ' ' GLY . . . . . . . . . . . . . . . -156.94 -177.67 30.29 Favored Glycine 0 C--N 1.335 0.503 0 CA-C-N 114.436 -1.256 . . . . 0.0 115.741 177.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 152' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -58.46 158.26 23.78 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 CA-C-O 125.179 2.075 . . . . 0.0 111.573 176.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 153' ' ' ALA . . . . . . . . . . . . . . . -71.52 -9.14 57.73 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-N 112.402 -2.181 . . . . 0.0 112.743 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 154' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -149.68 143.69 25.64 Favored 'General case' 0 N--CA 1.45 -0.439 1 O-C-N 116.14 -4.1 . . . . 0.0 109.738 -176.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 155' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -159.5 80.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 O-C-N 125.07 1.481 . . . . 0.0 108.584 -175.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 156' ' ' ILE . . . . . . . . . . . . . 33.1 pt -105.45 166.76 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.434 0 C-N-CA 126.71 2.004 . . . . 0.0 114.782 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 157' ' ' THR . . . . . . . . . . . . . 80.5 p -69.06 -5.68 23.49 Favored 'General case' 0 N--CA 1.451 -0.405 1 O-C-N 116.059 -4.151 . . . . 0.0 112.744 176.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 158' ' ' LEU . . . . . . . . . . . . . 52.5 mt -91.61 68.14 5.58 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 122.212 2.278 . . . . 0.0 110.135 170.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 159' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -74.5 120.72 20.45 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 111.199 -2.728 . . . . 0.0 106.036 -169.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 160' ' ' ALA . . . . . . . . . . . . . . . -70.39 132.2 45.26 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 123.012 1.386 . . . . 0.0 107.851 -177.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 161' ' ' ILE . . . . . 0.41 HD13 HG21 ' L' ' 161' ' ' ILE . 34.2 pt -88.44 -23.26 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 120.189 3.403 . . . . 0.0 120.189 -167.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 162' ' ' ASP . . . . . . . . . . . . 0.257 24.5 t0 -101.26 127.64 47.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 CA-C-N 113.561 -1.654 . . . . 0.0 110.894 157.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 163' ' ' ASN . . . . . . . . . . . . . 37.2 t30 -89.4 115.95 27.23 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.474 -1.239 . . . . 0.0 110.296 -171.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 164' ' ' GLN . . . . . . . . . . . . . 25.2 tp60 -98.18 132.9 43.3 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-O 117.15 -1.405 . . . . 0.0 110.577 -167.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 165' ' ' ASP . . . . . . . . . . . . . 30.6 t0 -119.47 155.66 31.66 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-O 128.425 3.964 . . . . 0.0 110.167 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.67 -34.02 2.98 Favored Glycine 0 CA--C 1.523 0.59 0 O-C-N 117.59 -3.194 . . . . 0.0 115.802 -169.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 167' ' ' THR . . . . . . . . . . . . 0.252 6.6 m -73.63 127.29 32.37 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 116.825 -1.559 . . . . 0.0 115.17 -174.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 168' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -116.6 126.09 52.75 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-O 115.337 -2.268 . . . . 0.0 112.015 158.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 169' ' ' THR . . . . . . . . . . . . . 6.3 t -146.11 156.78 43.68 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 129.427 3.091 . . . . 0.0 110.338 169.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 170' ' ' ALA . . . . . . . . . . . . . . . -153.27 171.1 19.06 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 126.851 2.06 . . . . 0.0 107.103 -175.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 171' ' ' ALA . . . . . . . . . . . . . . . -59.87 -44.88 93.92 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 174.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 172' ' ' TYR . . . . . . . . . . . . . 39.6 m-85 -121.73 166.09 14.84 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 117.092 2.256 . . . . 0.0 117.092 -175.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 173' ' ' SER . . . . . . . . . . . . . 11.4 m -77.83 157.61 29.84 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 114.833 1.42 . . . . 0.0 114.833 170.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 174' ' ' LEU . . . . . . . . . . . . . 7.4 mp -62.89 168.69 3.74 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 126.176 1.791 . . . . 0.0 107.837 -157.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 175' ' ' VAL . . . . . . . . . . . . . 7.5 p -159.37 133.06 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 127.125 2.17 . . . . 0.0 109.415 166.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 176' ' ' GLY . . . . . . . . . . . . . . . -65.39 163.42 39.1 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 116.233 1.253 . . . . 0.0 116.233 179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 177' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -67.09 111.51 3.92 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 115.962 -1.971 . . . . 0.0 109.836 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 178' ' ' GLY . . . . . . . . . . . . . . . -96.69 -137.98 9.74 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 129.024 3.953 . . . . 0.0 114.359 170.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 179' ' ' ARG . . . . . . . . . . . . . 13.8 ttt180 -90.73 75.62 6.52 Favored 'General case' 0 N--CA 1.447 -0.575 0 O-C-N 120.527 -1.572 . . . . 0.0 106.886 -175.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 180' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -157.46 128.64 6.73 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 130.462 3.505 . . . . 0.0 113.984 178.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 181' ' ' SER . . . . . . . . . . . . . 14.9 m -83.07 115.03 21.69 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 128.214 2.606 . . . . 0.0 112.145 -157.559 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 182' ' ' THR . . . . . . . . . . . . . 19.7 p -95.96 146.88 24.24 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 122.724 1.25 . . . . 0.0 111.093 -177.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 183' ' ' GLY . . . . . . . . . . . . . . . 126.1 169.14 12.77 Favored Glycine 0 CA--C 1.522 0.531 0 C-N-CA 128.764 3.078 . . . . 0.0 113.893 -172.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 184' ' ' VAL . . . . . . . . . . . . 0.327 11.2 p -131.28 30.48 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.467 1 CA-C-O 128.786 4.136 . . . . 0.0 115.839 171.104 . . . . . . . . 3 2 . 1 . 003 nuclear nobuild full ' L' L ' 185' ' ' LYS . . . . . . . . . . . . . 72.6 tttt -110.08 -23.33 11.35 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 117.323 -3.361 . . . . 0.0 109.655 -171.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 186' ' ' LEU . . . . . . . . . . . . . 46.1 tp -137.44 148.76 46.36 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 129.07 2.948 . . . . 0.0 108.586 175.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 187' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -45.65 120.33 2.55 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 124.134 0.973 . . . . 0.0 113.187 168.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 188' ' ' GLY . . . . . . . . . . . . . . . -72.2 -13.67 76.58 Favored Glycine 0 N--CA 1.447 -0.597 0 O-C-N 117.751 -3.093 . . . . 0.0 113.959 -174.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 189' ' ' LYS . . . . . . . . . . . . . 20.1 tptp -59.69 -26.58 65.69 Favored 'General case' 0 N--CA 1.447 -0.578 0 CA-C-N 120.606 2.203 . . . . 0.0 116.053 175.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 190' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -75.4 157.26 34.44 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-O 116.926 -1.511 . . . . 0.0 108.39 173.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 191' ' ' ILE . . . . . . . . . . . . . 10.0 tp -148.86 164.97 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 125.773 2.701 . . . . 0.0 107.967 -170.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 192' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -74.08 122.54 22.84 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 128.041 2.537 . . . . 0.0 110.121 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 193' ' ' GLY . . . . . . . . . . . . . . . 122.33 -179.14 16.27 Favored Glycine 0 C--N 1.335 0.487 0 C-N-CA 126.247 1.879 . . . . 0.0 115.351 174.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 194' ' ' SER . . . . . . . . . . . . . 41.3 t -93.49 119.9 66.87 Favored Pre-proline 0 N--CA 1.45 -0.45 0 CA-C-O 118.768 -0.634 . . . . 0.0 110.793 173.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 195' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -81.18 138.94 11.52 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 CA-C-O 124.405 1.752 . . . . 0.0 110.26 176.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 196' ' ' PHE . . . . . . . . . . . . . 40.6 p90 -179.96 -13.22 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 115.296 -2.288 . . . . 0.0 114.031 -171.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 197' ' ' LYS . . . . . . . . . . . . . 69.7 tttt -59.51 -23.24 62.64 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 125.83 2.728 . . . . 0.0 117.505 166.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 198' ' ' GLN . . . . . . . . . . . . . 62.4 tt0 -78.1 109.84 12.54 Favored 'General case' 0 N--CA 1.45 -0.464 1 O-C-N 116.245 -4.034 . . . . 0.0 111.749 153.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 199' ' ' VAL . . . . . . . . . . . . . 86.4 t -77.88 109.83 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 O-C-N 118.824 -2.422 . . . . 0.0 104.585 -175.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 200' ' ' LEU . . . . . . . . . . . . . 66.9 mt -88.39 173.91 8.45 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 115.418 1.636 . . . . 0.0 115.418 167.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 201' ' ' GLY . . . . . . . . . . . . . . . -69.55 144.31 40.28 Favored Glycine 0 C--N 1.336 0.552 0 CA-C-N 121.536 1.971 . . . . 0.0 111.665 -171.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 202' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -148.8 152.78 37.12 Favored 'General case' 0 N--CA 1.448 -0.565 0 O-C-N 126.0 1.647 . . . . 0.0 110.597 -171.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 203' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -38.3 127.77 1.37 Allowed 'General case' 0 N--CA 1.447 -0.623 0 O-C-N 126.547 2.405 . . . . 0.0 109.346 161.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 204' ' ' LEU . . . . . . . . . . . . . 4.8 tp -77.67 143.76 37.89 Favored 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 129.542 3.137 . . . . 0.0 110.363 0.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 205' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -101.54 -64.0 1.09 Allowed 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 170.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 206' ' ' SER . . . . . . . . . . . . . 2.5 p -132.6 128.49 37.27 Favored 'General case' 0 N--CA 1.448 -0.547 0 C-N-CA 126.318 1.847 . . . . 0.0 110.572 -179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 207' ' ' THR . . . . . . . . . . . . . 25.4 m -45.3 125.6 5.8 Favored Pre-proline 0 N--CA 1.45 -0.459 0 CA-C-N 111.523 -2.58 . . . . 0.0 111.289 171.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 208' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -63.24 169.73 8.92 Favored 'Trans proline' 0 N--CA 1.448 -1.15 1 C-N-CA 126.057 4.505 . . . . 0.0 112.755 168.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 209' ' ' VAL . . . . . . . . . . . . . 26.8 m -140.14 -175.15 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 126.012 1.725 . . . . 0.0 108.648 -171.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 210' ' ' TRP . . . . . . . . . . . . . 24.0 p90 -90.31 163.98 14.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 114.885 1.439 . . . . 0.0 114.885 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 211' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.08 109.0 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 CA-C-O 128.445 3.974 . . . . 0.0 113.873 165.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 212' ' ' SER . . . . . . . . . . . . . 30.4 m -71.84 94.01 1.37 Allowed 'General case' 0 N--CA 1.448 -0.546 0 O-C-N 118.888 -2.383 . . . . 0.0 112.115 178.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 213' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -145.46 134.14 22.22 Favored 'General case' 0 N--CA 1.449 -0.495 0 O-C-N 121.246 -0.909 . . . . 0.0 111.796 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 214' ' ' ALA . . . . . . . . . . . . . . . -62.35 149.71 41.53 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 115.286 1.587 . . . . 0.0 115.286 -176.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 215' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -155.89 136.35 13.2 Favored 'General case' 0 N--CA 1.45 -0.469 0 O-C-N 126.182 2.176 . . . . 0.0 113.351 178.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 216' ' ' GLY . . . . . . . . . . . . . . . -113.44 150.45 18.51 Favored Glycine 0 C--N 1.337 0.592 0 N-CA-C 106.586 -2.605 . . . . 0.0 106.586 -176.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 217' ' ' ILE . . . . . . . . . . . . . 8.2 tp -154.43 -25.99 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -174.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 218' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -105.5 136.39 45.15 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-O 125.676 2.655 . . . . 0.0 113.029 -179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 219' ' ' ALA . . . . . . . . . . . . 0.273 . . -84.72 164.65 18.43 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 113.647 -1.615 . . . . 0.0 112.827 -174.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 220' ' ' GLY . . . . . . . . . . . . . . . -68.97 157.15 53.52 Favored Glycine 0 C--N 1.335 0.515 0 O-C-N 117.573 -3.204 . . . . 0.0 115.353 -171.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 221' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo . . . . . 0 C--O 1.251 1.162 1 C-N-CA 125.87 4.38 . . . . 0.0 116.991 170.089 . . . . . . . . 1 1 . 1 stop_ save_